<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16139213</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0960-9822</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>17</Issue><PubDate><Year>2005</Year><Month>Sep</Month><Day>06</Day></PubDate></JournalIssue><Title>Current biology : CB</Title><ISOAbbreviation>Curr Biol</ISOAbbreviation></Journal><ArticleTitle>Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease.</ArticleTitle><Pagination><StartPage>1572</StartPage><EndPage>1577</EndPage><MedlinePgn>1572-7</MedlinePgn></Pagination><Abstract><AbstractText>Parkinson's disease (PD) is a common neurodegenerative disorder that displays both sporadic and inherited forms. Exposure to several common environmental toxins acting through oxidative stress has been shown to be associated with PD. One recently identified inherited PD gene, DJ-1, may have a role in protection from oxidative stress, thus potentially linking a genetic cause with critical environmental risk factors. To develop an animal model that would allow integrative study of genetic and environmental influences, we have generated Drosophila lacking DJ-1 function. Fly DJ-1 homologs exhibit differential expression: DJ-1beta is ubiquitous, while DJ-1alpha is predominantly expressed in the male germline. DJ-1alpha and DJ-1beta double knockout flies are viable, fertile, and have a normal lifespan; however, they display a striking selective sensitivity to those environmental agents, including paraquat and rotenone, linked to PD in humans. This sensitivity results primarily from loss of DJ-1beta protein, which also becomes modified upon oxidative stress. These studies demonstrate that fly DJ-1 activity is selectively involved in protection from environmental oxidative insult in vivo and that the DJ-1beta protein is biochemically responsive to oxidative stress. Study of these flies will provide insight into the critical interplay of genetics and environment in PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meulener</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitworth</LastName><ForeName>Alexander J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Armstrong-Gold</LastName><ForeName>Cecilia E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Rizzu</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Heutink</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Wes</LastName><ForeName>Paul D</ForeName><Initials>PD</Initials></Author><Author ValidYN="Y"><LastName>Pallanck</LastName><ForeName>Leo J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Bonini</LastName><ForeName>Nancy M</ForeName><Initials>NM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1R21NS048362-01</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Biol</MedlineTA><NlmUniqueID>9107782</NlmUniqueID><ISSNLinking>0960-9822</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C506878">DJ-1alpha protein, Drosophila</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>03L9OT429T</RegistryNumber><NameOfSubstance UI="D012402">Rotenone</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.2.-</RegistryNumber><NameOfSubstance UI="C506879">DJ-1beta protein, Drosophila</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.2.-</RegistryNumber><NameOfSubstance UI="D000071617">Protein Deglycase DJ-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>PLG39H7695</RegistryNumber><NameOfSubstance UI="D010269">Paraquat</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003433" MajorTopicYN="N">Crosses, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029721" MajorTopicYN="N">Drosophila Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010269" MajorTopicYN="N">Paraquat</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071617" MajorTopicYN="N">Protein Deglycase DJ-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012402" MajorTopicYN="N">Rotenone</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16139213</ArticleId><ArticleId IdType="doi">10.1016/j.cub.2005.07.064</ArticleId><ArticleId IdType="pii">S0960-9822(05)00848-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16148936</PMID><DateCompleted><Year>2005</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>437</Volume><Issue>7056</Issue><PubDate><Year>2005</Year><Month>Sep</Month><Day>08</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Amyloid-like fibrils of ribonuclease A with three-dimensional domain-swapped and native-like structure.</ArticleTitle><Pagination><StartPage>266</StartPage><EndPage>269</EndPage><MedlinePgn>266-9</MedlinePgn></Pagination><Abstract><AbstractText>Amyloid or amyloid-like fibrils are elongated, insoluble protein aggregates, formed in vivo in association with neurodegenerative diseases or in vitro from soluble native proteins, respectively. The underlying structure of the fibrillar or 'cross-beta' state has presented long-standing, fundamental puzzles of protein structure. These include whether fibril-forming proteins have two structurally distinct stable states, native and fibrillar, and whether all or only part of the native protein refolds as it converts to the fibrillar state. Here we show that a designed amyloid-like fibril of the well-characterized enzyme RNase A contains native-like molecules capable of enzymatic activity. In addition, these functional molecular units are formed from a core RNase A domain and a swapped complementary domain. These findings are consistent with the zipper-spine model in which a cross-beta spine is decorated with three-dimensional domain-swapped functional units, retaining native-like structure.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sambashivan</LastName><ForeName>Shilpa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA-DOE Institute for Genomics and Proteomics, Box 951570, UCLA, Los Angeles, California 90095-1570, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yanshun</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Sawaya</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Gingery</LastName><ForeName>Mari</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Eisenberg</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PDB</DataBankName><AccessionNumberList><AccessionNumber>2APQ</AccessionNumber><AccessionNumber>2APU</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.1.27.5</RegistryNumber><NameOfSubstance UI="D012259">Ribonuclease, Pancreatic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2005 Sep 8;437(7056):197-8. doi: 10.1038/437197a.</RefSource><PMID Version="1">16148916</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019281" MajorTopicYN="N">Dimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005612" MajorTopicYN="N">Freeze Drying</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008956" MajorTopicYN="N">Models, Chemical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011489" MajorTopicYN="N">Protein Denaturation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020836" MajorTopicYN="N">Protein Structure, Quaternary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012259" MajorTopicYN="N">Ribonuclease, Pancreatic</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013816" MajorTopicYN="N">Thermodynamics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>9</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16148936</ArticleId><ArticleId IdType="doi">10.1038/nature03916</ArticleId><ArticleId IdType="pii">nature03916</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16154999</PMID><DateCompleted><Year>2006</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>280</Volume><Issue>45</Issue><PubDate><Year>2005</Year><Month>Nov</Month><Day>11</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor.</ArticleTitle><Pagination><StartPage>37644</StartPage><EndPage>37650</EndPage><MedlinePgn>37644-50</MedlinePgn></Pagination><Abstract><AbstractText>Human genetic data have associated angiotensin-converting enzyme (ACE) with Alzheimer disease (AD), and purified ACE has been reported to cleave synthetic amyloid beta-protein (Abeta) in vitro. Whether deficiency in ACE activity, arising from genetic alteration or pharmacological inhibition, can decrease Abeta degradation and allow Abeta accumulation in intact cells is unknown. We cloned ACE from human neuroblastoma cells and showed that it had posttranslational processing and enzymatic activity typical of the endogenous protease. Cellular expression of ACE promoted degradation of naturally secreted Abeta40 and Abeta42, leading to significant clearance of both species. Using site-directed mutagenesis, we determined that both active sites within ACE contribute to Abeta clearance, and an ACE construct bearing mutations in each catalytic domain had no effect on Abeta levels. Pharmacological inhibition of ACE with a widely prescribed drug, captopril, promoted the accumulation of cell-derived Abeta in the media of beta-amyloid precursor-protein expressing cells. Together, these results show that ACE can lower the levels of secreted Abeta in living cells and that this effect is blocked by inhibiting the protease's activity with an ACE inhibitor. This work, combined with the genetic studies, supports the hypothesis that ACE may modulate the susceptibility to and progression of AD via degradation of Abeta. Our data encourage further analyses of the ACE gene for disease association and raise the question of whether currently prescribed ACE inhibitors could elevate cerebral Abeta levels in humans.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hemming</LastName><ForeName>Matthew L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG012749</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG12749</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>9G64RSX1XD</RegistryNumber><NameOfSubstance UI="D002216">Captopril</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber><NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002216" MajorTopicYN="N">Captopril</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002384" MajorTopicYN="N">Catalysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>6</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16154999</ArticleId><ArticleId IdType="mid">NIHMS47179</ArticleId><ArticleId IdType="pmc">PMC2409196</ArticleId><ArticleId IdType="doi">10.1074/jbc.M508460200</ArticleId><ArticleId IdType="pii">S0021-9258(20)59223-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM. Neurology. 2005;64:1553&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883316</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Ann. Intern. Med. 2004;140:627&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">15096334</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. Neuron. 2004;44:181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450169</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, deq Uervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM. Neuron. 2003;38:547&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">12765607</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC. Science. 2001;292:1550&#x2013;1552.</Citation><ArticleIdList><ArticleId IdType="pubmed">11375493</ArticleId></ArticleIdList></Reference><Reference><Citation>Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S. Proc. Natl. Acad. Sci. U. S. A. 2003;100:4162&#x2013;4167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC153065</ArticleId><ArticleId IdType="pubmed">12634421</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB. J. Biol. Chem. 2003;278:2081&#x2013;2084.</Citation><ArticleIdList><ArticleId IdType="pubmed">12464614</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker HM, Kihiko M, Caldwell JN, Wright S, Kawarabayashi T, Price D, Walker D, Scheff S, McGillis JP, Rydel RE, Estus S. J. Neurosci. 2000;20:3937&#x2013;3946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772619</ArticleId><ArticleId IdType="pubmed">10818128</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker HM, Simpson J, Kihiko-Ehmann M, Younkin LH, McGillis JP, Younkin SG, Degen JL, Estus S. Neurosci. Lett. 2004;368:285&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">15364412</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ. Neuron. 2003;40:1087&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pubmed">14687544</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei L, Alhenc-Gelas F, Corvol P, Clauser E. J. Biol. Chem. 1991;266:9002&#x2013;9008.</Citation><ArticleIdList><ArticleId IdType="pubmed">1851160</ArticleId></ArticleIdList></Reference><Reference><Citation>Beldent V, Michaud A, Wei L, Chauvet MT, Corvol P. J. Biol. Chem. 1993;268:26428&#x2013;26434.</Citation><ArticleIdList><ArticleId IdType="pubmed">8253769</ArticleId></ArticleIdList></Reference><Reference><Citation>Balyasnikova IV, Karran EH, Albrecht RF, II, Danilov SM. Biochem. J. 2002;362:585&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1222422</ArticleId><ArticleId IdType="pubmed">11879185</ArticleId></ArticleIdList></Reference><Reference><Citation>Coates D. Int. J. Biochem. Cell Biol. 2003;35:769&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">12676162</ArticleId></ArticleIdList></Reference><Reference><Citation>Skidgel RA, Erdos EG. Clin. Exp. Hypertens. A. 1987;9:243&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">2440624</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaud A, Williams TA, Chauvet MT, Corvol P. Mol. Pharmacol. 1997;51:1070&#x2013;1076.</Citation><ArticleIdList><ArticleId IdType="pubmed">9187274</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei L, Clauser E, Alhenc-Gelas F, Corvol P. J. Biol. Chem. 1992;267:13398&#x2013;13405.</Citation><ArticleIdList><ArticleId IdType="pubmed">1320019</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohlstedt K, Brandes RP, Muller-Esterl W, Busse R, Fleming I. Circ. Res. 2004;94:60&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">14615289</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehoe PG, Russ C, McIlory S, Williams H, Holmans P, Holmes C, Liolitsa D, Vahidassr D, Powell J, McGleenon B, Liddell M, Plomin R, Dynan K, Williams N, Neal J, Cairns NJ, Wilcock G, Passmore P, Lovestone S, Williams J, Owen MJ. Nat. Genet. 1999;21:71&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">9916793</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkins JS, Douglas VC, Johnston SC. Neurology. 2004;62:363&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">14872014</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann DJ, Cortina-Borja M, Warden DR, Smith AD, Sleegers K, Prince JA, van Duijn CM, Kehoe PG. Am. J. Epidemiol. 2005;162:305&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">16033878</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. J. Clin. Invest. 1990;86:1343&#x2013;1346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC296868</ArticleId><ArticleId IdType="pubmed">1976655</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolsch H, Jessen F, Freymann N, Kreis M, Hentschel F, Maier W, Heun R. Neurosci. Lett. 2005;377:37&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">15722183</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K, den Heijer T, van Dijk EJ, Hofman A, Bertoli-Avella AM, Koud-staal PJ, Breteler MM, van Duijn CM. Neurobiol. Aging. 2005;26:1153&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">15917098</ArticleId></ArticleIdList></Reference><Reference><Citation>Lendon CL, Thaker U, Harris JM, McDonagh AM, Lambert JC, Chartier-Harlin MC, Iwatsubo T, Pickering-Brown SM, Mann DM. Neurosci. Lett. 2002;328:314&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">12147333</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzov H, Bennet AM, Kehoe P, Wiman B, Gatz M, Blennow K, Lenhard B, Pedersen NL, de Faire U, Prince JA. Hum. Mol. Genet. 2004;13:2647&#x2013;2657.</Citation><ArticleIdList><ArticleId IdType="pubmed">15367486</ArticleId></ArticleIdList></Reference><Reference><Citation>Savaskan E, Hock C, Olivieri G, Bruttel S, Rosenberg C, Hulette C, Muller-Spahn F. Neurobiol. Aging. 2001;22:541&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pubmed">11445253</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes NM, Cheng CH, Costall B, Naylor RJ, Williams TJ, Wischik CM. Eur. J. Pharmacol. 1991;200:289&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">1664329</ArticleId></ArticleIdList></Reference><Reference><Citation>Arregui A, Perry EK, Rossor M, Tomlinson BE. J. Neurochem. 1982;38:1490&#x2013;1492.</Citation><ArticleIdList><ArticleId IdType="pubmed">6278093</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Igarashi A, Kamata M, Nakagawa H. J. Biol. Chem. 2001;276:47863&#x2013;47868.</Citation><ArticleIdList><ArticleId IdType="pubmed">11604391</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring MA, Farris W, Wu X, Christodoulou DC, Haigis MC, Guarente L, Selkoe DJ. Biochem. J. 2004;383:439&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1133736</ArticleId><ArticleId IdType="pubmed">15285718</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ. Nature. 1992;360:672&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">1465129</ArticleId></ArticleIdList></Reference><Reference><Citation>Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, Rosner MR, Selkoe DJ. J. Neurosci. 2000;20:1657&#x2013;1665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772918</ArticleId><ArticleId IdType="pubmed">10684867</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos RA, Krieger EM, Greene LJ. Hypertension. 1985;7:244&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">2984118</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L. Proc. Natl. Acad. Sci. U. S. A. 1997;94:1550&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs S, Xiao HD, Cole JM, Adams JW, Frenzel K, Michaud A, Zhao H, Keshelava G, Capecchi MR, Corvol P, Bernstein KE. J. Biol. Chem. 2004;279:15946&#x2013;15953.</Citation><ArticleIdList><ArticleId IdType="pubmed">14757757</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper NM, Turner AJ. Biochem. J. 1987;241:625&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1147610</ArticleId><ArticleId IdType="pubmed">2439065</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodman ZL, Oppong SY, Cook S, Hooper NM, Schwager SL, Brandt WF, Ehlers MR, Sturrock ED. Biochem. J. 2000;347:711&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1221007</ArticleId><ArticleId IdType="pubmed">10769174</ArticleId></ArticleIdList></Reference><Reference><Citation>Farris W, Leissring MA, Hemming ML, Chang AY, Selkoe DJ. Biochemistry. 2005;44:6513&#x2013;6525.</Citation><ArticleIdList><ArticleId IdType="pubmed">15850385</ArticleId></ArticleIdList></Reference><Reference><Citation>Oba R, Igarashi A, Kamata M, Nagata K, Takano S, Nakagawa H. Eur. J. Neurosci. 2005;21:733&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pubmed">15733091</ArticleId></ArticleIdList></Reference><Reference><Citation>Binevski PV, Sizova EA, Pozdnev VF, Kost OA. FEBS Lett. 2003;550:84&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">12935891</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohlstedt K, Busse R, Fleming I. Hypertension. 2005;45:126&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">15569856</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohrui T, Tomita N, Sato-Nakagawa T, Matsui T, Maruyama M, Niwa K, Arai H, Sasaki H. Neurology. 2004;63:1324&#x2013;1325.</Citation><ArticleIdList><ArticleId IdType="pubmed">15477567</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman D. Neurology. 2004;63:1145.</Citation><ArticleIdList><ArticleId IdType="pubmed">15277606</ArticleId></ArticleIdList></Reference><Reference><Citation>Birkenhager WH, Forette F, Staessen JA. Curr. Opin. Nephrol. Hypertens. 2004;13:225&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">15202617</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole J, Quach du L, Sundaram K, Corvol P, Capecchi MR, Bernstein KE. Circ. Res. 2002;90:87&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">11786523</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16155124</PMID><DateCompleted><Year>2005</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>102</Volume><Issue>38</Issue><PubDate><Year>2005</Year><Month>Sep</Month><Day>20</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy.</ArticleTitle><Pagination><StartPage>13592</StartPage><EndPage>13597</EndPage><MedlinePgn>13592-7</MedlinePgn></Pagination><Abstract><AbstractText>Amyloid oligomers, similar to the toxic entities found in Alzheimer's disease patients and in other amyloid-based diseases, are present in cardiomyocytes derived from human heart-failure patients and in animal models of desmin-related cardiomyopathy (DRM). The R120G mutation in alpha-B-crystallin (CryAB) causes DRM and is characterized by aggresomes containing CryAB(R120G) and amyloid oligomer. In this study, we show that aggresome levels do not correlate with disease. Blocking aggresome formation results in increased levels of toxic amyloid oligomer and decreased cardiomyocyte viability. We confirmed the primary toxicity of intrasarcoplasmic amyloid accumulation in the cardiomyocytes by ectopic expression of the amyloidogenic peptide PQ81, which consists of multiple repeats of a polyglutamine tract. We then addressed the issue of disease reversibility by placing CryAB(R120G) under inducible cardiomyocyte-specific expression in transgenic mice. The mice developed aggresomes and contained high concentrations of amyloid oligomer in the heart, resulting in cardiac disease. Cessation of CryAB(R120G) expression in symptomatic mice improved cardiac function and rescued all of the animals from premature death. Rescue was accompanied by significant decreases in amyloid oligomer without a significant reduction in aggresomes. Blocking cardiac amyloid oligomer formation, even after cardiac dysfunction presents, may be a therapeutic strategy in DRM as well as in other types of cardiac disease in which significant amyloid accumulation occurs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sanbe</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Molecular Cardiovascular Biology and Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229-3039, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osinska</LastName><ForeName>Hanna</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Villa</LastName><ForeName>Chet</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Gulick</LastName><ForeName>James</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Klevitsky</LastName><ForeName>Raisa</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Glabe</LastName><ForeName>Charles G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Kayed</LastName><ForeName>Rakez</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Robbins</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL066157</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HH61638</GrantID><Acronym>HH</Acronym><Agency>HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 HL069779</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL52318</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL69779</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 HL052318</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL056370</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 HL074728</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL074728</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL56370</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003893">Desmin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D038203">alpha-Crystallin B Chain</NameOfSubstance></Chemical><Chemical><RegistryNumber>25513-46-6</RegistryNumber><NameOfSubstance UI="D011099">Polyglutamic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009202" MajorTopicYN="N">Cardiomyopathies</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003893" MajorTopicYN="N">Desmin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009206" MajorTopicYN="N">Myocardium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032383" MajorTopicYN="N">Myocytes, Cardiac</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="N">Point Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011099" MajorTopicYN="N">Polyglutamic Acid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038203" MajorTopicYN="N">alpha-Crystallin B Chain</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>11</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>3</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16155124</ArticleId><ArticleId IdType="pmc">PMC1224623</ArticleId><ArticleId IdType="doi">10.1073/pnas.0503324102</ArticleId><ArticleId IdType="pii">0503324102</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kopito, R. R. (2000) Trends Cell Biol. 10, 524-530.</Citation><ArticleIdList><ArticleId IdType="pubmed">11121744</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopito, R. R. &amp; Sitia, R. (2000) EMBO Rep. 1, 225-231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1083726</ArticleId><ArticleId IdType="pubmed">11256604</ArticleId></ArticleIdList></Reference><Reference><Citation>Muchowski, P. J. &amp; Wacker, J. L. (2005) Nat. Rev. Neurosci. 6, 11-22.</Citation><ArticleIdList><ArticleId IdType="pubmed">15611723</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto, C. (2003) Nat. Rev. Neurosci. 4, 49-60.</Citation><ArticleIdList><ArticleId IdType="pubmed">12511861</ArticleId></ArticleIdList></Reference><Reference><Citation>Busciglio, J., Pelsman, A., Wong, C., Pigino, G., Yuan, M., Mori, H. &amp; Yankner, B. A. (2002) Neuron 33, 677-688.</Citation><ArticleIdList><ArticleId IdType="pubmed">11879646</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustbader, J. W., Cirilli, M., Lin, C., Xu, H. W., Takuma, K., Wang, N., Caspersen, C., Chen, X., Pollak, S., Chaney, M., et al. (2004) Science 304, 448-452.</Citation><ArticleIdList><ArticleId IdType="pubmed">15087549</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L. &amp; Bates, G. P. (1997) Cell 90, 537-548.</Citation><ArticleIdList><ArticleId IdType="pubmed">9267033</ArticleId></ArticleIdList></Reference><Reference><Citation>Becher, M. W., Kotzuk, J. A., Sharp, A. H., Davies, S. W., Bates, G. P., Price, D. L. &amp; Ross, C. A. (1998) Neurobiol. Dis. 4, 387-397.</Citation><ArticleIdList><ArticleId IdType="pubmed">9666478</ArticleId></ArticleIdList></Reference><Reference><Citation>DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P. &amp; Aronin, N. (1997) Science 277, 1990-1993.</Citation><ArticleIdList><ArticleId IdType="pubmed">9302293</ArticleId></ArticleIdList></Reference><Reference><Citation>Ordway, J. M., Tallaksen-Greene, S., Gutekunst, C. A., Bernstein, E. M., Cearley, J. A., Wiener, H. W., Dure, L. S. T., Lindsey, R., Hersch, S. M., Jope, R. S., et al. (1997) Cell 91, 753-763.</Citation><ArticleIdList><ArticleId IdType="pubmed">9413985</ArticleId></ArticleIdList></Reference><Reference><Citation>Saudou, F., Finkbeiner, S., Devys, D. &amp; Greenberg, M. E. (1998) Cell 95, 55-66.</Citation><ArticleIdList><ArticleId IdType="pubmed">9778247</ArticleId></ArticleIdList></Reference><Reference><Citation>Klement, I. A., Skinner, P. J., Kaytor, M. D., Yi, H., Hersch, S. M., Clark, H. B., Zoghbi, H. Y. &amp; Orr, H. T. (1998) Cell 95, 41-53.</Citation><ArticleIdList><ArticleId IdType="pubmed">9778246</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor, J. P., Tanaka, F., Robitschek, J., Sandoval, C. M., Taye, A., Markovic-Plese, S. &amp; Fischbeck, K. H. (2003) Hum. Mol. Genet. 12, 749-757.</Citation><ArticleIdList><ArticleId IdType="pubmed">12651870</ArticleId></ArticleIdList></Reference><Reference><Citation>Glabe, C. G. (2004) Trends Biochem. Sci. 29, 542-547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450609</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J. &amp; Selkoe, D. J. (2002) Nature 416, 535-539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh, D. M., Klyubin, I., Fadeeva, J. V., Rowan, M. J. &amp; Selkoe, D. J. (2002) Biochem. Soc. Trans. 30, 552-557.</Citation><ArticleIdList><ArticleId IdType="pubmed">12196135</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C. M. &amp; Stefani, M. (2002) Nature 416, 507-511.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932737</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W. &amp; Glabe, C. G. (2003) Science 300, 486-489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) Proc. Natl. Acad. Sci. USA 95, 6448-6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitschke, M., Prior, R., Haupt, M. &amp; Riesner, D. (1998) Nat. Med. 4, 832-834.</Citation><ArticleIdList><ArticleId IdType="pubmed">9662376</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo, Y. M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J. &amp; Roher, A. E. (1996) J. Biol. Chem. 271, 4077-4081.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626743</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean, C. A., Cherny, R. A., Fraser, F. W., Fuller, S. J., Smith, M. J., Beyreuther, K., Bush, A. I. &amp; Masters, C. L. (1999) Ann. Neurol. 46, 860-866.</Citation><ArticleIdList><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R. &amp; Finkbeiner, S. (2004) Nature 431, 805-810.</Citation><ArticleIdList><ArticleId IdType="pubmed">15483602</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicart, P., Caron, A., Guicheney, P., Li, Z., Prevost, M. C., Faure, A., Chateau, D., Chapon, F., Tome, F., Dupret, J. M., Paulin, D. &amp; Fardeau, M. (1998) Nat. Genet. 20, 92-95.</Citation><ArticleIdList><ArticleId IdType="pubmed">9731540</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, X., Osinska, H., Klevitsky, R., Gerdes, A. M., Nieman, M., Lorenz, J., Hewett, T. &amp; Robbins, J. (2001) Circ. Res. 89, 84-91.</Citation><ArticleIdList><ArticleId IdType="pubmed">11440982</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanbe, A., Osinska, H., Saffitz, J. E., Glabe, C. G., Kayed, R., Maloyan, A. &amp; Robbins, J. (2004) Proc. Natl. Acad. Sci. USA 101, 10132-10136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC454177</ArticleId><ArticleId IdType="pubmed">15220483</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanbe, A., Gulick, J., Hanks, M. C., Liang, Q., Osinska, H. &amp; Robbins, J. (2003) Circ. Res. 92, 609-616.</Citation><ArticleIdList><ArticleId IdType="pubmed">12623879</ArticleId></ArticleIdList></Reference><Reference><Citation>He, T. C., Zhou, S., da Costa, L. T., Yu, J., Kinzler, K. W. &amp; Vogelstein, B. (1998) Proc. Natl. Acad. Sci. USA 95, 2509-2514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19394</ArticleId><ArticleId IdType="pubmed">9482916</ArticleId></ArticleIdList></Reference><Reference><Citation>Onodera, O., Burke, J. R., Miller, S. E., Hester, S., Tsuji, S., Roses, A. D. &amp; Strittmatter, W. J. (1997) Biochem. Biophys. Res. Commun. 238, 599-605.</Citation><ArticleIdList><ArticleId IdType="pubmed">9299559</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanker, E. (1999) Methods Enzymol. 309, 375-386.</Citation><ArticleIdList><ArticleId IdType="pubmed">10507036</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Mata, R., Gao, Y. S. &amp; Sztul, E. (2002) Traffic 3, 388-396.</Citation><ArticleIdList><ArticleId IdType="pubmed">12010457</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman, M. Y. &amp; Goldberg, A. L. (2001) Neuron 29, 15-32.</Citation><ArticleIdList><ArticleId IdType="pubmed">11182078</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross, C. A. &amp; Poirier, M. A. (2004) Nat. Med. 10, Suppl., S10-S17.</Citation><ArticleIdList><ArticleId IdType="pubmed">15272267</ArticleId></ArticleIdList></Reference><Reference><Citation>Derham, B. K., van Boekel, M. A., Muchowski, P. J., Clark, J. I., Horwitz, J., Hepburne-Scott, H. W., de Jong, W. W., Crabbe, M. J. &amp; Harding, J. J. (2001) Eur. J. Biochem. 268, 713-721.</Citation><ArticleIdList><ArticleId IdType="pubmed">11168410</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavez Zobel, A. T., Loranger, A., Marceau, N., Theriault, J. R., Lambert, H. &amp; Landry, J. (2003) Hum. Mol. Genet. 12, 1609-1620.</Citation><ArticleIdList><ArticleId IdType="pubmed">12812987</ArticleId></ArticleIdList></Reference><Reference><Citation>Gestwicki, J. E., Crabtree, G. R. &amp; Graef, I. A. (2004) Science 306, 865-869.</Citation><ArticleIdList><ArticleId IdType="pubmed">15514157</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood, J. D., Beaujeux, T. P. &amp; Shaw, P. J. (2003) Neuropathol. Appl. Neurobiol. 29, 529-545.</Citation><ArticleIdList><ArticleId IdType="pubmed">14636160</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, S., Carson, K., Rice-Ficht, A. &amp; Good, T. (2005) Protein Sci. 14, 593-601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2279291</ArticleId><ArticleId IdType="pubmed">15722443</ArticleId></ArticleIdList></Reference><Reference><Citation>Stege, G. J., Renkawek, K., Overkamp, P. S., Verschuure, P., van Rijk, A. F., Reijnen-Aalbers, A., Boelens, W. C., Bosman, G. J. &amp; de Jong, W. W. (1999) Biochem. Biophys. Res. Commun. 262, 152-156.</Citation><ArticleIdList><ArticleId IdType="pubmed">10448084</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16157276</PMID><DateCompleted><Year>2005</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>47</Volume><Issue>6</Issue><PubDate><Year>2005</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>GABAergic excitation promotes neuronal differentiation in adult hippocampal progenitor cells.</ArticleTitle><Pagination><StartPage>803</StartPage><EndPage>815</EndPage><MedlinePgn>803-15</MedlinePgn></Pagination><Abstract><AbstractText>Hippocampal activity influences neurogenesis in the adult dentate gyrus; however, little is known about the involvement of the hippocampal circuitry in this process. In the subgranular zone of the adult dentate gyrus, neurogenesis involves a series of differentiation steps from radial glia-like stem/progenitor (type-1) cells, to transiently amplifying neuronal progenitor (type-2) cells, to postmitotic neurons. In this study, we conducted GFP-targeted recordings of progenitor cells in fresh hippocampal slices from nestin-GFP mice and found that neuronal progenitor (type-2) cells receive active direct neural inputs from the hippocampal circuitry. This input was GABAergic but not glutamatergic. The GABAergic inputs depolarized type-2 cells because of their elevated [Cl(-)](i). This excitation initiated an increase of [Ca(2+)](i) and the expression of NeuroD. A BrdU-pulse labeling study with GABA(A)-R agonists demonstrated the promotion of neuronal differentiation via this GABAergic excitation. Thus, it appears that GABAergic inputs to hippocampal progenitor cells promote activity-dependent neuronal differentiation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tozuka</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Integrated Biosciences, University of Tokyo, Kashiwa 277-8562, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukuda</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Namba</LastName><ForeName>Takashi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Seki</LastName><ForeName>Tatsunori</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hisatsune</LastName><ForeName>Tatsuhiro</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016456">Historical Article</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051792">Basic Helix-Loop-Helix Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064026">Calbindins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018690">Excitatory Amino Acid Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018756">GABA Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007381">Intermediate Filament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019394">Ki-67 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577485">Nes protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064231">Nestin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039842">Neural Cell Adhesion Molecule L1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026902">Potassium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064030">S100 Calcium Binding Protein G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012794">Sialic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578878">Slc12a2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D028021">Sodium-Potassium-Chloride Symporters</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064506">Solute Carrier Family 12, Member 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050495">Vesicular Inhibitory Amino Acid Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492244">Viaat protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C103469">polysialyl neural cell adhesion molecule</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>169238-82-8</RegistryNumber><NameOfSubstance UI="C093564">Neurogenic differentiation factor 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>4368-28-9</RegistryNumber><NameOfSubstance UI="D013779">Tetrodotoxin</NameOfSubstance></Chemical><Chemical><RegistryNumber>56-12-2</RegistryNumber><NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>6384-92-5</RegistryNumber><NameOfSubstance UI="D016202">N-Methylaspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>77521-29-0</RegistryNumber><NameOfSubstance UI="D018350">alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>7OV03QG267</RegistryNumber><NameOfSubstance UI="D009532">Nickel</NameOfSubstance></Chemical><Chemical><RegistryNumber>BH3B64OKL9</RegistryNumber><NameOfSubstance UI="D015761">4-Aminopyridine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.2.1.11</RegistryNumber><NameOfSubstance UI="D010751">Phosphopyruvate Hydratase</NameOfSubstance></Chemical><Chemical><RegistryNumber>G34N38R2N1</RegistryNumber><NameOfSubstance UI="D001973">Bromodeoxyuridine</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical><Chemical><RegistryNumber>TE7660XO1C</RegistryNumber><NameOfSubstance UI="D005998">Glycine</NameOfSubstance></Chemical><Chemical><RegistryNumber>Y37615DVKC</RegistryNumber><NameOfSubstance UI="D001640">Bicuculline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2005 Sep 15;47(6):775-7. doi: 10.1016/j.neuron.2005.08.029.</RefSource><PMID Version="1">16157270</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015761" MajorTopicYN="N">4-Aminopyridine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051792" MajorTopicYN="N">Basic Helix-Loop-Helix Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001640" MajorTopicYN="N">Bicuculline</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001973" MajorTopicYN="N">Bromodeoxyuridine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064026" MajorTopicYN="N">Calbindins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004558" MajorTopicYN="N">Electric Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018690" MajorTopicYN="N">Excitatory Amino Acid Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018756" MajorTopicYN="N">GABA Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005998" MajorTopicYN="N">Glycine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049690" MajorTopicYN="N">History, Ancient</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007381" MajorTopicYN="N">Intermediate Filament Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019394" MajorTopicYN="N">Ki-67 Antigen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008564" MajorTopicYN="N">Membrane Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016253" MajorTopicYN="N">Microscopy, Immunoelectron</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016202" MajorTopicYN="N">N-Methylaspartate</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064231" MajorTopicYN="N">Nestin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039842" MajorTopicYN="N">Neural Cell Adhesion Molecule L1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009532" MajorTopicYN="N">Nickel</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010751" MajorTopicYN="N">Phosphopyruvate Hydratase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026902" MajorTopicYN="N">Potassium Channel Blockers</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064030" MajorTopicYN="N">S100 Calcium Binding Protein G</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012794" MajorTopicYN="N">Sialic Acids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D028021" MajorTopicYN="N">Sodium-Potassium-Chloride Symporters</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064506" MajorTopicYN="N">Solute Carrier Family 12, Member 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013779" MajorTopicYN="N">Tetrodotoxin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050495" MajorTopicYN="N">Vesicular Inhibitory Amino Acid Transport Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018350" MajorTopicYN="N">alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005680" MajorTopicYN="N">gamma-Aminobutyric Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16157276</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2005.08.023</ArticleId><ArticleId IdType="pii">S0896-6273(05)00698-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16159306</PMID><DateCompleted><Year>2006</Year><Month>05</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1549-1676</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>10</Issue><PubDate><Year>2005</Year><Month>Oct</Month></PubDate></JournalIssue><Title>PLoS medicine</Title><ISOAbbreviation>PLoS Med</ISOAbbreviation></Journal><ArticleTitle>Impaired cross-modal inhibition in Alzheimer disease.</ArticleTitle><Pagination><StartPage>e288</StartPage><MedlinePgn>e288</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e288</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Successful cognitive performance depends not only on the activation of specific neuronal networks but also on selective suppression of task-irrelevant modalities, i.e., deactivation of non-required cerebral regions. This ability to suppress the activation of specific brain regions has, to our knowledge, never been systematically evaluated in patients with Alzheimer disease (AD). The aim of the current study was to evaluate both cerebral activation and deactivation in (1) healthy volunteers, (2) patients with mild cognitive impairment (MCI) who are at risk for AD, and (3) patients with moderate AD during active navigation, representing a cognitive task typically affected in AD.</AbstractText><AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">Changes in regional cerebral blood flow (rCBF) were assessed with PET imaging during an active navigation task in a 3D virtual-reality environment. The task was based on visual cues exclusively; no auditory cues were provided. Age-matched groups of healthy individuals, patients with MCI, and patients with AD were examined. Specific differences in the activation patterns were observed in the three groups, with stronger activation of cerebellar portions and visual association cortex in controls and stronger activation of primary visual and frontal cortical areas in patients with MCI and AD. Highly significant bilateral decrease of rCBF in task-irrelevant auditory cortical regions was detected in healthy individuals during performance of the task. This rCBF decrease was interpreted as a cross-modal inhibitory effect. It was diminished in patients with MCI and completely absent in patients with AD. A regression analysis across all individuals revealed a clear positive relation between cognitive status (mini mental state examination score) and the extent of auditory cortical deactivation.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">During active navigation, a high level of movement automation and an involvement of higher-order cerebral association functions were observed in healthy controls. Conversely, in patients with MCI and AD, increased cognitive effort and attention towards movement planning, as well as stronger involvement of lower-order cerebral systems, was found. Successful cognitive performance in healthy individuals is associated with deactivation of task-irrelevant cerebral regions, whereas the development of AD appears to be characterized by a progressive impairment of cross-modal cerebral deactivation functions. These changes may cause the generally decreased ability of patients with AD to direct attention primarily to the relevant cognitive modality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Drzezga</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany. a.drzezga@lrz.tum.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimmer</LastName><ForeName>Timo</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Peller</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wermke</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Siebner</LastName><ForeName>Hartwig</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Rauschecker</LastName><ForeName>Josef P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Schwaiger</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kurz</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Med</MedlineTA><NlmUniqueID>101231360</NlmUniqueID><ISSNLinking>1549-1277</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>PLoS Med. 2:e356.</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001331" MajorTopicYN="N">Automation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012039" MajorTopicYN="N">Regional Blood Flow</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>
<b>Competing Interests:</b> The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>5</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2005</Year><Month>9</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16159306</ArticleId><ArticleId IdType="pmc">PMC1216331</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.0020288</ArticleId><ArticleId IdType="pii">04-PLME-RA-0245R3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Posner MI, Petersen SE. The attention system of the human brain. Annu Rev Neurosci. 1990;13:25&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">2183676</ArticleId></ArticleIdList></Reference><Reference><Citation>Haxby JV, Horwitz B, Ungerleider LG, Maisog JM, Pietrini P, et al. The functional organization of human extrastriate cortex: A PET-rCBF study of selective attention to faces and locations. J Neurosci. 1994;14:6336&#x2013;6353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577268</ArticleId><ArticleId IdType="pubmed">7965040</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawashima R, O'Sullivan BT, Roland PE. Positron-emission tomography studies of cross-modality inhibition in selective attentional tasks: Closing the &#x201c;mind's eye&#x201d;. Proc Natl Acad Sci U S A. 1995;92:5969&#x2013;5972.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC41623</ArticleId><ArticleId IdType="pubmed">7597062</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurienti PJ, Burdette JH, Wallace MT, Yen YF, Field AS, et al. Deactivation of sensory-specific cortex by cross-modal stimuli. J Cogn Neurosci. 2002;14:420&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">11970801</ArticleId></ArticleIdList></Reference><Reference><Citation>Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med. 2000;343:450&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831477</ArticleId><ArticleId IdType="pubmed">10944562</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietrini P, Furey ML, Alexander GE, Mentis MJ, Dani A, et al. Association between brain functional failure and dementia severity in Alzheimer's disease: Resting versus stimulation PET study. Am J Psychiatry. 1999;156:470&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">10080567</ArticleId></ArticleIdList></Reference><Reference><Citation>Maguire EA, Burgess N, Donnett JG, Frackowiak RS, Frith CD, et al. Knowing where and getting there: A human navigation network. Science. 1998;280:921&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">9572740</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, et al. Mild cognitive impairment. Cinical characterization and outcome. Arch Neurol. 1999;56:303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: A PET follow-up study. Eur J Nucl Med Mol Imaging. 2003;30:1104&#x2013;1113.</Citation><ArticleIdList><ArticleId IdType="pubmed">12764551</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18&#x2013;FDG PET. J Nucl Med. 1995;36:1238&#x2013;1248.</Citation><ArticleIdList><ArticleId IdType="pubmed">7790950</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldfield RC. The assessment and analysis of handedness: The Edinburgh inventory. Neuropsychologia. 1971;9:97&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">5146491</ArticleId></ArticleIdList></Reference><Reference><Citation>Drzezga A, Grimmer T, Peller M, Wermke M, Nekolla S, et al. Functional reorganization of cerebral activation in patients with MCI and Alzheimer's disease during navigation in a virtual reality environment [abstract]. Neuroimage; 9th International Conference on Functional Mapping of the Human Brain; 2003 June 19&#x2013;22; New York, New York, United States. CD-Rom.</Citation></Reference><Reference><Citation>Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, et al. Statistical parametric mapping in functional imaging: A general linear approach. Hum Brain Mapp. 1995;2:189&#x2013;210.</Citation></Reference><Reference><Citation>Friston KJ, Frith CD, Liddle PF, Dolan RJ, Lammertsma AA, et al. The relationship between global and local changes in PET scans. J Cereb Blood Flow Metab. 1990;10:458&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">2347879</ArticleId></ArticleIdList></Reference><Reference><Citation>Friston KJ, Frith CD, Liddle PF, Frackowiak RS. Comparing functional (PET) images: The assessment of significant change. J Cereb Blood Flow Metab. 1991;11:690&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">2050758</ArticleId></ArticleIdList></Reference><Reference><Citation>Worsley KJ, Evans AC, Marrett S, Neelin P. A three-dimensional statistical analysis for CBF activation studies in human brain. J Cereb Blood Flow Metab. 1992;12:900&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pubmed">1400644</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartley T, Maguire EA, Spiers HJ, Burgess N. The well-worn route and the path less traveled: Distinct neural bases of route following and wayfinding in humans. Neuron. 2003;37:877&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">12628177</ArticleId></ArticleIdList></Reference><Reference><Citation>Maguire EA, Burgess N, O'Keefe J. Human spatial navigation: Cognitive maps, sexual dimorphism, and neural substrates. Curr Opin Neurobiol. 1999;9:171&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10322179</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawashima R, Imaizumi S, Mori K, Okada K, Goto R, et al. Selective visual and auditory attention toward utterances&#x2014;A PET study. Neuroimage. 1999;10:209&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">10417253</ArticleId></ArticleIdList></Reference><Reference><Citation>Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. New York: Thieme; 1988. 132 pp.</Citation></Reference><Reference><Citation>Penhune VB, Zatorre RJ, MacDonald JD, Evans AC. Interhemispheric anatomical differences in human primary auditory cortex: Probabilistic mapping and volume measurement from magnetic resonance scans. Cereb Cortex. 1996;6:661&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">8921202</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauschecker JP, Tian B. Mechanisms and streams for processing of &#x201c;what&#x201d; and &#x201c;where&#x201d; in auditory cortex. Proc Natl Acad Sci U S A. 2000;97:11800&#x2013;11806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34352</ArticleId><ArticleId IdType="pubmed">11050212</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman GL, Corbetta M, Buckner RL, Raichle ME, Fiez JA, et al. Top-down modulation of early sensory cortex. Cereb Cortex. 1997;7:193&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">9143441</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaas JH, Hackett TA. Subdivisions of auditory cortex and processing streams in primates. Proc Natl Acad Sci U S A. 2000;97:11793&#x2013;11799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34351</ArticleId><ArticleId IdType="pubmed">11050211</ArticleId></ArticleIdList></Reference><Reference><Citation>Finney EM, Fine I, Dobkins KR. Visual stimuli activate auditory cortex in the deaf. Nat Neurosci. 2001;4:1171&#x2013;1173.</Citation><ArticleIdList><ArticleId IdType="pubmed">11704763</ArticleId></ArticleIdList></Reference><Reference><Citation>Genovese CR, Lazar NA, Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage. 2002;15:870&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">11906227</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM. Spatial attention and neglect: Parietal, frontal and cingulate contributions to the mental representation and attentional targeting of salient extrapersonal events. Philos Trans R Soc Lond B Biol Sci. 1999;354:1325&#x2013;1346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1692628</ArticleId><ArticleId IdType="pubmed">10466154</ArticleId></ArticleIdList></Reference><Reference><Citation>Ungerleider LG, Mishkin M. Two cortical visual systems. In: Goodale MA, Mansfield RJW, editors. Analysis of visual behavior. Cambridge: MIT Press; 1982. pp. 549&#x2013;586.</Citation></Reference><Reference><Citation>Krause BJ, Schmidt D, Mottaghy FM, Taylor J, Halsband U, et al. Episodic retrieval activates the precuneus irrespective of the imagery content of word pair associates. A PET study. Brain. 1999;122:255&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">10071054</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeki S, Watson JD, Lueck CJ, Friston KJ, Kennard C, et al. A direct demonstration of functional specialization in human visual cortex. J Neurosci. 1991;11:641&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575357</ArticleId><ArticleId IdType="pubmed">2002358</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport SI. Positron emission tomography in Alzheimer's disease in relation to disease pathogenesis: A critical review. Cerebrovasc Brain Metab Rev. 1991;3:297&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">1772739</ArticleId></ArticleIdList></Reference><Reference><Citation>Rondi-Reig L, Burguiere E. Is the cerebellum ready for navigation? Prog Brain Res. 2004;148:199&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">15661192</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang CE, Bastian AJ. Cerebellar damage impairs automaticity of a recently practiced movement. J Neurophysiol. 2002;87:1336&#x2013;1347.</Citation><ArticleIdList><ArticleId IdType="pubmed">11877508</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman-Rakic PS. The prefrontal landscape: Implications of functional architecture for understanding human mentation and the central executive. Philos Trans R Soc Lond B Biol Sci. 1996;351:1445&#x2013;1453.</Citation><ArticleIdList><ArticleId IdType="pubmed">8941956</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbetta M, Miezin FM, Shulman GL, Petersen SE. A PET study of visuospatial attention. J Neurosci. 1993;13:1202&#x2013;1226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576604</ArticleId><ArticleId IdType="pubmed">8441008</ArticleId></ArticleIdList></Reference><Reference><Citation>Paus T. Location and function of the human frontal eye-field: A selective review. Neuropsychologia. 1996;34:475&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">8736560</ArticleId></ArticleIdList></Reference><Reference><Citation>Courtney SM, Petit L, Maisog JM, Ungerleider LG, Haxby JV. An area specialized for spatial working memory in human frontal cortex. Science. 1998;279:1347&#x2013;1351.</Citation><ArticleIdList><ArticleId IdType="pubmed">9478894</ArticleId></ArticleIdList></Reference><Reference><Citation>Born AP, Law I, Lund TE, Rostrup E, Hanson LG, et al. Cortical deactivation induced by visual stimulation in human slow-wave sleep. Neuroimage. 2002;17:1325&#x2013;1335.</Citation><ArticleIdList><ArticleId IdType="pubmed">12414272</ArticleId></ArticleIdList></Reference><Reference><Citation>Czisch M, Wehrle R, Kaufmann C, Wetter TC, Holsboer F, et al. Functional MRI during sleep: BOLD signal decreases and their electrophysiological correlates. Eur J Neurosci. 2004;20:566&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">15233766</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters A, Kara DA, Harriman KM. The neuronal composition of area 17 of rat visual cortex. III. Numerical considerations. J Comp Neurol. 1985;238:263&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">4044915</ArticleId></ArticleIdList></Reference><Reference><Citation>Mapstone M, Weintraub S, Nowinski C, Kaptanoglu G, Gitelman DR, et al. Cerebral hemispheric specialization for spatial attention: Spatial distribution of search-related eye fixations in the absence of neglect. Neuropsychologia. 2003;41:1396&#x2013;1409.</Citation><ArticleIdList><ArticleId IdType="pubmed">12757911</ArticleId></ArticleIdList></Reference><Reference><Citation>Zatorre RJ, Bouffard M, Ahad P, Belin P. Where is &#x2018;where' in the human auditory cortex? Nat Neurosci. 2002;5:905&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">12195426</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauschecker JP, Tian B, Hauser M. Processing of complex sounds in the macaque nonprimary auditory cortex. Science. 1995;268:111&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">7701330</ArticleId></ArticleIdList></Reference><Reference><Citation>Zatorre RJ, Bouffard M, Belin P. Sensitivity to auditory object features in human temporal neocortex. J Neurosci. 2004;24:3637&#x2013;3642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729744</ArticleId><ArticleId IdType="pubmed">15071112</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeder PP, Meuli RA, Adriani M, Bellmann A, Fornari E, et al. Distinct pathways involved in sound recognition and localization: A human fMRI study. Neuroimage. 2001;14:802&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pubmed">11554799</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian B, Reser D, Durham A, Kustov A, Rauschecker JP. Functional specialization in rhesus monkey auditory cortex. Science. 2001;292:290&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">11303104</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson VW, Mack W, Williams BW. Spatial disorientation in Alzheimer's disease. Arch Neurol. 1989;46:391&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">2705898</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzo M, Anderson SW, Dawson J, Myers R, Ball K. Visual attention impairments in Alzheimer's disease. Neurology. 2000;54:1954&#x2013;1959.</Citation><ArticleIdList><ArticleId IdType="pubmed">10822436</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavcic V, Duffy CJ. Attentional dynamics and visual perception: Mechanisms of spatial disorientation in Alzheimer's disease. Brain. 2003;126:1173&#x2013;1181.</Citation><ArticleIdList><ArticleId IdType="pubmed">12690056</ArticleId></ArticleIdList></Reference><Reference><Citation>Golob EJ, Miranda GG, Johnson JK, Starr A. Sensory cortical interactions in aging, mild cognitive impairment, and Alzheimer's disease. Neurobiol Aging. 2001;22:755&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pubmed">11705635</ArticleId></ArticleIdList></Reference><Reference><Citation>Filoteo JV, Delis DC, Massman PJ, Demadura T, Butters N, et al. Directed and divided attention in Alzheimer's disease: Impairment in shifting of attention to global and local stimuli. J Clin Exp Neuropsychol. 1992;14:871&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pubmed">1452635</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohr E, Cox C, Williams J, Chase TN, Fedio P. Impairment of central auditory function in Alzheimer's disease. J Clin Exp Neuropsychol. 1990;12:235&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">2341553</ArticleId></ArticleIdList></Reference><Reference><Citation>Parasuraman R, Greenwood PM, Haxby JV, Grady CL. Visuospatial attention in dementia of the Alzheimer type. Brain. 1992;115:711&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pubmed">1628198</ArticleId></ArticleIdList></Reference><Reference><Citation>Baddeley AD, Baddeley HA, Bucks RS, Wilcock GK. Attentional control in Alzheimer's disease. Brain. 2001;124:1492&#x2013;1508.</Citation><ArticleIdList><ArticleId IdType="pubmed">11459742</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurylo DD, Corkin S, Allard T, Zatorre RJ, Growdon JH. Auditory function in Alzheimer's disease. Neurology. 1993;43:1893&#x2013;1899.</Citation><ArticleIdList><ArticleId IdType="pubmed">8413944</ArticleId></ArticleIdList></Reference><Reference><Citation>Mapstone M, Steffenella TM, Duffy CJ. A visuospatial variant of mild cognitive impairment: Getting lost between aging and AD. Neurology. 2003;60:802&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">12629237</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnaiz E, Almkvist O. Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease. Acta Neurol Scand Suppl. 2003;179:34&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">12603249</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner AD. Early detection of Alzheimer's disease: An fMRI marker for people at risk? Nat Neurosci. 2000;3:973&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pubmed">11017166</ArticleId></ArticleIdList></Reference><Reference><Citation>Luhmann HJ, Heinemann U. Hypoxia-induced functional alterations in adult rat neocortex. J Neurophysiol. 1992;67:798&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">1316953</ArticleId></ArticleIdList></Reference><Reference><Citation>Liepert J, Bar KJ, Meske U, Weiller C. Motor cortex disinhibition in Alzheimer's disease. Clin Neurophysiol. 2001;112:1436&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pubmed">11459683</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16172374</PMID><DateCompleted><Year>2005</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>102</Volume><Issue>39</Issue><PubDate><Year>2005</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Human neural stem cells differentiate and promote locomotor recovery in spinal cord-injured mice.</ArticleTitle><Pagination><StartPage>14069</StartPage><EndPage>14074</EndPage><MedlinePgn>14069-74</MedlinePgn></Pagination><Abstract><AbstractText>We report that prospectively isolated, human CNS stem cells grown as neurospheres (hCNS-SCns) survive, migrate, and express differentiation markers for neurons and oligodendrocytes after long-term engraftment in spinal cord-injured NOD-scid mice. hCNS-SCns engraftment was associated with locomotor recovery, an observation that was abolished by selective ablation of engrafted cells by diphtheria toxin. Remyelination by hCNS-SCns was found in both the spinal cord injury NOD-scid model and myelin-deficient shiverer mice. Moreover, electron microscopic evidence consistent with synapse formation between hCNS-SCns and mouse host neurons was observed. Glial fibrillary acidic protein-positive astrocytic differentiation was rare, and hCNS-SCns did not appear to contribute to the scar. These data suggest that hCNS-SCns may possess therapeutic potential for CNS injury and disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Physical Medicine and Rehabilitation, Reeve-Irvine Research Center, University of California, Irvine, CA 92697, USA. cummings@uci.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uchida</LastName><ForeName>Nobuko</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Tamaki</LastName><ForeName>Stanley J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Salazar</LastName><ForeName>Desir&#xe9;e L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Hooshmand</LastName><ForeName>Mitra</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Summers</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Gage</LastName><ForeName>Fred H</ForeName><Initials>FH</Initials></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Aileen J</ForeName><Initials>AJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS049885</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS049885</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R43NS046975</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016688" MajorTopicYN="N">Mice, Inbred NOD</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013119" MajorTopicYN="N">Spinal Cord Injuries</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D033581" MajorTopicYN="Y">Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2005</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16172374</ArticleId><ArticleId IdType="pmc">PMC1216836</ArticleId><ArticleId IdType="doi">10.1073/pnas.0507063102</ArticleId><ArticleId IdType="pii">0507063102</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Taupin, P. &amp; Gage, F. H. (2002) J. Neurosci. Res. 69, 745-749.</Citation><ArticleIdList><ArticleId IdType="pubmed">12205667</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao, Q., Benton, R. L. &amp; Whittemore, S. R. (2002) J. Neurosci. Res. 68, 501-510.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111840</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao, Q. L., Zhang, Y. P., Howard, R. M., Walters, W. M., Tsoulfas, P. &amp; Whittemore, S. R. (2001) Exp. Neurol. 167, 48-58.</Citation><ArticleIdList><ArticleId IdType="pubmed">11161592</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, S., Suzuki, Y., Kitada, M., Kitaura, M., Kataoka, K., Takahashi, J., Ide, C. &amp; Nishimura, Y. (2001) Neurosci. Lett. 312, 173-176.</Citation><ArticleIdList><ArticleId IdType="pubmed">11602338</ArticleId></ArticleIdList></Reference><Reference><Citation>Vroemen, M., Aigner, L., Winkler, J. &amp; Weidner, N. (2003) Eur. J. Neurosci. 18, 743-751.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925000</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao, Q. L., Howard, R. M., Dennison, J. B. &amp; Whittemore, S. R. (2002) Exp. Neurol. 177, 349-359.</Citation><ArticleIdList><ArticleId IdType="pubmed">12429182</ArticleId></ArticleIdList></Reference><Reference><Citation>Wictorin, K. &amp; Bjorklund, A. (1992) NeuroReport 3, 1045-1048.</Citation><ArticleIdList><ArticleId IdType="pubmed">1493215</ArticleId></ArticleIdList></Reference><Reference><Citation>Stepanov, G. A., Karpenko, D. O., Aleksandrova, M. A., Podgornyi, O. V., Poltavtseva, R. A., Pevishchin, A. V., Marey, M. V. &amp; Sukhikh, G. T. (2003) Bull. Exp. Biol. Med. 135, 397-400.</Citation><ArticleIdList><ArticleId IdType="pubmed">12910319</ArticleId></ArticleIdList></Reference><Reference><Citation>Akesson, E., Holmberg, L., Jonhagen, M. E., Kjaeldgaard, A., Falci, S., Sundstrom, E. &amp; Seiger, A. (2001) Exp. Neurol. 170, 305-316.</Citation><ArticleIdList><ArticleId IdType="pubmed">11476597</ArticleId></ArticleIdList></Reference><Reference><Citation>Saporta, S., Kim, J. J., Willing, A. E., Fu, E. S., Davis, C. D. &amp; Sanberg, P. R. (2003) J. Hematother. Stem Cell Res. 12, 271-278.</Citation><ArticleIdList><ArticleId IdType="pubmed">12857368</ArticleId></ArticleIdList></Reference><Reference><Citation>Saporta, S., Makoui, A. S., Willing, A. E., Daadi, M., Cahill, D. W. &amp; Sanberg, P. R. (2002) J. Neurosurg. 97, 63-68.</Citation><ArticleIdList><ArticleId IdType="pubmed">12120653</ArticleId></ArticleIdList></Reference><Reference><Citation>Keirstead, H. S., Nistor, G., Bernal, G., Totoiu, M., Cloutier, F., Sharp, K. &amp; Steward, O. (2005) J. Neurosci. 25, 4694-4705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724772</ArticleId><ArticleId IdType="pubmed">15888645</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwanami, A., Kaneko, S., Nakamura, M., Kanemura, Y., Mori, H., Kobayashi, S., Yamasaki, M., Momoshima, S., Ishii, H., Ando, K., et al. (2005) J. Neurosci. Res. 80, 182-190.</Citation><ArticleIdList><ArticleId IdType="pubmed">15772979</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamaki, S., Eckert, K., He, D., Sutton, R., Doshe, M., Jain, G., Tushinski, R., Reitsma, M., Harris, B., Tsukamoto, A., et al. (2002) J. Neurosci. Res. 69, 976-986.</Citation><ArticleIdList><ArticleId IdType="pubmed">12205691</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida, N., Buck, D. W., He, D., Reitsma, M. J., Masek, M., Phan, T. V., Tsukamoto, A. S., Gage, F. H. &amp; Weissman, I. L. (2000) Proc. Natl. Acad. Sci. USA 97, 14720-14725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18985</ArticleId><ArticleId IdType="pubmed">11121071</ArticleId></ArticleIdList></Reference><Reference><Citation>Basso, D. M., Beattie, M. S. &amp; Bresnahan, J. C. (1995) J. Neurotrauma 12, 1-21.</Citation><ArticleIdList><ArticleId IdType="pubmed">7783230</ArticleId></ArticleIdList></Reference><Reference><Citation>Dergham, P., Ellezam, B., Essagian, C., Avedissian, H., Lubell, W. D. &amp; McKerracher, L. (2002) J. Neurosci. 22, 6570-6577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758168</ArticleId><ArticleId IdType="pubmed">12151536</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson, A. J., Cummings, B. J. &amp; Cotman, C. W. (1994) Exp. Neurol. 125, 286-295.</Citation><ArticleIdList><ArticleId IdType="pubmed">8313943</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappenheimer, A. M., Jr., Harper, A. A., Moynihan, M. &amp; Brockes, J. P. (1982) J. Infect. Dis. 145, 94-102.</Citation><ArticleIdList><ArticleId IdType="pubmed">6798133</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito, M., Iwawaki, T., Taya, C., Yonekawa, H., Noda, M., Inui, Y., Mekada, E., Kimata, Y., Tsuru, A. &amp; Kohno, K. (2001) Nat. Biotechnol. 19, 746-750.</Citation><ArticleIdList><ArticleId IdType="pubmed">11479567</ArticleId></ArticleIdList></Reference><Reference><Citation>Drago, J., Padungchaichot, P., Wong, J. Y., Lawrence, A. J., McManus, J. F., Sumarsono, S. H., Natoli, A. L., Lakso, M., Wreford, N., Westphal, H., et al. (1998) J. Neurosci. 18, 9845-9857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793326</ArticleId><ArticleId IdType="pubmed">9822743</ArticleId></ArticleIdList></Reference><Reference><Citation>Cailhier, J. F., Partolina, M., Vuthoori, S., Wu, S., Ko, K., Watson, S., Savill, J., Hughes, J. &amp; Lang, R. A. (2005) J. Immunol. 174, 2336-2342.</Citation><ArticleIdList><ArticleId IdType="pubmed">15699170</ArticleId></ArticleIdList></Reference><Reference><Citation>Privat, A., Jacque, C., Bourre, J. M., Dupouey, P. &amp; Baumann, N. (1979) Neurosci. Lett. 12, 107-112.</Citation><ArticleIdList><ArticleId IdType="pubmed">460693</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue, Y., Inoue, K., Terashima, T., Mikoshiba, K. &amp; Tsukada, Y. (1983) Anat. Embryol. 168, 159-171.</Citation><ArticleIdList><ArticleId IdType="pubmed">6660560</ArticleId></ArticleIdList></Reference><Reference><Citation>Pluchino, S., Quattrini, A., Brambilla, E., Gritti, A., Salani, G., Dina, G., Galli, R., Del Carro, U., Amadio, S., Bergami, A., et al. (2003) Nature 422, 688-694.</Citation><ArticleIdList><ArticleId IdType="pubmed">12700753</ArticleId></ArticleIdList></Reference><Reference><Citation>Keirstead, H. S., Ben-Hur, T., Rogister, B., O'Leary, M. T., Dubois-Dalcq, M. &amp; Blakemore, W. F. (1999) J. Neurosci. 19, 7529-7536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782511</ArticleId><ArticleId IdType="pubmed">10460259</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, S., Qu, Y., Stewart, T. J., Howard, M. J., Chakrabortty, S., Holekamp, T. F. &amp; McDonald, J. W. (2000) Proc. Natl. Acad. Sci. USA 97, 6126-6131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18569</ArticleId><ArticleId IdType="pubmed">10823956</ArticleId></ArticleIdList></Reference><Reference><Citation>Nistor, G. I., Totoiu, M. O., Haque, N., Carpenter, M. K. &amp; Keirstead, H. S. (2004) Glia 49, 385-396.</Citation><ArticleIdList><ArticleId IdType="pubmed">15538751</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama, Y., Radtke, C. &amp; Kocsis, J. D. (2002) J. Neurosci. 22, 6623-6630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605374</ArticleId><ArticleId IdType="pubmed">12151541</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki, M., Honmou, O., Akiyama, Y., Uede, T., Hashi, K. &amp; Kocsis, J. D. (2001) Glia 35, 26-34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605363</ArticleId><ArticleId IdType="pubmed">11424189</ArticleId></ArticleIdList></Reference><Reference><Citation>Harkany, T., Andang, M., Kingma, H. J., Gorcs, T. J., Holmgren, C. D., Zilberter, Y. &amp; Ernfors, P. (2004) J. Neurochem. 88, 1229-1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">15009679</ArticleId></ArticleIdList></Reference><Reference><Citation>Wernig, M., Benninger, F., Schmandt, T., Rade, M., Tucker, K. L., Bussow, H., Beck, H. &amp; Brustle, O. (2004) J. Neurosci. 24, 5258-5268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729190</ArticleId><ArticleId IdType="pubmed">15175396</ArticleId></ArticleIdList></Reference><Reference><Citation>Auerbach, J. M., Eiden, M. V. &amp; McKay, R. D. (2000) Eur. J. Neurosci. 12, 1696-1704.</Citation><ArticleIdList><ArticleId IdType="pubmed">10792447</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder, E. Y., Yoon, C., Flax, J. D. &amp; Macklis, J. D. (1997) Proc. Natl. Acad. Sci. USA 94, 11663-11668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23575</ArticleId><ArticleId IdType="pubmed">9326667</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishibashi, S., Sakaguchi, M., Kuroiwa, T., Yamasaki, M., Kanemura, Y., Shizuko, I., Shimazaki, T., Onodera, M., Okano, H. &amp; Mizusawa, H. (2004) J. Neurosci. Res. 78, 215-223.</Citation><ArticleIdList><ArticleId IdType="pubmed">15378509</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson, L. C., Frielingsdorf, H., Mirza, B., Hansson, S. J., Anderson, P., Czech, K. A., Strandberg, M. &amp; Widner, H. (2001) Exp. Neurol. 172, 100-114.</Citation><ArticleIdList><ArticleId IdType="pubmed">11681844</ArticleId></ArticleIdList></Reference><Reference><Citation>Greiner, D. L., Hesselton, R. A. &amp; Shultz, L. D. (1998) Stem Cells 16, 166-177.</Citation><ArticleIdList><ArticleId IdType="pubmed">9617892</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly, S., Bliss, T. M., Shah, A. K., Sun, G. H., Ma, M., Foo, W. C., Masel, J., Yenari, M. A., Weissman, I. L., Uchida, N., et al. (2004) Proc. Natl. Acad. Sci. USA 101, 11839-11844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC511061</ArticleId><ArticleId IdType="pubmed">15280535</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji, J. F., He, B. P., Dheen, S. T. &amp; Tay, S. S. (2004) Neurosci. Lett. 355, 236-240.</Citation><ArticleIdList><ArticleId IdType="pubmed">14732474</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16177050</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>38</Issue><PubDate><Year>2005</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice.</ArticleTitle><Pagination><StartPage>8807</StartPage><EndPage>8814</EndPage><MedlinePgn>8807-14</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) is a progressive neurodegenerative disorder pathologically characterized by deposition of beta-amyloid (Abeta) peptides as senile plaques in the brain. Recent studies suggest that green tea flavonoids may be used for the prevention and treatment of a variety of neurodegenerative diseases. Here, we report that (-)-epigallocatechin-3-gallate (EGCG), the main polyphenolic constituent of green tea, reduces Abeta generation in both murine neuron-like cells (N2a) transfected with the human "Swedish" mutant amyloid precursor protein (APP) and in primary neurons derived from Swedish mutant APP-overexpressing mice (Tg APPsw line 2576). In concert with these observations, we find that EGCG markedly promotes cleavage of the alpha-C-terminal fragment of APP and elevates the N-terminal APP cleavage product, soluble APP-alpha. These cleavage events are associated with elevated alpha-secretase activity and enhanced hydrolysis of tumor necrosis factor alpha-converting enzyme, a primary candidate alpha-secretase. As a validation of these findings in vivo, we treated Tg APPsw transgenic mice overproducing Abeta with EGCG and found decreased Abeta levels and plaques associated with promotion of the nonamyloidogenic alpha-secretase proteolytic pathway. These data raise the possibility that EGCG dietary supplementation may provide effective prophylaxis for AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rezai-Zadeh</LastName><ForeName>Kavon</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Silver Child Development Center, Department of Psychiatry and Behavioral Medicine, University of South Florida, Tampa, Florida 33613, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shytle</LastName><ForeName>Doug</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Nan</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Takashi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Huayan</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Jeanniton</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Ehrhart</LastName><ForeName>Jared</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Townsend</LastName><ForeName>Kirk</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Jin</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Town</LastName><ForeName>Terrence</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013662">Tea</NameOfSubstance></Chemical><Chemical><RegistryNumber>8R1V1STN48</RegistryNumber><NameOfSubstance UI="D002392">Catechin</NameOfSubstance></Chemical><Chemical><RegistryNumber>BQM438CTEL</RegistryNumber><NameOfSubstance UI="C045651">epigallocatechin gallate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002392" MajorTopicYN="N">Catechin</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005419" MajorTopicYN="N">Flavonoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013662" MajorTopicYN="Y">Tea</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>3</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16177050</ArticleId><ArticleId IdType="pmc">PMC6725500</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1521-05.2005</ArticleId><ArticleId IdType="pii">25/38/8807</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abbenante G, Kovacs DM, Leung DL, Craik DJ, Tanzi RE, Fairlie DP (2000) Inhibitors of beta-amyloid formation based on the beta-secretase cleavage site. Biochem Biophys Res Commun 268: 133&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">10652226</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed S, Rahman A, Hasnain A, Lalonde M, Goldberg VM, Haqqi TM (2002) Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1 beta-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. Free Radic Bio Med 33: 1097&#x2013;1105.</Citation><ArticleIdList><ArticleId IdType="pubmed">12374621</ArticleId></ArticleIdList></Reference><Reference><Citation>Aktas O, Prozorovski T, Smorodchenko A, Savaskan NE, Lauster R, Kloetzel PM, Infante-Duarte C, Brocke S, Zipp F (2004) Green tea epigallocatechin-3-gallate mediates T cellular NF-kappaB inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol 173: 5794&#x2013;5800.</Citation><ArticleIdList><ArticleId IdType="pubmed">15494532</ArticleId></ArticleIdList></Reference><Reference><Citation>Allinson TM, Parkin ET, Turner AJ, Hooper NM (2003) ADAMs family members as amyloid precursor protein alpha-secretases. J Neurosci Res 74: 342&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">14598310</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan NB, Siegel GJ (2003) Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576. J Neurosci Res 74: 142&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">13130516</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, Brooks CA, Dorr RT, Hara Y, Alberts DS (2003) Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 9: 3312&#x2013;3319.</Citation><ArticleIdList><ArticleId IdType="pubmed">12960117</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung FL, Schwartz J, Herzog CR, Yang YM (2003) Tea and cancer prevention: studies in animals and humans. J Nutr 133: 3268S&#x2013;3274S.</Citation><ArticleIdList><ArticleId IdType="pubmed">14519825</ArticleId></ArticleIdList></Reference><Reference><Citation>Chyu KY, Babbidge SM, Zhao X, Dandillaya R, Rietveld AG, Yano J, Dimayuga P, Cercek B, Shah PK (2004) Differential effects of green tea-derived catechin on developing versus established atherosclerosis in apolipoprotein E-null mice. Circulation 109: 2448&#x2013;2453.</Citation><ArticleIdList><ArticleId IdType="pubmed">15136500</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391: 387&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>Funamoto S, Morishima-Kawashima M, Tanimura Y, Hirotani N, Saido TC, Ihara Y (2004) Truncated carboxyl-terminal fragments of beta-amyloid precursor protein are processed to amyloid beta-proteins 40 and 42. Biochemistry 43: 13532&#x2013;13540.</Citation><ArticleIdList><ArticleId IdType="pubmed">15491160</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi S, Refolo LM, Sambamurti K (2004) Amyloid precursor protein compartmentalization restricts beta-amyloid production: therapeutic targets based on BACE compartmentalization. J Mol Neurosci 24: 137&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">15314262</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Eckman CB, Younkin SG (2000) Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim Biophys Acta 1502: 172&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">10899442</ArticleId></ArticleIdList></Reference><Reference><Citation>Han MK (2003) Epigallocatechin gallate, a constituent of green tea, suppresses cytokine-induced pancreatic beta-cell damage. Exp Mol Med 35: 136&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">12754418</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper NM, Turner AJ (2002) The search for alpha-secretase and its potential as a therapeutic approach to Alzheimer's disease. Curr Med Chem 9: 1107&#x2013;1119.</Citation><ArticleIdList><ArticleId IdType="pubmed">12052175</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Huse JT, Doms RW (2000) Closing in on the amyloid cascade: recent insights into the cell biology of Alzheimer's disease. Mol Neurobiol 22: 81&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">11414282</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon SY, Bae K, Seong YH, Song KS (2003) Green tea catechins as a BACE1 (beta-secretase) inhibitor. Bioorg Med Chem Lett 13: 3905&#x2013;3908.</Citation><ArticleIdList><ArticleId IdType="pubmed">14592472</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L (1997) Amyloid precursor protein processing and Abeta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA 94: 1550&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>Levites Y, Amit T, Youdim MB, Mandel S (2002) Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (-)-epigallocatechin 3-gallate neuroprotective action. J Biol Chem 277: 30574&#x2013;30580.</Citation><ArticleIdList><ArticleId IdType="pubmed">12058035</ArticleId></ArticleIdList></Reference><Reference><Citation>Levites Y, Amit T, Mandel S, Youdim MB (2003) Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. FASEB J 17: 952&#x2013;954.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670874</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Huang YG, Fang D, Le WD (2004) (-)-Epigallocatechin gallate inhibits lipopolysaccharide-induced microglial activation and protects against inflammation-mediated dopaminergic neuronal injury. J Neurosci Res 78: 723&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">15478178</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JK, Liang YC (2000) Cancer chemoprevention by tea polyphenols. Proc Natl Sci Counc Repub China 1: 1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">10786933</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandel S, Weinreb O, Amit T, Youdim MB (2004) Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3-gallate: implications for neurodegenerative diseases. J Neurochem 88: 1555&#x2013;1569.</Citation><ArticleIdList><ArticleId IdType="pubmed">15009657</ArticleId></ArticleIdList></Reference><Reference><Citation>Moro MA, Hurtado O, Cardenas A, Romera C, Madrigal JL, Fernandez-Tome P, Leza JC, Lorenzo P, Lizasoain I (2003) Expression and function of tumour necrosis factor-alpha-converting enzyme in the central nervous system. Neurosignals 12: 53&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">12876399</ArticleId></ArticleIdList></Reference><Reference><Citation>Moyers SB, Kumar NB (2004) Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. Nutr Rev 62: 204&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">15212320</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert S, Maillet M, Morel E, Launay JM, Fischmeister R, Mercken L, Lezoualc'h F (2005) Regulation of the amyloid precursor protein ectodomain shedding by the 5-HT4 receptor and Epac. FEBS Lett 579: 1136&#x2013;1142.</Citation><ArticleIdList><ArticleId IdType="pubmed">15710402</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossner S, Beck M, Stahl T, Mendla K, Schliebs R, Bigl V (2000) Constitutive overactivation of protein kinase C in guinea pig brain increases alpha-secretory APP processing without decreasing beta-amyloid generation. Eur J Neurosci 12: 3191&#x2013;3200.</Citation><ArticleIdList><ArticleId IdType="pubmed">10998103</ArticleId></ArticleIdList></Reference><Reference><Citation>Sambamurti K, Greig NH, Lahiri DK (2002) Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromolecular Med 1: 1&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">12025813</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, Lieberburg I (1999) Cellular mechanisms of beta-amyloid production and secretion. Proc Natl Acad Sci USA 96: 11049&#x2013;11053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34239</ArticleId><ArticleId IdType="pubmed">10500121</ArticleId></ArticleIdList></Reference><Reference><Citation>Skovronsky DM, Fath S, Lee VM, Milla ME (2001) Neuronal localization of the TNFalpha converting enzyme (TACE) in brain tissue and its correlation to amyloid plaques. J Neurobiol 49: 40&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">11536196</ArticleId></ArticleIdList></Reference><Reference><Citation>Slack BE, Ma LK, Seah CC (2001) Constitutive shedding of the amyloid precursor protein ectodomain is up-regulated by tumour necrosis factor-alpha converting enzyme. Biochem J 357: 787&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1222008</ArticleId><ArticleId IdType="pubmed">11463349</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Duff K, Capell A, Romig H, Grim MG, Lincoln S, Hardy J, Yu X, Picciano M, Fechteler K, Citron M, Kopan R, Pesold B, Keck S, Baader M, Tomita T, Iwatsubo T, Baumeister R, Haass C (1999) A loss of function mutation of presenilin-2 interferes with amyloid beta-peptide production and notch signaling. J Biol Chem 274: 28669&#x2013;28673.</Citation><ArticleIdList><ArticleId IdType="pubmed">10497236</ArticleId></ArticleIdList></Reference><Reference><Citation>Suganuma M, Sueoka E, Sueoka N, Okabe S, Fujiki H (2000) Mechanisms of cancer prevention by tea polyphenols based on inhibition of TNF-alpha expression. Biofactors 13: 67&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">11237202</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J, Town T, Crawford F, Mori T, DelleDonne A, Crescentini R, Obregon D, Flavell RA, Mullan MJ (2002) Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat Neurosci 5: 1288&#x2013;1293.</Citation><ArticleIdList><ArticleId IdType="pubmed">12402041</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullmann U, Haller J, Decourt JP, Girault N, Girault J, Richard-Caudron AS, Pineau B, Weber P (2003) A single ascending dose study of epigallocatechin gallate in healthy volunteers. J Int Med Res 31: 88&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">12760312</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, Carter DB, Tomasselli AG, Parodi LA, Heinrikson RL, Gurney ME (1999) Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402: 533&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591213</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16192374</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>39</Issue><PubDate><Year>2005</Year><Month>Sep</Month><Day>28</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>8843</StartPage><EndPage>8853</EndPage><MedlinePgn>8843-53</MedlinePgn></Pagination><Abstract><AbstractText>Inflammation is a critical component of the pathogenesis of Alzheimer's disease (AD). Although not an initiator of this disorder, inflammation nonetheless plays a pivotal role as a driving force that can modulate the neuropathology. Here, we characterized the time course of microglia activation in the brains of a transgenic model of AD (3xTg-AD) and discerned its relationship to the plaque and tangle pathology. We find that microglia became activated in a progressive and age-dependent manner, and this activation correlated with the onset of fibrillar amyloidbeta-peptide plaque accumulation and tau hyperphosphorylation. To determine whether microglial activation can exacerbate the pathology, we exposed young 3xTg-AD mice to lipopolysaccharide (LPS), a known inducer of CNS inflammation. Although amyloid precursor protein processing appeared unaffected, we find that LPS significantly induced tau hyperphosphorylation at specific sites that were mediated by the activation of cyclin-dependent kinase 5 (cdk5) through increased formation of the p25 fragment. We further show that administration of roscovitine, a selective and potent inhibitor of cdk5, markedly blocked the LPS-induced tau phosphorylation in the hippocampus. Therefore, this study clearly demonstrates that microglial activation exacerbates key neuropathological features such as tangle formation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kitazawa</LastName><ForeName>Masashi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California-Irvine, California 92697-4545, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oddo</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Yamasaki</LastName><ForeName>Tritia R</ForeName><Initials>TR</Initials></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Kim N</ForeName><Initials>KN</Initials></Author><Author ValidYN="Y"><LastName>LaFerla</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG017968</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG0212982</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG17968</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0ES1C2KQ94</RegistryNumber><NameOfSubstance UI="D000077546">Roscovitine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051360">Cyclin-Dependent Kinase 5</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051360" MajorTopicYN="N">Cyclin-Dependent Kinase 5</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004660" MajorTopicYN="N">Encephalitis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008070" MajorTopicYN="Y">Lipopolysaccharides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077546" MajorTopicYN="N">Roscovitine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>3</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16192374</ArticleId><ArticleId IdType="pmc">PMC6725603</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2868-05.2005</ArticleId><ArticleId IdType="pii">25/39/8843</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahlijanian MK, Barrezueta NX, Williams RD, Jakowski A, Kowsz KP, McCarthy S, Coskran T, Carlo A, Seymour PA, Burkhardt JE, Nelson RB, McNeish JD (2000) Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci USA 97: 2910&#x2013;2915.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16029</ArticleId><ArticleId IdType="pubmed">10706614</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, et al. (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez A, Toro R, Caceres A, Maccioni RB (1999) Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death. FEBS Lett 459: 421&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">10526177</ArticleId></ArticleIdList></Reference><Reference><Citation>Anthony JC, Breitner JC, Zandi PP, Meyer MR, Jurasova I, Norton MC, Stone SV (2000) Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology 54: 2066&#x2013;2071.</Citation><ArticleIdList><ArticleId IdType="pubmed">10851364</ArticleId></ArticleIdList></Reference><Reference><Citation>Apelt J, Schliebs R (2001) Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res 894: 21&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">11245811</ArticleId></ArticleIdList></Reference><Reference><Citation>Atzori C, Ghetti B, Piva R, Srinivasan AN, Zolo P, Delisle MB, Mirra SS, Migheli A (2001) Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J Neuropathol Exp Neurol 60: 1190&#x2013;1197.</Citation><ArticleIdList><ArticleId IdType="pubmed">11764091</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustinack JC, Sanders JL, Tsai LH, Hyman BT (2002) Colocalization and fluorescence resonance energy transfer between cdk5 and AT8 suggests a close association in pre-neurofibrillary tangles and neurofibrillary tangles. J Neuropathol Exp Neurol 61: 557&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">12071639</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, et al. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6: 916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, et al. (2003) Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 100: 2023&#x2013;2028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC149952</ArticleId><ArticleId IdType="pubmed">12566568</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumann K, Mandelkow EM, Biernat J, Piwnica-Worms H, Mandelkow E (1993) Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett 336: 417&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">8282104</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellucci A, Westwood AJ, Ingram E, Casamenti F, Goedert M, Spillantini MG (2004) Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. Am J Pathol 165: 1643&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618683</ArticleId><ArticleId IdType="pubmed">15509534</ArticleId></ArticleIdList></Reference><Reference><Citation>Broe GA, Grayson DA, Creasey HM, Waite LM, Casey BJ, Bennett HP, Brooks WS, Halliday GM (2000) Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol 57: 1586&#x2013;1591.</Citation><ArticleIdList><ArticleId IdType="pubmed">11074790</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen P, Frame S (2001) The renaissance of GSK3. Nat Rev Mol Cell Biol 2: 769&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584304</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH (2003) Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40: 471&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">14642273</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 27: 457&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Lee SC, Mattiace LA, Yen SH, Brosnan C (1993) Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 7: 75&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">8423065</ArticleId></ArticleIdList></Reference><Reference><Citation>Dringenberg HC (2000) Alzheimer's disease: more than a &#x201c;cholinergic disorder&#x201d;&#x2014;evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia. Behav Brain Res 115: 235&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">11000423</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans DB, Rank KB, Bhattacharya K, Thomsen DR, Gurney ME, Sharma SK (2000) Tau phosphorylation at serine 396 and serine 404 by human recombinant tau protein kinase II inhibits tau's ability to promote microtubule assembly. J Biol Chem 275: 24977&#x2013;24983.</Citation><ArticleIdList><ArticleId IdType="pubmed">10818091</ArticleId></ArticleIdList></Reference><Reference><Citation>Frautschy SA, Cole GM, Baird A (1992) Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid. Am J Pathol 140: 1389&#x2013;1399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886549</ArticleId><ArticleId IdType="pubmed">1376558</ArticleId></ArticleIdList></Reference><Reference><Citation>Frautschy SA, Yang F, Irrizarry M, Hyman B, Saido TC, Hsiao K, Cole GM (1998) Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 152: 307&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858113</ArticleId><ArticleId IdType="pubmed">9422548</ArticleId></ArticleIdList></Reference><Reference><Citation>Funato H, Yoshimura M, Yamazaki T, Saido TC, Ito Y, Yokofujita J, Okeda R, Ihara Y (1998) Astrocytes containing amyloid beta-protein (Abeta)-positive granules are associated with Abeta40-positive diffuse plaques in the aged human brain. Am J Pathol 152: 983&#x2013;992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858251</ArticleId><ArticleId IdType="pubmed">9546359</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannini MG, Scali C, Prosperi C, Bellucci A, Vannucchi MG, Rosi S, Pepeu G, Casamenti F (2002) Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol Dis 11: 257&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">12505419</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor K, Melachrino J, O'Callaghan JP, Morgan D (2002) Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol 173: 183&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">11822882</ArticleId></ArticleIdList></Reference><Reference><Citation>Grammas P, Ovase R (2002) Cerebrovascular transforming growth factor-beta contributes to inflammation in the Alzheimer's disease brain. Am J Pathol 160: 1583&#x2013;1587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850858</ArticleId><ArticleId IdType="pubmed">12000710</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White III CL, Araoz C (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 86: 7611&#x2013;7615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC298116</ArticleId><ArticleId IdType="pubmed">2529544</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WS, Sheng JG, Gentleman SM, Graham DI, Mrak RE, Roberts GW (1994) Microglial interleukin-1 alpha expression in human head injury: correlations with neuronal and neuritic beta-amyloid precursor protein expression. Neurosci Lett 176: 133&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833643</ArticleId><ArticleId IdType="pubmed">7830934</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WS, Sheng JG, Roberts GW, Mrak RE (1995) Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J Neuropathol Exp Neurol 54: 276&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">7876895</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetier E, Ayala J, Denefle P, Bousseau A, Rouget P, Mallat M, Prochiantz A (1988) Brain macrophages synthesize interleukin-1 and interleukin-1 mRNAs in vitro. J Neurosci Res 21: 391&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">3265161</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmlund L, Cortes Toro V, Iverfeldt K (2002) Additive effects of amyloid beta fragment and interleukin-1beta on interleukin-6 secretion in rat primary glial cultures. Int J Mol Med 10: 245&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">12165795</ArticleId></ArticleIdList></Reference><Reference><Citation>Huell M, Strauss S, Volk B, Berger M, Bauer J (1995) Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients. Acta Neuropathol (Berl) 89: 544&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">7676810</ArticleId></ArticleIdList></Reference><Reference><Citation>Humbert S, Dhavan R, Tsai L (2000) p39 activates cdk5 in neurons, and is associated with the actin cytoskeleton. J Cell Sci 113: 975&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pubmed">10683146</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiguro K, Omori A, Sato K, Tomizawa K, Imahori K, Uchida T (1991) A serine/threonine proline kinase activity is included in the tau protein kinase fraction forming a paired helical filament epitope. Neurosci Lett 128: 195&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1658692</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Tsai LH (2003) Cdk5: one of the links between senile plaques and neurofibrillary tangles? J Alzheimers Dis 5: 127&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">12719630</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH (2000) Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405: 360&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">10830966</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Liu L, Barger SW, Griffin WS (2003) Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38&#x2013;MAPK pathway. J Neurosci 23: 1605&#x2013;1611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833596</ArticleId><ArticleId IdType="pubmed">12629164</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, Cole GM (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20: 5709&#x2013;5714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772529</ArticleId><ArticleId IdType="pubmed">10908610</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu SJ, Zhang AH, Li HL, Wang Q, Deng HM, Netzer WJ, Xu H, Wang JZ (2003) Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J Neurochem 87: 1333&#x2013;1344.</Citation><ArticleIdList><ArticleId IdType="pubmed">14713290</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund ET, McKenna R, Evans DB, Sharma SK, Mathews WR (2001) Characterization of the in vitro phosphorylation of human tau by tau protein kinase II (cdk5/p20) using mass spectrometry. J Neurochem 76: 1221&#x2013;1232.</Citation><ArticleIdList><ArticleId IdType="pubmed">11181841</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch AM, Walsh C, Delaney A, Nolan Y, Campbell VA, Lynch MA (2004) Lipopolysaccharide-induced increase in signalling in hippocampus is abrogated by IL-10&#x2014;a role for IL-1 beta? J Neurochem 88: 635&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pubmed">14720213</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka Y, Picciano M, Malester B, LaFrancois J, Zehr C, Daeschner JM, Olschowka JA, Fonseca MI, O'Banion MK, Tenner AJ, Lemere CA, Duff K (2001) Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am J Pathol 158: 1345&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1891893</ArticleId><ArticleId IdType="pubmed">11290552</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Itagaki S, McGeer EG (1988) Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol (Berl) 76: 550&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">2974227</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrak RE, Griffin WS (2001) Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol Aging 22: 903&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pubmed">11754997</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J, Gaynor K, LaFrancois J, Wang L, Kondo T, Davies P, Burns M, Veeranna, Nixon R, Dickson D, Matsuoka Y, Ahlijanian M, Lau LF, Duff K (2003) Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38: 555&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pubmed">12765608</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39: 409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick GN, Zhou P, Kwon YT, Howley PM, Tsai LH (1998) p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway. J Biol Chem 273: 24057&#x2013;24064.</Citation><ArticleIdList><ArticleId IdType="pubmed">9727024</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402: 615&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">10604467</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei JJ, Grundke-Iqbal I, Iqbal K, Bogdanovic N, Winblad B, Cowburn RF (1998) Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res 797: 267&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">9666145</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlmutter LS, Barron E, Chui HC (1990) Morphologic association between microglia and senile plaque amyloid in Alzheimer's disease. Neurosci Lett 119: 32&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">2097581</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki A, Shoji M, Harigaya Y, Kawarabayashi T, Ikeda M, Naito M, Matsubara E, Abe K, Nakazato Y (2002) Amyloid cored plaques in Tg2576 transgenic mice are characterized by giant plaques, slightly activated microglia, and the lack of paired helical filament-typed, dystrophic neurites. Virchows Arch 441: 358&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">12404061</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage MJ, Lin YG, Ciallella JR, Flood DG, Scott RW (2002) Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J Neurosci 22: 3376&#x2013;3385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758401</ArticleId><ArticleId IdType="pubmed">11978814</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelton SB, Krishnamurthy P, Johnson GV (2004) Effects of cyclin-dependent kinase-5 activity on apoptosis and tau phosphorylation in immortalized mouse brain cortical cells. J Neurosci Res 76: 110&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">15048935</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Jones RA, Zhou XQ, McGinness JM, Van Eldik LJ, Mrak RE, Griffin WS (2001) Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation. Neurochem Int 39: 341&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833633</ArticleId><ArticleId IdType="pubmed">11578769</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Bora SH, Xu G, Borchelt DR, Price DL, Koliatsos VE (2003) Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol Dis 14: 133&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678674</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalder M, Phinney A, Probst A, Sommer B, Staufenbiel M, Jucker M (1999) Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol 154: 1673&#x2013;1684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866618</ArticleId><ArticleId IdType="pubmed">10362792</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart WF, Kawas C, Corrada M, Metter EJ (1997) Risk of Alzheimer's disease and duration of NSAID use. Neurology 48: 626&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">9065537</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W, Qureshi HY, Cafferty PW, Sobue K, Agarwal-Mawal A, Neufield KD, Paudel HK (2002) Glycogen synthase kinase-3beta is complexed with tau protein in brain microtubules. J Biol Chem 277: 11933&#x2013;11940.</Citation><ArticleIdList><ArticleId IdType="pubmed">11812770</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanda N, Ohyama H, Yamakawa M, Ericsson M, Tsuji T, McBride J, Elovic A, Wong DT, Login GR (1998) IL-1 beta and IL-6 in mouse parotid acinar cells: characterization of synthesis, storage, and release. Am J Physiol 274: G147&#x2013;G156.</Citation><ArticleIdList><ArticleId IdType="pubmed">9458784</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai LH, Delalle I, Caviness Jr VS, Chae T, Harlow E (1994) p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371: 419&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">8090221</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414: 212&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">11700559</ArticleId></ArticleIdList></Reference><Reference><Citation>Weldon DT, Rogers SD, Ghilardi JR, Finke MP, Cleary JP, O'Hare E, Esler WP, Maggio JE, Mantyh PW (1998) Fibrillar &#x3b2;-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo J Neurosci 18: 2161&#x2013;2173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792921</ArticleId><ArticleId IdType="pubmed">9482801</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Li J, Chakrabarty P, Bu B, Vincent I (2004) Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick type C mice. Am J Pathol 165: 843&#x2013;853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618588</ArticleId><ArticleId IdType="pubmed">15331409</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Su Y, Li B, Liu F, Ryder JW, Wu X, Gonzalez-DeWhitt PA, Gelfanova V, Hale JE, May PC, Paul SM, Ni B (2003) Nonsteroidal antiinflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 302: 1215&#x2013;1217.</Citation><ArticleIdList><ArticleId IdType="pubmed">14615541</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16207707</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>280</Volume><Issue>52</Issue><PubDate><Year>2005</Year><Month>Dec</Month><Day>30</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease.</ArticleTitle><Pagination><StartPage>43243</StartPage><EndPage>43256</EndPage><MedlinePgn>43243-56</MedlinePgn></Pagination><Abstract><AbstractText>ABCA1, a cholesterol transporter expressed in the brain, has been shown recently to be required to maintain normal apoE levels and lipidation in the central nervous system. In addition, ABCA1 has been reported to modulate beta-amyloid (Abeta) production in vitro. These observations raise the possibility that ABCA1 may play a role in the pathogenesis of Alzheimer disease. Here we report that the deficiency of ABCA1 does not affect soluble or guanidine-extractable Abeta levels in Tg-SwDI/B or amyloid precursor protein/presenilin 1 (APP/PS1) mice, but rather is associated with a dramatic reduction in soluble apoE levels in brain. Although this reduction in apoE was expected to reduce the amyloid burden in vivo, we observed that the parenchymal and vascular amyloid load was increased in Tg-SwDI/B animals and was not diminished in APP/PS1 mice. Furthermore, we observed an increase in the proportion of apoE retained in the insoluble fraction, particularly in the APP/PS1 model. These data suggested that ABCA1-mediated effects on apoE levels and lipidation influenced amyloidogenesis in vivo.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hirsch-Reinshagen</LastName><ForeName>Veronica</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V4Z 5H5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maia</LastName><ForeName>Luis F</ForeName><Initials>LF</Initials></Author><Author ValidYN="Y"><LastName>Burgess</LastName><ForeName>Braydon L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Blain</LastName><ForeName>Jean-Francois</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Naus</LastName><ForeName>Kathryn E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>McIsaac</LastName><ForeName>Sean A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Parkinson</LastName><ForeName>Pamela F</ForeName><Initials>PF</Initials></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Jennifer Y</ForeName><Initials>JY</Initials></Author><Author ValidYN="Y"><LastName>Tansley</LastName><ForeName>Gavin H</ForeName><Initials>GH</Initials></Author><Author ValidYN="Y"><LastName>Hayden</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Poirier</LastName><ForeName>Judes</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Van Nostrand</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Wellington</LastName><ForeName>Cheryl L</ForeName><Initials>CL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS36645</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577836">ABCA1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064286">ATP Binding Cassette Transporter 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018528">ATP-Binding Cassette Transporters</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical><Chemical><RegistryNumber>JU58VJ6Y3B</RegistryNumber><NameOfSubstance UI="D019791">Guanidine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D064286" MajorTopicYN="N">ATP Binding Cassette Transporter 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018528" MajorTopicYN="N">ATP-Binding Cassette Transporters</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003720" MajorTopicYN="N">Densitometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019791" MajorTopicYN="N">Guanidine</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019076" MajorTopicYN="N">Transgenes</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16207707</ArticleId><ArticleId IdType="doi">10.1074/jbc.M508781200</ArticleId><ArticleId IdType="pii">S0021-9258(19)47938-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16207708</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>280</Volume><Issue>52</Issue><PubDate><Year>2005</Year><Month>Dec</Month><Day>30</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease.</ArticleTitle><Pagination><StartPage>43236</StartPage><EndPage>43242</EndPage><MedlinePgn>43236-42</MedlinePgn></Pagination><Abstract><AbstractText>Apolipoprotein E (apoE) genotype has a major influence on the risk for Alzheimer disease (AD). Different apoE isoforms may alter AD pathogenesis via their interactions with the amyloid beta-peptide (Abeta). Mice lacking the lipid transporter ABCA1 were found to have markedly decreased levels and lipidation of apoE in the central nervous system. We hypothesized that if Abca1-/- mice were bred to the PDAPP mouse model of AD, PDAPP Abca1-/ mice would have a phenotype similar to that of PDAPP Apoe+/- and PDAPP Apoe-/- mice, which develop less amyloid deposition than PDAPP Apoe+/+ mice. In contrast to this prediction, 12-month-old PDAPP Abca -/- mice had significantly higher levels of hippocampal Abeta, and cerebral amyloid angiopathy was significantly more common compared with PDAPP Abca1+/+ mice. Amyloid precursor protein (APP) C-terminal fragments were not different between Abca1 genotypes prior to plaque deposition in 3-month-old PDAPP mice, suggesting that deletion of Abca1 did not affect APP processing or Abeta production. As expected, 3-month-old PDAPP Abca1-/- mice had decreased apoE levels, but they also had a higher percentage of carbonate-insoluble apoE, suggesting that poorly lipidated apoE is less soluble in vivo. We also found that 12-month-old PDAPP Abca1-/- mice had a higher percentage of carbonate-insoluble apoE and that apoE deposits co-localize with amyloid plaques, demonstrating that poorly lipidated apoE co-deposits with insoluble Abeta. Together, these data suggest that despite substantially lower apoE levels, poorly lipidated apoE produced in the absence of ABCA1 is strongly amyloidogenic in vivo.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wahrle</LastName><ForeName>Suzanne E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Program in Neurosciences, Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Parsadanian</LastName><ForeName>Maia</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hartman</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Bales</LastName><ForeName>Kelly R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG11355</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064286">ATP Binding Cassette Transporter 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018528">ATP-Binding Cassette Transporters</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>2390-54-7</RegistryNumber><NameOfSubstance UI="C009462">thioflavin T</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D064286" MajorTopicYN="N">ATP Binding Cassette Transporter 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018528" MajorTopicYN="N">ATP-Binding Cassette Transporters</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017353" MajorTopicYN="N">Gene Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008957" MajorTopicYN="N">Models, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16207708</ArticleId><ArticleId IdType="doi">10.1074/jbc.M508780200</ArticleId><ArticleId IdType="pii">S0021-9258(19)47937-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16207713</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>280</Volume><Issue>52</Issue><PubDate><Year>2005</Year><Month>Dec</Month><Day>30</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice.</ArticleTitle><Pagination><StartPage>43224</StartPage><EndPage>43235</EndPage><MedlinePgn>43224-35</MedlinePgn></Pagination><Abstract><AbstractText>ABCA1 (ATP-binding cassette transporter A1) is a major regulator of cholesterol efflux and high density lipoprotein (HDL) metabolism. Mutations in human ABCA1 cause severe HDL deficiencies characterized by the virtual absence of apoA-I and HDL and prevalent atherosclerosis. Recently, it has been reported that the lack of ABCA1 causes a significant reduction of apoE protein level in the brain of ABCA1 knock-out (ABCA1-/-) mice. ApoE isoforms strongly affect Alzheimer disease (AD) pathology and risk. To determine further the effect of ABCA1 on amyloid deposition, we used APP23 transgenic mice in which the human familial Swedish AD mutant is expressed only in neurons. We demonstrated that the targeted disruption of ABCA1 increases amyloid deposition in APP23 mice, and the effect is manifested by an increased level of Abeta immunoreactivity, as well as thioflavine S-positive plaques in brain parenchyma. We found that the lack of ABCA1 also considerably increased the level of cerebral amyloid angiopathy and exacerbated cerebral amyloid angiopathy-related microhemorrhage in APP23/ABCA1-/- mice. Remarkably, the elevation in parenchymal and vascular amyloid in APP23/ABCA1-/- mice was accompanied by a dramatic decrease in the level of soluble brain apoE, although insoluble apoE was not changed. The elevation of insoluble Abeta fraction in old APP23/ABCA1-/- mice, accompanied by a lack of changes in APP processing and soluble beta-amyloid in young APP23/ABCA1-/- animals, supports the conclusion that the ABCA1 deficiency increases amyloid deposition. These results suggest that ABCA1 plays a role in the pathogenesis of parenchymal and cerebrovascular amyloid pathology and thus may be considered a therapeutic target in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koldamova</LastName><ForeName>Radosveta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA. radak@pitt.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lefterov</LastName><ForeName>Iliya</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG023304</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG023662</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577836">ABCA1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064286">ATP Binding Cassette Transporter 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018528">ATP-Binding Cassette Transporters</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008075">Lipoproteins, HDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>2390-54-7</RegistryNumber><NameOfSubstance UI="C009462">thioflavin T</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D064286" MajorTopicYN="N">ATP Binding Cassette Transporter 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018528" MajorTopicYN="N">ATP-Binding Cassette Transporters</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050197" MajorTopicYN="N">Atherosclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008075" MajorTopicYN="N">Lipoproteins, HDL</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008811" MajorTopicYN="N">Mice, Inbred DBA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16207713</ArticleId><ArticleId IdType="doi">10.1074/jbc.M504513200</ArticleId><ArticleId IdType="pii">S0021-9258(19)47936-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16207876</PMID><DateCompleted><Year>2005</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>40</Issue><PubDate><Year>2005</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Ribosome dysfunction is an early event in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>9171</StartPage><EndPage>9175</EndPage><MedlinePgn>9171-5</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) is a progressive and devastating disorder that is often preceded by mild cognitive impairment (MCI). In the present study, we report that in multiple cortical areas of MCI and AD subjects, there is a significant impairment in ribosome function that is not observed in the cerebellum of the same subjects. The impairment in ribosome function is associated with a decreased rate and capacity for protein synthesis, decreased ribosomal RNA and tRNA levels, and increased RNA oxidation. No alteration in the level of initiation factors was observed in the brain regions exhibiting impairments in protein synthesis. Together, these data indicate for the first time that impairments in protein synthesis may be one of the earliest neurochemical alterations in AD and directly demonstrate that the polyribosome complex is adversely affected early in the development of AD. These data have important implications for AD studies involving proteomics and studies analyzing proteolysis in AD, indicate that oxidative damage may contribute to decreased protein synthesis, and suggest a role for alterations in protein synthesis as a novel contributor to the onset and development of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Qunxing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neurobiology, University of Kentucky, Lexington, Kentucky 40536-0230, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markesbery</LastName><ForeName>William R</ForeName><Initials>WR</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Qinghua</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Feng</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>Jeffrey N</ForeName><Initials>JN</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG018437</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG018437</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5P50-AG05114</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG005119</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5P01-AG005119</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012335">RNA, Ribosomal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>12133JR80S</RegistryNumber><NameOfSubstance UI="D006151">Guanosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>3868-31-3</RegistryNumber><NameOfSubstance UI="C046215">8-hydroxyguanosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9014-25-9</RegistryNumber><NameOfSubstance UI="D012343">RNA, Transfer</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Neurosci. 2006 Mar 15;26(11):3077</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006151" MajorTopicYN="N">Guanosine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011180" MajorTopicYN="N">Postmortem Changes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012335" MajorTopicYN="N">RNA, Ribosomal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012343" MajorTopicYN="N">RNA, Transfer</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012270" MajorTopicYN="N">Ribosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>4</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16207876</ArticleId><ArticleId IdType="pmc">PMC6725754</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3040-05.2005</ArticleId><ArticleId IdType="pii">25/40/9171</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aloni R, Peleg D, Meyuhas O (1992) Selective translational control and nonspecific posttranscriptional regulation of ribosomal protein gene expression during development and regeneration of rat liver. Mol Cell Biol 12: 2203-2212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC364392</ArticleId><ArticleId IdType="pubmed">1373810</ArticleId></ArticleIdList></Reference><Reference><Citation>An WL, Cowburn RF, Li L, Braak H, Alafuzoff I, Iqbal K, Iqbal IG, Winblad B, Pei JJ (2003) Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am J Pathol 163: 591-607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868198</ArticleId><ArticleId IdType="pubmed">12875979</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82: 239-259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang RC, Wong AK, Ng HK, Hugon J (2002) Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal degeneration in Alzheimer's disease. NeuroReport 13: 2429-2432.</Citation><ArticleIdList><ArticleId IdType="pubmed">12499843</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosgrove JW, Rapoport SI (1986) Preparation of a cell-free extract from rat brain which can initiate protein synthesis in vitro. Neurochem Res 11: 1289-1301.</Citation><ArticleIdList><ArticleId IdType="pubmed">3785546</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST (2003) Pathology and pathways of Alzheimer's disease with an update on new developments in treatment. J Am Geriatr Soc 51: S314-S320.</Citation><ArticleIdList><ArticleId IdType="pubmed">12801388</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Q, Lewis JJ, Strum KM, Dimayuga E, Bruce-Keller AJ, Dunn JC, Keller JN (2002) Polyglutamine expansion, protein aggregation, proteasome activity, and neural survival. J Biol Chem 277: 13935-13942.</Citation><ArticleIdList><ArticleId IdType="pubmed">11782460</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Q, Dimayuga E, Markesbery WR, Keller JN (2004) Proteasome inhibition increases DNA and RNA oxidation in astrocyte and neuron cultures. J Neurochem 91: 1211-1218.</Citation><ArticleIdList><ArticleId IdType="pubmed">15569264</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I (2002) Differential expression of phosphorylated translation initiation factor 2 alpha in Alzheimer's disease and Creutzfeldt-Jakob's disease. Neuropathol Appl Neurobiol 28: 441-451.</Citation><ArticleIdList><ArticleId IdType="pubmed">12445160</ArticleId></ArticleIdList></Reference><Reference><Citation>Flicker C, Ferris SH, Reisberg B (1991) Mild cognitive impairment in the elderly: predictors of dementia. Neurology 41: 1006-1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">2067629</ArticleId></ArticleIdList></Reference><Reference><Citation>Fromont-Racine M, Senger B, Saveanu C, Fasiolo F (2003) Ribosome assembly in eukaryotes. Gene 313: 17-42.</Citation><ArticleIdList><ArticleId IdType="pubmed">12957375</ArticleId></ArticleIdList></Reference><Reference><Citation>Granneman S, Baserga SJ (2004) Ribosome biogenesis: of knobs and RNA processing. Exp Cell Res 296: 43-50.</Citation><ArticleIdList><ArticleId IdType="pubmed">15120992</ArticleId></ArticleIdList></Reference><Reference><Citation>Han JM, Kim JY, Kim S (2003) Molecular network and functional implications of macromolecular tRNA synthetase complex. Biochem Biophys Res Commun 303: 985-993.</Citation><ArticleIdList><ArticleId IdType="pubmed">12684031</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna J, Leggett DS, Finley D (2003) Ubiquitin depletion as a key mediator of toxicity by translational inhibitors. Mol Cell Biol 23: 9251-9261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC309641</ArticleId><ArticleId IdType="pubmed">14645527</ArticleId></ArticleIdList></Reference><Reference><Citation>Honda K, Smith MA, Zhu X, Baus D, Merrick WC, Tartakoff AM, Hattier T, Harris PL, Siedlak SL, Fujioka H, Liu Q, Moreira PI, Miller FP, Nunomura A, Shimohama S, Perry G (2005) Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J Biol Chem 280: 20978-20986.</Citation><ArticleIdList><ArticleId IdType="pubmed">15767256</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, Markesbery WR (2005) Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64: 1152-1156.</Citation><ArticleIdList><ArticleId IdType="pubmed">15824339</ArticleId></ArticleIdList></Reference><Reference><Citation>Langstrom NS, Anderson JP, Lindroos HG, Winblad B, Wallace WC (1989) Alzheimer's disease-associated reduction of polysomal mRNA translation. Mol Brain Res 5: 259-269.</Citation><ArticleIdList><ArticleId IdType="pubmed">2747450</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, An WL, Alafuzoff I, Soininen H, Winblad B, Pei JJ (2004) Phosphorylated eukaryotic translation factor 4E is elevated in Alzheimer brain. NeuroReport 15: 2237-2240.</Citation><ArticleIdList><ArticleId IdType="pubmed">15371741</ArticleId></ArticleIdList></Reference><Reference><Citation>Luis CA, Loewenstein DA, Acevedo A, Barker WW, Duara R (2003) Mild cognitive impairment: directions for future research. Neurology 61: 438-444.</Citation><ArticleIdList><ArticleId IdType="pubmed">12939414</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L (2001) Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 58: 397-405.</Citation><ArticleIdList><ArticleId IdType="pubmed">11255443</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunomura A, Perry G, Pappolla MA, Wade R, Hirai K, Chiba S, Smith MA (1999) RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 19: 1959-1964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782583</ArticleId><ArticleId IdType="pubmed">10066249</ArticleId></ArticleIdList></Reference><Reference><Citation>Onuki R, Bando Y, Suyama E, Katayama T, Kawasaki H, Baba T, Tohyama M, Taira K (2004) An RNA-dependent protein kinase is involved in tunicamycin-induced apoptosis and Alzheimer's disease. EMBO J 23: 959-968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC380987</ArticleId><ArticleId IdType="pubmed">14765129</ArticleId></ArticleIdList></Reference><Reference><Citation>Peel AL, Bredesen DE (2003) Activation of the cell stress kinase PKR in Alzheimer's disease and human amyloid precursor protein transgenic mice. Neurobiol Dis 14: 52-62.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678666</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG (1997) Aging, memory, and mild cognitive impairment. Int Psychogeriatr 9 [Suppl 1]: 65-69.</Citation><ArticleIdList><ArticleId IdType="pubmed">9447429</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56: 303-308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley KP, Snowden DA, Markesbery WR (2002) Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the nun study. Ann Neurol 51: 567-577.</Citation><ArticleIdList><ArticleId IdType="pubmed">12112102</ArticleId></ArticleIdList></Reference><Reference><Citation>Sajdel-Sulkowska EM, Marotta CA (1984) Alzheimer's disease brain: alterations in RNA levels and in a ribonuclease-inhibitor complex. Science 225: 947-949.</Citation><ArticleIdList><ArticleId IdType="pubmed">6206567</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Wolf PA, Beiser A, Au R, McNulty K, White R, D'Agostino RB (1997) Lifetime risk of dementia and Alzheimer's disease. The impact of mortality on risk estimates in the Framingham Study. Neurology 49: 1498-1504.</Citation><ArticleIdList><ArticleId IdType="pubmed">9409336</ArticleId></ArticleIdList></Reference><Reference><Citation>Tschochner H, Hurt E (2003) Pre-ribosomes on the road from the nucleolus to the cytoplasm. Trends Cell Biol 13: 255-263.</Citation><ArticleIdList><ArticleId IdType="pubmed">12742169</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Sekiguchi T, Noguchi E, Nishimoto T (2004) A hamster temperature-sensitive alanyl-tRNA synthetase mutant causes degradation of cell-cycle related proteins and apoptosis. J Biochem (Tokyo) 135: 7-16.</Citation><ArticleIdList><ArticleId IdType="pubmed">14999004</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang DC (1996) Mammalian aminoacyl-tRNA synthetases. Curr Top Cell Regul 34: 101-136.</Citation><ArticleIdList><ArticleId IdType="pubmed">8646845</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16208376</PMID><DateCompleted><Year>2005</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>437</Volume><Issue>7060</Issue><PubDate><Year>2005</Year><Month>Oct</Month><Day>06</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Apolipoprotein-mediated pathways of lipid antigen presentation.</ArticleTitle><Pagination><StartPage>906</StartPage><EndPage>910</EndPage><MedlinePgn>906-10</MedlinePgn></Pagination><Abstract><AbstractText>Peptide antigens are presented to T cells by major histocompatibility complex (MHC) molecules, with endogenous peptides presented by MHC class I and exogenous peptides presented by MHC class II. In contrast to the MHC system, CD1 molecules bind lipid antigens that are presented at the antigen-presenting cell (APC) surface to lipid antigen-reactive T cells. Because CD1 molecules survey endocytic compartments, it is self-evident that they encounter antigens from extracellular sources. However, the mechanisms of exogenous lipid antigen delivery to CD1-antigen-loading compartments are not known. Serum apolipoproteins are mediators of extracellular lipid transport for metabolic needs. Here we define the pathways mediating markedly efficient exogenous lipid antigen delivery by apolipoproteins to achieve T-cell activation. Apolipoprotein E binds lipid antigens and delivers them by receptor-mediated uptake into endosomal compartments containing CD1 in APCs. Apolipoprotein E mediates the presentation of serum-borne lipid antigens and can be secreted by APCs as a mechanism to survey the local environment to capture antigens or to transfer microbial lipids from infected cells to bystander APCs. Thus, the immune system has co-opted a component of lipid metabolism to develop immunological responses to lipid antigens.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van den Elzen</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garg</LastName><ForeName>Salil</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Le&#xf3;n</LastName><ForeName>Luis</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Brigl</LastName><ForeName>Manfred</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Leadbetter</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Gumperz</LastName><ForeName>Jenny E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Dascher</LastName><ForeName>Chris C</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Tan-Yun</ForeName><Initials>TY</Initials></Author><Author ValidYN="Y"><LastName>Sacks</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials></Author><Author ValidYN="Y"><LastName>Illarionov</LastName><ForeName>Petr A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Besra</LastName><ForeName>Gurdyal S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Kent</LastName><ForeName>Sally C</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Moody</LastName><ForeName>D Branch</ForeName><Initials>DB</Initials></Author><Author ValidYN="Y"><LastName>Brenner</LastName><ForeName>Michael B</ForeName><Initials>MB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL071590</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007753</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018949">Antigens, CD1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011973">Receptors, LDL</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017951" MajorTopicYN="Y">Antigen Presentation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000938" MajorTopicYN="N">Antigen-Presenting Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018949" MajorTopicYN="N">Antigens, CD1</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003713" MajorTopicYN="N">Dendritic Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011973" MajorTopicYN="N">Receptors, LDL</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>10</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16208376</ArticleId><ArticleId IdType="doi">10.1038/nature04001</ArticleId><ArticleId IdType="pii">nature04001</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">16212664</PMID><DateCompleted><Year>2005</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1742-2094</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><PubDate><Year>2005</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>Journal of neuroinflammation</Title><ISOAbbreviation>J Neuroinflammation</ISOAbbreviation></Journal><ArticleTitle>Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice.</ArticleTitle><Pagination><StartPage>22</StartPage><MedlinePgn>22</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Inflammation is suspected to contribute to the progression and severity of neurodegeneration in Alzheimer's disease (AD). Transgenic mice overexpressing the london mutant of amyloid precursor protein, APP [V717I], robustly recapitulate the amyloid pathology of AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Early and late, temporal and spatial characteristics of inflammation were studied in APP [V717I] mice at 3 and 16 month of age. Glial activation and expression of inflammatory markers were determined by immunohistochemistry and RT-PCR. Amyloid deposition was assessed by immunohistochemistry, thioflavine S staining and western blot experiments. BACE1 activity was detected in brain lysates and in situ using the BACE1 activity kit from R&amp;D Systems, Wiesbaden, Germany.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Foci of activated micro- and astroglia were already detected at age 3 months, before any amyloid deposition. Inflammation parameters comprised increased mRNA levels coding for interleukin-1beta, interleukin-6, major histocompatibility complex II and macrophage-colony-stimulating-factor-receptor. Foci of CD11b-positive microglia expressed these cytokines and were neighbored by activated astrocytes. Remarkably, beta-secretase (BACE1) mRNA, neuronal BACE1 protein at sites of focal inflammation and total BACE1 enzyme activity were increased in 3 month old APP transgenic mice, relative to age-matched non-transgenic mice. In aged APP transgenic mice, the mRNA of all inflammatory markers analysed was increased, accompanied by astroglial iNOS expression and NO-dependent peroxynitrite release, and with glial activation near almost all diffuse and senile Abeta deposits.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The early and focal glial activation, in conjunction with upregulated BACE1 mRNA, protein and activity in the presence of its substrate APP, is proposed to represent the earliest sites of amyloid deposition, likely evolving into amyloid plaques.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heneka</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of M&#xfc;nster, 48149 M&#xfc;nster, Germany. heneka@uni-muenster.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sastre</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Dumitrescu-Ozimek</LastName><ForeName>Lucia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Dewachter</LastName><ForeName>Ilse</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>Jochen</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Klockgether</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Van Leuven</LastName><ForeName>Fred</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neuroinflammation</MedlineTA><NlmUniqueID>101222974</NlmUniqueID><ISSNLinking>1742-2094</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>10</Month><Day>11</Day><Hour>9</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2005</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16212664</ArticleId><ArticleId IdType="pmc">PMC1274341</ArticleId><ArticleId IdType="doi">10.1186/1742-2094-2-22</ArticleId><ArticleId IdType="pii">1742-2094-2-22</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dingwall C. Spotlight on BACE: the secretases as targets for treatment in Alzheimer disease. J Clin Invest. 2001;108:1243&#x2013;1246. doi: 10.1172/JCI200114402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI200114402</ArticleId><ArticleId IdType="pmc">PMC209454</ArticleId><ArticleId IdType="pubmed">11696563</ArticleId></ArticleIdList></Reference><Reference><Citation>Esler WP, Wolfe MS. A portrait of Alzheimer secretases--new features and familiar faces. Science. 2001;293:1449&#x2013;1454. doi: 10.1126/science.1064638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1064638</ArticleId><ArticleId IdType="pubmed">11520976</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. 1991;12:383&#x2013;388. doi: 10.1016/0165-6147(91)90609-V.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-6147(91)90609-V</ArticleId><ArticleId IdType="pubmed">1763432</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102. doi: 10.1126/science.274.5284.99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.274.5284.99</ArticleId><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A. 1997;94:13287&#x2013;13292. doi: 10.1073/pnas.94.24.13287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.24.13287</ArticleId><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Haute CV, Checler F, Godaux E, Cordell B, Van Leuven F. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem. 1999;274:6483&#x2013;6492. doi: 10.1074/jbc.274.10.6483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.10.6483</ArticleId><ArticleId IdType="pubmed">10037741</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dorpe J, Smeijers L, Dewachter I, Nuyens D, Spittaels K, Van Den HC, Mercken M, Moechars D, Laenen I, Kuiperi C, Bruynseels K, Tesseur I, Loos R, Vanderstichele H, Checler F, Sciot R, Van Leuven F. Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons. Am J Pathol. 2000;157:1283&#x2013;1298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850171</ArticleId><ArticleId IdType="pubmed">11021833</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb BT, Bardel KA, Kulnane LS, Anderson JJ, Holtz G, Wagner SL, Sisodia SS, Hoeger EJ. Amyloid production and deposition in mutant amyloid precursor protein and presenilin-1 yeast artificial chromosome transgenic mice. Nat Neurosci. 1999;2:695&#x2013;697. doi: 10.1038/11154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/11154</ArticleId><ArticleId IdType="pubmed">10412057</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett. 1987;79:195&#x2013;200. doi: 10.1016/0304-3940(87)90696-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3940(87)90696-3</ArticleId><ArticleId IdType="pubmed">3670729</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelenboom P, van Gool WA. Neuroinflammatory perspectives on the two faces of Alzheimer's disease. J Neural Transm. 2004;111:281&#x2013;294. doi: 10.1007/s00702-003-0055-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-003-0055-1</ArticleId><ArticleId IdType="pubmed">14991455</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383&#x2013;421. doi: 10.1016/S0197-4580(00)00124-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(00)00124-X</ArticleId><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S, Esiri MM, Murray LS, Dewar D, Love S, Moss T, Griffin WS. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol. 2000;47:365&#x2013;368. doi: 10.1002/1531-8249(200003)47:3&lt;365::AID-ANA13&gt;3.0.CO;2-G.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(200003)47:3&lt;365::AID-ANA13&gt;3.0.CO;2-G</ArticleId><ArticleId IdType="pmc">PMC3833599</ArticleId><ArticleId IdType="pubmed">10716257</ArticleId></ArticleIdList></Reference><Reference><Citation>Papassotiropoulos A, Bagli M, Jessen F, Bayer TA, Maier W, Rao ML, Heun R. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease. Ann Neurol. 1999;45:666&#x2013;668. doi: 10.1002/1531-8249(199905)45:5&lt;666::AID-ANA18&gt;3.0.CO;2-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(199905)45:5&lt;666::AID-ANA18&gt;3.0.CO;2-3</ArticleId><ArticleId IdType="pubmed">10319892</ArticleId></ArticleIdList></Reference><Reference><Citation>McCusker SM, Curran MD, Dynan KB, McCullagh CD, Urquhart DD, Middleton D, Patterson CC, McIlroy SP, Passmore AP. Association between polymorphism in regulatory region of gene encoding tumour necrosis factor alpha and risk of Alzheimer's disease and vascular dementia: a case-control study. Lancet. 2001;357:436&#x2013;439. doi: 10.1016/S0140-6736(00)04008-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(00)04008-3</ArticleId><ArticleId IdType="pubmed">11273064</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P, . Clinical trial of indomethacin in Alzheimer's disease. Neurology. 1993;43:1609&#x2013;1611.</Citation><ArticleIdList><ArticleId IdType="pubmed">8351023</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 1996;47:425&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">8757015</ArticleId></ArticleIdList></Reference><Reference><Citation>in t'Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MM, Stricker BH. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001;345:1515&#x2013;1521. doi: 10.1056/NEJMoa010178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa010178</ArticleId><ArticleId IdType="pubmed">11794217</ArticleId></ArticleIdList></Reference><Reference><Citation>Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, Van Leuven F, Heneka MT. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci. 2003;23:9796&#x2013;9804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740896</ArticleId><ArticleId IdType="pubmed">14586007</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, Cole GM. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci. 2000;20:5709&#x2013;5714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772529</ArticleId><ArticleId IdType="pubmed">10908610</ArticleId></ArticleIdList></Reference><Reference><Citation>Fluhrer R, Multhaup G, Schlicksupp A, Okochi M, Takeda M, Lammich S, Willem M, Westmeyer G, Bode W, Walter J, Haass C. Identification of a beta-secretase activity, which truncates amyloid beta-peptide after its presenilin-dependent generation. Journal of Biological Chemistry. 2003;278:5531&#x2013;5538. doi: 10.1074/jbc.M211485200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M211485200</ArticleId><ArticleId IdType="pubmed">12471021</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossner S, Apelt J, Schliebs R, Perez-Polo JR, Bigl V. Neuronal and glial beta-secretase (BACE) protein expression in transgenic Tg2576 mice with amyloid plaque pathology. J Neurosci Res. 2001;64:437&#x2013;446. doi: 10.1002/jnr.1095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.1095</ArticleId><ArticleId IdType="pubmed">11391698</ArticleId></ArticleIdList></Reference><Reference><Citation>Barger SW, Harmon AD. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature. 1997;388:878&#x2013;881. doi: 10.1038/42257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/42257</ArticleId><ArticleId IdType="pubmed">9278049</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasko I, Marx F, Steiner E, Hartmann T, Grubeck-Loebenstein B. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J. 1999;13:63&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">9872930</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173&#x2013;177. doi: 10.1038/22124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/22124</ArticleId><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehlhorn G, Hollborn M, Schliebs R. Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int J Dev Neurosci. 2000;18:423&#x2013;431. doi: 10.1016/S0736-5748(00)00012-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0736-5748(00)00012-5</ArticleId><ArticleId IdType="pubmed">10817926</ArticleId></ArticleIdList></Reference><Reference><Citation>Sly LM, Krzesicki RF, Brashler JR, Buhl AE, McKinley DD, Carter DB, Chin JE. Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res Bull. 2001;56:581&#x2013;588. doi: 10.1016/S0361-9230(01)00730-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0361-9230(01)00730-4</ArticleId><ArticleId IdType="pubmed">11786245</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbas N, Bednar I, Mix E, Marie S, Paterson D, Ljungberg A, Morris C, Winblad B, Nordberg A, Zhu J. Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice. J Neuroimmunol. 2002;126:50&#x2013;57. doi: 10.1016/S0165-5728(02)00050-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(02)00050-4</ArticleId><ArticleId IdType="pubmed">12020956</ArticleId></ArticleIdList></Reference><Reference><Citation>Benzing WC, Wujek JR, Ward EK, Shaffer D, Ashe KH, Younkin SG, Brunden KR. Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol Aging. 1999;20:581&#x2013;589. doi: 10.1016/S0197-4580(99)00065-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(99)00065-2</ArticleId><ArticleId IdType="pubmed">10674423</ArticleId></ArticleIdList></Reference><Reference><Citation>Apelt J, Schliebs R. Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res. 2001;894:21&#x2013;30. doi: 10.1016/S0006-8993(00)03176-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(00)03176-0</ArticleId><ArticleId IdType="pubmed">11245811</ArticleId></ArticleIdList></Reference><Reference><Citation>Szczepanik AM, Rampe D, Ringheim GE. Amyloid-beta peptide fragments p3 and p4 induce pro-inflammatory cytokine and chemokine production in vitro and in vivo. J Neurochem. 2001;77:304&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279286</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray CA, Lynch MA. Evidence that increased hippocampal expression of the cytokine interleukin-1 beta is a common trigger for age- and stress-induced impairments in long-term potentiation. J Neurosci. 1998;18:2974&#x2013;2981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792583</ArticleId><ArticleId IdType="pubmed">9526014</ArticleId></ArticleIdList></Reference><Reference><Citation>Tancredi V, D'Antuono M, Cafe C, Giovedi S, Bue MC, D'Arcangelo G, Onofri F, Benfenati F. The inhibitory effects of interleukin-6 on synaptic plasticity in the rat hippocampus are associated with an inhibition of mitogen-activated protein kinase ERK. J Neurochem. 2000;75:634&#x2013;643. doi: 10.1046/j.1471-4159.2000.0750634.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2000.0750634.x</ArticleId><ArticleId IdType="pubmed">10899938</ArticleId></ArticleIdList></Reference><Reference><Citation>Graber HU, Zurbriggen A, Vandevelde M. Identification of canine glial cells by nonradioactive in situ hybridization. Zentralbl Veterinarmed A. 1993;40:665&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pubmed">8135072</ArticleId></ArticleIdList></Reference><Reference><Citation>Vodovotz Y, Lucia MS, Flanders KC, Chesler L, Xie QW, Smith TW, Weidner J, Mumford R, Webber R, Nathan C, Roberts AB, Lippa CF, Sporn MB. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J Exp Med. 1996;184:1425&#x2013;1433. doi: 10.1084/jem.184.4.1425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.184.4.1425</ArticleId><ArticleId IdType="pmc">PMC2192831</ArticleId><ArticleId IdType="pubmed">8879214</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci. 1997;17:2653&#x2013;2657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573097</ArticleId><ArticleId IdType="pubmed">9092586</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigl M, Apelt J, Luschekina EA, Lange-Dohna C, Rossner S, Schliebs R. Expression of beta-secretase mRNA in transgenic Tg2576 mouse brain with Alzheimer plaque pathology. Neurosci Lett. 2000;292:107&#x2013;110. doi: 10.1016/S0304-3940(00)01452-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(00)01452-X</ArticleId><ArticleId IdType="pubmed">10998560</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, Locascio JJ, Hyman BT. beta-site APP cleaving enzyme mRNA expression in APP transgenic mice: anatomical overlap with transgene expression and static levels with aging. Am J Pathol. 2001;158:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850271</ArticleId><ArticleId IdType="pubmed">11141490</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16216935</PMID><DateCompleted><Year>2005</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>10</Issue><PubDate><Year>2005</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Risk factors associated with beta-amyloid(1-42) immunotherapy in preimmunization gene expression patterns of blood cells.</ArticleTitle><Pagination><StartPage>1531</StartPage><EndPage>1536</EndPage><MedlinePgn>1531-6</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A phase 2a, double-blind, placebo-controlled, multicenter study was conducted to evaluate safety, tolerability, and pilot efficacy of immunization with beta-amyloid((1-42)) in patients with Alzheimer disease. Six immunizations were planned but were halted when meningoencephalitis was recognized as an adverse event in 6% of immunized patients.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To identify biomarkers associated with both the risk of meningoencephalitis and antibody responsiveness.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">One hundred fifty-three patients with mild to moderate Alzheimer disease.Main Outcome Measure Association between response to immunization and preimmunization expression levels of 8239 messenger RNA transcripts expressed in peripheral blood mononuclear cells that had been collected at the screening visit.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Expression patterns of genes related to apoptosis and proinflammatory pathways (tumor necrosis factor pathway in particular) were identified as biomarkers of risk for the development of meningoencephalitis. Expression patterns of genes related to protein synthesis, protein trafficking, DNA recombination, DNA repair, and cell cycle were strongly associated with IgG response to immunization.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Candidate biomarkers associated with risk of immunotherapy-related meningoencephalitis were detected in blood collected prior to treatment. In addition, a different set of biomarkers were identified that were associated with the desired outcome of IgG response.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>O'Toole</LastName><ForeName>Margot</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biological Technologies, Wyeth Research, Cambridge, MA 02140, USA. mtoole@wyeth.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janszen</LastName><ForeName>Derek B</ForeName><Initials>DB</Initials></Author><Author ValidYN="Y"><LastName>Slonim</LastName><ForeName>Donna K</ForeName><Initials>DK</Initials></Author><Author ValidYN="Y"><LastName>Reddy</LastName><ForeName>Padmalatha S</ForeName><Initials>PS</Initials></Author><Author ValidYN="Y"><LastName>Ellis</LastName><ForeName>Debra K</ForeName><Initials>DK</Initials></Author><Author ValidYN="Y"><LastName>Legault</LastName><ForeName>Holly M</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Andrew A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Whitley</LastName><ForeName>Maryann Z</ForeName><Initials>MZ</Initials></Author><Author ValidYN="Y"><LastName>Mounts</LastName><ForeName>William M</ForeName><Initials>WM</Initials></Author><Author ValidYN="Y"><LastName>Zuberek</LastName><ForeName>Krystyna</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Immermann</LastName><ForeName>Frederick W</ForeName><Initials>FW</Initials></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>Ronald S</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>Dorner</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2005 Oct;62(10):1506-7. doi: 10.1001/archneur.62.10.1506.</RefSource><PMID Version="1">16216931</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004660" MajorTopicYN="N">Encephalitis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020411" MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>11</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16216935</ArticleId><ArticleId IdType="doi">10.1001/archneur.62.10.1531</ArticleId><ArticleId IdType="pii">62/10/1531</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16216938</PMID><DateCompleted><Year>2005</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>10</Issue><PubDate><Year>2005</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease.</ArticleTitle><Pagination><StartPage>1556</StartPage><EndPage>1560</EndPage><MedlinePgn>1556-60</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Vascular risk factors play a role in the development of dementia, including Alzheimer disease (AD). However, little is known about the effect of body mass index and clustering of vascular risk factors on the development of dementia.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the relation between midlife body mass index and clustering of vascular risk factors and subsequent dementia and AD.</AbstractText><AbstractText Label="DESIGN AND SETTING" NlmCategory="METHODS">Participants of the Cardiovascular Risk Factors, Aging, and Dementia (CAIDE) study were derived from random, population-based samples previously studied in a survey carried out in 1972, 1977, 1982, or 1987. After an average follow-up of 21 years, 1449 individuals (73%) aged 65 to 79 years participated in the reexamination in 1998.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Dementia and AD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Obesity at midlife (body mass index&gt;30 kg/m2) was associated with the risk of dementia and AD even after adjusting for sociodemographic variables (odds ratio [OR], 2.4 [95% confidence interval (CI), 1.2-5.1]). The association was somewhat modified by further adjusting for midlife blood pressure, total cholesterol level, and smoking (OR, 2.1 [95% CI, 1.0-4.6]) and also for apolipoprotein E genotype and history of vascular disorders (OR, 1.9 [95% CI, 0.8-4.6]). Midlife obesity, high total cholesterol level, and high systolic blood pressure were all significant risk factors for dementia with ORs of around 2 for each factor, and they increased the risk additively (OR, 6.2 for the combination).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Obesity at midlife is associated with an increased risk of dementia and AD later in life. Clustering of vascular risk factors increases the risk in an additive manner. The role of weight reduction for the prevention of dementia needs to be further investigated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kivipelto</LastName><ForeName>Miia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Aging Research Center, Division of Geriatric Epidemiology, Neurotec, Karolinska Institutet, Stockholm, Sweden. miia.kivipelto@neurotec.ki.se</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ngandu</LastName><ForeName>Tiia</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Fratiglioni</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Viitanen</LastName><ForeName>Matti</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>K&#xe5;reholt</LastName><ForeName>Ingemar</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Winblad</LastName><ForeName>Bengt</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Helkala</LastName><ForeName>Eeva-Liisa</ForeName><Initials>EL</Initials></Author><Author ValidYN="Y"><LastName>Tuomilehto</LastName><ForeName>Jaakko</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Soininen</LastName><ForeName>Hilkka</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Nissinen</LastName><ForeName>Aulikki</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>11</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16216938</ArticleId><ArticleId IdType="doi">10.1001/archneur.62.10.1556</ArticleId><ArticleId IdType="pii">62/10/1556</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16221845</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>41</Issue><PubDate><Year>2005</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production.</ArticleTitle><Pagination><StartPage>9367</StartPage><EndPage>9377</EndPage><MedlinePgn>9367-77</MedlinePgn></Pagination><Abstract><AbstractText>Acute brain injuries have been identified as a risk factor for developing Alzheimer's disease (AD). Because glutamate plays a pivotal role in these pathologies, we studied the influence of glutamate receptor activation on amyloid-beta (Abeta) production in primary cultures of cortical neurons. We found that sublethal NMDA receptor activation increased the production and secretion of Abeta. This effect was preceded by an increased expression of neuronal Kunitz protease inhibitory domain (KPI) containing amyloid-beta precursor protein (KPI-APP) followed by a shift from alpha-secretase to beta-secretase-mediated APP processing. This shift is a result of the inhibition of the alpha-secretase candidate tumor necrosis factor-alpha converting enzyme (TACE) when associated with neuronal KPI-APPs. This KPI-APP/TACE interaction was also present in AD brains. Thus, our findings reveal a cellular mechanism linking NMDA receptor activation to neuronal Abeta secretion. These results suggest that even mild deregulation of the glutamatergic neurotransmission may increase Abeta production and represent a causal risk factor for developing AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lesn&#xe9;</LastName><ForeName>Sylvain</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Unit&#xe9; Mixte de Recherche, Centre National de la Recherche Scientifique 6185, Centre Cyceron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Carine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Gabriel</LastName><ForeName>Cec&#xed;lia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Croci</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>MacKenzie</LastName><ForeName>Eric T</ForeName><Initials>ET</Initials></Author><Author ValidYN="Y"><LastName>Glabe</LastName><ForeName>Charles G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Plotkine</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Marchand-Verrecchia</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Vivien</LastName><ForeName>Denis</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Buisson</LastName><ForeName>Alain</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018690">Excitatory Amino Acid Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>6384-92-5</RegistryNumber><NameOfSubstance UI="D016202">N-Methylaspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018690" MajorTopicYN="N">Excitatory Amino Acid Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016202" MajorTopicYN="N">N-Methylaspartate</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>4</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16221845</ArticleId><ArticleId IdType="pmc">PMC6725703</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0849-05.2005</ArticleId><ArticleId IdType="pii">25/41/9367</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abe K, Tanzi RE, Kogure K (1991) Selective induction of Kunitz-type protease inhibitor domain-containing amyloid precursor protein mRNA after persistent focal ischemia in rat cerebral cortex. Neurosci Lett 125: 172-174.</Citation><ArticleIdList><ArticleId IdType="pubmed">1908958</ArticleId></ArticleIdList></Reference><Reference><Citation>Arundine M, Tymianski M (2004) Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cell Mol Life Sci 61: 657-668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11138528</ArticleId><ArticleId IdType="pubmed">15052409</ArticleId></ArticleIdList></Reference><Reference><Citation>Barelli H, Lebeau A, Vizzavona J, Delaere P, Chevallier N, Drouot C, Marambaud P, Ancolio K, Buxbaum JD, Khorkova O, Heroux J, Sahasrabudhe S, Martinez J, Warter JM, Mohr M, Checler F (1997) Characterization of new polyclonal antibodies specific for 40 and 42 amino acid-long amyloid beta peptides: their use to examine the cell biology of presenilins and the immunohistochemistry of sporadic Alzheimer's disease and cerebral amyloid angiopathy cases. Mol Med 3: 695-707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2230230</ArticleId><ArticleId IdType="pubmed">9392006</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrouz N, Defossez A, Delacourte A, Hublau P, Mazzuca M (1989) Alzheimer's disease: glycolytic pretreatment dramatically enhances immunolabeling of senile plaques and cerebrovascular amyloid substance. Lab Invest 61: 576-583.</Citation><ArticleIdList><ArticleId IdType="pubmed">2478759</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasko I, Beer R, Bigl M, Apelt J, Franz G, Rudzki D, Ransmayr G, Kampfl A, Schliebs R (2004) Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer's disease beta-secretase (BACE-1). J Neural Transm 111: 523-536.</Citation><ArticleIdList><ArticleId IdType="pubmed">15057522</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramlett HM, Dietrich WD (2004) Pathophysiology of cerebral ischemia and brain trauma: similarities and differences. J Cereb Blood Flow Metab 24: 133-150.</Citation><ArticleIdList><ArticleId IdType="pubmed">14747740</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussiere T, Friend PD, Sadeghi N, Wicinski B, Lin GI, Bouras C, Giannakopoulos P, Robakis NK, Morrison JH, Perl DP, Hof PR (2002) Stereologic assessment of the total cortical volume occupied by amyloid deposits and its relationship with cognitive status in aging and Alzheimer's disease. Neuroscience 112: 75-91.</Citation><ArticleIdList><ArticleId IdType="pubmed">12044473</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, Johnson RS, Castner BJ, Cerretti DP, Black RA (1998) Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 273: 27765-27767.</Citation><ArticleIdList><ArticleId IdType="pubmed">9774383</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi DW (1988) Glutamate neurotoxicity and diseases of the nervous system. Neuron 1: 623-634.</Citation><ArticleIdList><ArticleId IdType="pubmed">2908446</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi DW (1995) Calcium: still center-stage in hypoxic-ischemic neuronal death. Trends Neurosci 18: 58-60.</Citation><ArticleIdList><ArticleId IdType="pubmed">7537408</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotman CW, Tenner AJ, Cummings BJ (1996) Beta-amyloid converts an acute phase injury response to chronic injury responses. Neurobiol Aging 17: 723-731.</Citation><ArticleIdList><ArticleId IdType="pubmed">8892345</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleminger S, Oliver DL, Lovestone S, Rabe-Hesketh S, Giora A (2003) Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. J Neurol Neurosurg Psychiatry 74: 857-862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738550</ArticleId><ArticleId IdType="pubmed">12810767</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner GG, Wong CW (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120: 885-890.</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Z, Cupples LA, Kurz A, Auerbach SH, Volicer L, Chui H, Green RC, Sadovnick AD, Duara R, DeCarli C, Johnson K, Go RC, Growdon JH, Haines JL, Kukull WA, Farrer LA (2000) Head injury and the risk of AD in the MIRAGE study. Neurology 54: 1316-1323.</Citation><ArticleIdList><ArticleId IdType="pubmed">10746604</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB, Selkoe DJ (1992) Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359: 322-325.</Citation><ArticleIdList><ArticleId IdType="pubmed">1383826</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Hung AY, Schlossmacher MG, Teplow DB, Selkoe DJ (1993) Beta-amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. J Biol Chem 268: 3021-3024.</Citation><ArticleIdList><ArticleId IdType="pubmed">8428976</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellal F, Pruneau D, Palmier B, Faye P, Croci N, Plotkine M, Marchand-Verrecchia C (2003) Detrimental role of bradykinin B2 receptor in a murine model of diffuse brain injury. J Neurotrauma 20: 841-851.</Citation><ArticleIdList><ArticleId IdType="pubmed">14577862</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyman A, Wilkinson WE, Stafford JA, Helms MJ, Sigmon AH, Weinberg T (1984) Alzheimer's disease: a study of epidemiological aspects. Ann Neurol 15: 335-341.</Citation><ArticleIdList><ArticleId IdType="pubmed">6742780</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho L, Fukuchi K, Younkin SG (1996) The alternatively spliced Kunitz protease inhibitor domain alters amyloid beta protein precursor processing and amyloid beta protein production in cultured cells. J Biol Chem 271: 30929-30934.</Citation><ArticleIdList><ArticleId IdType="pubmed">8940079</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K (1998) Transgenic mice expressing Alzheimer amyloid precursor proteins. Exp Gerontol 33: 883-889.</Citation><ArticleIdList><ArticleId IdType="pubmed">9951631</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99-102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Husi H, Grant SG (2001) Proteomics of the nervous system. Trends Neurosci 24: 259-266.</Citation><ArticleIdList><ArticleId IdType="pubmed">11311377</ArticleId></ArticleIdList></Reference><Reference><Citation>Husi H, Ward MA, Choudhary JS, Blackstock WP, Grant SG (2000) Proteomic analysis of NMDA receptor-adhesion protein signaling complexes. Nat Neurosci 3: 661-669.</Citation><ArticleIdList><ArticleId IdType="pubmed">10862698</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HS, Lee SH, Kim SS, Kim YK, Jeong SJ, Ma J, Han DH, Cho BK, Suh YH (1998) Post-ischemic changes in the expression of Alzheimer's APP isoforms in rat cerebral cortex. NeuroReport 9: 533-537.</Citation><ArticleIdList><ArticleId IdType="pubmed">9512402</ArticleId></ArticleIdList></Reference><Reference><Citation>LeBlanc AC, Chen HY, Autilio-Gambetti L, Gambetti P (1991) Differential APP gene expression in rat cerebral cortex, meninges, and primary astroglial, microglial and neuronal cultures. FEBS Lett 292: 171-178.</Citation><ArticleIdList><ArticleId IdType="pubmed">1959603</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JM, Zipfel GJ, Choi DW (1999) The changing landscape of ischaemic brain injury mechanisms. Nature 399: A7-14.</Citation><ArticleIdList><ArticleId IdType="pubmed">10392575</ArticleId></ArticleIdList></Reference><Reference><Citation>Linnik MD, Zobrist RH, Hatfield MD (1993) Evidence supporting a role for programmed cell death in focal cerebral ischemia in rats. Stroke 24: 2002-2009.</Citation><ArticleIdList><ArticleId IdType="pubmed">8248983</ArticleId></ArticleIdList></Reference><Reference><Citation>MacDermott AB, Mayer ML, Westbrook GL, Smith SJ, Barker JL (1986) NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones. Nature 321: 519-522.</Citation><ArticleIdList><ArticleId IdType="pubmed">3012362</ArticleId></ArticleIdList></Reference><Reference><Citation>MacManus JP, Buchan AM, Hill IE, Rasquinha I, Preston E (1993) Global ischemia can cause DNA fragmentation indicative of apoptosis in rat brain. Neurosci Lett 164: 89-92.</Citation><ArticleIdList><ArticleId IdType="pubmed">8152622</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82: 4245-4249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC397973</ArticleId><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I, Rydel RE (1993) Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 10: 243-254.</Citation><ArticleIdList><ArticleId IdType="pubmed">8094963</ArticleId></ArticleIdList></Reference><Reference><Citation>Moir RD, Lynch T, Bush AI, Whyte S, Henry A, Portbury S, Multhaup G, Small DH, Tanzi RE, Beyreuther K, Masters CL (1998) Relative increase in Alzheimer's disease of soluble forms of cerebral Abeta amyloid protein precursor containing the Kunitz protease inhibitory domain. J Biol Chem 273: 5013-5019.</Citation><ArticleIdList><ArticleId IdType="pubmed">9478949</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortimer JA, van Duijn CM, Chandra V, Fratiglioni L, Graves AB, Heyman A, Jorm AF, Kokmen E, Kondo K, Rocca WA (1991) Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 20 [Suppl 2]: S28-S35.</Citation><ArticleIdList><ArticleId IdType="pubmed">1833351</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy Z, Esiri MM, Jobst KA, Morris JH, King EM, McDonald B, Joachim C, Litchfield S, Barnetson L, Smith AD (1997) The effects of additional pathology on the cognitive deficit in Alzheimer disease. J Neuropathol Exp Neurol 56: 165-170.</Citation><ArticleIdList><ArticleId IdType="pubmed">9034370</ArticleId></ArticleIdList></Reference><Reference><Citation>Plassman BL, Havlik RJ, Steffens DC, Helms MJ, Newman TN, Drosdick D, Phillips C, Gau BA, Welsh-Bohmer KA, Burke JR, Guralnik JM, Breitner JC (2000) Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology 55: 1158-1166.</Citation><ArticleIdList><ArticleId IdType="pubmed">11071494</ArticleId></ArticleIdList></Reference><Reference><Citation>Popa-Wagner A, Schroder E, Walker LC, Kessler C (1998) Beta-amyloid precursor protein and ss-amyloid peptide immunoreactivity in the rat brain after middle cerebral artery occlusion: effect of age. Stroke 29: 2196-2202.</Citation><ArticleIdList><ArticleId IdType="pubmed">9756603</ArticleId></ArticleIdList></Reference><Reference><Citation>Refolo LM, Salton SR, Anderson JP, Mehta P, Robakis NK (1989) Nerve and epidermal growth factors induce the release of the Alzheimer amyloid precursor from PC 12 cell cultures. Biochem Biophys Res Commun 164: 664-670.</Citation><ArticleIdList><ArticleId IdType="pubmed">2510719</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts GW, Gentleman SM, Lynch A, Graham DI (1991) Beta A4 amyloid protein deposition in brain after head trauma. Lancet 338: 1422-1423.</Citation><ArticleIdList><ArticleId IdType="pubmed">1683421</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, Graham DI (1994) Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J Neurol Neurosurg Psychiatry 57: 419-425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1072869</ArticleId><ArticleId IdType="pubmed">8163989</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose K, Goldberg MP, Choi DW (1993) Cytotoxicity in murine neocortical cell culture. In: In vitro biological methods. Methods in toxicology (Tyson CA, Frazier JM, eds), pp 46-60. San Diego: Academic.</Citation></Reference><Reference><Citation>Roses AD, Saunders A (1995) Head injury, amyloid beta and Alzheimer's disease. Nat Med 1: 603-604.</Citation><ArticleIdList><ArticleId IdType="pubmed">7585131</ArticleId></ArticleIdList></Reference><Reference><Citation>Saido TC, Yokota M, Maruyama K, Yamao-Harigaya W, Tani E, Ihara Y, Kawashima S (1994) Spatial resolution of the primary beta-amyloidogenic process induced in postischemic hippocampus. J Biol Chem 269: 15253-15257.</Citation><ArticleIdList><ArticleId IdType="pubmed">8195161</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlondorff J, Becherer JD, Blobel CP (2000) Intracellular maturation and localization of the tumour necrosis factor alpha convertase (TACE). Biochem J 347: 131-138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1220940</ArticleId><ArticleId IdType="pubmed">10727411</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz JB, Weller M, Moskowitz MA (1999) Caspases as treatment targets in stroke and neurodegenerative diseases. Ann Neurol 45: 421-429.</Citation><ArticleIdList><ArticleId IdType="pubmed">10211465</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741-766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Sergeant N, David JP, Champain D, Ghestem A, Wattez A, Delacourte A (2002) Progressive decrease of amyloid precursor protein carboxy terminal fragments (APP-CTFs), associated with tau pathology stages, in Alzheimer's disease. J Neurochem 81: 663-672.</Citation><ArticleIdList><ArticleId IdType="pubmed">12065626</ArticleId></ArticleIdList></Reference><Reference><Citation>Skovronsky DM, Moore DB, Milla ME, Doms RW, Lee VM (2000) Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network. J Biol Chem 275: 2568-2575.</Citation><ArticleIdList><ArticleId IdType="pubmed">10644715</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DH, Nakamura M, McIntosh TK, Wang J, Rodriguez A, Chen XH, Raghupathi R, Saatman KE, Clemens J, Schmidt ML, Lee VM, Trojanowski JQ (1998) Brain trauma induces massive hippocampal neuron death linked to a surge in beta-amyloid levels in mice overexpressing mutant amyloid precursor protein. Am J Pathol 153: 1005-1010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853010</ArticleId><ArticleId IdType="pubmed">9736050</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DH, Chen XH, Iwata A, Graham DI (2003) Amyloid beta accumulation in axons after traumatic brain injury in humans. J Neurosurg 98: 1072-1077.</Citation><ArticleIdList><ArticleId IdType="pubmed">12744368</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR (1997) Brain infarction and the clinical expression of Alzheimer disease. The nun study. JAMA 277: 813-817.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052711</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94: 13287-13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao X, Finkbeiner S, Arnold DB, Shaywitz AJ, Greenberg ME (1998) Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 20: 709-726.</Citation><ArticleIdList><ArticleId IdType="pubmed">9581763</ArticleId></ArticleIdList></Reference><Reference><Citation>Uryu K, Laurer H, McIntosh T, Pratico D, Martinez D, Leight S, Lee VM, Trojanowski JQ (2002) Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis. J Neurosci 22: 446-454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758680</ArticleId><ArticleId IdType="pubmed">11784789</ArticleId></ArticleIdList></Reference><Reference><Citation>West AE, Chen WG, Dalva MB, Dolmetsch RE, Kornhauser JM, Shaywitz AJ, Takasu MA, Tao X, Greenberg ME (2001) Calcium regulation of neuronal gene expression. Proc Natl Acad Sci USA 98: 11024-11031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC58677</ArticleId><ArticleId IdType="pubmed">11572963</ArticleId></ArticleIdList></Reference><Reference><Citation>Willoughby DA, Rozovsky I, Lo AC, Finch CE (1995) Beta-amyloid precursor protein (APP) and APP-RNA are rapidly affected by glutamate in cultured neurons: selective increase of mRNAs encoding a Kunitz protease inhibitor domain. J Mol Neurosci 6: 257-276.</Citation><ArticleIdList><ArticleId IdType="pubmed">8860237</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J, Black DL (2001) A CaMK IV responsive RNA element mediates depolarization-induced alternative splicing of ion channels. Nature 410: 936-939.</Citation><ArticleIdList><ArticleId IdType="pubmed">11309619</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16227967</PMID><DateCompleted><Year>2006</Year><Month>01</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1465-7392</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>11</Issue><PubDate><Year>2005</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature cell biology</Title><ISOAbbreviation>Nat Cell Biol</ISOAbbreviation></Journal><ArticleTitle>Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin.</ArticleTitle><Pagination><StartPage>1118</StartPage><EndPage>1123</EndPage><MedlinePgn>1118-23</MedlinePgn></Pagination><Abstract><AbstractText>Amyloid beta peptide (Abeta) has a key role in the pathological process of Alzheimer's disease (AD), but the physiological function of Abeta and of the amyloid precursor protein (APP) is unknown. Recently, it was shown that APP processing is sensitive to cholesterol and other lipids. Hydroxymethylglutaryl-CoA reductase (HMGR) and sphingomyelinases (SMases) are the main enzymes that regulate cholesterol biosynthesis and sphingomyelin (SM) levels, respectively. We show that control of cholesterol and SM metabolism involves APP processing. Abeta42 directly activates neutral SMase and downregulates SM levels, whereas Abeta40 reduces cholesterol de novo synthesis by inhibition of HMGR activity. This process strictly depends on gamma-secretase activity. In line with altered Abeta40/42 generation, pathological presenilin mutations result in increased cholesterol and decreased SM levels. Our results demonstrate a biological function for APP processing and also a functional basis for the link that has been observed between lipids and Alzheimer's disease (AD).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grimm</LastName><ForeName>Marcus O W</ForeName><Initials>MO</Initials><AffiliationInfo><Affiliation>Centre for Molecular Biology Heidelberg, INF 282, D-69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimm</LastName><ForeName>Heike S</ForeName><Initials>HS</Initials></Author><Author ValidYN="Y"><LastName>P&#xe4;tzold</LastName><ForeName>Andreas J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Zinser</LastName><ForeName>Eva G</ForeName><Initials>EG</Initials></Author><Author ValidYN="Y"><LastName>Halonen</LastName><ForeName>Riikka</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Duering</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tsch&#xe4;pe</LastName><ForeName>Jakob A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Jie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hartmann</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS041783</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS041783</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Cell Biol</MedlineTA><NlmUniqueID>100890575</NlmUniqueID><ISSNLinking>1465-7392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508861">PSEN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013109">Sphingomyelins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C444321">amyloid beta-protein (1-34)</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.12</RegistryNumber><NameOfSubstance UI="D013108">Sphingomyelin Phosphodiesterase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Cell Biol. 2006 Apr;8(4):424</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Cell Biol. 2005 Nov;7(11):1045-7. doi: 10.1038/ncb1105-1045.</RefSource><PMID Version="1">16385731</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019556" MajorTopicYN="N">COS Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050356" MajorTopicYN="Y">Lipid Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013108" MajorTopicYN="N">Sphingomyelin Phosphodiesterase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013109" MajorTopicYN="N">Sphingomyelins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>1</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16227967</ArticleId><ArticleId IdType="doi">10.1038/ncb1313</ArticleId><ArticleId IdType="pii">ncb1313</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16227987</PMID><DateCompleted><Year>2005</Year><Month>12</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1078-8956</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>11</Issue><PubDate><Year>2005</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Dopamine covalently modifies and functionally inactivates parkin.</ArticleTitle><Pagination><StartPage>1214</StartPage><EndPage>1221</EndPage><MedlinePgn>1214-21</MedlinePgn></Pagination><Abstract><AbstractText>Inherited mutations in PARK2, the gene encoding parkin, cause selective degeneration of catecholaminergic neurons in the substantia nigra and locus coeruleus of the brainstem, resulting in early-onset parkinsonism. But the role of parkin in common, sporadic forms of Parkinson disease remains unclear. Here we report that the neurotransmitter dopamine covalently modifies parkin in living dopaminergic cells, a process that increases parkin insolubility and inactivates its E3 ubiquitin ligase function. In the brains of individuals with sporadic Parkinson disease, we observed decreases in parkin solubility consistent with its functional inactivation. Using a new biochemical method, we detected catechol-modified parkin in the substantia nigra but not other regions of normal human brain. These findings show a vulnerability of parkin to modification by dopamine, the principal transmitter lost in Parkinson disease, suggesting a mechanism for the progressive loss of parkin function in dopaminergic neurons during aging and sporadic Parkinson disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>LaVoie</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, 77 Avenue Louis Pasteur, HIM 7th Floor, Boston, Massachusetts 02115, USA. mlavoie@rics.bwh.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostaszewski</LastName><ForeName>Beth L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Weihofen</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Schlossmacher</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS38375</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002250">Carbon Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>44RAL3456C</RegistryNumber><NameOfSubstance UI="D008694">Methamphetamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="C111567">parkin protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2005 Nov;11(11):1159-61. doi: 10.1038/nm1105-1159.</RefSource><PMID Version="1">16270070</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002250" MajorTopicYN="N">Carbon Radioisotopes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008125" MajorTopicYN="N">Locus Coeruleus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008694" MajorTopicYN="N">Methamphetamine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011233" MajorTopicYN="N">Precipitin Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044767" MajorTopicYN="N">Ubiquitin-Protein Ligases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16227987</ArticleId><ArticleId IdType="doi">10.1038/nm1314</ArticleId><ArticleId IdType="pii">nm1314</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16229831</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0012-1606</ISSN><JournalIssue CitedMedium="Print"><Volume>288</Volume><Issue>1</Issue><PubDate><Year>2005</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Developmental biology</Title><ISOAbbreviation>Dev Biol</ISOAbbreviation></Journal><ArticleTitle>The insect homologue of the amyloid precursor protein interacts with the heterotrimeric G protein Go alpha in an identified population of migratory neurons.</ArticleTitle><Pagination><StartPage>160</StartPage><EndPage>178</EndPage><MedlinePgn>160-78</MedlinePgn></Pagination><Abstract><AbstractText>The amyloid precursor protein (APP) is the source of Abeta fragments implicated in the formation of senile plaques in Alzheimer's disease (AD). APP-related proteins are also expressed at high levels in the embryonic nervous system and may serve a variety of developmental functions, including the regulation of neuronal migration. To investigate this issue, we have cloned an orthologue of APP (msAPPL) from the moth, Manduca sexta, a preparation that permits in vivo manipulations of an identified set of migratory neurons (EP cells) within the developing enteric nervous system. Previously, we found that EP cell migration is regulated by the heterotrimeric G protein Goalpha: when activated by unknown receptors, Goalpha induces the onset of Ca2+ spiking in these neurons, which in turn down-regulates neuronal motility. We have now shown that msAPPL is first expressed by the EP cells shortly before the onset of migration and that this protein undergoes a sequence of trafficking, processing, and glycosylation events that correspond to discrete phases of neuronal migration and differentiation. We also show that msAPPL interacts with Goalpha in the EP cells, suggesting that msAPPL may serve as a novel G-protein-coupled receptor capable of modulating specific aspects of migration via Goalpha-dependent signal transduction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Swanson</LastName><ForeName>T L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Department of Cell &amp; Developmental Biology, L-215, Oregon Health &amp; Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knittel</LastName><ForeName>L M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Coate</LastName><ForeName>T M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Farley</LastName><ForeName>S M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Copenhaver</LastName><ForeName>P F</ForeName><Initials>PF</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GENBANK</DataBankName><AccessionNumberList><AccessionNumber>DQ008058</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG025525</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS034439</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG08017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS34439</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dev Biol</MedlineTA><NlmUniqueID>0372762</NlmUniqueID><ISSNLinking>0012-1606</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.1</RegistryNumber><NameOfSubstance UI="D019206">GTP-Binding Protein alpha Subunits, Gi-Go</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019206" MajorTopicYN="N">GTP-Binding Protein alpha Subunits, Gi-Go</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018507" MajorTopicYN="N">Gene Expression Regulation, Developmental</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018402" MajorTopicYN="N">Manduca</DescriptorName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16229831</ArticleId><ArticleId IdType="mid">NIHMS196886</ArticleId><ArticleId IdType="pmc">PMC2862231</ArticleId><ArticleId IdType="doi">10.1016/j.ydbio.2005.09.029</ArticleId><ArticleId IdType="pii">S0012-1606(05)00636-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akaaboune M, Allinquant B, Farza H, Roy K, Magoul R, Fiszman M, Festoff BW, Hantai D. Developmental regulation of amyloid precursor protein at the neuromuscular junction in mouse skeletal muscle. Mol Cell Neurosci. 2000;15:355&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">10845772</ArticleId></ArticleIdList></Reference><Reference><Citation>Annaert W, De Strooper B. A cell biological perspective on Alzheimer&#x2019;s disease. Annu Rev Cell Dev Biol. 2002;18:25&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">12142279</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashley J, Packard M, Ataman B, Budnik V. Fasciclin II signals new synapse formation through amyloid precursor protein and the scaffolding protein dX11/Mint. J Neurosci. 2005;25:5943&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724788</ArticleId><ArticleId IdType="pubmed">15976083</ArticleId></ArticleIdList></Reference><Reference><Citation>Beher D, Hesse L, Masters CL, Multhaup G. Regulation of amyloid protein precursor (APP) binding to collagen and mapping of the binding sites on APP and collagen type I. J Biol Chem. 1996;271:1613&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">8576160</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouillet E, Trembleau A, Galanaud D, Volovitch M, Bouillot C, Valenza C, Prochiantz A, Allinquant B. The amyloid precursor protein interacts with Go heterotrimeric protein within a cell compartment specialized in signal transduction. J Neurosci. 1999;19:1717&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782156</ArticleId><ArticleId IdType="pubmed">10024358</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush AI, Pettingell WH, Jr, de Paradis M, Tanzi RE, Wasco W. The amyloid beta-protein precursor and its mammalian homologues. Evidence for a zinc-modulated heparin-binding superfamily. J Biol Chem. 1994;269:26618&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">7929392</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, Sudhof TC. Dissection of amyloid-beta precursor protein-dependent transcriptional transactivation. J Biol Chem. 2004;279:24601&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">15044485</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Yankner BA. An antibody to beta amyloid and the amyloid precursor protein inhibits cell-substratum adhesion in many mammalian cell types. Neurosci Lett. 1991;125:223&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1715534</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarris HJ, Key B, Beyreuther K, Masters CL, Small DH. Expression of the amyloid protein precursor of Alzheimer&#x2019;s disease in the developing rat olfactory system. Brain Res Dev Brain Res. 1995;88:87&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">7493410</ArticleId></ArticleIdList></Reference><Reference><Citation>Copenhaver PF. Origins, migration, and differentiation of glial cells in the insect nervous system from a discrete set of glial precursors. Devt. 1993;117:59&#x2013;74.</Citation></Reference><Reference><Citation>Copenhaver PF, Horgan AM, Combes S. An identified set of visceral muscle bands is essential for the guidance of migratory neurons in the enteric nervous system of Manduca sexta. Dev Biol. 1996;179:412&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">8903356</ArticleId></ArticleIdList></Reference><Reference><Citation>Copenhaver PF, Taghert PH. Position-dependent expression of peptidergic phenotype in post-migratory neurons of the insect enteric system. Soc Neurosci Abs. 1988;14:770.</Citation></Reference><Reference><Citation>Copenhaver PF, Taghert PH. Development of the enteric nervous system in the moth I. Diversity of cell types and the embryonic expression of FMRFamide-related neuropeptides. Developmental Biology. 1989a;131:70&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">2909410</ArticleId></ArticleIdList></Reference><Reference><Citation>Copenhaver PF, Taghert PH. Development of the enteric nervous system in the moth II. Stereotyped cell migration precedes the differentiation of embryonic neurons. Developmental Biology. 1989b;131:85&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">2909411</ArticleId></ArticleIdList></Reference><Reference><Citation>Copenhaver PF, Taghert PH. Neurogenesis in the insect enteric nervous system: generation of pre-migratory neurons from an epithelial placode. Development. 1990;109:17&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">2209463</ArticleId></ArticleIdList></Reference><Reference><Citation>Copenhaver PF, Taghert PH. Origins of the insect enteric nervous system: differentiation of the enteric ganglia from a neurogenic epithelium. Development. 1991;113:1115&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pubmed">1811931</ArticleId></ArticleIdList></Reference><Reference><Citation>Coulson EJ, Paliga K, Beyreuther K, Masters CL. What the evolution of the amyloid protein precursor supergene family tells us about its function. Neurochem Int. 2000;36:175&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">10676850</ArticleId></ArticleIdList></Reference><Reference><Citation>Daigle I, Li C. apl-1, a Caenorhabditis elegans gene encoding a protein related to the human beta-amyloid protein precursor. Proc Natl Acad Sci U S A. 1993;90:12045&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC48122</ArticleId><ArticleId IdType="pubmed">8265668</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W. Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci. 2000;113 ( Pt 11):1857&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">10806097</ArticleId></ArticleIdList></Reference><Reference><Citation>Edmond BT, Moomaw CR, Hsu JT, Slaughter C, Ellis L. The p38 and p34 polypeptides of growth cone particle membranes are the &#x3b1; and b subunits of G proteins. Developmental Brain Research. 1990;56:131&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">2126227</ArticleId></ArticleIdList></Reference><Reference><Citation>Giambarella U, Yamatsuji T, Okamoto T, Matsui T, Ikezu T, Murayama Y, Levine MA, Katz A, Gautam N, Nishimoto I. G protein betagamma complex-mediated apoptosis by familial Alzheimer&#x2019;s disease mutant of APP. Embo J. 1997;16:4897&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1170125</ArticleId><ArticleId IdType="pubmed">9305632</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner GG, Wong CW. Alzheimer&#x2019;s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Greeve I, Kretzschmar D, Tschape JA, Beyn A, Brellinger C, Schweizer M, Nitsch RM, Reifegerste R. Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J Neurosci. 2004;24:3899&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729409</ArticleId><ArticleId IdType="pubmed">15102905</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunawardena S, Goldstein LS. Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron. 2001;32:389&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">11709151</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer&#x2019;s disease. Trends Pharmacol Sci. 1991;12:383&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1763432</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi JH, Hildebrand JG. Insect olfactory neurons in vitro: morphological and physiological characterization of cells from the developing antennal lobes of Manduca sexta. Journal of Neuroscience. 1990;10:848&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570118</ArticleId><ArticleId IdType="pubmed">2156962</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi JH, Levine RB. Calcium and potassium currents in leg motoneurons during postembryonic development in the hawkmoth Manduca sexta. J Exp Biol. 1992;171:15&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">1431728</ArticleId></ArticleIdList></Reference><Reference><Citation>Heber S, Herms J, Gajic V, Hainfellner J, Aguzzi A, Rulicke T, von Kretzschmar H, von Koch C, Sisodia S, Tremml P, Lipp HP, Wolfer DP, Muller U. Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. J Neurosci. 2000;20:7951&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772747</ArticleId><ArticleId IdType="pubmed">11050115</ArticleId></ArticleIdList></Reference><Reference><Citation>Herms J, Anliker B, Heber S, Ring S, Fuhrmann M, Kretzschmar H, Sisodia S, Muller U. Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. Embo J 2004</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524337</ArticleId><ArticleId IdType="pubmed">15385965</ArticleId></ArticleIdList></Reference><Reference><Citation>Horgan AM, Copenhaver PF. G protein-mediated inhibition of neuronal migration requires calcium influx. J Neurosci. 1998;18:4189&#x2013;4200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792790</ArticleId><ArticleId IdType="pubmed">9592098</ArticleId></ArticleIdList></Reference><Reference><Citation>Horgan AM, Lagrange MT, Copenhaver PF. Developmental expression of G proteins in a migratory population of embryonic neurons. Development. 1994;120:729&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">7600953</ArticleId></ArticleIdList></Reference><Reference><Citation>Horgan AM, Lagrange MT, Copenhaver PF. A developmental role for the heterotrimeric G protein Go&#x3b1; in a migratory population of embryonic neurons. Dev Biol. 1995;172:640&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pubmed">8612978</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikezu T, Okamoto T, Komatsuzaki K, Matsui T, Martyn JA, Nishimoto I. Negative transactivation of cAMP response element by familial Alzheimer&#x2019;s mutants of APP. Embo J. 1996;15:2468&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC450179</ArticleId><ArticleId IdType="pubmed">8665854</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B. The precursor of Alzheimer&#x2019;s disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987;325:733&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">2881207</ArticleId></ArticleIdList></Reference><Reference><Citation>Kibbey MC, Jucker M, Weeks BS, Neve RL, Van Nostrand WE, Kleinman HK. beta-Amyloid precursor protein binds to the neurite-promoting IKVAV site of laminin. Proc Natl Acad Sci U S A. 1993;90:10150&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47731</ArticleId><ArticleId IdType="pubmed">8234269</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita A, Whelan CM, Berezovska O, Hyman BT. The gamma secretase-generated carboxyl-terminal domain of the amyloid precursor protein induces apoptosis via Tip60 in H4 cells. J Biol Chem. 2002;277:28530&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12032152</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirazov E, Kirazov L, Bigl V, Schliebs R. Ontogenetic changes in protein level of amyloid precursor protein (APP) in growth cones and synaptosomes from rat brain and prenatal expression pattern of APP mRNA isoforms in developing rat embryo. Int J Dev Neurosci. 2001;19:287&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337197</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitaguchi N, Takahashi Y, Tokushima Y, Shiojiri S, Ito H. Novel precursor of Alzheimer&#x2019;s disease amyloid protein shows protease inhibitory activity. Nature. 1988;331:530&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">2893291</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL. Abeta toxicity in Alzheimer&#x2019;s disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int. 2002;41:345&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">12176077</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahiri DK, Nall C, Chen D, Zaphiriou M, Morgan C, Nurnberger JI., Sr Developmental expression of the beta-amyloid precursor protein and heat-shock protein 70 in the cerebral hemisphere region of the rat brain. Ann N Y Acad Sci. 2002;965:324&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">12105108</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Morfini GA, Lee EB, Farah MH, Szodorai A, DeBoer SR, Koliatsos VE, Kins S, Lee VM, Wong PC, Price DL, Brady ST, Sisodia SS. Axonal transport, amyloid precursor protein, kinesin-1, and the processing apparatus: revisited. J Neurosci. 2005;25:2386&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6726084</ArticleId><ArticleId IdType="pubmed">15745965</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Kao SC, Lemere CA, Xia W, Tseng HC, Zhou Y, Neve R, Ahlijanian MK, Tsai LH. APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol. 2003;163:83&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173445</ArticleId><ArticleId IdType="pubmed">14557249</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HL, Roch JM, Sundsmo M, Otero D, Sisodia S, Thomas R, Saitoh T. Defective neurite extension is caused by a mutation in amyloid beta/A4 (A beta) protein precursor found in familial Alzheimer&#x2019;s disease. J Neurobiol. 1997;32:469&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">9110259</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Liu T, Peng Y, Yuan C, Guo A. Specific functions of Drosophila amyloid precursor-like protein in the development of nervous system and nonneural tissues. J Neurobiol. 2004;61:343&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">15389603</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Wang H, Wang S, Quon D, Liu YW, Cordell B. Positive and negative regulation of APP amyloidogenesis by sumoylation. Proc Natl Acad Sci U S A. 2003;100:259&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140945</ArticleId><ArticleId IdType="pubmed">12506199</ArticleId></ArticleIdList></Reference><Reference><Citation>Loffler J, Huber G. Beta-amyloid precursor protein isoforms in various rat brain regions and during brain development. J Neurochem. 1992;59:1316&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">1402883</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo L, Tully T, White K. Human amyloid precursor protein ameliorates behavioral deficit of flies deleted for Appl gene. Neuron. 1992;9:595&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">1389179</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo LQ, Martin-Morris LE, White K. Identification, secretion, and neural expression of APPL, a Drosophila protein similar to human amyloid protein precursor. J Neurosci. 1990;10:3849&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570036</ArticleId><ArticleId IdType="pubmed">2125311</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Morris LE, White K. The Drosophila transcript encoded by the beta-amyloid protein precursor-like gene is restricted to the nervous system. Development. 1990;110:185&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">2127912</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Mallory M, Ge N, Saitoh T. Amyloid precursor protein is localized in growing neurites of neonatal rat brain. Brain Res. 1992;593:323&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1450940</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985;82:4245&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC397973</ArticleId><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>Moya KL, Benowitz LI, Schneider GE, Allinquant B. The amyloid precursor protein is developmentally regulated and correlated with synaptogenesis. Dev Biol. 1994;161:597&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">8314003</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Johnson WB, Ruppe MD, Alford M, Rockenstein EM, Forss-Petter S, Pietropaolo M, Mallory M, Abraham CR. Synaptotrophic effects of human amyloid beta protein precursors in the cortex of transgenic mice. Brain Res. 1994;666:151&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">7882025</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimoto I, Okamoto T, Matsaura Y, Takahashi S. Alzheimer amyloid protein precursor complexes with brain GTP-binding protein Go. Nature. 1993;362:75&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446172</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, Cataldo AM, Mathews PM. The endosomal-lysosomal system of neurons in Alzheimer&#x2019;s disease pathogenesis: a review. Neurochem Res. 2000;25:1161&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">11059790</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohta M, Kitamoto T, Iwaki T, Ohgami T, Fukui M, Tateishi J. Immunohistochemical distribution of amyloid precursor protein during normal rat development. Brain Res Dev Brain Res. 1993;75:151&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">7505208</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto T, Takeda S, Giambarella U, Murayama Y, Matsui T, Katada T, Matsuura Y, Nishimoto I. Intrinsic signaling function of APP as a novel target of three V642 mutations linked to familial Alzheimer&#x2019;s disease. Embo J. 1996;15:3769&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC452057</ArticleId><ArticleId IdType="pubmed">8670881</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto T, Takeda S, Murayama Y, Ogata E, Nishimoto I. Ligand-dependent G protein coupling function of amyloid transmembrane precursor. J Biol Chem. 1995;270:4205&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7876177</ArticleId></ArticleIdList></Reference><Reference><Citation>Oltersdorf T, Ward PJ, Henriksson T, Beattie EC, Neve R, Lieberburg I, Fritz LC. The Alzheimer amyloid precursor protein. Identification of a stable intermediate in the biosynthetic/degradative pathway. J Biol Chem. 1990;265:4492&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">1968460</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel NH, Goodman CS. DIG-labeled single-stranded DNA probes for in situ hybridization. In: Kessler C, editor. Non-radioactive labelling and detection of biomolecules. Springer; Heidelberg: 1992. pp. 377&#x2013;381.</Citation></Reference><Reference><Citation>Perez RG, Zheng H, Van der Ploeg LH, Koo EH. The beta-amyloid precursor protein of Alzheimer&#x2019;s disease enhances neuron viability and modulates neuronal polarity. J Neurosci. 1997;17:9407&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573428</ArticleId><ArticleId IdType="pubmed">9390996</ArticleId></ArticleIdList></Reference><Reference><Citation>Plummer TH, Jr, Tarentino AL. Purification of the oligosaccharide-cleaving enzymes of Flavobacterium meningosepticum. Glycobiology. 1991;1:257&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">1794038</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu WQ, Ferreira A, Miller C, Koo EH, Selkoe DJ. Cell-surface beta-amyloid precursor protein stimulates neurite outgrowth of hippocampal neurons in an isoform-dependent manner. J Neurosci. 1995;15:2157&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578166</ArticleId><ArticleId IdType="pubmed">7891158</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinow S, White K. Characterization and spatial distribution of the ELAV protein during Drosophila melanogaster development. Journal of Neurobiology. 1991;22:443&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">1716300</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Martin-Morris L, Luo LQ, White K. A Drosophila gene encoding a protein resembling the human beta-amyloid protein precursor. Proc Natl Acad Sci U S A. 1989;86:2478&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC286936</ArticleId><ArticleId IdType="pubmed">2494667</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo C, Venezia V, Repetto E, Nizzari M, Violani E, Carlo P, Schettini G. The amyloid precursor protein and its network of interacting proteins: physiological and pathological implications. Brain Res Brain Res Rev. 2005;48:257&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">15850665</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabo SL, Ikin AF, Buxbaum JD, Greengard P. The Alzheimer amyloid precursor protein (APP) and FE65, an APP-binding protein, regulate cell movement. J Cell Biol. 2001;153:1403&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2150733</ArticleId><ArticleId IdType="pubmed">11425871</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabo SL, Ikin AF, Buxbaum JD, Greengard P. The amyloid precursor protein and its regulatory protein, FE65, in growth cones and synapses in vitro and in vivo. J Neurosci. 2003;23:5407&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741254</ArticleId><ArticleId IdType="pubmed">12843239</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandbrink R, Masters CL, Beyreuther K. Beta A4-amyloid protein precursor mRNA isoforms without exon 15 are ubiquitously expressed in rat tissues including brain, but not in neurons. J Biol Chem. 1994a;269:1510&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8288617</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandbrink R, Masters CL, Beyreuther K. Similar alternative splicing of a non-homologous domain in beta A4-amyloid protein precursor-like proteins. J Biol Chem. 1994b;269:14227&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">8188705</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuermann S, Hambsch B, Hesse L, Stumm J, Schmidt C, Beher D, Bayer TA, Beyreuther K, Multhaup G. Homodimerization of amyloid precursor protein and its implication in the amyloidogenic pathway of Alzheimer&#x2019;s disease. J Biol Chem. 2001;276:33923&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11438549</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer&#x2019;s disease. Trends Cell Biol. 1998;8:447&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">9854312</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Toward a comprehensive theory for Alzheimer&#x2019;s disease. Hypothesis: Alzheimer&#x2019;s disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci. 2000;924:17&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193794</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer&#x2019;s disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern EA, Bacskai BJ, Hickey GA, Attenello FJ, Lombardo JA, Hyman BT. Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. J Neurosci. 2004;24:4535&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729398</ArticleId><ArticleId IdType="pubmed">15140924</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, Raman R, Davies P, Masliah E, Williams DS, Goldstein LS. Axonopathy and transport deficits early in the pathogenesis of Alzheimer&#x2019;s disease. Science. 2005;307:1282&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15731448</ArticleId></ArticleIdList></Reference><Reference><Citation>Struble RG, Dhanraj DN, Mei Y, Wilson M, Wang R, Ramkumar V. Beta-amyloid precursor protein-like immunoreactivity is upregulated during olfactory nerve regeneration in adult rats. Brain Res. 1998;780:129&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">9473628</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh YH, Checler F. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer&#x2019;s disease. Pharmacol Rev. 2002;54:469&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">12223532</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, Milner TA, Gouras GK. Oligomerization of Alzheimer&#x2019;s beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci. 2004;24:3592&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729733</ArticleId><ArticleId IdType="pubmed">15071107</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong L, Balazs R, Thornton PL, Cotman CW. Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J Neurosci. 2004;24:6799&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729714</ArticleId><ArticleId IdType="pubmed">15282285</ArticleId></ArticleIdList></Reference><Reference><Citation>Torroja L, Chu H, Kotovsky I, White K. Neuronal overexpression of APPL, the Drosophila homologue of the amyloid precursor protein (APP), disrupts axonal transport. Curr Biol. 1999a;9:489&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">10322116</ArticleId></ArticleIdList></Reference><Reference><Citation>Torroja L, Packard M, Gorczyca M, White K, Budnik V. The Drosophila beta-amyloid precursor protein homolog promotes synapse differentiation at the neuromuscular junction. J Neurosci. 1999b;19:7793&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782486</ArticleId><ArticleId IdType="pubmed">10479682</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner PR, O&#x2019;Connor K, Tate WP, Abraham WC. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol. 2003;70:1&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">12927332</ArticleId></ArticleIdList></Reference><Reference><Citation>von Koch CS, Zheng H, Chen H, Trumbauer M, Thinakaran G, van der Ploeg LH, Price DL, Sisodia SS. Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice. Neurobiol Aging. 1997;18:661&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9461064</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter J, Kaether C, Steiner H, Haass C. The cell biology of Alzheimer&#x2019;s disease: uncovering the secrets of secretases. Curr Opin Neurobiol. 2001;11:585&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">11595492</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Yang G, Mosier DR, Chang P, Zaidi T, Gong YD, Zhao NM, Dominguez B, Lee KF, Gan WB, Zheng H. Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-Like protein 2. J Neurosci. 2005;25:1219&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725967</ArticleId><ArticleId IdType="pubmed">15689559</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasco W, Bupp K, Magendantz M, Gusella JF, Tanzi RE, Solomon F. Identification of a mouse brain cDNA that encodes a protein related to the Alzheimer disease-associated amyloid beta protein precursor. Proc Natl Acad Sci U S A. 1992;89:10758&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC50421</ArticleId><ArticleId IdType="pubmed">1279693</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasco W, Gurubhagavatula S, Paradis MD, Romano DM, Sisodia SS, Hyman BT, Neve RL, Tanzi RE. Isolation and characterization of APLP2 encoding a homologue of the Alzheimer&#x2019;s associated amyloid beta protein precursor. Nat Genet. 1993;5:95&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">8220435</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidemann A, Konig G, Bunke D, Fischer P, Salbaum JM, Masters CL, Beyreuther K. Identification, biogenesis, and localization of precursors of Alzheimer&#x2019;s disease A4 amyloid protein. Cell. 1989;57:115&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">2649245</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright JW, Copenhaver PF. Different isoforms of fasciclin II play distinct roles in the guidance of neuronal migration during insect embryogenesis. Dev Biol. 2000;225:59&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">10964464</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright JW, Copenhaver PF. Cell type-specific expression of fasciclin II isoforms reveals neuronal-glial interactions during peripheral nerve growth. Dev Biol. 2001;234:24&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">11356017</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright JW, Schwinof KM, Snyder MA, Copenhaver PF. A delayed role for nitric oxide-sensitive guanylate cyclases in a migratory population of embryonic neurons. Dev Biol. 1998;203:15&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">9851840</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright JW, Snyder MA, Schwinof KM, Combes S, Copenhaver PF. A role for fasciclin II in the guidance of neuronal migration. Development. 1999;126:3217&#x2013;3228.</Citation><ArticleIdList><ArticleId IdType="pubmed">10375511</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki T, Koo EH, Selkoe DJ. Cell surface amyloid beta-protein precursor colocalizes with beta 1 integrins at substrate contact sites in neural cells. J Neurosci. 1997;17:1004&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573178</ArticleId><ArticleId IdType="pubmed">8994055</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner BA. Mechanisms of neuronal degeneration in Alzheimer&#x2019;s disease. Neuron. 1996;16:921&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">8630250</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambrano N, Bimonte M, Arbucci S, Gianni D, Russo T, Bazzicalupo P. feh-1 and apl-1, the Caenorhabditis elegans orthologues of mammalian Fe65 and beta-amyloid precursor protein genes, are involved in the same pathway that controls nematode pharyngeal pumping. J Cell Sci. 2002;115:1411&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">11896189</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16237129</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>12</Issue><PubDate><Year>2005</Year><Month>Dec</Month><Day>27</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.</ArticleTitle><Pagination><StartPage>1863</StartPage><EndPage>1872</EndPage><MedlinePgn>1863-72</MedlinePgn></Pagination><Abstract><AbstractText>The dementia with Lewy bodies (DLB) Consortium has revised criteria for the clinical and pathologic diagnosis of DLB incorporating new information about the core clinical features and suggesting improved methods to assess them. REM sleep behavior disorder, severe neuroleptic sensitivity, and reduced striatal dopamine transporter activity on functional neuroimaging are given greater diagnostic weighting as features suggestive of a DLB diagnosis. The 1-year rule distinguishing between DLB and Parkinson disease with dementia may be difficult to apply in clinical settings and in such cases the term most appropriate to each individual patient should be used. Generic terms such as Lewy body (LB) disease are often helpful. The authors propose a new scheme for the pathologic assessment of LBs and Lewy neurites (LN) using alpha-synuclein immunohistochemistry and semiquantitative grading of lesion density, with the pattern of regional involvement being more important than total LB count. The new criteria take into account both Lewy-related and Alzheimer disease (AD)-type pathology to allocate a probability that these are associated with the clinical DLB syndrome. Finally, the authors suggest patient management guidelines including the need for accurate diagnosis, a target symptom approach, and use of appropriate outcome measures. There is limited evidence about specific interventions but available data suggest only a partial response of motor symptoms to levodopa: severe sensitivity to typical and atypical antipsychotics in approximately 50%, and improvements in attention, visual hallucinations, and sleep disorders with cholinesterase inhibitors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McKeith</LastName><ForeName>I G</ForeName><Initials>IG</Initials><AffiliationInfo><Affiliation>Institute for Ageing and Health, University of Newcastle upon Tyne, UK. i.g.mckeith@ncl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>D W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Lowe</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Emre</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>J T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Duda</LastName><ForeName>J E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Lippa</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>E K</ForeName><Initials>EK</Initials></Author><Author ValidYN="Y"><LastName>Aarsland</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Arai</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>C G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>D J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Del Ser</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Gauthier</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Goetz</LastName><ForeName>C G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Gomez-Tortosa</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Halliday</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>L A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Iwatsubo</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kalaria</LastName><ForeName>R N</ForeName><Initials>RN</Initials></Author><Author ValidYN="Y"><LastName>Kaufer</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Kenny</LastName><ForeName>R A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Korczyn</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kosaka</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>V M Y</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Lees</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Litvan</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Londos</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>O L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Minoshima</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mizuno</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Molina</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Mukaetova-Ladinska</LastName><ForeName>E B</ForeName><Initials>EB</Initials></Author><Author ValidYN="Y"><LastName>Pasquier</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>R H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Schulz</LastName><ForeName>J B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>J Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><CollectiveName>Consortium on DLB</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0400074</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017065">Practice Guideline</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050483">Dopamine Plasma Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Neurology. 2005 Dec 27;65(12):1992</RefSource></CommentsCorrections><CommentsCorrections RefType="SummaryForPatientsIn"><RefSource>Neurology. 2005 Dec 27;65(12):E26-7. doi: 10.1212/01.wnl.0000194990.62816.4c.</RefSource><PMID Version="1">16380603</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2006 May 9;66(9):1455; author reply 1455. doi: 10.1212/01.wnl.0000224698.67660.45.</RefSource><PMID Version="1">16682691</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050483" MajorTopicYN="N">Dopamine Plasma Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004361" MajorTopicYN="N">Drug Tolerance</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020187" MajorTopicYN="N">REM Sleep Behavior Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>105</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000187889.17253.b1</ArticleId><ArticleId IdType="pii">01.wnl.0000187889.17253.b1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16239176</PMID><DateCompleted><Year>2005</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1474-4422</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>11</Issue><PubDate><Year>2005</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease.</ArticleTitle><Pagination><StartPage>705</StartPage><EndPage>711</EndPage><MedlinePgn>705-11</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Physical activity may help maintain cognitive function and decrease dementia risk, but epidemiological findings remain controversial. The aim of our study was to investigate the association between leisure-time physical activity at midlife and the subsequent development of dementia and Alzheimer's disease (AD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Participants were randomly selected from the survivors of a population-based cohort previously surveyed in 1972, 1977, 1982, or 1987. 1449 persons (72.5%) age 65-79 years participated in the re-examination in 1998 (mean follow-up, 21 years). 117 persons had dementia and 76 had AD. Multiple logistic regression methods were used to analyse the association between leisure-time physical activity and dementia or AD.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Leisure-time physical activity at midlife at least twice a week was associated with a reduced risk of dementia and AD (odds ratio [OR] 0.48 [95% CI 0.25-0.91] and 0.38 [0.17-0.85], respectively), even after adjustments for age, sex, education, follow-up time, locomotor disorders, APOE genotype, vascular disorders, smoking, and alcohol drinking. The associations were more pronounced among the APOE epsilon4 carriers.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Leisure-time physical activity at midlife is associated with a decreased risk of dementia and AD later in life. Regular physical activity may reduce the risk or delay the onset of dementia and AD, especially among genetically susceptible individuals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rovio</LastName><ForeName>Suvi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Aging Research Center, Division of Geriatric Epidemiology, Neurotec, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xe5;reholt</LastName><ForeName>Ingemar</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Helkala</LastName><ForeName>Eeva-Liisa</ForeName><Initials>EL</Initials></Author><Author ValidYN="Y"><LastName>Viitanen</LastName><ForeName>Matti</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Winblad</LastName><ForeName>Bengt</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Tuomilehto</LastName><ForeName>Jaakko</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Soininen</LastName><ForeName>Hilkka</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Nissinen</LastName><ForeName>Aulikki</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kivipelto</LastName><ForeName>Miia</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2005 Nov;4(11):690-1. doi: 10.1016/S1474-4422(05)70203-9.</RefSource><PMID Version="1">16239172</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007899" MajorTopicYN="N">Leisure Activities</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008019" MajorTopicYN="N">Life Style</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>11</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16239176</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(05)70198-8</ArticleId><ArticleId IdType="pii">S1474-4422(05)70198-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16239972</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9738</ISSN><JournalIssue CitedMedium="Print"><Volume>115</Volume><Issue>11</Issue><PubDate><Year>2005</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model.</ArticleTitle><Pagination><StartPage>3285</StartPage><EndPage>3290</EndPage><MedlinePgn>3285-90</MedlinePgn></Pagination><Abstract><AbstractText>Accumulation of amyloid-beta (Abeta) within extracellular spaces of the brain is a hallmark of Alzheimer disease (AD). In sporadic, late-onset AD, there is little evidence for increased Abeta production, suggesting that decreased elimination from the brain may contribute to elevated levels of Abeta and plaque formation. Efflux transport of Abeta across the blood-brain barrier (BBB) contributes to Abeta removal from the brain. P-glycoprotein (Pgp) is highly expressed on the luminal surface of brain capillary endothelial cells and contributes to the BBB. In Pgp-null mice, we show that [I]Abeta40 and [I]Abeta42 microinjected into the CNS clear at half the rate that they do in WT mice. When amyloid precursor protein-transgenic (APP-transgenic) mice were administered a Pgp inhibitor, Abeta levels within the brain interstitial fluid significantly increased within hours of treatment. Furthermore, APP-transgenic, Pgp-null mice had increased levels of brain Abeta and enhanced Abeta deposition compared with APP-transgenic, Pgp WT mice. These data establish a direct link between Pgp and Abeta metabolism in vivo and suggest that Pgp activity at the BBB could affect risk for developing AD as well as provide a novel diagnostic and therapeutic target.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University Medical School, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deane</LastName><ForeName>Rashid</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Spinner</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Parsadanian</LastName><ForeName>Maia</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Finn</LastName><ForeName>Mary Beth</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Prior</LastName><ForeName>Julie L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Sagare</LastName><ForeName>Abhay</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bales</LastName><ForeName>Kelly R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Zlokovic</LastName><ForeName>Berislav V</ForeName><Initials>BV</Initials></Author><Author ValidYN="Y"><LastName>Piwnica-Worms</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 CA094056</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS034467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG023084</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG023084</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG023316</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS034467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS034467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG23084</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG023316</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 CA94056</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI13956</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020168">ATP Binding Cassette Transporter, Subfamily B, Member 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020168" MajorTopicYN="N">ATP Binding Cassette Transporter, Subfamily B, Member 1</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2005</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16239972</ArticleId><ArticleId IdType="pmc">PMC1257538</ArticleId><ArticleId IdType="doi">10.1172/JCI25247</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Farris W, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U. S. A. 2003;100:4162&#x2013;4167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC153065</ArticleId><ArticleId IdType="pubmed">12634421</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N, et al. Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J. Neurosci. 2004;24:991&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729819</ArticleId><ArticleId IdType="pubmed">14749444</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO, et al. Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer&#x2019;s disease. Am. J. Pathol. 1998;153:725&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853019</ArticleId><ArticleId IdType="pubmed">9736023</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer&#x2019;s disease. Science. 2002;295:2264&#x2013;2267.</Citation><ArticleIdList><ArticleId IdType="pubmed">11910111</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata M, et al. Clearance of Alzheimer&#x2019;s amyloid-ss(1&#x2013;40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 2000;106:1489&#x2013;1499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC387254</ArticleId><ArticleId IdType="pubmed">11120756</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Neurovascular mechanisms of Alzheimer&#x2019;s neurodegeneration. Trends Neurosci. 2005;28:202&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">15808355</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 2004;43:333&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294142</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV, Yamada S, Holtzman D, Ghiso J, Frangione B. Clearance of amyloid beta-peptide from brain: transport or metabolism? Nat. Med. 2000;6:718&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">10888893</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer. 2002;2:48&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">11902585</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambudkar SV, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 1999;39:361&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">10331089</ArticleId></ArticleIdList></Reference><Reference><Citation>Schinkel AH, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77:491&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">7910522</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam FC, et al. beta-Amyloid efflux mediated by P-glycoprotein. J. Neurochem. 2001;76:1121&#x2013;1128.</Citation><ArticleIdList><ArticleId IdType="pubmed">11181832</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogelgesang S, et al. Deposition of Alzheimer&#x2019;s beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics. 2002;12:535&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">12360104</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, et al. Correlative memory deficits, A&#x3b2; elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Mistry P, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 2001;61:749&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">11212278</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J. Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, et al. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron. 2004;41:193&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">14741101</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma V, Piwnica-Worms D. Monitoring multidrug resistance P-glycoprotein drug transport activity with SPECT and PET radiopharmaceuticals. Topics Curr. Chem. 2005;252:155&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">20645914</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyszlewski M, Blake HM, Dahlheimer JL, Pica CM, Piwnica-Worms D. Characterization of a novel 99mTc-carbonyl complex as a functional probe of MDR1 P-glycoprotein transport activity. Mol. Imaging. 2002;1:24&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">12920858</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 2003;9:907&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">12808450</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Wu Z, Zlokovic BV. RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke. 2004;35:2628&#x2013;2631.</Citation><ArticleIdList><ArticleId IdType="pubmed">15459432</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmeyer S, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 2000;97:3473&#x2013;3478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16264</ArticleId><ArticleId IdType="pubmed">10716719</ArticleId></ArticleIdList></Reference><Reference><Citation>Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 2004;75:13&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">14749689</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeb MB, et al. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer&#x2019;s disease. J. Am. Geriatr. Soc. 2004;52:381&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">14962152</ArticleId></ArticleIdList></Reference><Reference><Citation>Piwnica-Worms D, Rao VV, Kronauge JF, Croop JM. Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation. Biochemistry. 1995;34:12210&#x2013;12220.</Citation><ArticleIdList><ArticleId IdType="pubmed">7547962</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen WS, et al. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin. Biochem. Pharmacol. 2000;60:413&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">10856437</ArticleId></ArticleIdList></Reference><Reference><Citation>Luker GD, Rao VV, Crankshaw CL, Dahlheimer J, Piwnica-Worms D. Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier. Biochemistry. 1997;36:14218&#x2013;14227.</Citation><ArticleIdList><ArticleId IdType="pubmed">9369495</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer&#x2019;s disease model. Ann. Neurol. 2000;47:739&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">10852539</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 1997;17:263&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354781</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV, Mackic JB, Wang L, McComb JG, McDonough A. Differential expression of Na,K-ATPase alpha and beta subunit isoforms at the blood-brain barrier and the choroid plexus. J. Biol. Chem. 1993;268:8019&#x2013;8025.</Citation><ArticleIdList><ArticleId IdType="pubmed">8385133</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16246844</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>281</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs.</ArticleTitle><Pagination><StartPage>1205</StartPage><EndPage>1214</EndPage><MedlinePgn>1205-14</MedlinePgn></Pagination><Abstract><AbstractText>We generated several cell models of tauopathy in order to study the mechanisms of neurodegeneration in diseases involving abnormal changes of tau protein. N2a neuroblastoma cell lines were created that inducibly express different variants of the repeat domain of tau (tau(RD)) when exposed to doxycycline (Tet-On system). The following three constructs were chosen: (i) the repeat domain of tau that coincides with the core of Alzheimer paired helical filaments; (ii) the repeat domain with the deletion mutation DeltaK280 known from frontotemporal dementia and highly prone to spontaneous aggregation; and (iii) the repeat domain with DeltaK280 and two proline point mutations that inhibit aggregation. The comparison of wild-type, pro-aggregation, and anti-aggregation mutants shows the following. (a) Aggregation of tau(RD) is toxic to cells. (b) The degree of aggregation and toxicity depends on the propensity for beta-structure. (c) Soluble mutants of tau(RD) that cannot aggregate are not toxic. (d) Aggregation is preceded by fragmentation. (e) Fragmentation of tau(RD) in cells is initially due to a thrombin-like protease activity. (f) Phosphorylation of tau(RD) (at KXGS motifs) precedes aggregation but is not correlated with the degree of aggregation. (g) Aggregates of tau(RD) disappear when the expression is silenced, showing that aggregation is reversible. (h) Aggregation can be prevented by drugs and even pre-formed aggregates can be dissolved again by drugs. Thus, the cell models open up new insights into the relationship between the structure, expression, phosphorylation, aggregation, and toxicity of tau(RD) that can be used to test current hypotheses on tauopathy and to develop drugs that prevent the aggregation and degeneration of cells.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khlistunova</LastName><ForeName>Inna</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Max-Planck-Unit for Structural Molecular Biology, DESY, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biernat</LastName><ForeName>Jacek</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yipeng</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Pickhardt</LastName><ForeName>Marcus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>von Bergen</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gazova</LastName><ForeName>Zuzana</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eckhard</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eva-Maria</ForeName><Initials>EM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>2390-54-7</RegistryNumber><NameOfSubstance UI="C009462">thioflavin T</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010447">Peptide Hydrolases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.5</RegistryNumber><NameOfSubstance UI="D013917">Thrombin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020816" MajorTopicYN="N">Amino Acid Motifs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002499" MajorTopicYN="N">Centrifugation, Density Gradient</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002845" MajorTopicYN="N">Chromatography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053938" MajorTopicYN="N">DNA Fragmentation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004591" MajorTopicYN="N">Electrophoresis, Polyacrylamide Gel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017353" MajorTopicYN="N">Gene Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008856" MajorTopicYN="N">Microscopy, Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008956" MajorTopicYN="N">Models, Chemical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010447" MajorTopicYN="N">Peptide Hydrolases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010957" MajorTopicYN="N">Plasmids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013917" MajorTopicYN="N">Thrombin</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16246844</ArticleId><ArticleId IdType="doi">10.1074/jbc.M507753200</ArticleId><ArticleId IdType="pii">S0021-9258(19)47565-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16251272</PMID><DateCompleted><Year>2006</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>102</Volume><Issue>49</Issue><PubDate><Year>2005</Year><Month>Dec</Month><Day>06</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2.</ArticleTitle><Pagination><StartPage>17551</StartPage><EndPage>17558</EndPage><MedlinePgn>17551-8</MedlinePgn></Pagination><Abstract><AbstractText>Rett syndrome (RTT) is a postnatal neurodevelopmental disorder characterized by the loss of acquired motor and language skills, autistic features, and unusual stereotyped movements. RTT is caused by mutations in the X-linked gene encoding methyl-CpG binding protein 2 (MeCP2). Mutations in MECP2 cause a variety of neurodevelopmental disorders including X-linked mental retardation, psychiatric disorders, and some cases of autism. Although MeCP2 was identified as a methylation-dependent transcriptional repressor, transcriptional profiling of RNAs from mice lacking MeCP2 did not reveal significant gene expression changes, suggesting that MeCP2 does not simply function as a global repressor. Changes in expression of a few genes have been observed, but these alterations do not explain the full spectrum of Rett-like phenotypes, raising the possibility that additional MeCP2 functions play a role in pathogenesis. In this study, we show that MeCP2 interacts with the RNA-binding protein Y box-binding protein 1 and regulates splicing of reporter minigenes. Importantly, we found aberrant alternative splicing patterns in a mouse model of RTT. Thus, we uncovered a previously uncharacterized function of MeCP2 that involves regulation of splicing, in addition to its role as a transcriptional repressor.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Juan I</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Eugene P</ForeName><Initials>EP</Initials></Author><Author ValidYN="Y"><LastName>Castle</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Crespo-Barreto</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bowman</LastName><ForeName>Aaron B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>Matthew F</ForeName><Initials>MF</Initials></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Dongcheul</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Richman</LastName><ForeName>Ron</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Jason M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Berget</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Zoghbi</LastName><ForeName>Huda Y</ForeName><Initials>HY</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 HD040301</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 HD024064</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HD24064</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051783">Methyl-CpG-Binding Protein 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1656</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="Y">DNA Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017930" MajorTopicYN="N">Genes, Reporter</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051783" MajorTopicYN="N">Methyl-CpG-Binding Protein 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008957" MajorTopicYN="N">Models, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012326" MajorTopicYN="N">RNA Splicing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015518" MajorTopicYN="N">Rett Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>1</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2005</Year><Month>12</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16251272</ArticleId><ArticleId IdType="pmc">PMC1266160</ArticleId><ArticleId IdType="doi">10.1073/pnas.0507856102</ArticleId><ArticleId IdType="pii">0507856102</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hagberg, B., Aicardi, J., Dias, K. &amp; Ramos, O. (1983) Ann. Neurol., 14, 471&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">6638958</ArticleId></ArticleIdList></Reference><Reference><Citation>Rett, A. (1966) Wien. Med. Wochenschr., 116, 723&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">5300597</ArticleId></ArticleIdList></Reference><Reference><Citation>Einspieler, C., Kerr, A. M. &amp; Prechtl, H. F. (2004) Pediatr. Res., 57, 696&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">15718369</ArticleId></ArticleIdList></Reference><Reference><Citation>Neul, J. L. &amp; Zoghbi, H. Y. (2004) Neuroscientist 10, 118&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">15070486</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaving, L. S., Ellaway, C. J., Gecz, J. &amp; Christodoulou, J. (2005) J. Med. Genet. 42, 1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1735910</ArticleId><ArticleId IdType="pubmed">15635068</ArticleId></ArticleIdList></Reference><Reference><Citation>Glaze, D. G. (2004) Ment. Retard. Dev. Disabil. Res. Rev. 10, 154&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">15362175</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoghbi, H. (1988) J. Child Neurol. 3, S76&#x2013;S78.</Citation><ArticleIdList><ArticleId IdType="pubmed">3058791</ArticleId></ArticleIdList></Reference><Reference><Citation>Amir, R. E., Van den Veyver, I. B., Wan, M., Tran, C. Q., Francke, U. &amp; Zoghbi, H. Y. (1999) Nat. Genet. 23, 185&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">10508514</ArticleId></ArticleIdList></Reference><Reference><Citation>Meloni, I., Bruttini, M., Longo, I., Mari, F., Rizzolio, F., D'Adamo, P., Denvriendt, K., Fryns, J. P., Toniolo, D. &amp; Renieri, A. (2000) Am. J. Hum. Genet. 67, 982&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1287900</ArticleId><ArticleId IdType="pubmed">10986043</ArticleId></ArticleIdList></Reference><Reference><Citation>Orrico, A., Lam, C., Galli, L., Dotti, M. T., Hayek, G., Tong, S. F., Poon, P. M., Zappella, M., Federico A. &amp; Sorrentino, V. (2000) FEBS Lett. 481, 285&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">11007980</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Esch, H., Bauters, M., Ignatius, J., Jansen, M., Raynaud, M., Hollanders, K., Lugtenberg, D., Bienvenu, T., Jensen, L. R., Gecz, J., et al. (2005) Am. J. Hum. Genet. 77, 442&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1226209</ArticleId><ArticleId IdType="pubmed">16080119</ArticleId></ArticleIdList></Reference><Reference><Citation>Couvert, P., Bienvenu, T., Aquaviva, C., Poirier, K., Moraine, C., Gendrot, C., Verloes, A., Andres, C., Le Fevre, A. C., Souville, I., et al. (2001) Hum. Mol. Genet. 10, 941&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pubmed">11309367</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibayama, A., Cook, E. H., Jr., Feng, J., Glanzmann, C., Yan, J., Craddock, N., Jones, I. R., Goldman, D., Heston, L. L. &amp; Sommer, S. S. Am. J. Med. Genet. (2004) 128, 50&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">15211631</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch, S. A., Whatley, S. D., Ramesh, V., Sinha, S. &amp; Ravine, D. (2003) Arch. Dis. Child Fetal Neonatal Ed. 88, F250&#x2013;F252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1721560</ArticleId><ArticleId IdType="pubmed">12719401</ArticleId></ArticleIdList></Reference><Reference><Citation>Carney, R. M., Wolpert, C. M., Ravan, S. A., Shahbazian, M., Ashley-Koch, A., Cuccaro, M. L., Vance, J. M. &amp; Pericak-Vance, M. A. (2003) Pediatr. Neurol. 28, 205&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">12770674</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson, P., Black, G., Ramsden, S., Barrow, M., Super, M., Kerr, B. &amp; Clayton-Smith, J. J. (2001) J. Med. Genet. 38, 224&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1734853</ArticleId><ArticleId IdType="pubmed">11283202</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammer, S., Dorrani, N., Dragich, J., Kudo, S. &amp; Schanen, C. (2002) Ment. Retard. Dev. Disabil. Res. Rev. 8, 94&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">12112734</ArticleId></ArticleIdList></Reference><Reference><Citation>Young, J. I. &amp; Zoghbi, H. Y. (2004) Am. J. Hum. Genet. 74, 511&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182264</ArticleId><ArticleId IdType="pubmed">14973779</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahbazian, M. D., Antalffy, B., Armstrong, D. L. &amp; Zoghbi, H. Y. (2002) Hum. Mol. Genet. 11, 115&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">11809720</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoghbi, H. Y. (2003) Science 302, 826&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593168</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishi, N. &amp; Macklis, J. D. (2004) Mol. Cell. Neurosci. 27, 306&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">15519245</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis, J. D., Meehan, R. R., Henzel, W. J., Maurer-Fogy, I., Jeppesen, P., Klein, F. &amp; Bird, A. (1992) Cell 69, 905&#x2013;914.</Citation><ArticleIdList><ArticleId IdType="pubmed">1606614</ArticleId></ArticleIdList></Reference><Reference><Citation>Nan, X., Tate, P., Li, E. &amp; Bird, A. (1996) Mol. Cell. Biol. 16, 414&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC231017</ArticleId><ArticleId IdType="pubmed">8524323</ArticleId></ArticleIdList></Reference><Reference><Citation>Nan, X., Campoy, F. J. &amp; Bird, A. (1997) Cell 88, 471&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">9038338</ArticleId></ArticleIdList></Reference><Reference><Citation>Nan, X, Ng, H. H., Johnson, C. A., Laherty, C. D., Turner, B. M., Eisenman, R. N. &amp; Bird, A. (1998) Nature 393, 386&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">9620804</ArticleId></ArticleIdList></Reference><Reference><Citation>Harikrishnan, K. N., Chow, M. Z., Baker, E. K., Pal, S., Bassal, S., Brasacchio, D., Wang, L., Craig, J. M., Jones, P. L., Sif, S. &amp; El-Osta, A. (2005) Nat. Genet. 37, 254&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">15696166</ArticleId></ArticleIdList></Reference><Reference><Citation>Tudor, M., Akbarian, S., Chen, R. Z. &amp; Jaenisch, R. (2002) Proc. Natl. Acad. Sci. USA 99, 15536&#x2013;15541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC137752</ArticleId><ArticleId IdType="pubmed">12432090</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, W. G., Chang, Q., Lin, Y., Meissner, A., West, A. E., Griffith, E. C., Jaenisch, R. &amp; Greenberg, M. E. (2003) Science 302, 885&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593183</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinowich, K., Hattori, D., Wu, H., Fouse, S., He, F., Hu, Y., Fan, G. &amp; Sun, Y. E. (2003) Science 302, 890&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593184</ArticleId></ArticleIdList></Reference><Reference><Citation>Horike, S., Cai, S., Miyano, M., Cheng, J. F. &amp; Kohwi-Shigematsu, T. (2005) Nat. Genet. 37, 31&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608638</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuber, U. A., Kriaucionis, S., Roloff, T. C., Guy, J., Selfridge, J., Steinhoff, C., Schulz, R., Lipkowitz, B., Ropers, H. H., Holmes, M. C. &amp; Bird, A. (2005) Hum. Mol. Genet. 14, 2247&#x2013;2256.</Citation><ArticleIdList><ArticleId IdType="pubmed">16002417</ArticleId></ArticleIdList></Reference><Reference><Citation>Rietveld, L. E., Caldenhoven, E. &amp; Stunnenberg, H. G. (2002) EMBO J. 21, 1389&#x2013;1397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125357</ArticleId><ArticleId IdType="pubmed">11889044</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohno, K., Izumi, H., Uchiumi, T., Ashizuka, M. &amp; Kuwano, M. (2003) BioEssays 25, 691&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pubmed">12815724</ArticleId></ArticleIdList></Reference><Reference><Citation>Stickeler, E., Fraser, S. D., Honig, A., Chen, A. L., Berget, S. M. &amp; Cooper, T. A. (2001) EMBO J. 20, 3821&#x2013;3830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125550</ArticleId><ArticleId IdType="pubmed">11447123</ArticleId></ArticleIdList></Reference><Reference><Citation>Auboeuf, D., Honig, A., Berget, S. M. &amp; O'Malley B. W. (2002) Science 298, 416&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">12376702</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke, A., DeCamillis, M., Zink, D., Cheng, N., Brock, H. W. &amp; Paro, R. (1992) EMBO J. 11, 2941&#x2013;2950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556776</ArticleId><ArticleId IdType="pubmed">1353445</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu, Y., Otsuka, T., Horton, A., Scott, D. &amp; Ehlers, M. (2003) Neuron 40, 581&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">14642281</ArticleId></ArticleIdList></Reference><Reference><Citation>Schadt, E. E., Edwards, S. W., GuhaThakurta, D., Holder, D., Ying, L., Svetnik, V., Leonardson, A., Hart, K. W., Russell, A., Li, G., et al. (2004) Genome Biol. 5, R73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC545593</ArticleId><ArticleId IdType="pubmed">15461792</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson, J. M., Castle, J., Garrett-Engele, P., Kan, Z., Loerch, P. M., Armour, C. D., Santos, R., Schadt, E. E., Stoughton, R. &amp; Shoemaker, D. D. (2003) Science 302, 2141&#x2013;2144.</Citation><ArticleIdList><ArticleId IdType="pubmed">14684825</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes, T. R., Mao, M., Jones, A. R., Burchard, J., Marton, M. J., Shannon, K. W., Lefkowitz, S. M., Ziman, M., Schelter, J. M., Meyer, M. R., et al. (2001) Nat. Biotechnol. 19, 342&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">11283592</ArticleId></ArticleIdList></Reference><Reference><Citation>He, Y. D., Dai, H., Schadt, E. E., Cavet, G., Edwards, S. W., Stepaniants, S. B., Duenwald, S., Kleinhanz, R., Jones, A. R., Shoemaker, D. D. &amp; Stoughton, R. B. (2003) Bioinformatics 19, 956&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pubmed">12761058</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogryzko, V. V., Kotani, T., Zhang, X., Schiltz, R. L., Howard, T., Yang, X. J., Howard, B. H., Qin, J. &amp; Nakatani, Y. (1998) Cell 94, 35&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">9674425</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue, S., Serra, H. G., Zoghbi, H. Y. &amp; Orr, H. T. (2001) Hum. Mol. Genet. 10, 25&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">11136710</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin, S., Vandelft, M., Pinchev, D., Howell, J. L., Graczyk, J., Orr, H. T. &amp; Truant, R. (2005) J. Cell Sci. 118, 233&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615787</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez, G., Guichet, A., Ephrussi, A. &amp; Casanova, J. (2000) Genes Dev. 14, 224&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC316342</ArticleId><ArticleId IdType="pubmed">10652276</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudo, S., Nomura, Y., Segawa, M., Fujita, N., Nakao, M., Dragich, J., Schanen, C. &amp; Tamura, M. (2001) Brain Dev. 23, S165&#x2013;S173.</Citation><ArticleIdList><ArticleId IdType="pubmed">11738866</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Osta, A., Kantharidis, P., Zalcberg, J. R. &amp; Wolffe, A. P. (2002) Mol. Cell. Biol. 22, 1844&#x2013;1857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC135609</ArticleId><ArticleId IdType="pubmed">11865062</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballestar, E., Paz, M. F., Valle, L., Wei, S., Fraga, M. F., Espada, J., Cigudosa, J. C., Huang, T. H. &amp; Esteller, M. (2003) EMBO J. 22, 6335&#x2013;6345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC291845</ArticleId><ArticleId IdType="pubmed">14633992</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornblihtt, A. R., de la Mata, M., Fededa, J. P., Munoz, M. J. &amp; Nogues, G. (2004) RNA 10, 1489&#x2013;1498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1370635</ArticleId><ArticleId IdType="pubmed">15383674</ArticleId></ArticleIdList></Reference><Reference><Citation>Black, D. L. (2003) Annu. Rev. Biochem. 72, 291&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">12626338</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou, H., Helfman, D. M., Gagel, R. F. &amp; Berget, S. M. (1999) Mol. Cell. Biol. 19, 78&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC83867</ArticleId><ArticleId IdType="pubmed">9858533</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahbazian, M., Young, J. I., Yuva-Paylor, L., Spencer, C., Antalffy, B., Noebels, J., Armstrong, D., Paylor, R. &amp; Zoghbi, H. Y. (2002) Neuron 35, 243&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">12160743</ArticleId></ArticleIdList></Reference><Reference><Citation>Moretti, P., Bouwknecht, J. A., Teague, R., Paylor, R. &amp; Zoghbi, H. Y. (2005) Hum. Mol. Genet. 14, 205&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">15548546</ArticleId></ArticleIdList></Reference><Reference><Citation>Coulter, L. R., Landree, M. A. &amp; Cooper, T. A. (1997) Mol. Cell. Biol. 17, 2143&#x2013;2150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC232062</ArticleId><ArticleId IdType="pubmed">9121463</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones, P. L., Veenstra, G. J., Wade, P. A., Vermaak, D., Kass, S. U., Landsberger, N., Strouboulis, J. &amp; Wolffe, A. P. (1998) Nat. Genet. 19, 187&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">9620779</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuks, F., Hurd, P. J., Wolf, D., Nan, X., Bird, A. P. &amp; Kouzarides, T. (2003) J. Biol. Chem. 278, 4035&#x2013;4040.</Citation><ArticleIdList><ArticleId IdType="pubmed">12427740</ArticleId></ArticleIdList></Reference><Reference><Citation>Skabkin, M. A., Kiselyova, O. I., Chernov, K. G., Sorokin, A. V., Dubrovin, E. V., Yaminsky, I. V., Vasiliev, V. D. &amp; Ovchinnikov, L. P. (2004) Nucleic Acids Res. 32, 5621&#x2013;5635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524299</ArticleId><ArticleId IdType="pubmed">15494450</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips, A. V., Timchenko, L. T. &amp; Cooper, T. A. (1998) Science 280, 737&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">9563950</ArticleId></ArticleIdList></Reference><Reference><Citation>Evdokimova, V., Ruzanov, P., Imataka, H., Raught, B., Svitkin, Y., Ovchinnikov, L. P. &amp; Sonenberg, N. (2001) EMBO J. 20, 5491&#x2013;5502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125650</ArticleId><ArticleId IdType="pubmed">11574481</ArticleId></ArticleIdList></Reference><Reference><Citation>Evdokimova, V. M. &amp; Ovchinnikov, L. P. (1999) Int. J. Biochem. Cell Biol. 31, 139&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">10216949</ArticleId></ArticleIdList></Reference><Reference><Citation>Minich, W. B. &amp; Ovchinnikov, L. P. (1992) Biochimie 74, 477&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">1637873</ArticleId></ArticleIdList></Reference><Reference><Citation>Evdokimova, V. M., Kovrigina, E. A., Nashchekin, D. V., Davydova, E. K., Hershey, J. W. &amp; Ovchinnikov, L. P. (1998) J. Biol. Chem. 273, 3574&#x2013;3581.</Citation><ArticleIdList><ArticleId IdType="pubmed">9452484</ArticleId></ArticleIdList></Reference><Reference><Citation>Nekrasov, M. P., Ivshina, M. P., Chernov, K. G., Kovrigina, E. A., Evdokimova, V. M., Thomas, A. A., Hershey, J. W. &amp; Ovchinnikov, L. P. (2003) J. Biol. Chem. 278, 13936&#x2013;13943.</Citation><ArticleIdList><ArticleId IdType="pubmed">12582179</ArticleId></ArticleIdList></Reference><Reference><Citation>Davydova, E. K., Evdokimova, V. M., Ovchinnikov, L. P. &amp; Hershey, J. W. (1997) Nucleic Acids Res. 25, 2911&#x2013;2916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC146798</ArticleId><ArticleId IdType="pubmed">9207042</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceman, S., Nelson, R. &amp; Warren, S. T. (2000) Biochem. Biophys. Res. Commun. 279, 904&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pubmed">11162447</ArticleId></ArticleIdList></Reference><Reference><Citation>Khandjian, E. W., Huot, M.-E., Tremblay, S., Davidovic, L., Mazroui, R. &amp; Bardoni, B. (2004) Proc. Natl. Acad. Sci. USA 101, 13357&#x2013;13362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC516571</ArticleId><ArticleId IdType="pubmed">15329415</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagne, J. P., Bonicalzi, M. E., Gagne, P., Ouellet, M. E., Hendzel, M. J. &amp; Poirier, G. G. (August 23, 2005) Biochem. J., 10.1042/BJ20050792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20050792</ArticleId><ArticleId IdType="pmc">PMC1316289</ArticleId><ArticleId IdType="pubmed">16117724</ArticleId></ArticleIdList></Reference><Reference><Citation>Swamynathan, S. K., Nambiar, A. &amp; Guntaka, R. V. (1998) FASEB J. 12, 515&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">9576478</ArticleId></ArticleIdList></Reference><Reference><Citation>Ise, T., Nagatani, G., Imamura, T., Kato, K., Takano, H., Nomoto, M., Izumi, H., Ohmori, H., Okamoto, T., Ohga, T., et al. (1999) Cancer Res. 59, 342&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pubmed">9927044</ArticleId></ArticleIdList></Reference><Reference><Citation>Marenstein, D. R., Ocampo, M. T., Chan, M. K., Altamirano, A., Basu, A. K. Boorstein, R. J., Cunningham, R. P. &amp; Teebor, G. W. (2001) J. Biol. Chem. 276, 21242&#x2013;21249.</Citation><ArticleIdList><ArticleId IdType="pubmed">11287425</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm, P. S., Bergmann, S., Jurchott, K., Lage, H., Brand, K., Ladhoff, A., Mantwill, K., Curiel, D. T., Dobbelstein, M., Dietel, M., et al. (2002) J. Biol. Chem. 277, 10427&#x2013;10434.</Citation><ArticleIdList><ArticleId IdType="pubmed">11788582</ArticleId></ArticleIdList></Reference><Reference><Citation>Dansithong, W., Paul, S., Comai, L. &amp; Reddy, S. (2004) J. Biol. Chem. 280, 5773&#x2013;5780.</Citation><ArticleIdList><ArticleId IdType="pubmed">15546872</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckanovich, R. J., Yang, Y. Y. &amp; Darnell, R. B. (1996) J. Neurosci. 16, 1114&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578795</ArticleId><ArticleId IdType="pubmed">8558240</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiledjian, M., Wang, X. &amp; Liebhaber, S. A. (1995) EMBO J. 14, 4357&#x2013;4364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC394520</ArticleId><ArticleId IdType="pubmed">7556077</ArticleId></ArticleIdList></Reference><Reference><Citation>Musunuru, K. &amp; Darnell, R. B. (2001) Annu. Rev. Neurosci. 24, 239&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">11283311</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashley, C. T., Jr., Wilkinson, K. D., Reines, D. &amp; Warren, S. T. (1993) Science 262, 563&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">7692601</ArticleId></ArticleIdList></Reference><Reference><Citation>Frugier, T., Nicole, S., Cifuentes-Diaz, C. &amp; Melki, J. (2002) Curr. Opin. Genet. Dev. 12, 294&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">12076672</ArticleId></ArticleIdList></Reference><Reference><Citation>Raffetseder, U., Frye, B., Rauen, T., Jurchott, K., Royer, H. D., Jansen, P. L. &amp; Mertens, P. R. (2003) J. Biol. Chem. 278, 18241&#x2013;18248.</Citation><ArticleIdList><ArticleId IdType="pubmed">12604611</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Donovan, K. J. &amp; Darnell, R. B. (2001) Sci STKE, PE2.</Citation><ArticleIdList><ArticleId IdType="pubmed">11752670</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeffery, L.&amp; Nakielny, S. (2004) J. Biol. Chem. 279, 49479&#x2013;49487.</Citation><ArticleIdList><ArticleId IdType="pubmed">15342650</ArticleId></ArticleIdList></Reference><Reference><Citation>Grigoryev, S. A., Nikitina, T., Pehrson, J. R., Singh, P. B &amp; Woodcock, C. L. (2004) J. Cell Sci. 117, 6153&#x2013;6162.</Citation><ArticleIdList><ArticleId IdType="pubmed">15564378</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh, S. I., Pyun, H. Y., Cho, J. W., Baek, W. K., Park, J. B., Kwon, T., Park, J. W., Suh, M. H. &amp; Carson, D. A. (2000) Cancer Lett. 160, 81&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">11098088</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh, S. I., Cho, J. W., Baek, W. K., Suh, M. H. &amp; Carson, D. A. (2000) Cancer Lett. 153, 175&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">10779647</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16251967</PMID><DateCompleted><Year>2005</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>437</Volume><Issue>7063</Issue><PubDate><Year>2005</Year><Month>Oct</Month><Day>27</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Wnt signalling regulates adult hippocampal neurogenesis.</ArticleTitle><Pagination><StartPage>1370</StartPage><EndPage>1375</EndPage><MedlinePgn>1370-5</MedlinePgn></Pagination><Abstract><AbstractText>The generation of new neurons from neural stem cells is restricted to two regions of the adult mammalian central nervous system: the subventricular zone of the lateral ventricle, and the subgranular zone of the hippocampal dentate gyrus. In both regions, signals provided by the microenvironment regulate the maintenance, proliferation and neuronal fate commitment of the local stem cell population. The identity of these signals is largely unknown. Here we show that adult hippocampal stem/progenitor cells (AHPs) express receptors and signalling components for Wnt proteins, which are key regulators of neural stem cell behaviour in embryonic development. We also show that the Wnt/beta-catenin pathway is active and that Wnt3 is expressed in the hippocampal neurogenic niche. Overexpression of Wnt3 is sufficient to increase neurogenesis from AHPs in vitro and in vivo. By contrast, blockade of Wnt signalling reduces neurogenesis from AHPs in vitro and abolishes neurogenesis almost completely in vivo. Our data show that Wnt signalling is a principal regulator of adult hippocampal neurogenesis and provide evidence that Wnt proteins have a role in adult hippocampal function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lie</LastName><ForeName>Dieter-Chichung</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute, La Jolla, California 92037, USA. chichung.lie@gsf.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colamarino</LastName><ForeName>Sophia A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Hong-Jun</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>D&#xe9;sir&#xe9;</LastName><ForeName>Laurent</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Mira</LastName><ForeName>Helena</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Consiglio</LastName><ForeName>Antonella</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lein</LastName><ForeName>Edward S</ForeName><Initials>ES</Initials></Author><Author ValidYN="Y"><LastName>Jessberger</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lansford</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Dearie</LastName><ForeName>Alejandro R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Gage</LastName><ForeName>Fred H</ForeName><Initials>FH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>GFP01004</GrantID><Acronym>TI_</Acronym><Agency>Telethon</Agency><Country>Italy</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051153">Wnt Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D060508">Wnt3 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C555508">Wnt3 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051153" MajorTopicYN="N">Wnt Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060508" MajorTopicYN="N">Wnt3 Protein</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16251967</ArticleId><ArticleId IdType="doi">10.1038/nature04108</ArticleId><ArticleId IdType="pii">nature04108</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">1625800</PMID><DateCompleted><Year>1992</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0304-3940</ISSN><JournalIssue CitedMedium="Print"><Volume>135</Volume><Issue>2</Issue><PubDate><Year>1992</Year><Month>Feb</Month><Day>03</Day></PubDate></JournalIssue><Title>Neuroscience letters</Title><ISOAbbreviation>Neurosci Lett</ISOAbbreviation></Journal><ArticleTitle>Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid.</ArticleTitle><Pagination><StartPage>235</StartPage><EndPage>238</EndPage><MedlinePgn>235-8</MedlinePgn></Pagination><Abstract><AbstractText>Many biochemically diverse proteins can give rise to amyloid fibrils; however, they are all accompanied by P component and glucosaminoglycans. With antibodies specific to apolipoprotein E (apo E) we used immunohistochemical techniques to test for the presence of this protein in both cerebral and systemic amyloid. We found apo E immunoreactivity in all tested types of cerebral and systemic amyloid. In amyloid deposits apo E P, component and glucosaminoglycans may be acting as 'pathological molecular chaperones'. The latter we define as a group of unrelated proteins that induce beta-pleated conformation in amyloidogenic polypeptides.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology, New York University Medical Center, New York 10016.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frangione</LastName><ForeName>B</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 08721</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AR 02594</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Neurosci Lett</MedlineTA><NlmUniqueID>7600130</NlmUniqueID><ISSNLinking>0304-3940</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006025">Glycosaminoglycans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000683">Serum Amyloid P-Component</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006025" MajorTopicYN="N">Glycosaminoglycans</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016253" MajorTopicYN="N">Microscopy, Immunoelectron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016612" MajorTopicYN="N">Paraffin Embedding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000683" MajorTopicYN="N">Serum Amyloid P-Component</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>2</Month><Day>3</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>2</Month><Day>3</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1625800</ArticleId><ArticleId IdType="doi">10.1016/0304-3940(92)90444-c</ArticleId><ArticleId IdType="pii">0304-3940(92)90444-C</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16269331</PMID><DateCompleted><Year>2005</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0092-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>123</Volume><Issue>3</Issue><PubDate><Year>2005</Year><Month>Nov</Month><Day>04</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration.</ArticleTitle><Pagination><StartPage>383</StartPage><EndPage>396</EndPage><MedlinePgn>383-96</MedlinePgn></Pagination><Abstract><AbstractText>Alpha-synuclein and cysteine-string protein-alpha (CSPalpha) are abundant synaptic vesicle proteins independently linked to neurodegeneration. Dominantly inherited mutations in alpha-synuclein cause Parkinson's disease, but the physiological role of alpha-synuclein remains unknown. Deletion of CSPalpha produces rapidly progressive neurodegeneration in mice, presumably because the cochaperone function of CSPalpha is essential for neuronal survival. Here, we report the surprising finding that transgenic expression of alpha-synuclein abolishes the lethality and neurodegeneration caused by deletion of CSPalpha. Conversely, ablation of endogenous synucleins exacerbates these phenotypes. Deletion of CSPalpha inhibits SNARE complex assembly; transgenic alpha-synuclein ameliorates this inhibition. In preventing neurodegeneration in CSPalpha-deficient mice, alpha-synuclein does not simply substitute for CSPalpha but acts by a downstream mechanism that requires phospholipid binding by alpha-synuclein. These observations reveal a powerful in vivo activity of alpha-synuclein in protecting nerve terminals against injury and suggest that this activity operates in conjunction with CSPalpha and SNARE proteins on the presynaptic membrane interface.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chandra</LastName><ForeName>Sreeganga</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Basic Neuroscience, Department of Molecular Genetics, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallardo</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Chac&#xf3;n</LastName><ForeName>Rafael</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Schl&#xfc;ter</LastName><ForeName>Oliver M</ForeName><Initials>OM</Initials></Author><Author ValidYN="Y"><LastName>S&#xfc;dhof</LastName><ForeName>Thomas C</ForeName><Initials>TC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5 R01 NS40057-04</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050956">HSP40 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010743">Phospholipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050600">SNARE Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051846">beta-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2005 Nov 4;123(3):359-61. doi: 10.1016/j.cell.2005.10.017.</RefSource><PMID Version="1">16269324</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050956" MajorTopicYN="N">HSP40 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010743" MajorTopicYN="N">Phospholipids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050600" MajorTopicYN="N">SNARE Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013570" MajorTopicYN="N">Synaptic Membranes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051846" MajorTopicYN="N">beta-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16269331</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2005.09.028</ArticleId><ArticleId IdType="pii">S0092-8674(05)01022-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16282321</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>281</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Jan</Month><Day>20</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology.</ArticleTitle><Pagination><StartPage>1599</StartPage><EndPage>1604</EndPage><MedlinePgn>1599-604</MedlinePgn></Pagination><Abstract><AbstractText>Accumulation of amyloid-beta (Abeta) is one of the earliest molecular events in Alzheimer disease (AD), whereas tau pathology is thought to be a later downstream event. It is now well established that Abeta exists as monomers, oligomers, and fibrils. To study the temporal profile of Abeta oligomer formation in vivo and to determine their interaction with tau pathology, we used the 3xTg-AD mice, which develop a progressive accumulation of plaques and tangles and cognitive impairments. We show that SDS-resistant Abeta oligomers accumulate in an age-dependent fashion, and we present evidence to show that oligomerization of Abeta appears to first occur intraneuronally. Finally, we show that a single intrahippocampal injection of a specific oligomeric antibody is sufficient to clear Abeta pathology, and more importantly, tau pathology. Therefore, Abeta oligomers may play a role in the induction of tau pathology, making the interference of Abeta oligomerization a valid therapeutic target.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oddo</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, California 92697-4545, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caccamo</LastName><ForeName>Antonella</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Levina</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Mary P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Glabe</LastName><ForeName>Charles G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>William L</ForeName><Initials>WL</Initials></Author><Author ValidYN="Y"><LastName>LaFerla</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 11385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 18877</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 22547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG00538</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG0212982</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>11</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D046911">Macromolecular Substances</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007839" MajorTopicYN="N">Functional Laterality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046911" MajorTopicYN="N">Macromolecular Substances</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16282321</ArticleId><ArticleId IdType="doi">10.1074/jbc.M507892200</ArticleId><ArticleId IdType="pii">S0021-9258(20)66265-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16300414</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-7885</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>1</Issue><PubDate><Year>2006</Year><Month>Jan</Month></PubDate></JournalIssue><Title>PLoS biology</Title><ISOAbbreviation>PLoS Biol</ISOAbbreviation></Journal><ArticleTitle>Functional amyloid formation within mammalian tissue.</ArticleTitle><Pagination><StartPage>e6</StartPage><MedlinePgn>e6</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e6</ELocationID><Abstract><AbstractText>Amyloid is a generally insoluble, fibrous cross-beta sheet protein aggregate. The process of amyloidogenesis is associated with a variety of neurodegenerative diseases including Alzheimer, Parkinson, and Huntington disease. We report the discovery of an unprecedented functional mammalian amyloid structure generated by the protein Pmel17. This discovery demonstrates that amyloid is a fundamental nonpathological protein fold utilized by organisms from bacteria to humans. We have found that Pmel17 amyloid templates and accelerates the covalent polymerization of reactive small molecules into melanin-a critically important biopolymer that protects against a broad range of cytotoxic insults including UV and oxidative damage. Pmel17 amyloid also appears to play a role in mitigating the toxicity associated with melanin formation by sequestering and minimizing diffusion of highly reactive, toxic melanin precursors out of the melanosome. Intracellular Pmel17 amyloidogenesis is carefully orchestrated by the secretory pathway, utilizing membrane sequestration and proteolytic steps to protect the cell from amyloid and amyloidogenic intermediates that can be toxic. While functional and pathological amyloid share similar structural features, critical differences in packaging and kinetics of assembly enable the usage of Pmel17 amyloid for normal function. The discovery of native Pmel17 amyloid in mammals provides key insight into the molecular basis of both melanin formation and amyloid pathology, and demonstrates that native amyloid (amyloidin) may be an ancient, evolutionarily conserved protein quaternary structure underpinning diverse pathways contributing to normal cell and tissue physiology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fowler</LastName><ForeName>Douglas M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Chemistry, The Skaggs Institute of Chemical Biology, The Scripps Research Institute, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koulov</LastName><ForeName>Atanas V</ForeName><Initials>AV</Initials></Author><Author ValidYN="Y"><LastName>Alory-Jost</LastName><ForeName>Christelle</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Marks</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Balch</LastName><ForeName>William E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>Jeffery W</ForeName><Initials>JW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG18917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY011606</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EY11606</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AR041855</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK046335</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR048155</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 DK046335</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EY014919</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DK46335</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 EY014919</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Biol</MedlineTA><NlmUniqueID>101183755</NlmUniqueID><ISSNLinking>1544-9173</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008543">Melanins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C548637">PMEL protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058951">gp100 Melanoma Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>2390-54-7</RegistryNumber><NameOfSubstance UI="C009462">thioflavin T</NameOfSubstance></Chemical><Chemical><RegistryNumber>3U05FHG59S</RegistryNumber><NameOfSubstance UI="D003224">Congo Red</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>PLoS Biol. 4:e8.</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003224" MajorTopicYN="N">Congo Red</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005123" MajorTopicYN="N">Eye</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008543" MajorTopicYN="N">Melanins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020460" MajorTopicYN="N">Melanosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008856" MajorTopicYN="N">Microscopy, Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017550" MajorTopicYN="N">Spectroscopy, Fourier Transform Infrared</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013194" MajorTopicYN="N">Staining and Labeling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014961" MajorTopicYN="N">X-Ray Diffraction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058951" MajorTopicYN="N">gp100 Melanoma Antigen</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2005</Year><Month>11</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16300414</ArticleId><ArticleId IdType="pmc">PMC1288039</ArticleId><ArticleId IdType="doi">10.1371/journal.pbio.0040006</ArticleId><ArticleId IdType="pii">05-PLBI-RA-1107R2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, et al. Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science. 2005;307:262&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653506</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Berthelier V, Hamilton JB, O'Nuallain B, Wetzel R. Amyloid-like features of polyglutamine aggregates and their assembly kinetics. Biochemistry. 2002;41:7391&#x2013;7399.</Citation><ArticleIdList><ArticleId IdType="pubmed">12044172</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekijima Y, Wiseman RL, Matteson J, Hammarstrom P, Miller SR, et al. The biological and chemical basis for tissue-selective amyloid disease. Cell. 2005;121:73&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">15820680</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M, Chien P, Yonekura K, Weissman JS. Mechanism of cross-species prion transmission: An infectious conformation compatible with two highly divergent yeast prion proteins. Cell. 2005;121:49&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">15820678</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson CM. Protein chemistry: In the footsteps of alchemists. Science. 2004;304:1259&#x2013;1262. 1261.</Citation><ArticleIdList><ArticleId IdType="pubmed">15166354</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen FE, Kelly JW. Therapeutic approaches to protein-misfolding diseases. Nature. 2003;426:905&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">14685252</ArticleId></ArticleIdList></Reference><Reference><Citation>Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003;26:267&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">12704221</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks MS, Seabra MC. The melanosome: membrane dynamics in black and white. Nat Rev Mol Cell Biol. 2001;2:738&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584301</ArticleId></ArticleIdList></Reference><Reference><Citation>Hearing VJ. The melanosome: The perfect model for cellular responses to the environment. Pigment Cell Res. 2000;13(Suppl):23&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">11041354</ArticleId></ArticleIdList></Reference><Reference><Citation>Berson JF, Theos AC, Harper DC, Tenza D, Raposo G, et al. Proprotein convertase cleavage liberates a fibrillogenic fragment of a resident glycoprotein to initiate melanosome biogenesis. J Cell Biol. 2003;161:521&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172928</ArticleId><ArticleId IdType="pubmed">12732614</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly JW, Balch WE. Amyloid as a natural product. J Cell Biol. 2003;161:461&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172945</ArticleId><ArticleId IdType="pubmed">12743097</ArticleId></ArticleIdList></Reference><Reference><Citation>Berson JF, Harper DC, Tenza D, Raposo G, Marks MS. Pmel17 initiates premelanosome morphogenesis within multivesicular bodies. Mol Biol Cell. 2001;12:3451&#x2013;3464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC60267</ArticleId><ArticleId IdType="pubmed">11694580</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty AK, Platt JT, Kim KK, Kwon BS, Bennett DC, et al. Polymerization of 5,6-dihydroxyindole-2-carboxylic acid to melanin by the Pmel17/Silver locus protein. Eur J Biochem. 1996;236:180.</Citation><ArticleIdList><ArticleId IdType="pubmed">8617263</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee ZH, Hou L, Moellmann G, Kuklinska E, Antol K, et al. Characterization and subcellular localization of human Pmel17/Silver, a 100-kDa (pre)melanosomal membrane protein associated with 5,6-dihydroxyindole-2carboxylic acid (DHCIA) converting activity. J Invest Dermatol. 1996;106:605.</Citation><ArticleIdList><ArticleId IdType="pubmed">8617992</ArticleId></ArticleIdList></Reference><Reference><Citation>Land EJ, Ramsden CA, Riley PA. Quinone chemistry and melanogenesis. In: Packer L, Sies H, editors. Quinones and quinone enzymes, part A. New York: Academic Press; 2004. pp. 88&#x2013;109.</Citation></Reference><Reference><Citation>Raposo G, Marks MS. The dark side of lysosome-related organelles: Specialization of the endocytic pathway for melanosome biogenesis. Traffic. 2002;3:237&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">11929605</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvers WK. The coat colors of mice: A model for mammalian gene action and interaction. New York: Springer-Verlag; 1979. 379 pp.</Citation></Reference><Reference><Citation>Spanakis E, Lamina P, Bennett DC. Effects of the developmental colour mutations silver and recessive spotting on proliferation of diploid and immortal mouse melanocytes in culture. Development. 1992;114:675&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">1618134</ArticleId></ArticleIdList></Reference><Reference><Citation>Quevedo WC, Fleischmann RD, Dyckman J. Premature loss of melanocytes from hair follicles of light (B lt) and silver (si) mice. In: Seiji M, editor. Phenotypic expression in pigment cells. Tokyo: Tokyo University Press; 1981. pp. 177&#x2013;184.</Citation></Reference><Reference><Citation>Schonthaler HB, Lampert JM, von Lintig J, Schwarz H, Geisler R, et al. A mutation in the silver gene leads to defects in melanosome biogenesis and alterations in the visual system in the zebra fish mutant fading vision. Dev Biol. 2005;284:421&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">16024012</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerje S, Sharma P, Gunnarsson U, Kim H, Bagchi S, et al. The Dominant white, Dun and Smoky color variants in chicken are associated with insertion/deletion polymorphisms in the Pmel17 gene. Genetics. 2004;168:1507&#x2013;1518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1448810</ArticleId><ArticleId IdType="pubmed">15579702</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott G, Zhao Q. Rab3a and SNARE proteins: Potential regulators of melanosome movement. J Invest Dermatol. 2001;116:296&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">11180007</ArticleId></ArticleIdList></Reference><Reference><Citation>Linke RP. Highly sensitive diagnosis of amyloid and various amyloid syndromes using Congo red fluorescence. Virchows Arch. 2000;436:439&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pubmed">10881737</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Pettegrew JW, Abraham DJ. Quantitative evaluation of Congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J Histochem and Cytochem. 1989;37:1273&#x2013;1281.</Citation><ArticleIdList><ArticleId IdType="pubmed">2666510</ArticleId></ArticleIdList></Reference><Reference><Citation>Westermark GT, Johnson KH, Westermark P. Staining methods for identification of amyloid in tissue. Methods Enzymol. 1999;309:3&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">10507013</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F, Stefani M, Taddei N, Ramponi G, Dobson CM. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature. 2003;424:805&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">12917692</ArticleId></ArticleIdList></Reference><Reference><Citation>Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT. Neurodegenerative disease: Amyloid pores from pathogenic mutations. Nature. 2002;418:291.</Citation><ArticleIdList><ArticleId IdType="pubmed">12124613</ArticleId></ArticleIdList></Reference><Reference><Citation>Eanes ED, Glenner GG. Physical and chemical properties of amyloid fibers. I. X-ray diffraction studies on amyloid filaments. J Histochem Cytochem. 1968;16:673&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pubmed">5723775</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink AL, Khurana SR, Oberg KA. Determination of secondary structure in protein aggregates using attenuated total reflectance FTIR. In: Singh BR, editor. Infrared analysis of peptides and proteins: Principles and application. Washington (D. C.): American Chemical Society; 2000. pp. 132&#x2013;144.</Citation></Reference><Reference><Citation>Baxa U, Taylor KL, Wall JS, Simon MN, Cheng N, et al. Architecture of Ure2p prion filaments: The N-terminal domains form a central core fiber. J Biol Chem. 2003;278:43717&#x2013;43727.</Citation><ArticleIdList><ArticleId IdType="pubmed">12917441</ArticleId></ArticleIdList></Reference><Reference><Citation>Krebs MR, Bromley EH, Donald AM. The binding of thioflavin-T to amyloid fibrils: Localisation and implications. J Struct Biol. 2005;149:30&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">15629655</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoashi T, Watabe H, Muller J, Yamaguchi Y, Vieira WD, et al. MART-1 is required for the function of the melanosomal matrix protein Pmel17/GP100 and the maturation of melanosomes. J Biol Chem. 2005;280:14006&#x2013;14016.</Citation><ArticleIdList><ArticleId IdType="pubmed">15695812</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman MR, Robinson LS, Pinkner JS, Roth R, Heuser J, et al. Role of Escherichia coli curli operons in directing amyloid fiber formation. Science. 2002;295:851&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838482</ArticleId><ArticleId IdType="pubmed">11823641</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenney JM, Knight D, Wise MJ, Vollrath F. Amyloidogenic nature of spider silk. Eur J Biochem. 2002;269:4159&#x2013;4163.</Citation><ArticleIdList><ArticleId IdType="pubmed">12180993</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorter J, Lindquist S. Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers. Science. 2004;304:1793&#x2013;1797.</Citation><ArticleIdList><ArticleId IdType="pubmed">15155912</ArticleId></ArticleIdList></Reference><Reference><Citation>Si K, Lindquist S, Kandel ER. A neuronal isoform of the aplysia CPEB has prion-like properties. Cell. 2003;115:879&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pubmed">14697205</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CD, Huff ME, Matteson J, Page L, Phillips R, et al. Furin initiates gelsolin familial amyloidosis in the Golgi through a defect in Ca(2+) stabilization. EMBO J. 2001;20:6277&#x2013;6287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125307</ArticleId><ArticleId IdType="pubmed">11707399</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawelek JM, Lerner AB. 5,6-Dihydroxyindole is a melanin precursor showing potent cytotoxicity. Nature. 1978;276:626&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pubmed">723948</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Pettegrew JW, Abraham DJ. Two simple methods for quantifying low-affinity dye-substrate binding. J Histochem Cytochem. 1989;37:1293&#x2013;1297.</Citation><ArticleIdList><ArticleId IdType="pubmed">2666512</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson WC. Analyzing protein circular dichroism spectra for accurate secondary structures. Proteins. 1999;35:307&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">10328265</ArticleId></ArticleIdList></Reference><Reference><Citation>Provencher SW, Glockner J. Estimation of globular protein secondary structure from circular dichroism. Biochemistry. 1981;20:33&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">7470476</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreerama N, Woody RW. A self-consistent method for the analysis of protein secondary structure from circular dichroism. Anal Biochem. 1993;209:32&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">8465960</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh BR. Basic aspects of the technique and applications of infrared spectroscopy of peptides and proteins. In: Singh BR, editor. Infrared analysis of peptides and proteins: Principles and application. Washington (D. C.): American Chemical Society; 2000. pp. 2&#x2013;37.</Citation></Reference><Reference><Citation>Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, et al. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol. 2002;322:1089&#x2013;1102.</Citation><ArticleIdList><ArticleId IdType="pubmed">12367530</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16315276</PMID><DateCompleted><Year>2006</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0364-5134</ISSN><JournalIssue CitedMedium="Print"><Volume>58</Volume><Issue>6</Issue><PubDate><Year>2005</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Model-guided microarray implicates the retromer complex in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>909</StartPage><EndPage>919</EndPage><MedlinePgn>909-19</MedlinePgn></Pagination><Abstract><AbstractText>Although, in principle, gene expression profiling is well suited to isolate pathogenic molecules associated with Alzheimer's disease (AD), techniques such as microarray present unique analytic challenges when applied to disorders of the brain. Here, we addressed these challenges by first constructing a spatiotemporal model, predicting a priori how a molecule underlying AD should behave anatomically and over time. Then, guided by the model, we generated gene expression profiles of the entorhinal cortex and the dentate gyrus, harvested from the brains of AD cases and controls covering a broad age span. Among many expression differences, the retromer trafficking molecule VPS35 best conformed to the spatiotemporal model of AD. Western blotting confirmed the abnormality, establishing that VPS35 levels are reduced in brain regions selectively vulnerable to AD. VPS35 is the core molecule of the retromer trafficking complex and further analysis revealed that VPS26, another member of the complex, is also downregulated in AD. Cell culture studies, using small interfering RNAs or expression vectors, showed that VPS35 regulates Abeta peptide levels, establishing the relevance of the retromer complex to AD. Reviewing our findings in the context of recent studies suggests how downregulation of the retromer complex in AD can regulate local levels of Abeta peptide.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Small</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology, and the Center for Neurobiology and Behavior, Columbia University College of Physicians and Surgeons, New York, NY, USA. sas68@columbia.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kent</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Pierce</LastName><ForeName>Aimee</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>Conrad</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Min Suk</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Okada</LastName><ForeName>Hirokazu</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Vonsattel</LastName><ForeName>Jean-Paul</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Tae-Wan</ForeName><Initials>TW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 07232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 08702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS 43467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016477" MajorTopicYN="N">Artifacts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020411" MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021601" MajorTopicYN="N">trans-Golgi Network</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16315276</ArticleId><ArticleId IdType="doi">10.1002/ana.20667</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16337919</PMID><DateCompleted><Year>2006</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>48</Volume><Issue>5</Issue><PubDate><Year>2005</Year><Month>Dec</Month><Day>08</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory.</ArticleTitle><Pagination><StartPage>825</StartPage><EndPage>838</EndPage><MedlinePgn>825-38</MedlinePgn></Pagination><Abstract><AbstractText>While deregulation of cyclin-dependent kinase 5 (Cdk5) has been implicated in neurodegenerative diseases, its precise role in synaptic plasticity and memory remains elusive. Proteolytic cleavage of p35, a regulatory subunit of Cdk5, by calpain results in the generation of the truncated p25 protein, which causes hyperactivation of Cdk5. Using region-specific and inducible transgenic mice, we show that transiently increased p25 expression in the hippocampus enhanced long-term potentiation (LTP) and facilitated hippocampus-dependent memory. Moreover, p25 expression increased the number of dendritic spines and synapses. Importantly, enhanced memory achieved by a transient expression of p25 followed by its repression did not cause neurodegeneration. In contrast, prolonged p25 production caused severe cognitive deficits, which were accompanied by synaptic and neuronal loss and impaired LTP. Our data suggest a role for p25 in synaptic plasticity, synaptogenesis, learning, and memory and provide a model whereby deregulation of a plasticity factor can contribute to neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Andre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Department of Pathology, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sananbenesi</LastName><ForeName>Farahnaz</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Pang</LastName><ForeName>Petti T</ForeName><Initials>PT</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Bai</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Li-Huei</ForeName><Initials>LH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS051874</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492236">Cdk5r1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D010770">Phosphotransferases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2005 Dec 8;48(5):711-2. doi: 10.1016/j.neuron.2005.11.022.</RefSource><PMID Version="1">16337907</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001245" MajorTopicYN="N">Association Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003213" MajorTopicYN="N">Conditioning, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003712" MajorTopicYN="N">Dendrites</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005239" MajorTopicYN="N">Fear</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010770" MajorTopicYN="N">Phosphotransferases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013028" MajorTopicYN="N">Space Perception</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013550" MajorTopicYN="N">Swimming</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>1</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16337919</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2005.10.033</ArticleId><ArticleId IdType="pii">S0896-6273(05)00951-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16344336</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men.</ArticleTitle><Pagination><StartPage>177</StartPage><EndPage>185</EndPage><MedlinePgn>177-85</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">There is a compelling need for therapies that prevent, defer the onset, slow the progression, or improve the symptoms of Alzheimer disease (AD).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the effects of testosterone therapy on cognition, neuropsychiatric symptoms, and quality of life in male patients with mild AD and healthy elderly men.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Twenty-four-week, randomized, double-blind, placebo-controlled, parallel-group study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Memory disorders clinics as well as general neurology and medicine clinics from University of California medical centers at Los Angeles, San Francisco, and Irvine.</AbstractText><AbstractText Label="PATIENTS OR OTHER PARTICIPANTS" NlmCategory="METHODS">Sixteen male patients with AD and 22 healthy male control subjects. Healthy elderly control men were recruited from the community through advertisements as well as through the university-based clinics.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Testosterone and placebo, in the form of hydroalcoholic gel (75 mg), were applied daily to the skin of the participants.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Instruments assessing cognitive functioning (Alzheimer's Disease Assessment Scale-Cognitive Subscale, California Verbal Learning Test, Block Design Subtest, Judgment of Line Orientation, Developmental Test of Visual-Motor Integration), neuropsychiatric symptoms (Neuropsychiatric Inventory), global functioning (Clinician's Interview-Based Impression of Change), and quality of life (Quality of Life-Alzheimer Disease Scale).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">For the patients with AD, the testosterone-treated group had significantly greater improvements in the scores on the caregiver version of the quality-of-life scale (P = .01). No significant treatment group differences were detected in the cognitive scores at end of study, although numerically greater improvement or less decline on measures of visuospatial functions was demonstrated with testosterone treatment compared with placebo. In the healthy control group, a nonsignificant trend toward greater improvement in self-rated quality of life was observed in the testosterone-treated group (P = .09) compared with placebo treatment. No difference between the treatment groups was detected in the remaining outcome measures. Testosterone treatment was well tolerated with few adverse effects relative to placebo.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Results suggest that testosterone replacement therapy improved overall quality of life in patients with AD. Testosterone had minimal effects on cognition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Po H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, USA. plu@mednet.ucla.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masterman</LastName><ForeName>Donna A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Mulnard</LastName><ForeName>Ruth</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Cotman</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Yaffe</LastName><ForeName>Kristine</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Reback</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Porter</LastName><ForeName>Verna</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Swerdloff</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG16573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3XMK78S47O</RegistryNumber><NameOfSubstance UI="D013739">Testosterone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013739" MajorTopicYN="N">Testosterone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16344336</ArticleId><ArticleId IdType="doi">10.1001/archneur.63.2.nct50002</ArticleId><ArticleId IdType="pii">63.2.nct50002</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16354912</PMID><DateCompleted><Year>2006</Year><Month>05</Month><Day>11</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>50</Issue><PubDate><Year>2005</Year><Month>Dec</Month><Day>14</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Suppression of cyclin-dependent kinase 5 activation by amyloid precursor protein: a novel excitoprotective mechanism involving modulation of tau phosphorylation.</ArticleTitle><Pagination><StartPage>11542</StartPage><EndPage>11552</EndPage><MedlinePgn>11542-52</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease is cytopathologically characterized by loss of synapses and neurons, neuritic amyloid plaques consisting of beta-amyloid (Abeta) peptides, and neurofibrillary tangles consisting of hyperphosphorylated tau protein in susceptible brain regions. Abeta, which triggers a cascade of pathogenic events including tau phosphorylation and neuronal excitotoxicity, is proteolytically derived from beta-amyloid precursor protein (APP); the pathological and physiological functions of APP, however, remain undefined. Here we demonstrate that the level of tau phosphorylation in cells and brains deficient in APP is significantly higher than that in wild-type controls, resulting from activation of cyclin-dependent kinase 5 (CDK5) but not glycogen synthase kinase 3, the two major tau kinases. In addition, we show that overexpression of APP or its non-amyloidogenic homolog amyloid precursor-like protein 1 suppresses both basal and stress-induced CDK5 activation. The ectodomain of APP, sAPPalpha, is responsible for inhibiting CDK5 activation. Furthermore, neurons derived from APP-deficient mice exhibit reduced metabolism and survival rates and are more susceptible to excitotoxic glutamate-induced apoptosis. These neurons also manifest significant defects in neurite outgrowth compared with neurons from the wild-type littermates. The observed neuronal excitotoxicity/apoptosis is mediated through a mechanism involving CDK5 activation. Our study defines a novel neuroprotective function for APP in preventing tau hyperphosphorylation via suppressing overactivation of CDK5. We suggest that CDK5 activation, through a calcium/calpain/p25 pathway, plays a key role in neuronal excitotoxicity and represents an underlying mechanism for the physiological functions of APP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Neuroscience and Aging, The Burnham Institute, La Jolla, California 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dou</LastName><ForeName>Fei</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Feng</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xue</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yun-Wu</ForeName><Initials>YW</Initials></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Hui</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Lipton</LastName><ForeName>Stuart A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Huaxi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Francesca-Fang</ForeName><Initials>FF</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 HD029587</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG024895</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 HD29587</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG024895</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS046673</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051360">Cyclin-Dependent Kinase 5</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051360" MajorTopicYN="N">Cyclin-Dependent Kinase 5</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>5</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>6</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16354912</ArticleId><ArticleId IdType="pmc">PMC6726015</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3831-05.2005</ArticleId><ArticleId IdType="pii">25/50/11542</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahlijanian MK, Barrezueta NX, Williams RD, Jakowski A, Kowsz KP, McCarthy S, Coskran T, Carlo A, Seymour PA, Burkhardt JE, Nelson RB, McNeish JD (2000) Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci USA 97: 2910&#x2013;2915.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16029</ArticleId><ArticleId IdType="pubmed">10706614</ArticleId></ArticleIdList></Reference><Reference><Citation>Ankarcrona M, Dypbukt JM, Bonfoco E, Zhivotovsky B, Orrenius S, Lipton SA, Nicotera P (1995) Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 15: 961&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">7576644</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonfoco E, Krainc D, Ankarcrona M, Nicotera P, Lipton SA (1995) Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-d-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci USA 92: 7162&#x2013;7166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC41299</ArticleId><ArticleId IdType="pubmed">7638161</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossy-Wetzel E, Schwarzenbacher R, Lipton SA (2004) Molecular pathways to neurodegeneration. Nat Med [Suppl] 10: S2&#x2013;S9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15272266</ArticleId></ArticleIdList></Reference><Reference><Citation>Buee L, Bussiere T, Buee-Scherrer V, Delacoutte A, Hof PR (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33: 95&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">10967355</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai D, Leem JY, Greenfield JP, Wang P, Kim BS, Wang R, Lopes KO, Kim SH, Zheng H, Greengard P, Sisodia SS, Thinakaran G, Xu H (2003) Presenilin-1 regulates intracellular trafficking and cell surface delivery of beta-amyloid precursor protein. J Biol Chem 278: 3446&#x2013;3454.</Citation><ArticleIdList><ArticleId IdType="pubmed">12435726</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng G, Yu Z, Zhou D, Mattson MP (2002) Phosphatidylinositol-3-kinase-Akt kinase and p42/p44 mitogen-activated protein kinases mediate neurotrophic and excitoprotective actions of a secreted form of amyloid precursor protein. Exp Neurol 175: 407&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">12061870</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung ZH, Ip NY (2004) Cdk5: mediator of neuronal death and survival. Neurosci Lett 361: 47&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">15135890</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, Tsai L (2004) Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol Med 10: 452&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">15350898</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, Tseng H, Goldman JA, Shih H, Tsai L (2003) Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40: 471&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">14642273</ArticleId></ArticleIdList></Reference><Reference><Citation>Darios F, Muriel M, Khondiker E, Brice A, Ruberg M (2005) Neurotoxic calcium transfer from endoplasmic reticulum to mitochondria is regulated by cyclin-dependent kinase 5-dependent phosphorylation of tau. J Neurosci 25: 4159&#x2013;4168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724963</ArticleId><ArticleId IdType="pubmed">15843619</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson GR, Seabrook GR, Zheng H, Smith DW, Graham S, O'Dowd G, Bowery BJ, Boyce S, Trumbauer ME, Chen HY, Van der Ploeg LH, Sirinathsinghji DJ (1999) Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience 90: 1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">10188929</ArticleId></ArticleIdList></Reference><Reference><Citation>Delobel P, Mailliot C, Hamdane M, Sambo AV, Begard S, Violleau A, Delacourte A, Buee L (2004) Stable-tau overexpression in human neuroblastoma cells: an open door for explaining neuronal death in tauopathies. Ann NY Acad Sci 1010: 623&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">15033802</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW (2004) Apoptotic mechanisms in Alzheimer neurofibrillary degeneration: cause or effect? J Clin Invest 114: 23&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC437977</ArticleId><ArticleId IdType="pubmed">15232608</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehehalt R, Keller P, Haass C, Thiele C, Simons K (2003) Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 160: 113&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172747</ArticleId><ArticleId IdType="pubmed">12515826</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito L, Gan L, Yu GQ, Essrich C, Mucke L (2004) Intracellularly generated amyloid-beta peptide counteracts the antiapoptotic function of its precursor protein and primes proapoptotic pathways for activation by other insults in neuroblastoma cells. J Neurochem 91: 1260&#x2013;1274.</Citation><ArticleIdList><ArticleId IdType="pubmed">15584903</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamblin CT, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL (2003) Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci USA 100: 10032&#x2013;10037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC187753</ArticleId><ArticleId IdType="pubmed">12888622</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Abeta 42 fibrils. Science 293: 1491&#x2013;1494.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenfield JP, Gross RS, Gouras GK, Xu H (2000) Cellular and molecular basis of beta-amyloid precursor protein metabolism. Front Biosci 5: D72&#x2013;D83.</Citation><ArticleIdList><ArticleId IdType="pubmed">10702374</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q (2003) Cyclin-dependent kinase 5&#x2014;a neuronal killer? Sci Aging Knowledge Environ 50: pe36.</Citation><ArticleIdList><ArticleId IdType="pubmed">14681576</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper SJ, Bilslaud JG, Shearman MS, Zheng H, Van der Ploeg L, Sirinathsinghhi DJ (1998) Mouse cortical neurons lacking APP show normal neurite outgrowth and survival responses in vitro. NeuroReport 9: 3053&#x2013;3058.</Citation><ArticleIdList><ArticleId IdType="pubmed">9804315</ArticleId></ArticleIdList></Reference><Reference><Citation>Heber S, Herms J, Gajic V, Hainfellner J, Aguzzi A, Rulicke T, von Kretzschmar H, von Koch C, Sisodia S, Tremml P, Lipp HP, Wolfer DP, Muller U (2000) Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. J Neurosci 20: 7951&#x2013;7963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772747</ArticleId><ArticleId IdType="pubmed">11050115</ArticleId></ArticleIdList></Reference><Reference><Citation>Herms J, Anliker B, Heber S, Ring S, Fuhrmann M, Kretzschmar H, Sisodia S, Muller U (2004) Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. EMBO J 23: 4106&#x2013;4115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524337</ArticleId><ArticleId IdType="pubmed">15385965</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof PR, Bouras C, Perl DP, Sparks DL, Mehta N, Morrison JH (1995) Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome. Quantitative regional analysis and comparison with Alzheimer's disease. Arch Neurol 52: 379&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pubmed">7710374</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, Khatoon S, Li B, Liu F, Rahman A, Tanimukai H, Grundke-Iqbal I (2005) Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 1739: 198&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615638</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal A, Almenar-Queralt A, LeBlanc JF, Rfberts EA, Goldstein LS (2001) Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature 14: 643&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">11740561</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH (2002) The &#x3b2;-amyloid precursor protein (APP) and Alzheimer's disease: does the tail wag the dog? Traffic 3: 763&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">12383342</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K, Fischer P, Masters CL, Price DL (1990) Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde exonal transport. Proc Natl Acad Sci USA 87: 1561&#x2013;1565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC53515</ArticleId><ArticleId IdType="pubmed">1689489</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Tsai LH (2003) Cdk5: one of the links between senile plaques and neurofibrillary tangles? J Alzheimers Dis 2: 127&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">12719630</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH (2000) Neurotoxicity induced cleavage of p35 to p25 by calpain. Nature 405: 360&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">10830966</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293: 1487&#x2013;1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520987</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton SA, Rosenberg PA (1994) Mechanisms of disease: excitatory amino acids as a final common pathway for neurological disorders. N Engl J Med 330: 613&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">7905600</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Su Y, Li B, Zhou Y, Ryder J, Gonzalez-DeWhitt P, May PC, Ni B (2003) Regulation of amyloid precursor protein (APP) phosphorylation and processing by p35/Cdk5 and p25/Cdk5. FEBS Lett 547: 193&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">12860412</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Perry G, Chan HW, Verdile G, Martins RN, Smith MA, Atwood CS (2004) Amyloid-beta-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression. J Neurochem 88: 554&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pubmed">14720205</ArticleId></ArticleIdList></Reference><Reference><Citation>Magara F, Muller U, Li ZW, Lipp HP, Weissmann C, Stagljar M, Wolfer DP (1999) Genetic background changes the pattern of forebrain commissure defects in transgenic mice underexpressing the beta-amyloid-precursor protein. Proc Natl Acad Sci USA 96: 4656&#x2013;4661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16388</ArticleId><ArticleId IdType="pubmed">10200318</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Westland CE, Rockenstein EM, Abraham CR, Mallory M, Veinberg I, Sheldon E, Mucke L (1997) Amyloid precursor proteins protect neurons of transgenic mice against acute and chronic excitotoxic injuries in vivo. Neuroscience 78: 135&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">9135095</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP (1997) Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 77: 1081&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354812</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Abraham CR, Masliah E (1996) Neurotrophic and neuroprotective effects of hAPP in transgenic mice. Ann NY Acad Sci 777: 82&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">8624131</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller U, Cristina N, Li ZW, Wolfer DP, Lipp HP, Rulicke T, Brandner S, Aguzzi A, Weissmann C (1994) Behavioral and anatomical deficits in mice homozygous for a modified beta-amyloid precursor protein gene. Cell 79: 755&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">8001115</ArticleId></ArticleIdList></Reference><Reference><Citation>Neve R, McPhie DL, Chen Y (2000) Alzheimer's disease: a dysfunction of the amyloid precursor protein. Brain Res 886: 54&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">11119687</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicotera P, Ankarcrona M, Bonfoco E, Orrenius S, Lipton SA (1997) Neuronal necrosis and apoptosis: two distinct events induced by exposure to glutamate or oxidative stress. Adv Neurol 72: 95&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">8993688</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J, Gaynor K, LaFrancois J, Wang L, Kondo T, Davies P, Burns M, Veeranna, Nixon R, Dickson D, Matsuola Y, Ahlijanian M, Lau LF, Duff K (2003) Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38: 555&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pubmed">12765608</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39: 409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43: 321&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294141</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohshima T, Gilmore EC, Longenecker G, Jacobowitz DM, Brady RO, Herrup K, Kulkami AB (1999) Migration defects of CDk5 (&#x2013;/&#x2013;) neurons in the developing cerebellum is cell autonomous. J Neurosci 19: 6017&#x2013;6026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6783065</ArticleId><ArticleId IdType="pubmed">10407039</ArticleId></ArticleIdList></Reference><Reference><Citation>Oishi M, Nairn AC, Czernik AJ, Lim GS, Isohara T, Gandy SE, Greengard P, Suzuki T (1997) The cytoplasmic domain of Alzheimer's amyloid precursor protein is phosphorylated at Thr654, Ser655, and Thr668 in adult rat brain and cultured cells. Mol Med 3: 111&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2230054</ArticleId><ArticleId IdType="pubmed">9085254</ArticleId></ArticleIdList></Reference><Reference><Citation>Otth C, Concha II, Arendt T, Stieler J, Schliebs R, Gonzalez-Billault C, Maccioni RB (2002) AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. J Alzheimers Dis 4: 417&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">12446973</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez RG, Zheng H, Lex HT, Ploeg V, Koo EH (1997) The &#x3b2;-amyloid precursor protein of Alzheimer's disease enhances neuron viability and modulates neuronal polarity. J Neurosci 17: 9407&#x2013;9414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573428</ArticleId><ArticleId IdType="pubmed">9390996</ArticleId></ArticleIdList></Reference><Reference><Citation>Prunell GF, Troy CM (2004) Balancing neuronal death. J Neurosci Res 78: 1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15372573</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzuto R, Pinton P, Carrington W, Fay FS, Fogarty KE, Lifshitz LM, Tuft RA, Pozzan T (1998) Close contacts with the endoplasmic reticulum as determinants of mitochondrial Ca2+ responses. Science 280: 1763&#x2013;1766.</Citation><ArticleIdList><ArticleId IdType="pubmed">9624056</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohn TT, Ivins KJ, Bahr BA, Cotman CW, Cribbs DH (2000) A monoclonal antibody to amyloid precursor protein induces neuronal apoptosis. J Neurochem 74: 2331&#x2013;2342.</Citation><ArticleIdList><ArticleId IdType="pubmed">10820193</ArticleId></ArticleIdList></Reference><Reference><Citation>Seabrook GR, Smith DW, Bowery BJ, Easter A, Reynolds T, Fitzjohn SM, Morton RA, Zheng H, Dawson GR, Sirinathsinghji DJ, Davies CH, Collingridge Gl, Hill RG (1999) Mechanisms contributing to the deficits in hippocampual synaptic plasticity in mice lacking amyloid precursor protein. Neuropharmacology 38: 349&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">10219973</ArticleId></ArticleIdList></Reference><Reference><Citation>Sindou P, Lesort M, Couratier P, Yardin C, Esclaire F, Hugon J (1994) Glutamate increases tau phosphorylation in primary neuronal cultures from fetal rat cerebral cortex. Brain Res 646: 124&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">7914466</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM (2002) Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 156: 1051&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173473</ArticleId><ArticleId IdType="pubmed">11901170</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinbach JP, Muller U, Leist M, LiZW, Nicotera P, Aguzzi A (1998) Hypersensitivity to seizures in beta-amyloid precursor protein deficient mice. Cell Death Differ 5: 858&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pubmed">10203685</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, Raman R, Davies P, Masliah E, Williams DS, Goldstein LS (2005) Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307: 1282&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pubmed">15731448</ArticleId></ArticleIdList></Reference><Reference><Citation>Tandon A, Yu H, Wang L, Rogaeva E, Sato C, Chishti MA, Kawarai T, Hasegawa H, Chen F, Davies P, Fraser PE, Westaway D, St. George-Hyslop PH (2003) Brain levels of CDK5 activator p25 are not increased in Alzheimer's or other neurodegenerative diseases with neurofibrillary tangles. J Neurochem 86: 572&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">12859671</ArticleId></ArticleIdList></Reference><Reference><Citation>Tikkanen R, Icking A, Beicht P, Waneck GL, Volker H (2002) The receptor-bound N-terminal ectodomain of the amyloid precursor protein is associated with membrane rafts. J Biol Chem 383: 1855&#x2013;1864.</Citation><ArticleIdList><ArticleId IdType="pubmed">12553722</ArticleId></ArticleIdList></Reference><Reference><Citation>Town T, Zolton J, Shaffner R, Schnell B, Crescentini R, Wu Y, Zeng J, Delle-Donne A, Obregon D, Tan J, Mullan M (2002) p35/Cdk5 pathway mediates soluble amyloid-&#x3b2; peptide-induced tau phosphorylation in vitro J Neurosci Res 69: 362&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">12125077</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HJ, Guay G, Pogan L, Sauve R, Nabi IR (2000) Calcium regulates the association between mitochondria and a smooth subdomain of the endoplasmic reticulum. J Cell Biol 150: 1489&#x2013;1498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2150689</ArticleId><ArticleId IdType="pubmed">10995452</ArticleId></ArticleIdList></Reference><Reference><Citation>Weishaupt JH, Kussmaul L, Grotsch P, Heckel A, Rohde G, Romig H, Bahr M, Gillardon F (2003) Inhibition of CDK5 is protective in necrotic and apoptotic paradigms of neuronal cell death and prevents mitochondrial dysfunction. Mol Cell Neurosci 24: 489&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">14572469</ArticleId></ArticleIdList></Reference><Reference><Citation>White AR, Zheng H, Galatis D, Maher F, Hesse L, Multhaup G, Beyreuther K, Masters Cl, Cappai R (1998) Survival of cultured neurons from amyloid precursor protein knock-out mice against Alzheimer's amyloid &#x3b2; toxicity and oxidative stress. J Neurosci 18: 6207&#x2013;6217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793217</ArticleId><ArticleId IdType="pubmed">9698314</ArticleId></ArticleIdList></Reference><Reference><Citation>White AR, Multhaup G, Maher F, Bellingham S, Camakaris J, Zheng H, Bush AI, Beyreuther K, Masters Cl, Cappai R (1999) The Alzheimer's disease amyloid precursor protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures. J Neurosci 19: 9170&#x2013;9179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782934</ArticleId><ArticleId IdType="pubmed">10531420</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L, Fried G, Jovanovic JN, Seeger M, Relkin NR, Liao F, Checler F, Buxbaum JD, Chait BT, Thinakaran G, Sisodia SS, Wang R, Greengard P, Gandy S (1998) Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med 4: 447&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">9546791</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J, Lipinski M, Degterev A (2003) Diversity in the mechanisms of neuronal cell death. Neuron 40: 401&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">14556717</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Eckman C, Younkin S, Hsiso KK, Iadecola C (1997) Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein. J Neurosci 17: 7655&#x2013;7661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793926</ArticleId><ArticleId IdType="pubmed">9315887</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Jiang M, Trumbauer ME, Sirinathsinghji DJ, Hopkins R, Smith DW, Heavens RP, Dawson GR, Boyce S, Conner MW, Stevens KA, Slunt HH, Sisodia SS, Chen HY, Van de Ploeg LH (1995) &#x3b2;-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomoter activity. Cell 81: 525&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">7758106</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y, Kesavapany S, Gravell M, Hamilton RS, Schubert M, Amin N, Albers W, Grant P, Pant HC (2005) A Cdk5 inhibitory peptide reduces tau hyperphosphorylationand apoptosis in neurons. EMBO J 24: 209&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC544899</ArticleId><ArticleId IdType="pubmed">15592431</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16354928</PMID><DateCompleted><Year>2006</Year><Month>05</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>50</Issue><PubDate><Year>2005</Year><Month>Dec</Month><Day>14</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions.</ArticleTitle><Pagination><StartPage>11693</StartPage><EndPage>11709</EndPage><MedlinePgn>11693-709</MedlinePgn></Pagination><Abstract><AbstractText>A transmembrane aspartyl protease termed beta-site APP cleavage enzyme 1 (BACE1) that cleaves the amyloid-beta precursor protein (APP), which is abundant in neurons, is required for the generation of amyloid-beta (Abeta) peptides implicated in the pathogenesis of Alzheimer's disease (AD). We now demonstrate that BACE1, enriched in neurons of the CNS, is a major determinant that predisposes the brain to Abeta amyloidogenesis. The physiologically high levels of BACE1 activity coupled with low levels of BACE2 and alpha-secretase anti-amyloidogenic activities in neurons is a major contributor to the accumulation of Abeta in the CNS, whereas other organs are spared. Significantly, deletion of BACE1 in APPswe;PS1DeltaE9 mice prevents both Abeta deposition and age-associated cognitive abnormalities that occur in this model of Abeta amyloidosis. Moreover, Abeta deposits are sensitive to BACE1 dosage and can be efficiently cleared from the CNS when BACE1 is silenced. However, BACE1 null mice manifest alterations in hippocampal synaptic plasticity as well as in performance on tests of cognition and emotion. Importantly, memory deficits but not emotional alterations in BACE1(-/-) mice are prevented by coexpressing APPswe;PS1DeltaE9 transgenes, indicating that other potential substrates of BACE1 may affect neural circuits related to emotion. Our results establish BACE1 and APP processing pathways as critical for cognitive, emotional, and synaptic functions, and future studies should be alert to potential mechanism-based side effects that may occur with BACE1 inhibitors designed to ameliorate Abeta amyloidosis in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laird</LastName><ForeName>Fiona M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Huaibin</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Savonenko</LastName><ForeName>Alena V</ForeName><Initials>AV</Initials></Author><Author ValidYN="Y"><LastName>Farah</LastName><ForeName>Mohamed H</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Kaiwen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Melnikova</LastName><ForeName>Tatyana</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Hongjin</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>Hsueh-Cheng</ForeName><Initials>HC</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Guilian</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Koliatsos</LastName><ForeName>Vassilis E</ForeName><Initials>VE</Initials></Author><Author ValidYN="Y"><LastName>Borchelt</LastName><ForeName>David R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Donald L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hey-Kyoung</ForeName><Initials>HK</Initials></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Philip C</ForeName><Initials>PC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS41438</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS047308</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z01 AG000959</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z99 AG999999</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS045150</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG02556</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041438</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS45150</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.45</RegistryNumber><NameOfSubstance UI="C509284">BACE2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>5</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>6</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16354928</ArticleId><ArticleId IdType="mid">NIHMS44739</ArticleId><ArticleId IdType="pmc">PMC2564291</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2766-05.2005</ArticleId><ArticleId IdType="pii">25/50/11693</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abeliovich A, Chen C, Goda Y, Silva AJ, Stevens CF, Tonegawa S (1993) Modified hippocampal long-term potentiation in PKC gamma-mutant mice. Cell 75: 1253&#x2013;1262.</Citation><ArticleIdList><ArticleId IdType="pubmed">8269509</ArticleId></ArticleIdList></Reference><Reference><Citation>Allinson TM, Parkin ET, Turner AJ, Hooper NM (2003) ADAMs family members as amyloid precursor protein alpha-secretases. J Neurosci Res 74: 342&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">14598310</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasson KI, Savonenko A, Vidensky S, Goellner JJ, Zhang Y, Shaffer A, Kaufmann WE, Worley PF, Isakson P, Markowska AL (2001) Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice. J Neurosci 21: 8198&#x2013;8209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763862</ArticleId><ArticleId IdType="pubmed">11588192</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendash GW, King DL, Gordon MN, Morgan D, Hatcher JM, Hope CE, Diamond DM (2001) Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res 891: 42&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">11164808</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashe KH (2001) Learning and memory in transgenic mice modeling Alzheimer's disease. Learn Mem 8: 301&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">11773429</ArticleId></ArticleIdList></Reference><Reference><Citation>Baek SH, Ohgi KA, Rose DW, Koo EH, Glass CK, Rosenfeld MG (2002) Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Cell 110: 55&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">12150997</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett BD, Babu-Khan S, Loeloff R, Louis JC, Curran E, Citron M, Vassar R (2000) Expression analysis of BACE2 in brain and peripheral tissues. J Biol Chem 275: 20647&#x2013;20651.</Citation><ArticleIdList><ArticleId IdType="pubmed">10749877</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodendorf U, Danner S, Fischer F, Stefani M, Sturchler-Pierrat C, Wiederhold KH, Staufenbiel M, Paganetti P (2002) Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-amyloid. J Neurochem 80: 799&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">11948243</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS (1996) Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1&#x2013;42/1&#x2013;40 ratio in vitro and in vivo. Neuron 17: 1005&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum JD, Thinakaran G, Koliatsos V, O'Callahan J, Slunt HH, Price DL, Sisodia SS (1998) Alzheimer amyloid protein precursor in the rat hippocampus: transport and processing through the perforant path. J Neurosci 18: 9629&#x2013;9637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793291</ArticleId><ArticleId IdType="pubmed">9822724</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC (2001) BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci 4: 233&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, Sudhof TC (2001) A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science [Erratum (2001) 293:1436] 293: 115&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441186</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, Sudhof TC (2004) Dissection of amyloid-beta precursor protein-dependent transcriptional transactivation. J Biol Chem 279: 24601&#x2013;24611.</Citation><ArticleIdList><ArticleId IdType="pubmed">15044485</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M (2002) Beta-secretase as a target for the treatment of Alzheimer's disease. J Neurosci Res 70: 373&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">12391600</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawley JN (1999) Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res 835: 18&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">10448192</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson GR, Seabrook GR, Zheng H, Smith DW, Graham S, O'Dowd G, Bowery BJ, Boyce S, Trumbauer ME, Chen HY, Van der Ploeg LH, Sirinathsinghji DJ (1999) Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience 90: 1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">10188929</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B (2003) Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron 38: 9&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12691659</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB (2004) Apolipoprotein E dose-dependent modulation of beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. J Mol Neurosci 23: 255&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">15181254</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudchenko PA (2004) An overview of the tasks used to test working memory in rodents. Neurosci Biobehav Rev 28: 699&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pubmed">15555679</ArticleId></ArticleIdList></Reference><Reference><Citation>Dykxhoorn DM, Novina CD, Sharp PA (2003) Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 4: 457&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">12778125</ArticleId></ArticleIdList></Reference><Reference><Citation>Eichenbaum H, Stewart C, Morris RG (1990) Hippocampal representation in place learning. J Neurosci 10: 3531&#x2013;3542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570096</ArticleId><ArticleId IdType="pubmed">2230943</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbashir SM, Harborth J, Weber K, Tuschl T (2002) Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26: 199&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">12054897</ArticleId></ArticleIdList></Reference><Reference><Citation>Farzan M, Schnitzler CE, Vasilieva N, Leung D, Choe H (2000) BACE2, a beta-secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. Proc Natl Acad Sci USA 97: 9712&#x2013;9717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16930</ArticleId><ArticleId IdType="pubmed">10931940</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis R, McGrath G, Zhang J, Ruddy DA, Sym M, Apfeld J, Nicoll M, Maxwell M, Hai B, Ellis MC, Parks AL, Xu W, Li J, Gurney M, Myers RL, Himes CS, Hiebsch R, Ruble C, Nye JS, Curtis D (2002) aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell 3: 85&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">12110170</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL (2003) Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 100: 10417&#x2013;10422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC193576</ArticleId><ArticleId IdType="pubmed">12925731</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruninger-Leitch F, Schlatter D, Kung E, Nelbock P, Dobeli H (2002) Substrate and inhibitor profile of BACE (beta-secretase) and comparison with other mammalian aspartic proteases. J Biol Chem 277: 4687&#x2013;4693.</Citation><ArticleIdList><ArticleId IdType="pubmed">11741910</ArticleId></ArticleIdList></Reference><Reference><Citation>Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G (2002) Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol 51: 783&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pubmed">12112088</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, Bales K, Ashe KH, Irizarry MC, Hyman BT (2000) Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol 47: 739&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">10852539</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, Gloger IS, Murphy KE, Southan CD, Ryan DM, Smith TS, Simmons DL, Walsh FS, Dingwall C, Christie G (1999) Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci 14: 419&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pubmed">10656250</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC (2001) Metabolic regulation of brain Abeta by neprilysin. Science 292: 1550&#x2013;1552.</Citation><ArticleIdList><ArticleId IdType="pubmed">11375493</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N, Mizukami H, Shirotani K, Takaki Y, Muramatsu S, Lu B, Gerard NP, Gerard C, Ozawa K, Saido TC (2004) Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-&#x3b2; peptide in mouse brain. J Neurosci 24: 991&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729819</ArticleId><ArticleId IdType="pubmed">14749444</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Xu G, Fromholt D, Gonzales V, Borchelt DR (2003) Environmental enrichment exacerbates amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Neuropathol Exp Neurol 62: 1220&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pubmed">14692698</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, Goldstein LS (2001) Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature 414: 643&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">11740561</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R (2003) APP processing and synaptic function. Neuron 37: 925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimberly WT, Zheng JB, Town T, Flavell RA, Selkoe DJ (2005) Physiological regulation of the &#x3b2;-amyloid precursor protein signaling domain by c-Jun N-terminal kinase JNK3 during neuronal differentiation. J Neurosci 25: 5533&#x2013;5543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724978</ArticleId><ArticleId IdType="pubmed">15944381</ArticleId></ArticleIdList></Reference><Reference><Citation>King JA, Burgess N, Hartley T, Vargha-Khadem F, O'Keefe J (2002) Human hippocampus and viewpoint dependence in spatial memory. Hippocampus 12: 811&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">12542232</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazume S, Tachida Y, Oka R, Shirotani K, Saido TC, Hashimoto Y (2001) Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. Proc Natl Acad Sci USA 98: 13554&#x2013;13559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC61079</ArticleId><ArticleId IdType="pubmed">11698669</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL, Krafft GA, Finch CE (2001) Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci 24: 219&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">11250006</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998) Diffusible, nonfibrillar ligands derived from Abeta1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95: 6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Lee M, Peterson DA, Sisodia SS (2002) Evidence that synaptically released &#x3b2;-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci 22: 9785&#x2013;9793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757836</ArticleId><ArticleId IdType="pubmed">12427834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Morfini GA, Lee EB, Farah MH, Szodorai A, DeBoer SR, Koliatsos VE, Kins S, Lee VM, Wong PC, Price DL, Brady ST, Sisodia SS (2005) Axonal transport, amyloid precursor protein, kinesin-1, and the processing apparatus: revisited. J Neurosci 25: 2386&#x2013;2395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6726084</ArticleId><ArticleId IdType="pubmed">15745965</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Zhang B, Liu K, Greenbaum EA, Doms RW, Trojanowski JQ, Lee VM (2005) BACE overexpression alters the subcellular processing of APP and inhibits Abeta deposition in vivo. J Cell Biol 168: 291&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171598</ArticleId><ArticleId IdType="pubmed">15642747</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HK, Barbarosie M, Kameyama K, Bear MF, Huganir RL (2000) Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity. Nature 405: 955&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pubmed">10879537</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MK, Borchelt DR, Kim G, Thinakaran G, Slunt HH, Ratovitski T, Martin LJ, Kittur A, Gandy S, Levey AI, Jenkins N, Copeland N, Price DL, Sisodia SS (1997) Hyperaccumulation of FAD-linked presenilin 1 variants in vivo. Nat Med 3: 756&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">9212102</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ (2003) Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40: 1087&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pubmed">14687544</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Sudhof TC (2004) Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1. J Biol Chem 279: 10542&#x2013;10550.</Citation><ArticleIdList><ArticleId IdType="pubmed">14699153</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenthaler SF, Dominguez DI, Westmeyer GG, Reiss K, Haass C, Saftig P, De Strooper B, Seed B (2003) The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J Biol Chem 278: 48713&#x2013;48719.</Citation><ArticleIdList><ArticleId IdType="pubmed">14507929</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J (2000) Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci USA 97: 1456&#x2013;1460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26455</ArticleId><ArticleId IdType="pubmed">10677483</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis JC, Yan Q, Richards WG, Citron M, Vassar R (2001) Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4: 231&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224535</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Bolon B, Damore MA, Fitzpatrick D, Liu H, Zhang J, Yan Q, Vassar R, Citron M (2003) BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time. Neurobiol Dis 14: 81&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678669</ArticleId></ArticleIdList></Reference><Reference><Citation>Manabe T, Wyllie DJ, Perkel DJ, Nicoll RA (1993) Modulation of synaptic transmission and long-term potentiation: effects on paired pulse facilitation and EPSC variance in the CA1 region of the hippocampus. J Neurophysiol 70: 1451&#x2013;1459.</Citation><ArticleIdList><ArticleId IdType="pubmed">7904300</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowska AL, Long JM, Johnson CT, Olton DS (1993) Variable-interval probe test as a tool for repeated measurements of spatial memory in the water maze. Behav Neurosci 107: 627&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">8397867</ArticleId></ArticleIdList></Reference><Reference><Citation>Marr RA, Rockenstein E, Mukherjee A, Kindy MS, Hersh LB, Gage FH, Verma IM, Masliah E (2003) Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci 23: 1992&#x2013;1996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742010</ArticleId><ArticleId IdType="pubmed">12657655</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R (2003) Apolipoprotein E, Alzheimer disease, and African Americans. Arch Neurol 60: 161&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">12580698</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46: 860&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Price AL (2001) Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci 17: 101&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">11816784</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11: 47&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">6471907</ArticleId></ArticleIdList></Reference><Reference><Citation>Naruse S, Thinakaran G, Luo JJ, Kusiak JW, Tomita T, Iwatsubo T, Qian X, Ginty DD, Price DL, Borchelt DR, Wong PC, Sisodia SS (1998) Effects of PS1 deficiency on membrane protein trafficking in neurons. Neuron 21: 1213&#x2013;1221.</Citation><ArticleIdList><ArticleId IdType="pubmed">9856475</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, Vassar R, Disterhoft JF (2004) BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 41: 27&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">14715132</ArticleId></ArticleIdList></Reference><Reference><Citation>Paddison PJ, Hannon GJ (2002) RNA interference: the new somatic cell genetics? Cancer Cell 2: 17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">12150821</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC (2003) Mild cognitive impairment clinical trials. Nat Rev Drug Discov 2: 646&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pubmed">12904814</ArticleId></ArticleIdList></Reference><Reference><Citation>Price DL, Sisodia SS (1998) Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci 21: 479&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">9530504</ArticleId></ArticleIdList></Reference><Reference><Citation>Prut L, Belzung C (2003) The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 463: 3&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">12600700</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, Johnson-Wood K, Kappenman KE, Kawabe TT, Kola I, Kuehn R, Lee M, Liu W, Motter R, Nichols NF, Power M, et al. (2001) BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 10: 1317&#x2013;1324.</Citation><ArticleIdList><ArticleId IdType="pubmed">11406613</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein E, Mante M, Alford M, Adame A, Crews L, Hashimoto M, Esposito L, Mucke L, Masliah E (2005) High beta-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-beta levels: implications for the treatment of Alzheimer disease. J Biol Chem 280: 32957&#x2013;32967.</Citation><ArticleIdList><ArticleId IdType="pubmed">16027115</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozov A, Zilberter Y, Wollmuth LP, Burnashev N (1998) Facilitation of currents through rat Ca2+-permeable AMPA receptor channels by activity-dependent relief from polyamine block. J Physiol (Lond) 511: 361&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2231126</ArticleId><ArticleId IdType="pubmed">9706016</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, Rooney DL, Ihrig MM, McManus MT, Gertler FB, Scott ML, Van Parijs L (2003) A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 33: 401&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">12590264</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabo SL, Ikin AF, Buxbaum JD, Greengard P (2003) The amyloid precursor protein and its regulatory protein, FE65, in growth cones and synapses in vitro and in vivo J Neurosci 23: 5407&#x2013;5415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741254</ArticleId><ArticleId IdType="pubmed">12843239</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher III RJ, Kandel ER, Duff K, Kirkwood A, Shen J (2004) Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 42: 23&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP, Price DL, Tang F, Markowska AL, Borchelt DR (2005) Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 18: 602&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">15755686</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D, Kopan R (2003) Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci 26: 565&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730322</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Price DL, Koliatsos VE (2002) Disruption of corticocortical connections ameliorates amyloid burden in terminal fields in a transgenic model of A&#x3b2; amyloidosis. J Neurosci 22: 9794&#x2013;9799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757847</ArticleId><ArticleId IdType="pubmed">12427835</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Price DL, Koliatsos VE (2003) The beta-amyloid-related proteins presenilin 1 and BACE1 are axonally transported to nerve terminals in the brain. Exp Neurol 184: 1053&#x2013;1057.</Citation><ArticleIdList><ArticleId IdType="pubmed">14769400</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin J, Shen F, Huguenard JR (2005) Polyamines modulate AMPA receptor dependent synaptic responses in immature layer V pyramidal neurons. J Neurophysiol 93: 2634&#x2013;2643.</Citation><ArticleIdList><ArticleId IdType="pubmed">15574796</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer O, Marr RA, Rockenstein E, Crews L, Coufal NG, Gage FH, Verma IM, Masliah E (2005) Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 8: 1343&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">16136043</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, et al. (1999) Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402: 537&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591214</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasugi N, Tomita T, Hayashi I, Tsuruoka M, Niimura M, Takahashi Y, Thinakaran G, Iwatsubo T (2003) The role of presenilin cofactors in the gamma-secretase complex. Nature 422: 438&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">12660785</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R (2002) Beta-secretase (BACE) as a drug target for Alzheimer's disease. Adv Drug Deliv Rev 54: 1589&#x2013;1602.</Citation><ArticleIdList><ArticleId IdType="pubmed">12453676</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, et al. (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286: 735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Hu Q, Hearn MG, Shimizu K, Ware CB, Liggitt DH, Jin LW, Cool BH, Storm DR, Martin GM (2004) Isoform-specific knockout of FE65 leads to impaired learning and memory. J Neurosci Res 75: 12&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">14689444</ArticleId></ArticleIdList></Reference><Reference><Citation>Winocur G, Hasher L (2004) Age and time-of-day effects on learning and memory in a non-matching-to-sample test. Neurobiol Aging 25: 1107&#x2013;1115.</Citation><ArticleIdList><ArticleId IdType="pubmed">15212835</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfer DP, Muller U, Stogliar M, Lipp HP (1997) Assessing the effects of the 129/Sv genetic background on swimming navigation learning in transgenic mutants: a study using mice with a modified &#x3b2;-amyloid precursor protein gene. Brain Res 771: 1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">9383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HK, Sakurai T, Oyama F, Kaneko K, Wada K, Miyazaki H, Kurosawa M, De Strooper B, Saftig P, Nukina N (2005) &#x3b2;-Subunits of voltage-gated sodium channels are novel substrates of &#x3b2;-site amyloid precursor protein-cleaving enzyme (BACE1) and &#x3b3;-secretase. J Biol Chem 280: 23009&#x2013;23017.</Citation><ArticleIdList><ArticleId IdType="pubmed">15824102</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong PC, Price DL, Cai H (2001) The brain's susceptibility to amyloid plaques. Science 293: 1434.</Citation><ArticleIdList><ArticleId IdType="pubmed">11526940</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong PC, Cai H, Borchelt DR, Price DL (2002) Genetically engineered mouse models of neurodegenerative diseases. Nat Neurosci 5: 633&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">12085093</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu G, Gonzales V, Borchelt DR (2002) Rapid detection of protein aggregates in the brains of Alzheimer patients and transgenic mouse models of amyloidosis. Alzheimer Dis Assoc Disord 16: 191&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">12218651</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto T, Hirano A (1986) A comparative study of modified Bielschowsky, Bodian and thioflavin S stains on Alzheimer's neurofibrillary tangles. Neuropathol Appl Neurobiol 12: 3&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2422580</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, Carter DB, Tomasselli AG, Parodi LA, Heinrikson RL, Gurney ME (1999) Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402: 533&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591213</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Munzner JB, Shuck ME, Bienkowski MJ (2001) BACE2 functions as an alternative alpha-secretase in cells. J Biol Chem 276: 34019&#x2013;34027.</Citation><ArticleIdList><ArticleId IdType="pubmed">11423558</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, Beach T, Sue L, Wong P, Price D, Li R, Shen Y (2003) Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 9: 3&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">12514700</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Q, Lee FS (2003) The transcriptional activity of the APP intracellular domain-Fe65 complex is inhibited by activation of the NF-kappaB pathway. Biochemistry 42: 3627&#x2013;3634.</Citation><ArticleIdList><ArticleId IdType="pubmed">12653567</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Jiang M, Trumbauer ME, Sirinathsinghji DJ, Hopkins R, Smith DW, Heavens RP, Dawson GR, Boyce S, Conner MW, Stevens KA, Slunt HH, Sisodia SS, Chen HY, Van der Ploeg LH (1995) beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 81: 525&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">7758106</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16369530</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1061-4036</ISSN><JournalIssue CitedMedium="Print"><Volume>38</Volume><Issue>1</Issue><PubDate><Year>2006</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy.</ArticleTitle><Pagination><StartPage>24</StartPage><EndPage>26</EndPage><MedlinePgn>24-6</MedlinePgn></Pagination><Abstract><AbstractText>We report duplication of the APP locus on chromosome 21 in five families with autosomal dominant early-onset Alzheimer disease (ADEOAD) and cerebral amyloid angiopathy (CAA). Among these families, the duplicated segments had a minimal size ranging from 0.58 to 6.37 Mb. Brains from individuals with APP duplication showed abundant parenchymal and vascular deposits of amyloid-beta peptides. Duplication of the APP locus, resulting in accumulation of amyloid-beta peptides, causes ADEOAD with CAA.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rovelet-Lecrux</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Inserm U614-IFRMP, Faculty of Medicine, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hannequin</LastName><ForeName>Didier</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Raux</LastName><ForeName>Gregory</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Le Meur</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Laquerri&#xe8;re</LastName><ForeName>Annie</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Vital</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Dumanchin</LastName><ForeName>C&#xe9;cile</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Feuillette</LastName><ForeName>S&#xe9;bastien</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Brice</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Vercelletto</LastName><ForeName>Martine</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Dubas</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Frebourg</LastName><ForeName>Thierry</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Campion</LastName><ForeName>Dominique</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>OMIM</DataBankName><AccessionNumberList><AccessionNumber>104311</AccessionNumber><AccessionNumber>104760</AccessionNumber><AccessionNumber>600759</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Genet. 2006 Jan;38(1):11-2. doi: 10.1038/ng0106-11.</RefSource><PMID Version="1">16380721</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020440" MajorTopicYN="Y">Gene Duplication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005799" MajorTopicYN="N">Genes, Dominant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018895" MajorTopicYN="N">Microsatellite Repeats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>12</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>12</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16369530</ArticleId><ArticleId IdType="doi">10.1038/ng1718</ArticleId><ArticleId IdType="pii">ng1718</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16372280</PMID><DateCompleted><Year>2006</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0364-5134</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.</ArticleTitle><Pagination><StartPage>512</StartPage><EndPage>519</EndPage><MedlinePgn>512-9</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Amyloid-beta(42) (Abeta(42)) appears central to Alzheimer's disease (AD) pathogenesis and is a major component of amyloid plaques. Mean cerebrospinal fluid (CSF) Abeta(42) is decreased in dementia of the Alzheimer's type. This decrease may reflect plaques acting as an Abeta(42) "sink," hindering transport of soluble Abeta(42) between brain and CSF. We investigated this hypothesis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We compared the in vivo brain amyloid load (via positron emission tomography imaging of the amyloid-binding agent, Pittsburgh Compound-B [PIB]) with CSF Abeta(42) and other measures (via enzyme-linked immunosorbent assay) in clinically characterized research subjects.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Subjects fell into two nonoverlapping groups: those with positive PIB binding had the lowest CSF Abeta(42) level, and those with negative PIB binding had the highest CSF Abeta(42) level. No relation was observed between PIB binding and CSF Abeta(40), tau, phospho-tau(181), plasma Abeta(40), or plasma Abeta(42). Importantly, PIB binding and CSF Abeta(42) did not consistently correspond with clinical diagnosis; three cognitively normal subjects were PIB-positive with low CSF Abeta(42), suggesting the presence of amyloid in the absence of cognitive impairment (ie, preclinical AD).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">These observations suggest that brain amyloid deposition results in low CSF Abeta(42), and that amyloid imaging and CSF Abeta(42) may potentially serve as antecedent biomarkers of (preclinical) AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA. fagana@neuro.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Mach</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sang-Yoon</ForeName><Initials>SY</Initials></Author><Author ValidYN="Y"><LastName>Dence</LastName><ForeName>Carmen S</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Aarti R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>LaRossa</LastName><ForeName>Gina N</ForeName><Initials>GN</Initials></Author><Author ValidYN="Y"><LastName>Spinner</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chester A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR00036</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003952" MajorTopicYN="Y">Diagnostic Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>12</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>12</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId><ArticleId IdType="doi">10.1002/ana.20730</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16377636</PMID><DateCompleted><Year>2006</Year><Month>05</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>281</Volume><Issue>8</Issue><PubDate><Year>2006</Year><Month>Feb</Month><Day>24</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Formation of tau inclusions in knock-in mice with familial Alzheimer disease (FAD) mutation of presenilin 1 (PS1).</ArticleTitle><Pagination><StartPage>5037</StartPage><EndPage>5041</EndPage><MedlinePgn>5037-41</MedlinePgn></Pagination><Abstract><AbstractText>Mutations in the presenilin 1 (PS1) gene are responsible for the early onset of familial Alzheimer disease (FAD). Accumulating evidence shows that PS1 is involved in gamma-secretase activity and that FAD-associated mutations of PS1 commonly accelerate Abeta(1-42) production, which causes Alzheimer disease (AD). Recent studies suggest, however, that PS1 is involved not only in Abeta production but also in other processes that lead to neurodegeneration. To better understand the causes of neurodegeneration linked to the PS1 mutation, we analyzed the development of tau pathology, another key feature of AD, in PS1 knock-in mice. Hippocampal samples taken from FAD mutant (I213T) PS1 knock-in mice contained hyperphosphorylated tau that reacted with various phosphodependent tau antibodies and with Alz50, which recognizes the conformational change of PHF tau. Some neurons exhibited Congo red birefringence and Thioflavin T reactivity, both of which are histological criteria for neurofibrillary tangles (NFTs). Biochemical analysis of the samples revealed SDS-insoluble tau, which under electron microscopy examination, resembled tau fibrils. These results indicate that our mutant PS1 knock-in mice exhibited NFT-like tau pathology in the absence of Abeta deposition, suggesting that PS1 mutations contribute to the onset of AD not only by enhancing Abeta(1-42) production but by also accelerating the formation and accumulation of filamentous tau.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tanemura</LastName><ForeName>Kentaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory for Alzheimer Disease and Neural Architecture, Brain Science Institute, RIKEN, Wako, Saitama 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chui</LastName><ForeName>Du-Hua</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Fukuda</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Murayama</LastName><ForeName>Miyuki</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jung-Mi</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Akagi</LastName><ForeName>Takumi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Tatebayashi</LastName><ForeName>Yoshitaka</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Miyasaka</LastName><ForeName>Tomohiro</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hashikawa</LastName><ForeName>Tsutomu</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Nakano</LastName><ForeName>Yuka</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kudo</LastName><ForeName>Takashi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Takeda</LastName><ForeName>Masatoshi</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Takashima</LastName><ForeName>Akihiko</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>12</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>2390-54-7</RegistryNumber><NameOfSubstance UI="C009462">thioflavin T</NameOfSubstance></Chemical><Chemical><RegistryNumber>368GB5141J</RegistryNumber><NameOfSubstance UI="D012967">Sodium Dodecyl Sulfate</NameOfSubstance></Chemical><Chemical><RegistryNumber>3U05FHG59S</RegistryNumber><NameOfSubstance UI="D003224">Congo Red</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003224" MajorTopicYN="N">Congo Red</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012967" MajorTopicYN="N">Sodium Dodecyl Sulfate</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>12</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>5</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>12</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16377636</ArticleId><ArticleId IdType="doi">10.1074/jbc.M509145200</ArticleId><ArticleId IdType="pii">S0021-9258(19)76802-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16384915</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>103</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Jan</Month><Day>10</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Regulation of tyrosinase trafficking and processing by presenilins: partial loss of function by familial Alzheimer's disease mutation.</ArticleTitle><Pagination><StartPage>353</StartPage><EndPage>358</EndPage><MedlinePgn>353-8</MedlinePgn></Pagination><Abstract><AbstractText>Presenilins (PS) are required for gamma-secretase cleavage of multiple type I membrane proteins including the amyloid precursor protein and Notch and also have been implicated in regulating intracellular protein trafficking and turnover. Using genetic and pharmacological approaches, we reveal here a unique function of PS in the pigmentation of retinal pigment epithelium and epidermal melanocytes. PS deficiency leads to aberrant accumulation of tyrosinase (Tyr)-containing 50-nm post-Golgi vesicles that are normally destined to melanosomes. This trafficking is gamma-secretase-dependent, and abnormal localization of Tyr in the absence of PS is accompanied by the simultaneous accumulation of its C-terminal fragment. Furthermore, we show that the PS1M146V familial Alzheimer's disease mutation exhibits a partial loss-of-function in pigment synthesis. Our results identify Tyr and related proteins as physiological substrates of PS and link gamma-secretase activity with intracellular protein transport.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Runsheng</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Huffington Center on Aging and Departments of Molecular and Human Genetics and Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Phuong</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Pei</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Boissy</LastName><ForeName>Raymond E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Hui</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 AG000183</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS040039</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS40039</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AR45429</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020670</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR045429</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG20670</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>12</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008543">Melanins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>42HK56048U</RegistryNumber><NameOfSubstance UI="D014443">Tyrosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.18.1</RegistryNumber><NameOfSubstance UI="D014442">Monophenol Monooxygenase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004848" MajorTopicYN="N">Epithelium</DescriptorName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006056" MajorTopicYN="N">Golgi Apparatus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008543" MajorTopicYN="N">Melanins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008544" MajorTopicYN="N">Melanocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046529" MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014442" MajorTopicYN="N">Monophenol Monooxygenase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010858" MajorTopicYN="N">Pigmentation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012160" MajorTopicYN="N">Retina</DescriptorName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014443" MajorTopicYN="N">Tyrosine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>12</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>12</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>7</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16384915</ArticleId><ArticleId IdType="pmc">PMC1326180</ArticleId><ArticleId IdType="doi">10.1073/pnas.0509822102</ArticleId><ArticleId IdType="pii">0509822102</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Annaert, W. &amp; De Strooper, B. (2002) Annu. Rev. Cell Dev. Biol. 18, 25-51.</Citation><ArticleIdList><ArticleId IdType="pubmed">12142279</ArticleId></ArticleIdList></Reference><Reference><Citation>Siman, R., Reaume, A. G., Savage, M. J., Trusko, S., Lin, Y. G., Scott, R. W. &amp; Flood, D. G. (2000) J. Neurosci. 20, 8717-8726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6773081</ArticleId><ArticleId IdType="pubmed">11102478</ArticleId></ArticleIdList></Reference><Reference><Citation>Moehlmann, T., Winkler, E., Xia, X., Edbauer, D., Murrell, J., Capell, A., Kaether, C., Zheng, H., Ghetti, B., Haass, C. &amp; Steiner, H. (2002) Proc. Natl. Acad. Sci. USA 99, 8025-8030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123014</ArticleId><ArticleId IdType="pubmed">12048239</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown, M. S., Ye, J., Rawson, R. B. &amp; Goldstein, J. L. (2000) Cell 100, 391-398.</Citation><ArticleIdList><ArticleId IdType="pubmed">10693756</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J. S., Schroeter, E. H., Schrijvers, V., Wolfe, M. S., Ray, W. J., et al. (1999) Nature 398, 518-522.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206645</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe, D. &amp; Kopan, R. (2003) Annu. Rev. Neurosci. 26, 565-597.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730322</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah, S., Lee, S. F., Tabuchi, K., Hao, Y. H., Yu, C., LaPlant, Q., Ball, H., Dann, C. E., III, Sudhof, T. &amp; Yu, G. (2005) Cell 122, 435-447.</Citation><ArticleIdList><ArticleId IdType="pubmed">16096062</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopan, R. &amp; Ilagan, M. X. (2004) Nat. Rev. Mol. Cell Biol. 5, 499-504.</Citation><ArticleIdList><ArticleId IdType="pubmed">15173829</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia, S. S. &amp; St. George-Hyslop, P. H. (2002) Nat. Rev. Neurosci. 3, 281-290.</Citation><ArticleIdList><ArticleId IdType="pubmed">11967558</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaether, C., Lammich, S., Edbauer, D., Ertl, M., Rietdorf, J., Capell, A., Steiner, H. &amp; Haass, C. (2002) J. Cell Biol. 158, 551-561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173840</ArticleId><ArticleId IdType="pubmed">12147673</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai, D., Leem, J. Y., Greenfield, J. P., Wang, P., Kim, B. S., Wang, R., Lopes, K. O., Kim, S. H., Zheng, H., Greengard, P., et al. (2003) J. Biol. Chem. 278, 3446-3454.</Citation><ArticleIdList><ArticleId IdType="pubmed">12435726</ArticleId></ArticleIdList></Reference><Reference><Citation>Levitan, D. &amp; Greenwald, I. (1998) Development (Cambridge, U.K.) 125, 3599-3606.</Citation><ArticleIdList><ArticleId IdType="pubmed">9716525</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo, Y., Livne-Bar, I., Zhou, L. &amp; Boulianne, G. L. (1999) J. Neurosci. 19, 8435-8442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6783002</ArticleId><ArticleId IdType="pubmed">10493744</ArticleId></ArticleIdList></Reference><Reference><Citation>Naruse, S., Thinakaran, G., Luo, J. J., Kusiak, J. W., Tomita, T., Iwatsubo, T., Qian, X., Ginty, D. D., Price, D. L., Borchelt, D. R., et al. (1998) Neuron 21, 1213-1221.</Citation><ArticleIdList><ArticleId IdType="pubmed">9856475</ArticleId></ArticleIdList></Reference><Reference><Citation>Noll, E., Medina, M., Hartley, D., Zhou, J., Perrimon, N. &amp; Kosik, K. S. (2000) Dev. Biol. 227, 450-464.</Citation><ArticleIdList><ArticleId IdType="pubmed">11071766</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura, M., Yu, G., Levesque, G., Zhang, D. M., Ruel, L., Chen, F., Milman, P., Holmes, E., Liang, Y., Kawarai, T., et al. (1999) Nat. Med. 5, 164-169.</Citation><ArticleIdList><ArticleId IdType="pubmed">9930863</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, F., Tandon, A., Sanjo, N., Gu, Y. J., Hasegawa, H., Arawaka, S., Lee, F. J., Ruan, X., Mastrangelo, P., Erdebil, S., et al. (2003) J. Biol. Chem. 278, 19974-19979.</Citation><ArticleIdList><ArticleId IdType="pubmed">12646573</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman, A., Van Gassen, G., Bentahir, M., Nyabi, O., Craessaerts, K., Mueller, U., Annaert, W. &amp; De Strooper, B. (2003) J. Cell Sci. 116, 1127-1136.</Citation><ArticleIdList><ArticleId IdType="pubmed">12584255</ArticleId></ArticleIdList></Reference><Reference><Citation>Leem, J. Y., Vijayan, S., Han, P., Cai, D., Machura, M., Lopes, K. O., Veselits, M. L., Xu, H. &amp; Thinakaran, G. (2002) J. Biol. Chem. 277, 19236-19240.</Citation><ArticleIdList><ArticleId IdType="pubmed">11943765</ArticleId></ArticleIdList></Reference><Reference><Citation>Esselens, C., Oorschot, V., Baert, V., Raemaekers, T., Spittaels, K., Serneels, L., Zheng, H., Saftig, P., De Strooper, B., Klumperman, J., et al. (2004) J. Cell Biol. 166, 1041-1054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172014</ArticleId><ArticleId IdType="pubmed">15452145</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson, C. A., Murphy, D. D., Giasson, B. I., Zhang, B., Trojanowski, J. Q. &amp; Lee, V. M. (2004) J. Cell Biol. 165, 335-346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172178</ArticleId><ArticleId IdType="pubmed">15123735</ArticleId></ArticleIdList></Reference><Reference><Citation>del Marmol, V. &amp; Beermann, F. (1996) FEBS Lett. 381, 165-168.</Citation><ArticleIdList><ArticleId IdType="pubmed">8601447</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturm, R. A., Teasdale, R. D. &amp; Box, N. F. (2001) Gene 277, 49-62.</Citation><ArticleIdList><ArticleId IdType="pubmed">11602344</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks, M. S. &amp; Seabra, M. C. (2001) Nat. Rev. Mol. Cell Biol. 2, 738-748.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584301</ArticleId></ArticleIdList></Reference><Reference><Citation>Maul, G. G. (1969) J. Ultrastruct. Res. 26, 163-176.</Citation><ArticleIdList><ArticleId IdType="pubmed">4887010</ArticleId></ArticleIdList></Reference><Reference><Citation>Maul, G. G. &amp; Brumbaugh, J. A. (1971) J. Cell Biol. 48, 41-48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2108216</ArticleId><ArticleId IdType="pubmed">4993485</ArticleId></ArticleIdList></Reference><Reference><Citation>Oetting, W. S. &amp; King, R. A. (1999) Hum. Mutat. 13, 99-115.</Citation><ArticleIdList><ArticleId IdType="pubmed">10094567</ArticleId></ArticleIdList></Reference><Reference><Citation>Huizing, M., Boissy, R. E. &amp; Gahl, W. A. (2002) Pigm. Cell. Res. 15, 405-419.</Citation><ArticleIdList><ArticleId IdType="pubmed">12453182</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia, X., Qian, S., Soriano, S., Wu, Y., Fletcher, A. M., Wang, X.-J., Koo, E. H., Wu, X. &amp; Zheng, H. (2001) Proc. Natl. Acad. Sci. USA 98, 10863-10868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC58565</ArticleId><ArticleId IdType="pubmed">11517342</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong, P. C., Zheng, H., Chen, H., Becher, M. W., Sirinathsinghji, D. J., Trumbauer, M. E., Chen, H. Y., Price, D. L., Van der Ploeg, L. H. &amp; Sisodia, S. S. (1997) Nature 387, 288-292.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153393</ArticleId></ArticleIdList></Reference><Reference><Citation>Donoviel, D. B., Hadjantonakis, A. K., Ikeda, M., Zheng, H., St. George-Hyslop, P. &amp; Bernstein, A. (1999) Genes Dev. 13, 2801-2810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC317124</ArticleId><ArticleId IdType="pubmed">10557208</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo, Q., Fu, W., Sopher, B. L., Miller, M. W., Ware, C. B., Martin, G. M. &amp; Mattson, M. P. (1999) Nat. Med. 5, 101-106.</Citation><ArticleIdList><ArticleId IdType="pubmed">9883847</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, P., Pereira, F. A., Beasley, D. &amp; Zheng, H. (2003) Development (Cambridge, U.K.) 130, 5019-5029.</Citation><ArticleIdList><ArticleId IdType="pubmed">12930775</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Y. M., Xu, M., Lai, M. T., Huang, Q., Castro, J. L., DiMuzio-Mower, J., Harrison, T., Lellis, C., Nadin, A., Neduvelil, J. G., et al. (2000) Nature 405, 689-694.</Citation><ArticleIdList><ArticleId IdType="pubmed">10864326</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng, H. T., Miner, J. H., Lin, M., Tansey, M. G., Roth, K. &amp; Kopan, R. (2003) Development (Cambridge, U.K.) 130, 5031-5042.</Citation><ArticleIdList><ArticleId IdType="pubmed">12952904</ArticleId></ArticleIdList></Reference><Reference><Citation>Qyang, Y., Chambers, S. M., Wang, P., Xia, X., Chen, X., Goodell, M. A. &amp; Zheng, H. (2004) Biochemistry 43, 5352-5359.</Citation><ArticleIdList><ArticleId IdType="pubmed">15122901</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, R., Dineley, K. T., Sweatt, J. D. &amp; Zheng, H. (2004) Neuroscience 126, 305-312.</Citation><ArticleIdList><ArticleId IdType="pubmed">15207348</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson, M. S. &amp; Bonifacino, J. S. (2001) Curr. Opin. Cell Biol. 13, 444-453.</Citation><ArticleIdList><ArticleId IdType="pubmed">11454451</ArticleId></ArticleIdList></Reference><Reference><Citation>Huizing, M., Sarangarajan, R., Strovel, E., Zhao, Y., Gahl, W. A. &amp; Boissy, R. E. (2001) Mol. Biol. Cell 12, 2075-2085.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC55657</ArticleId><ArticleId IdType="pubmed">11452004</ArticleId></ArticleIdList></Reference><Reference><Citation>Raposo, G., Tenza, D., Murphy, D. M., Berson, J. F. &amp; Marks, M. S. (2001) J. Cell Biol. 152, 809-824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2195785</ArticleId><ArticleId IdType="pubmed">11266471</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayasaradhi, S., Xu, Y., Bouchard, B. &amp; Houghton, A. N. (1995) J. Cell Biol. 130, 807-820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2199968</ArticleId><ArticleId IdType="pubmed">7642699</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo, P. A., Frank, D. W., Bieler, B. M., Berson, J. F. &amp; Marks, M. S. (1999) J. Biol. Chem. 274, 12780-12789.</Citation><ArticleIdList><ArticleId IdType="pubmed">10212263</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmen, T., Schmidt, A., Hunziker, W. &amp; Beermann, F. (1999) J. Cell Sci. 112, 45-53.</Citation><ArticleIdList><ArticleId IdType="pubmed">9841903</ArticleId></ArticleIdList></Reference><Reference><Citation>Boissy, R. E., Richmond, B., Huizing, M., Helip-Wooley, A., Zhao, Y., Koshoffer, A. &amp; Gahl, W. A. (2005) Am. J. Pathol. 166, 231-240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1602298</ArticleId><ArticleId IdType="pubmed">15632015</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortini, M. E. (2002) Nat. Rev. Mol. Cell Biol. 3, 673-684.</Citation><ArticleIdList><ArticleId IdType="pubmed">12209127</ArticleId></ArticleIdList></Reference><Reference><Citation>Parent, A. T., Barnes, N. Y., Taniguchi, Y., Thinakaran, G. &amp; Sisodia, S. S. (2005) J. Neurosci. 25, 1540-1549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725985</ArticleId><ArticleId IdType="pubmed">15703408</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16385451</PMID><DateCompleted><Year>2006</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0002-9297</ISSN><JournalIssue CitedMedium="Print"><Volume>78</Volume><Issue>1</Issue><PubDate><Year>2006</Year><Month>Jan</Month></PubDate></JournalIssue><Title>American journal of human genetics</Title><ISOAbbreviation>Am J Hum Genet</ISOAbbreviation></Journal><ArticleTitle>A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease.</ArticleTitle><Pagination><StartPage>78</StartPage><EndPage>88</EndPage><MedlinePgn>78-88</MedlinePgn></Pagination><Abstract><AbstractText>Strong evidence of linkage to late-onset Alzheimer disease (LOAD) has been observed on chromosome 10, which implicates a wide region and at least one disease-susceptibility locus. Although significant associations with several biological candidate genes on chromosome 10 have been reported, these findings have not been consistently replicated, and they remain controversial. We performed a chromosome 10-specific association study with 1,412 gene-based single-nucleotide polymorphisms (SNPs), to identify susceptibility genes for developing LOAD. The scan included SNPs in 677 of 1,270 known or predicted genes; each gene contained one or more markers, about half (48%) of which represented putative functional mutations. In general, the initial testing was performed in a white case-control sample from the St. Louis area, with 419 LOAD cases and 377 age-matched controls. Markers that showed significant association in the exploratory analysis were followed up in several other white case-control sample sets to confirm the initial association. Of the 1,397 markers tested in the exploratory sample, 69 reached significance (P &lt; .05). Five of these markers replicated at P &lt; .05 in the validation sample sets. One marker, rs498055, located in a gene homologous to RPS3A (LOC439999), was significantly associated with Alzheimer disease in four of six case-control series, with an allelic P value of .0001 for a meta-analysis of all six samples. One of the case-control samples with significant association to rs498055 was derived from the linkage sample (P = .0165). These results indicate that variants in the RPS3A homologue are associated with LOAD and implicate this gene, adjacent genes, or other functional variants (e.g., noncoding RNAs) in the pathogenesis of this disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grupe</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Celera Diagnostics, Alameda, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yonghong</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Rowland</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Nowotny</LastName><ForeName>Petra</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Hinrichs</LastName><ForeName>Anthony L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Smemo</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kauwe</LastName><ForeName>John S K</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Maxwell</LastName><ForeName>Taylor J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Cherny</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Doil</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Tacey</LastName><ForeName>Kristina</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>van Luchene</LastName><ForeName>Ryan</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Wavrant-De Vri&#xe8;ze</LastName><ForeName>Fabienne</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Kaleem</LastName><ForeName>Mona</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hollingworth</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Jehu</LastName><ForeName>Luke</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Foy</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Archer</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Gillian</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Holmans</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Chris M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Catanese</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Sninsky</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>O'Donovan</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lovestone</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Lesley</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 05146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS39764</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 GM065509</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HG000045</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM065509</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH046290</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG16208</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH046281</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 MH060451</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG08671</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH60451</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008671</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005128</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH046373</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS039764</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0300429</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>AG05128</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G9810900</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG016208</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>11</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hum Genet</MedlineTA><NlmUniqueID>0370475</NlmUniqueID><ISSNLinking>0002-9297</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C031016">RPS3A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012269">Ribosomal Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Hum Genet. 2006 Jul;79(1):180-3; author reply 183-4. doi: 10.1086/505032.</RefSource><PMID Version="1">16773580</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="Y">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002879" MajorTopicYN="N">Chromosomes, Human, Pair 10</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="Y">Genetic Linkage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008923" MajorTopicYN="N" Type="Geographic">Missouri</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012269" MajorTopicYN="N">Ribosomal Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>12</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>5</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>12</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16385451</ArticleId><ArticleId IdType="pmc">PMC1380225</ArticleId><ArticleId IdType="doi">10.1086/498851</ArticleId><ArticleId IdType="pii">S0002-9297(07)60807-6</ArticleId></ArticleIdList><ReferenceList><Title>Web Resources</Title><Reference><Citation>Alzheimer Disease Forum, http://www.alzforum.org/res/com/gen/alzgene/chromo.asp?c=10</Citation></Reference><Reference><Citation>Entrez Gene, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene</Citation></Reference><Reference><Citation>Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/Omim/ (for AD, APP, PSEN1, PSEN2, LOAD, APOE, GAPD, RPS3A, PYCS, ALDH18A1, ENTPD1, CTNNA3, PLAU, IDE, BCL2, PARP1, SORBS1, and SORCS1)</Citation></Reference></ReferenceList><ReferenceList><Reference><Citation>Agresti A (1990) Categorical data analysis. John Wiley &amp; Sons, New York</Citation></Reference><Reference><Citation>Balciuniene J, Emilsson L, Oreland L, Pettersson U, Jazin E (2002) Investigation of the functional effect of monoamine oxidase polymorphisms in human brain. Hum Genet 110:1&#x2013;710.1007/s00439-001-0652-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00439-001-0652-8</ArticleId><ArticleId IdType="pubmed">11810289</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, McKeel DW Jr, Miller JP, Storandt M, Rubin EH, Morris JC, Baty J, Coats M, Norton J, Goate AM, Price JL, Gearing M, Mirra SS, Saunders AM (1998) Clinicopathologic studies in cognitively healthy aging and Alzheimer&#x2019;s disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 55:326&#x2013;33510.1001/archneur.55.3.326</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.55.3.326</ArticleId><ArticleId IdType="pubmed">9520006</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S, Yhu S, McInnis MG, Go RC, Vekrellis K, Selkoe DJ, Saunders AJ, Tanzi RE (2000) Evidence for genetic linkage of Alzheimer&#x2019;s disease to chromosome 10q. Science 290:2302&#x2013;230310.1126/science.290.5500.2302</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.290.5500.2302</ArticleId><ArticleId IdType="pubmed">11125142</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacker D, Bertram L, Saunders AJ, Moscarillo TJ, Albert MS, Wiener H, Perry RT, Collins JS, Harrell LE, Go RC, Mahoney A, Beaty T, Fallin MD, Avramopoulos D, Chase GA, Folstein MF, McInnis MG, Bassett SS, Doheny KJ, Pugh EW, Tanzi RE (2003) Results of a high-resolution genome screen of 437 Alzheimer&#x2019;s disease families. Hum Mol Genet 12:23&#x2013;3210.1093/hmg/ddg007</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddg007</ArticleId><ArticleId IdType="pubmed">12490529</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW (2004) Incipient Alzheimer&#x2019;s disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA 101:2173&#x2013;217810.1073/pnas.0308512100</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0308512100</ArticleId><ArticleId IdType="pmc">PMC357071</ArticleId><ArticleId IdType="pubmed">14769913</ArticleId></ArticleIdList></Reference><Reference><Citation>Busby V, Goossens S, Nowotny P, Hamilton G, Smemo S, Harold D, Turic D, et al (2004) &#x3b1;-t-catenin is expressed in human brain and interacts with the Wnt signaling pathway but is not responsible for linkage to chromosome 10 in Alzheimer&#x2019;s disease. Neuromolecular Med 5:133&#x2013;14610.1385/NMM:5:2:133</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/NMM:5:2:133</ArticleId><ArticleId IdType="pubmed">15075440</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement M, Posada D, Crandall KA (2000) TCS: a computer program to estimate gene genealogies. Mol Ecol 9:1657&#x2013;165910.1046/j.1365-294x.2000.01020.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-294x.2000.01020.x</ArticleId><ArticleId IdType="pubmed">11050560</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science 261:921&#x2013;923</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, Baker M, Adamson J, Ronald J, Blangero J, Hutton M, Younkin SG (2000) Linkage of plasma A&#x3b2;42 to a quantitative locus on chromosome 10 in late-onset Alzheimer&#x2019;s disease pedigrees. Science 290:2303&#x2013;230410.1126/science.290.5500.2303</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.290.5500.2303</ArticleId><ArticleId IdType="pubmed">11125143</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Bowirrat A, Friedland RP, Waraska K, Korczyn AD, Baldwin CT (2003) Identification of multiple loci for Alzheimer disease in a consanguineous Israeli-Arab community. Hum Mol Genet 12:415&#x2013;42210.1093/hmg/ddg037</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddg037</ArticleId><ArticleId IdType="pubmed">12566388</ArticleId></ArticleIdList></Reference><Reference><Citation>Germer S, Holland MJ, Higuchi R (2000) High-throughput SNP allele-frequency determination in pooled DNA samples by kinetic PCR. Genome Res 10:258&#x2013;26610.1101/gr.10.2.258</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.10.2.258</ArticleId><ArticleId IdType="pmc">PMC310828</ArticleId><ArticleId IdType="pubmed">10673283</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A, Chartier-Harlin M-C, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Pericak-Vance M, Roses A, Williamson R, Rossor M, Owen M, Hardy J (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer&#x2019;s disease. Nature 349:704&#x2013;70610.1038/349704a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/349704a0</ArticleId><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermey G, Plath N, Hubner CA, Kuhl D, Schaller HC, Hermans-Borgmeyer I (2004) The three Sorcs genes are differentially expressed and regulated by synaptic activity. J Neurochem 88:1470&#x2013;1476</Citation><ArticleIdList><ArticleId IdType="pubmed">15009648</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermey G, Riedel IB, Hampe W, Schaller HC, Hermans-Borgmeyer I (1999) Identification and characterization of SorCS, a third member of a novel receptor family. Biochem Biophys Res Commun 266:347&#x2013;35110.1006/bbrc.1999.1822</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.1999.1822</ArticleId><ArticleId IdType="pubmed">10600506</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu ZB, Minden MD, McCulloch EA, Stahl J (2000) Regulation of drug sensitivity by ribosomal protein S3a. Blood 95:1047&#x2013;1055</Citation><ArticleIdList><ArticleId IdType="pubmed">10648421</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehoe P, Wavrant-De Vrieze F, Crook R, Wu WS, Holmans P, Fenton I, Spurlock G, Norton N, Williams H, Williams N, Lovestone S, Perez-Tur J, Hutton M, Chartier-Harlin MC, Shears S, Roehl K, Booth J, Van Voorst W, Ramic D, Williams J, Goate A, Hardy J, Owen MJ (1999) A full genome scan for late onset Alzheimer&#x2019;s disease. Hum Mol Genet 8:237&#x2013;24510.1093/hmg/8.2.237</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/8.2.237</ArticleId><ArticleId IdType="pubmed">9931331</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoblauch H, Bauerfeind A, Krahenbuhl C, Daury A, Rohde K, Bejanin S, Essioux L, Schuster H, Luft FC, Reich JG (2002) Common haplotypes in five genes influence genetic variance of LDL and HDL cholesterol in the general population. Hum Mol Genet 11:1477&#x2013;148510.1093/hmg/11.12.1477</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/11.12.1477</ArticleId><ArticleId IdType="pubmed">12023990</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K, Crowley A, Fu Y-H, Guenette S, Galas D, Nemens E, Wijsman E, Bird T, Schellenberg G, Tanzi R (1995) Candidate gene for the chromosome 1 familial Alzheimer&#x2019;s disease locus. Science 269:973&#x2013;977</Citation><ArticleIdList><ArticleId IdType="pubmed">7638622</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Hollingworth P, Moore P, Foy C, Archer N, Powell J, Nowotny P, Holmans P, O&#x2019;Donovan M, Tacey K, Doil L, van Luchene R, Garcia V, Rowland C, Lau K, Cantanese J, Sninsky J, Hardy J, Thal L, Morris JC, Goate A, Lovestone S, Owen M, Williams J, Grupe A (2005) Genetic association of the APP binding protein 2 gene (APBB2) with late onset Alzheimer disease. Hum Mutat 25:270&#x2013;27710.1002/humu.20138</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.20138</ArticleId><ArticleId IdType="pubmed">15714520</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Nowotny P, Holmans P, Smemo S, Kauwe JS, Hinrichs AL, Tacey K, et al (2004) Association of late-onset Alzheimer&#x2019;s disease with genetic variation in multiple members of the GAPD gene family. Proc Natl Acad Sci USA 101:15688&#x2013;1569310.1073/pnas.0403535101</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0403535101</ArticleId><ArticleId IdType="pmc">PMC524264</ArticleId><ArticleId IdType="pubmed">15507493</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology 34:939&#x2013;944</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers A, Holmans P, Marshall H, Kwon J, Meyer D, Ramic D, Shears S, Booth J, DeVrieze FW, Crook R, Hamshere M, Abraham R, Tunstall N, Rice F, Carty S, Lillystone S, Kehoe P, Rudrasingham V, Jones L, Lovestone S, Perez-Tur J, Williams J, Owen MJ, Hardy J, Goate AM (2000) Susceptibility locus for Alzheimer&#x2019;s disease on chromosome 10. Science 290:2304&#x2013;230510.1126/science.290.5500.2304</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.290.5500.2304</ArticleId><ArticleId IdType="pubmed">11125144</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers A, Wavrant De-Vrieze F, Holmans P, Hamshere M, Crook R, Compton D, Marshall H, et al (2002) Full genome screen for Alzheimer disease: stage II analysis. Am J Med Genet 114:235&#x2013;24410.1002/ajmg.10183</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.10183</ArticleId><ArticleId IdType="pubmed">11857588</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers AJ, Marshall H, Holmans P, Compton D, Crook RJ, Mander AP, Nowotny P, Smemo S, Dunstan M, Jehu L, Wang JC, Hamshere M, Morris JC, Norton J, Chakraventy S, Tunstall N, Lovestone S, Petersen R, O&#x2019;Donovan M, Jones L, Williams J, Owen MJ, Hardy J, Goate A (2004) Variation in the urokinase-plasminogen activator gene does not explain the chromosome 10 linkage signal for late onset AD. Am J Med Genet B Neuropsychiatr Genet 124:29&#x2013;3710.1002/ajmg.b.20036</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.b.20036</ArticleId><ArticleId IdType="pubmed">14681909</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowotny P, Hinrichs AL, Smemo S, Kauwe J, Maxwell T, Holmans P, Hamshere M, et al (2005) Association studies between risk for late-onset Alzheimer&#x2019;s disease and variants in insulin degrading enzyme. Am J Med Genet B Neuropsychiatr Genet 136:62&#x2013;68</Citation><ArticleIdList><ArticleId IdType="pubmed">15858813</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor P, Goate AM (2004) Molecular genetics of Alzheimer&#x2019;s disease. Curr Psychiatry Rep 6:125&#x2013;133</Citation><ArticleIdList><ArticleId IdType="pubmed">15038915</ArticleId></ArticleIdList></Reference><Reference><Citation>Pericak-Vance MA, Bass MP, Yamaoka LH, Gaskell PC, Scott WK, Terwedow HA, Menold MM, Conneally PM, Small GW, Vance JM, Saunders AM, Roses AD, Haines JL (1997) Complete genomic screen in late-onset familial Alzheimer disease: evidence for a new locus on chromosome 12. JAMA 278:1237&#x2013;124110.1001/jama.278.15.1237</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.278.15.1237</ArticleId><ArticleId IdType="pubmed">9333264</ArticleId></ArticleIdList></Reference><Reference><Citation>Pericak-Vance MA, Grubber J, Bailey LR, Hedges D, West S, Santoro L, Kemmerer B, Hall JL, Saunders AM, Roses AD, Small GW, Scott WK, Conneally PM, Vance JM, Haines JL (2000) Identification of novel genes in late-onset Alzheimer&#x2019;s disease. Exp Gerontol 35:1343&#x2013;135210.1016/S0531-5565(00)00196-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0531-5565(00)00196-0</ArticleId><ArticleId IdType="pubmed">11113612</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Premkumar S, Song Y, Sorbi S, Brindle N, Paterson A, Duara R, Levesque G, Yu G, Nishimura M, Ikeda M, O&#x2019;Toole C, Kawarai T, Jorge R, Vilarino D, Bruni AC, Farrer LA, St George-Hyslop PH (1998) Evidence for an Alzheimer disease susceptibility locus on chromosome 12 and for further locus heterogeneity. JAMA 280:614&#x2013;61810.1001/jama.280.7.614</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.280.7.614</ArticleId><ArticleId IdType="pubmed">9718052</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, et al (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer&#x2019;s disease. Nature 375:754&#x2013;76010.1038/375754a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/375754a0</ArticleId><ArticleId IdType="pubmed">7596406</ArticleId></ArticleIdList></Reference><Reference><Citation>Song D, Sakamoto S, Taniguchi T (2002) Inhibition of poly(ADP-ribose) polymerase activity by Bcl-2 in association with the ribosomal protein S3a. Biochemistry 41:929&#x2013;93410.1021/bi015669c</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi015669c</ArticleId><ArticleId IdType="pubmed">11790116</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephens M, Donnelly P (2003) A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73:1162&#x2013;1169</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1180495</ArticleId><ArticleId IdType="pubmed">14574645</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978&#x2013;989</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1275651</ArticleId><ArticleId IdType="pubmed">11254454</ArticleId></ArticleIdList></Reference><Reference><Citation>Templeton AR, Maxwell T, Posada D, Stengard JH, Boerwinkle E, Sing CF (2005) Tree scanning: a method for using haplotype trees in phenotype/genotype association studies. Genetics 169:441&#x2013;45310.1534/genetics.104.030080</Citation><ArticleIdList><ArticleId IdType="doi">10.1534/genetics.104.030080</ArticleId><ArticleId IdType="pmc">PMC1448891</ArticleId><ArticleId IdType="pubmed">15371364</ArticleId></ArticleIdList></Reference><Reference><Citation>Templeton AR, Weiss KM, Nickerson DA, Boerwinkle E, Sing CF (2000) Cladistic structure within the human lipoprotein lipase gene and its implications for phenotypic association studies. Genetics 156:1259&#x2013;1275</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1461336</ArticleId><ArticleId IdType="pubmed">11063700</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Eerdewegh P, Little RD, Dupuis J, Del Mastro RG, Falls K, Simon J, Torrey D, et al (2002) Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 418:426&#x2013;43010.1038/nature00878</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature00878</ArticleId><ArticleId IdType="pubmed">12110844</ArticleId></ArticleIdList></Reference><Reference><Citation>Westfall P, Young S (1993) Resampling-based multiple testing. John Wiley &amp; Sons, New York</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16385556</PMID><DateCompleted><Year>2006</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0360-4012</ISSN><JournalIssue CitedMedium="Print"><Volume>83</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of neuroscience research</Title><ISOAbbreviation>J Neurosci Res</ISOAbbreviation></Journal><ArticleTitle>Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro.</ArticleTitle><Pagination><StartPage>374</StartPage><EndPage>384</EndPage><MedlinePgn>374-84</MedlinePgn></Pagination><Abstract><AbstractText>Although active and passive immunization against the beta-amyloid peptide (Abeta) of amyloid plaque-bearing transgenic mice markedly reduces amyloid plaque deposition and improves cognition, the mechanisms of neuroprotection and impact on toxic oligomer species are not understood. We demonstrate that compared to control IgG2b, passive immunization with intracerebroventricular (icv) anti-Abeta (1-15) antibody into the AD HuAPPsw (Tg2576) transgenic mouse model reduced specific oligomeric forms of Abeta, including the dodecamers that correlate with cognitive decline. Interestingly, the reduction of soluble Abeta oligomers, but not insoluble Abeta, significantly correlated with reduced tau phosphorylation by glycogen synthase kinase-3beta (GSK-3beta), a major tau kinase implicated previously in mediating Abeta toxicity. A conformationally-directed antibody against amyloid oligomers (larger than tetramer) also reduced Abeta oligomer-induced activation of GSK3beta and protected human neuronal SH-SY5Y cells from Abeta oligomer-induced neurotoxicity, supporting a role for Abeta oligomers in human tau kinase activation. These data suggest that antibodies that are highly specific for toxic oligomer subspecies may reduce toxicity via reduction of GSK-3beta, which could be an important strategy for Alzheimer's disease (AD) therapeutics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Qiu-Lan</ForeName><Initials>QL</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of California, Los Angeles, California 91343, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Giselle P</ForeName><Initials>GP</Initials></Author><Author ValidYN="Y"><LastName>Harris-White</LastName><ForeName>Marni E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Fusheng</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Ambegaokar</LastName><ForeName>Surendra S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Ubeda</LastName><ForeName>Oliver J</ForeName><Initials>OJ</Initials></Author><Author ValidYN="Y"><LastName>Glabe</LastName><ForeName>Charles G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Teter</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Frautschy</LastName><ForeName>Sally A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>Greg M</ForeName><Initials>GM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG022080</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS043946</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG10685</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021975</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG010685</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS43946</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci Res</MedlineTA><NlmUniqueID>7600111</NlmUniqueID><ISSNLinking>0360-4012</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004793">Enzyme Reactivators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C000605506">GSK3B protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C000605507">Gsk3b protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004793" MajorTopicYN="N">Enzyme Reactivators</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011897" MajorTopicYN="N">Random Allocation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016622" MajorTopicYN="N">Silver Staining</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>12</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>5</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>12</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16385556</ArticleId><ArticleId IdType="doi">10.1002/jnr.20734</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16389197</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>1</Issue><PubDate><Year>2006</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people.</ArticleTitle><Pagination><StartPage>57</StartPage><EndPage>62</EndPage><MedlinePgn>57-62</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">The recent focus on the development of preventive interventions for Alzheimer disease has fueled the search for biomarkers of presymptomatic disease. Patients with Alzheimer disease and mild cognitive impairment have marked atrophy of the hippocampus and amygdala compared with healthy elderly people. Whether atrophy of these structures is also present in persons without cognitive impairment who later develop dementia is unknown.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess whether volumetric assessment of the hippocampus and amygdala using magnetic resonance imaging (MRI) predicts dementia in elderly people without cognitive impairment.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Longitudinal cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">A general community in the Netherlands.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Five hundred eleven persons, aged 60 to 90 years, free of dementia at baseline were followed up during 3043 person-years (mean per person, 6.0 years). We performed volumetric assessment of the hippocampus and amygdala, obtained information about daily memory problems, and performed extensive neuropsychological testing in all study participants.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Dementia, as assessed by repeated neuropsychological screening and monitoring of medical records.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-five persons developed dementia (26 with Alzheimer disease). Hippocampal and amygdalar volumes were strongly associated with the risk of dementia; the age-, sex-, and education-adjusted hazard ratio per 1-SD decrease in volume was 3.0 (95% confidence interval, 2.0-4.6) for the hippocampus and 2.1 (95% confidence interval, 1.5-2.9) for the amygdala. The hazard ratios associated with atrophy were similar in persons without memory complaints or low cognitive function at baseline. Compared with those remaining free of dementia, baseline brain volumes were 17% smaller in persons who received a clinical diagnosis of dementia within 2 to 3 years after MRI and still 5% smaller in those whose conditions were diagnosed 6 years after MRI.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Atrophy of the hippocampus and amygdala on MRI in cognitively intact elderly people predicts dementia during a 6-year follow-up.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>den Heijer</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Erasmus Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geerlings</LastName><ForeName>Mirjam I</ForeName><Initials>MI</Initials></Author><Author ValidYN="Y"><LastName>Hoebeek</LastName><ForeName>Freek E</ForeName><Initials>FE</Initials></Author><Author ValidYN="Y"><LastName>Hofman</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Koudstaal</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Breteler</LastName><ForeName>Monique M B</ForeName><Initials>MM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000679" MajorTopicYN="N">Amygdala</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002544" MajorTopicYN="N">Cerebral Infarction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16389197</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.63.1.57</ArticleId><ArticleId IdType="pii">63/1/57</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16401644</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-6860</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Mar</Month></PubDate></JournalIssue><Title>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</Title><ISOAbbreviation>FASEB J</ISOAbbreviation></Journal><ArticleTitle>The neuropeptide PACAP promotes the alpha-secretase pathway for processing the Alzheimer amyloid precursor protein.</ArticleTitle><Pagination><StartPage>512</StartPage><EndPage>514</EndPage><MedlinePgn>512-4</MedlinePgn></Pagination><Abstract><AbstractText>The neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) has neurotrophic as well as anti-apoptotic properties and is involved in learning and memory processes. Its specific G protein-coupled receptor PAC1 is expressed in several central nervous system (CNS) regions, including the hippocampal formation. Here we examined the effect of PAC1 receptor activation on alpha-secretase cleavage of the amyloid precursor protein (APP) and the production of secreted APP (APPsalpha). Stimulation of endogenously expressed PAC1 receptors with PACAP in human neuroblastoma cells increased APPsalpha secretion, which was completely inhibited by the PAC1 receptor specific antagonist PACAP-(6-38). In HEK cells stably overexpressing functional PAC1 receptors, PACAP-27 and PACAP-38 strongly stimulated alpha-secretase cleavage of APP. The PACAP-induced APPsalpha production was dose dependent and saturable. This increase of alpha-secretase activity was completely abolished by hydroxamate-based metalloproteinase inhibitors, including a preferential ADAM 10 inhibitor. By using several specific protein kinase inhibitors, we show that the MAP-kinase pathway [including extracellular-regulated kinase (ERK) 1 and ERK2] and phosphatidylinositol 3-kinase mediate the PACAP-induced alpha-secretase activation. Our findings provide evidence for a role of the neuropeptide PACAP in stimulation of the nonamyloidogenic pathway, which might be related to its neuroprotective properties.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kojro</LastName><ForeName>Elzbieta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute of Biochemistry, Johannes Gutenberg University, Becherweg, Mainz, Germany. kojro@uni-mainz.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Postina</LastName><ForeName>Rolf</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Buro</LastName><ForeName>Corinna</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Meiringer</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Gehrig-Burger</LastName><ForeName>Katja</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Fahrenholz</LastName><ForeName>Falk</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>01</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>FASEB J</MedlineTA><NlmUniqueID>8804484</NlmUniqueID><ISSNLinking>0892-6638</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000730">Androstadienes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C115163">CREB1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017362">Cyclic AMP Response Element-Binding Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000081082">Phosphoinositide-3 Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051219">Pituitary Adenylate Cyclase-Activating Polypeptide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051237">Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.11</RegistryNumber><NameOfSubstance UI="D017868">Cyclic AMP-Dependent Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.13</RegistryNumber><NameOfSubstance UI="D011493">Protein Kinase C</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048049">Extracellular Signal-Regulated MAP Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.-</RegistryNumber><NameOfSubstance UI="D051722">ADAM Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.-</RegistryNumber><NameOfSubstance UI="C098339">ADAM9 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.81</RegistryNumber><NameOfSubstance UI="D000072197">ADAM10 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.81</RegistryNumber><NameOfSubstance UI="C491236">ADAM10 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.86</RegistryNumber><NameOfSubstance UI="D000072198">ADAM17 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.6.1.1</RegistryNumber><NameOfSubstance UI="D000262">Adenylyl Cyclases</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical><Chemical><RegistryNumber>XVA4O219QW</RegistryNumber><NameOfSubstance UI="D000077191">Wortmannin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051722" MajorTopicYN="N">ADAM Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072197" MajorTopicYN="N">ADAM10 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072198" MajorTopicYN="N">ADAM17 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000262" MajorTopicYN="N">Adenylyl Cyclases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000730" MajorTopicYN="N">Androstadienes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017362" MajorTopicYN="N">Cyclic AMP Response Element-Binding Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017868" MajorTopicYN="N">Cyclic AMP-Dependent Protein Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048049" MajorTopicYN="N">Extracellular Signal-Regulated MAP Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016716" MajorTopicYN="N">PC12 Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000081082" MajorTopicYN="N">Phosphoinositide-3 Kinase Inhibitors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051219" MajorTopicYN="N">Pituitary Adenylate Cyclase-Activating Polypeptide</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011493" MajorTopicYN="N">Protein Kinase C</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="Y">Protein Processing, Post-Translational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051237" MajorTopicYN="N">Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077191" MajorTopicYN="N">Wortmannin</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16401644</ArticleId><ArticleId IdType="doi">10.1096/fj.05-4812fje</ArticleId><ArticleId IdType="pii">05-4812fje</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16407538</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Jan</Month><Day>11</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme.</ArticleTitle><Pagination><StartPage>418</StartPage><EndPage>428</EndPage><MedlinePgn>418-28</MedlinePgn></Pagination><Abstract><AbstractText>sorLA is a recently identified neuronal receptor for amyloid precursor protein (APP) that is known to interact with APP and affect its intracellular transport and processing. Decreased levels of sorLA in the brain of Alzheimer's disease (AD) patients and elevated levels of amyloid-beta peptide (Abeta) in sorLA-deficient mice point to the importance of the receptor in this neurodegenerative disorder. We analyzed APP cleavage in an APP-shedding assay and found that both sorLA and, surprisingly, a sorLA tail construct inhibited APP cleavage in a beta-site APP-cleaving enzyme (BACE)-dependent manner. In line with this finding, sorLA and the sorLA tail significantly reduced secreted Abeta levels when BACE was overexpressed, suggesting that sorLA influences beta-cleavage. To understand the effect of sorLA on APP cleavage by BACE, we analyzed whether sorLA interacts with APP and/or BACE. Because both full-length sorLA and sorLA C-terminal tail constructs were functionally relevant for APP processing, we analyzed sorLA-APP for a potential cytoplasmatic interaction domain. sorLA and C99 coimmunoprecipitated, pointing toward the existence of a new cytoplasmatic interaction site between sorLA and APP. Moreover, sorLA and BACE also coimmunoprecipitate. Thus, sorLA interacts both with BACE and APP and might therefore directly affect BACE-APP complex formation. To test whether sorLA impacts BACE-APP interactions, we used a fluorescence resonance energy transfer assay to evaluate BACE-APP interactions in cells. We discovered that sorLA significantly reduced BACE-APP interactions in Golgi. We postulate that sorLA acts as a trafficking receptor that prevents BACE-APP interactions and hence BACE cleavage of APP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spoelgen</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Laboratory, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Arnim</LastName><ForeName>Christine A F</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Anne V</ForeName><Initials>AV</Initials></Author><Author ValidYN="Y"><LastName>Peltan</LastName><ForeName>Ithan D</ForeName><Initials>ID</Initials></Author><Author ValidYN="Y"><LastName>Koker</LastName><ForeName>Mirjam</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Irizarry</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Olav M</ForeName><Initials>OM</Initials></Author><Author ValidYN="Y"><LastName>Willnow</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG012406</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG012406</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 12406</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026502">LDL-Receptor Related Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D046912">Multiprotein Complexes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011973">Receptors, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102582">SORL1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019921" MajorTopicYN="N">Biotinylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003600" MajorTopicYN="N">Cytosol</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006056" MajorTopicYN="N">Golgi Apparatus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026502" MajorTopicYN="N">LDL-Receptor Related Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046912" MajorTopicYN="N">Multiprotein Complexes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016297" MajorTopicYN="N">Mutagenesis, Site-Directed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025941" MajorTopicYN="Y">Protein Interaction Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011973" MajorTopicYN="N">Receptors, LDL</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>7</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16407538</ArticleId><ArticleId IdType="pmc">PMC6674411</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3882-05.2006</ArticleId><ArticleId IdType="pii">26/2/418</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J, von Arnim CA, Breiderhoff T, Jansen P, Wu X, Bales KR, Cappai R, Masters CL, Gliemann J, Mufson EJ, Hyman BT, Paul SM, Nykjaer A, Willnow TE (2005) Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci USA 102: 13461&#x2013;13466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224625</ArticleId><ArticleId IdType="pubmed">16174740</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacskai BJ, Skoch J, Hickey GA, Allen R, Hyman BT (2003) Fluorescence resonance energy transfer determinations using multiphoton fluorescence lifetime imaging microscopy to characterize amyloid-&#x3b2; plaques. J Biomed Opt 8: 368&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">12880341</ArticleId></ArticleIdList></Reference><Reference><Citation>Berezovska O, Bacskai BJ, Hyman BT (2003) Monitoring proteins in intact cells. Sci Aging Knowledge Environ 2003: PE14.</Citation><ArticleIdList><ArticleId IdType="pubmed">12844526</ArticleId></ArticleIdList></Reference><Reference><Citation>Chyung AS, Greenberg BD, Cook DG, Doms RW, Lee VM (1997) Novel &#x3b2;-secretase cleavage of beta-amyloid precursor protein in the endoplasmic reticulum/intermediate compartment of NT2N cells. J Cell Biol 138: 671&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2141643</ArticleId><ArticleId IdType="pubmed">9245794</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook DG, Forman MS, Sung JC, Leight S, Kolson DL, Iwatsubo T, Lee VM, Doms RW (1997) Alzheimer's A beta(1&#x2013;42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat Med 3: 1021&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pubmed">9288730</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Tomita T, Matsunaga H, Ishibashi Y, Saido TC, Iwatsubo T (1999) Primary cultures of neuronal and non-neuronal rat brain cells secrete similar proportions of amyloid beta peptides ending at A &#x3b2;40 and A &#x3b2;42. NeuroReport 10: 2965&#x2013;2969.</Citation><ArticleIdList><ArticleId IdType="pubmed">10549806</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC (2003) Age but not diagnosis is the main predictor of plasma amyloid &#x3b2;-protein levels. Arch Neurol 60: 958&#x2013;964.</Citation><ArticleIdList><ArticleId IdType="pubmed">12873852</ArticleId></ArticleIdList></Reference><Reference><Citation>Gliemann J, Hermey G, Nykjaer A, Petersen CM, Jacobsen C, Andreasen PA (2004) The mosaic receptor sorLA/LR11 binds components of the plasminogen-activating system and platelet-derived growth factor-BB similarly to LRP1 (low-density lipoprotein receptor-related protein), but mediates slow internalization of bound ligand. Biochem J 381: 203&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1133778</ArticleId><ArticleId IdType="pubmed">15053742</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ (1992) Targeting of cell-surface &#x3b2;-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 357: 500&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">1608449</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann T, Bieger SC, Bruhl B, Tienari PJ, Ida N, Allsop D, Roberts GW, Masters CL, Dotti CG, Unsicker K, Beyreuther K (1997) Distinct sites of intracellular production for Alzheimer's disease A &#x3b2;40/42 amyloid peptides. Nat Med 3: 1016&#x2013;1020.</Citation><ArticleIdList><ArticleId IdType="pubmed">9288729</ArticleId></ArticleIdList></Reference><Reference><Citation>He X, Li F, Chang WP, Tang J (2005) GGA proteins mediate the recycling pathway of memapsin 2 (BACE). J Biol Chem 280: 11696&#x2013;11703.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615712</ArticleId></ArticleIdList></Reference><Reference><Citation>Huse JT, Pijak DS, Leslie GJ, Lee VM, Doms RW (2000) Maturation and endosomal targeting of &#x3b2;-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease &#x3b2;-secretase. J Biol Chem 275: 33729&#x2013;33737.</Citation><ArticleIdList><ArticleId IdType="pubmed">10924510</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, Gloger IS, Murphy KE, Southan CD, Ryan DM, Smith TS, Simmons DL, Walsh FS, Dingwall C, Christie G (1999) Identification of a novel aspartic protease (Asp 2) as &#x3b2;-secretase. Mol Cell Neurosci 14: 419&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pubmed">10656250</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, Deng A, Lleo A, Berezovska O, Von Arnim CA, Martin-Rehrmann M, Manelli A, LaDu MJ, Hyman BT, Rebeck GW (2004) Apolipoprotein E modulates &#x3b3;-secretase cleavage of the amyloid precursor protein. J Neurochem 90: 1132&#x2013;1143.</Citation><ArticleIdList><ArticleId IdType="pubmed">15312168</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen L, Madsen P, Jacobsen C, Nielsen MS, Gliemann J, Petersen CM (2001) Activation and functional characterization of the mosaic receptor SorLA/LR11. J Biol Chem 276: 22788&#x2013;22796.</Citation><ArticleIdList><ArticleId IdType="pubmed">11294867</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen L, Madsen P, Nielsen MS, Geraerts WP, Gliemann J, Smit AB, Petersen CM (2002) The sorLA cytoplasmic domain interacts with GGA1 and -2 and defines minimum requirements for GGA binding. FEBS Lett 511: 155&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">11821067</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita A, Whelan CM, Smith CJ, Mikhailenko I, Rebeck GW, Strickland DK, Hyman BT (2001) Demonstration by fluorescence resonance energy transfer of two sites of interaction between the low-density lipoprotein receptor-related protein and the amyloid precursor protein: role of the intracellular adapter protein Fe65. J Neurosci 21: 8354&#x2013;8361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762817</ArticleId><ArticleId IdType="pubmed">11606623</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita A, Shah T, Tangredi MM, Strickland DK, Hyman BT (2003) The intracellular domain of the low density lipoprotein receptor-related protein modulates transactivation mediated by amyloid precursor protein and Fe65. J Biol Chem 278: 41182&#x2013;41188.</Citation><ArticleIdList><ArticleId IdType="pubmed">12888553</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Squazzo SL (1994) Evidence that production and release of amyloid &#x3b2;-protein involves the endocytic pathway. J Biol Chem 269: 17386&#x2013;17389.</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Squazzo SL, Selkoe DJ, Koo CH (1996) Trafficking of cell-surface amyloid &#x3b2;-protein precursor. I. Secretion, endocytosis and recycling as detected by labeled monoclonal antibody. J Cell Sci 109: 991&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pubmed">8743946</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosaka T, Imagawa M, Seki K, Arai H, Sasaki H, Tsuji S, Asami-Odaka A, Fukushima T, Imai K, Iwatsubo T (1997) The &#x3b2; APP717 Alzheimer mutation increases the percentage of plasma amyloid-&#x3b2; protein ending at A &#x3b2;42(43). Neurology 48: 741&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">9065558</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuentzel SL, Ali SM, Altman RA, Greenberg BD, Raub TJ (1993) The Alzheimer &#x3b2;-amyloid protein precursor/protease nexin-II is cleaved by secretase in a trans-Golgi secretory compartment in human neuroglioma cells. Biochem J 295: 367&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1134891</ArticleId><ArticleId IdType="pubmed">8240235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai A, Sisodia SS, Trowbridge IS (1995) Characterization of sorting signals in the &#x3b2;-amyloid precursor protein cytoplasmic domain. J Biol Chem 270: 3565&#x2013;3573.</Citation><ArticleIdList><ArticleId IdType="pubmed">7876092</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenthaler SF, Dominguez DI, Westmeyer GG, Reiss K, Haass C, Saftig P, De Strooper B, Seed B (2003) The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J Biol Chem 278: 48713&#x2013;48719.</Citation><ArticleIdList><ArticleId IdType="pubmed">14507929</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J (2000) Human aspartic protease memapsin 2 cleaves the &#x3b2;-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci USA 97: 1456&#x2013;1460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26455</ArticleId><ArticleId IdType="pubmed">10677483</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez RG, Squazzo SL, Koo EH (1996) Enhanced release of amyloid &#x3b2;-protein from codon 670/671 &#x201c;Swedish&#x201d; mutant &#x3b2;-amyloid precursor protein occurs in both secretory and endocytic pathways. J Biol Chem 271: 9100&#x2013;9107.</Citation><ArticleIdList><ArticleId IdType="pubmed">8621560</ArticleId></ArticleIdList></Reference><Reference><Citation>Puertollano R, Randazzo PA, Presley JF, Hartnell LM, Bonifacino JS (2001) The GGAs promote ARF-dependent recruitment of clathrin to the TGN. Cell 105: 93&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">11301005</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR, Offe K, Gearing M, Rees HD, Fang G, Heilman CJ, Schaller C, Bujo H, Levey AI, Lah JJ (2004) Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol 61: 1200&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pubmed">15313836</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, et al. (1996) Secreted amyloid &#x3b2;-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2: 864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiba T, Kametaka S, Kawasaki M, Shibata M, Waguri S, Uchiyama Y, Wakatsuki S (2004) Insights into the phosphoregulation of &#x3b2;-secretase sorting signal by the VHS domain of GGA1. Traffic 5: 437&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pubmed">15117318</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, Lieberburg I (1999) Cellular mechanisms of &#x3b2;-amyloid production and secretion. Proc Natl Acad Sci USA 96: 11049&#x2013;11053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34239</ArticleId><ArticleId IdType="pubmed">10500121</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, et al. (1999) Purification and cloning of amyloid precursor protein &#x3b2;-secretase from human brain. Nature 402: 537&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591214</ArticleId></ArticleIdList></Reference><Reference><Citation>Taira K, Bujo H, Hirayama S, Yamazaki H, Kanaki T, Takahashi K, Ishii I, Miida T, Schneider WJ, Saito Y (2001) LR11, a mosaic LDL receptor family member, mediates the uptake of ApoE-rich lipoproteins in vitro. Arterioscler Thromb Vasc Biol 21: 1501&#x2013;1506.</Citation><ArticleIdList><ArticleId IdType="pubmed">11557679</ArticleId></ArticleIdList></Reference><Reference><Citation>Takatsu H, Katoh Y, Shiba Y, Nakayama K (2001) Golgi-localizing, &#x3b3;-adaptin ear homology domain, ADP-ribosylation factor-binding (GGA) proteins interact with acidic dileucine sequences within the cytoplasmic domains of sorting receptors through their Vps27p/Hrs/STAM (VHS) domains. J Biol Chem 276: 28541&#x2013;28545.</Citation><ArticleIdList><ArticleId IdType="pubmed">11390366</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, et al. (1999) &#x3b2;-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286: 735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>von Arnim CA, Tangredi MM, Peltan ID, Lee BM, Irizarry MC, Kinoshita A, Hyman BT (2004) Demonstration of BACE (&#x3b2;-secretase) phosphorylation and its interaction with GGA1 in cells by fluorescence-lifetime imaging microscopy. J Cell Sci 117: 5437&#x2013;5445.</Citation><ArticleIdList><ArticleId IdType="pubmed">15466887</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, Kopan R (2004) Intramembrane proteolysis: theme and variations. Science 305: 1119&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pubmed">15326347</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and &#x3b3;-secretase activity. Nature 398: 513&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W, Ray WJ, Ostaszewski BL, Rahmati T, Kimberly WT, Wolfe MS, Zhang J, Goate AM, Selkoe DJ (2000) Presenilin complexes with the C-terminal fragments of amyloid precursor protein at the sites of amyloid &#x3b2;-protein generation. Proc Natl Acad Sci USA 97: 9299&#x2013;9304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16862</ArticleId><ArticleId IdType="pubmed">10922078</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki H, Bujo H, Kusunoki J, Seimiya K, Kanaki T, Morisaki N, Schneider WJ, Saito Y (1996) Elements of neural adhesion molecules and a yeast vacuolar protein sorting receptor are present in a novel mammalian low density lipoprotein receptor family member. J Biol Chem 271: 24761&#x2013;24768.</Citation><ArticleIdList><ArticleId IdType="pubmed">8798746</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, Carter DB, Tomasselli AG, Parodi LA, Heinrikson RL, Gurney ME (1999) Membrane-anchored aspartyl protease with Alzheimer's disease &#x3b2;-secretase activity. Nature 402: 533&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591213</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Doray B, Poussu A, Lehto VP, Kornfeld S (2001) Binding of GGA2 to the lysosomal enzyme sorting motif of the mannose 6-phosphate receptor. Science 292: 1716&#x2013;1718.</Citation><ArticleIdList><ArticleId IdType="pubmed">11387476</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16407541</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Jan</Month><Day>11</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2.</ArticleTitle><Pagination><StartPage>440</StartPage><EndPage>447</EndPage><MedlinePgn>440-7</MedlinePgn></Pagination><Abstract><AbstractText>The mechanisms underlying dopamine neuron loss in Parkinson's disease (PD) are not clearly defined. Here, we delineate a pathway by which dopaminergic loss induced by 1-methyl-4-phenyl 1,2,3,6 tetrahydropyridine (MPTP) is controlled in vivo. We reported previously that calpains play a central required role in dopamine loss after MPTP treatment. Here, we provide evidence that the downstream effector pathway of calpains is through cyclin-dependent kinase 5 (cdk5)-mediated modulation of the transcription factor myocyte enhancer factor 2 (MEF2). We show that MPTP-induced conversion of the cdk5 activator p35 to a pathogenic p25 form is dependent on calpain activity in vivo. In addition, p35 deficiency attenuates MPTP-induced dopamine neuron loss and behavioral outcome. Moreover, MEF2 is phosphorylated on Ser444, an inactivating site, after MPTP treatment. This phosphorylation is dependent on both calpain and p35 activity, consistent with the model that calpain-mediated activation of cdk5 results in phosphorylation of MEF2 in vivo. Finally, we provide evidence that MEF2 is critical for dopaminergic loss because "cdk5 phosphorylation site mutant" of MEF2D provides neuroprotection in an MPTP mouse model of PD. Together, these data indicate that calpain-p35-p25/cdk5-mediated inactivation of MEF2 plays a critical role in dopaminergic loss in vivo.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Patrice D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Ottawa Health Research Institute, Ottawa, Ontario, K1H 8M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mount</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Shree</LastName><ForeName>Raj</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Callaghan</LastName><ForeName>Steve</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Slack</LastName><ForeName>Ruth S</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>Anisman</LastName><ForeName>Hymie</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Vincent</LastName><ForeName>Inez</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xuemin</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Zixu</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HD039446</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS048254</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HD39446</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS048254</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002135">Calcium-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064326">MEF2 Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578041">Mef2c protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578044">Mef2d protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018006">Myogenic Regulatory Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C089495">neuronal Cdk5 activator (p25-p35)</NameOfSubstance></Chemical><Chemical><RegistryNumber>79079-11-1</RegistryNumber><NameOfSubstance UI="C033668">calpastatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051360">Cyclin-Dependent Kinase 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="C495906">Cdk5 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D002154">Calpain</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002135" MajorTopicYN="N">Calcium-Binding Proteins</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002154" MajorTopicYN="N">Calpain</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051360" MajorTopicYN="N">Cyclin-Dependent Kinase 5</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064326" MajorTopicYN="N">MEF2 Transcription Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018006" MajorTopicYN="N">Myogenic Regulatory Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="N">Point Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>7</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16407541</ArticleId><ArticleId IdType="pmc">PMC6674390</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2875-05.2006</ArticleId><ArticleId IdType="pii">26/2/440</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abercrombie M (1946) Estimation of nuclear population from microtome sections. Anat Rec 94: 239&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">21015608</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu B, Li J, Davies P, Vincent I (2002) Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. J Neurosci 22: 6515&#x2013;6525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758154</ArticleId><ArticleId IdType="pubmed">12151531</ArticleId></ArticleIdList></Reference><Reference><Citation>Carafoli E, Molinari M (1998) Calpain: a protease in search of a function? Biochem Biophys Res Commun 247: 193&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">9642102</ArticleId></ArticleIdList></Reference><Reference><Citation>Chae T, Kwon YT, Bronson R, Dikkes P, Li E, Tsai LH (1997) Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality. Neuron 18: 29&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">9010203</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan SL, Mattson MP (1999) Caspase and calpain substrates: roles in synaptic plasticity and cell death. J Neurosci Res 58: 167&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">10491581</ArticleId></ArticleIdList></Reference><Reference><Citation>Chergui K, Svenningsson P, Greengard P (2004) Cyclin-dependent kinase 5 regulates dopaminergic and glutamatergic transmission in the striatum. Proc Natl Acad Sci USA 101: 2191&#x2013;2196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC357074</ArticleId><ArticleId IdType="pubmed">14769920</ArticleId></ArticleIdList></Reference><Reference><Citation>Croall DE, McGrody KS (1994) Domain structure of calpain: mapping the binding site for calpastatin. Biochemistry 33: 13223&#x2013;13230.</Citation><ArticleIdList><ArticleId IdType="pubmed">7947729</ArticleId></ArticleIdList></Reference><Reference><Citation>Crocker SJ, Lamba WR, Smith PD, Callaghan SM, Slack RS, Anisman H, Park DS (2001) c-Jun mediates axotomy-induced dopamine neuron death in vivo. Proc Natl Acad Sci USA 98: 13385&#x2013;13390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC60880</ArticleId><ArticleId IdType="pubmed">11687617</ArticleId></ArticleIdList></Reference><Reference><Citation>Crocker SJ, Smith PD, Jackson-Lewis V, Lamba WR, Hayley SP, Grimm E, Callaghan SM, Slack RS, Melloni E, Przedborski S, Robertson GS, Anisman H, Merali Z, Park DS (2003) Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J Neurosci 23: 4081&#x2013;4091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741113</ArticleId><ArticleId IdType="pubmed">12764095</ArticleId></ArticleIdList></Reference><Reference><Citation>Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39: 889&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">12971891</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin KB, Paxinos G (2001) The mouse brain in stereotaxic coordinates. New York: Academic.</Citation></Reference><Reference><Citation>Goll DE, Thompson VF, Li H, Wei W, Cong J (2003) The calpain system. Physiol Rev 83: 731&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">12843408</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong X, Tang X, Wiedmann M, Wang X, Peng J, Zheng D, Blair LA, Marshall J, Mao Z (2003) Cdk5-mediated inhibition of the protective effects of transcription factor MEF2 in neurotoxicity-induced apoptosis. Neuron 38: 33&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">12691662</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallows JL, Chen K, DePinho RA, Vincent I (2003) Decreased cyclin-dependent kinase 5 (cdk5) activity is accompanied by redistribution of cdk5 and cytoskeletal proteins and increased cytoskeletal protein phosphorylation in p35 null mice. J Neurosci 23: 10633&#x2013;10644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740918</ArticleId><ArticleId IdType="pubmed">14627648</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayley S, Lacosta S, Merali Z, van Rooijen N, Anisman H (2001) Central monoamine and plasma corticosterone changes induced by a bacterial endotoxin: sensitization and cross-sensitization effects. Eur J Neurosci 13: 1155&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11285013</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayley S, Crocker SJ, Smith PD, Shree T, Jackson-Lewis V, Przedborski S, Mount M, Slack R, Anisman H, Park DS (2004) Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci 24: 2045&#x2013;2053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730390</ArticleId><ArticleId IdType="pubmed">14985447</ArticleId></ArticleIdList></Reference><Reference><Citation>Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311: 467&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pubmed">6332989</ArticleId></ArticleIdList></Reference><Reference><Citation>Hisanaga S, Saito T (2003) The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator. NeuroSignals 12: 221&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">14673209</ArticleId></ArticleIdList></Reference><Reference><Citation>Humbert S, Dhavan R, Tsai L (2000) p39 activates cdk5 in neurons, and is associated with the actin cytoskeleton. J Cell Sci 113: 975&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pubmed">10683146</ArticleId></ArticleIdList></Reference><Reference><Citation>Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82: 2173&#x2013;2177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC397515</ArticleId><ArticleId IdType="pubmed">3872460</ArticleId></ArticleIdList></Reference><Reference><Citation>Julien JP, Mushynski WE (1998) Neurofilaments in health and disease. Prog Nucleic Acid Res Mol Biol 61: 1&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">9752717</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko J, Humbert S, Bronson RT, Takahashi S, Kulkarni AB, Li E, Tsai LH (2001) p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. J Neurosci 21: 6758&#x2013;6771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763073</ArticleId><ArticleId IdType="pubmed">11517264</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusakawa G, Saito T, Onuki R, Ishiguro K, Kishimoto T, Hisanaga S (2000) Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J Biol Chem 275: 17166&#x2013;17172.</Citation><ArticleIdList><ArticleId IdType="pubmed">10748088</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH (2000) Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405: 360&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">10830966</ArticleId></ArticleIdList></Reference><Reference><Citation>Li BS, Zhang L, Takahashi S, Ma W, Jaffe H, Kulkarni AB, Pant HC (2002) Cyclin-dependent kinase 5 prevents neuronal apoptosis by negative regulation of c-Jun N-terminal kinase 3. EMBO J 21: 324&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125822</ArticleId><ArticleId IdType="pubmed">11823425</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Linseman DA, Allen MP, Meintzer MK, Wang X, Laessig T, Wierman ME, Heidenreich KA (2001) Myocyte enhancer factor 2A and 2D undergo phosphorylation and caspase-mediated degradation during apoptosis of rat cerebellar granule neurons. J Neurosci 21: 6544&#x2013;6552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763101</ArticleId><ArticleId IdType="pubmed">11517243</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Z, Wiedmann M (1999) Calcineurin enhances MEF2 DNA binding activity in calcium-dependent survival of cerebellar granule neurons. J Biol Chem 274: 31102&#x2013;31107.</Citation><ArticleIdList><ArticleId IdType="pubmed">10521511</ArticleId></ArticleIdList></Reference><Reference><Citation>Melloni E, Salamino F, Sparatore B (1992) The calpain-calpastatin system in mammalian cells: properties and possible functions. Biochimie 74: 217&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">1610935</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouatt-Prigent A, Karlsson JO, Agid Y, Hirsch EC (1996) Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? Neuroscience 73: 979&#x2013;987.</Citation><ArticleIdList><ArticleId IdType="pubmed">8809817</ArticleId></ArticleIdList></Reference><Reference><Citation>Moy LY, Tsai LH (2004) Cyclin-dependent kinase 5 phosphorylates serine 31 of tyrosine hydroxylase and regulates its stability. J Biol Chem 279: 54487&#x2013;54493.</Citation><ArticleIdList><ArticleId IdType="pubmed">15471880</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura S, Kawamoto Y, Nakano S, Akiguchi I, Kimura J (1997) p35nck5a and cyclin-dependent kinase 5 colocalize in Lewy bodies of brains with Parkinson's disease. Acta Neuropathol (Berl) 94: 153&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">9255390</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen MD, Lariviere RC, Julien JP (2001) Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. Neuron 30: 135&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">11343650</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishi A, Bibb JA, Matsuyama S, Hamada M, Higashi H, Nairn AC, Greengard P (2002) Regulation of DARPP-32 dephosphorylation at PKA- and Cdk5-sites by NMDA and AMPA receptors: distinct roles of calcineurin and protein phosphatase-2A. J Neurochem 81: 832&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pubmed">12065642</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Hare MJ, Kushwaha N, Zhang Y, Aleyasin H, Callaghan SM, Slack RS, Albert PR, Vincent I, Park DS (2005) Differential roles of nuclear and cytoplasmic cyclin-dependent kinase 5 in apoptotic and excitotoxic neuronal death. J Neurosci 25: 8954&#x2013;8966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725602</ArticleId><ArticleId IdType="pubmed">16192386</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohshima T, Ward JM, Huh CG, Longenecker G, Veeranna, Pant HC, Brady RO, Martin LJ, Kulkarni AB (1996) Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci USA 93: 11173&#x2013;11178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC38303</ArticleId><ArticleId IdType="pubmed">8855328</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402: 615&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">10604467</ArticleId></ArticleIdList></Reference><Reference><Citation>Pines J (1993) Cyclins and their associated cyclin-dependent kinases in the human cell cycle. Biochem Soc Trans 21: 921&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">8132094</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray SK, Banik NL (2003) Calpain and its involvement in the pathophysiology of CNS injuries and diseases: therapeutic potential of calpain inhibitors for prevention of neurodegeneration. Curr Drug Targets CNS Neurol Disord 2: 173&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">12769798</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosales JL, Nodwell MJ, Johnston RN, Lee KY (2000) Cdk5/p25(nck5a) interaction with synaptic proteins in bovine brain. J Cell Biochem 78: 151&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">10797574</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosales J, Han B, Lee KY (2003) Cdk7 functions as a cdk5 activating kinase in brain. Cell Physiol Biochem 13: 285&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">14586172</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedarous M, Keramaris E, O'Hare M, Melloni E, Slack RS, Elce JS, Greer PA, Park DS (2003) Calpains mediate p53 activation and neuronal death evoked by DNA damage. J Biol Chem 278: 26031&#x2013;26038.</Citation><ArticleIdList><ArticleId IdType="pubmed">12721303</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma P, Sharma M, Amin ND, Albers RW, Pant HC (1999) Regulation of cyclin-dependent kinase 5 catalytic activity by phosphorylation. Proc Natl Acad Sci USA 96: 11156&#x2013;11160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18003</ArticleId><ArticleId IdType="pubmed">10500146</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelton SB, Johnson GV (2004) Cyclin-dependent kinase-5 in neurodegeneration. J Neurochem 88: 1313&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pubmed">15009631</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith PD, Crocker SJ, Jackson-Lewis V, Jordan-Sciutto KL, Hayley S, Mount MP, O'Hare MJ, Callaghan S, Slack RS, Przedborski S, Anisman H, Park DS (2003) Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 100: 13650&#x2013;13655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC263868</ArticleId><ArticleId IdType="pubmed">14595022</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith PD, O'Hare MJ, Park DS (2004) CDKs: taking on a role as mediators of dopaminergic loss in Parkinson's disease. Trends Mol Med 10: 445&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">15350897</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang X, Wang X, Gong X, Tong M, Park D, Xia Z, Mao Z (2005) Cyclin-dependent kinase 5 mediates neurotoxin-induced degradation of the transcription factor myocyte enhancer factor 2. J Neurosci 25: 4823&#x2013;4834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724765</ArticleId><ArticleId IdType="pubmed">15888658</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatton NA, Kish SJ (1997) In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77: 1037&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pubmed">9130785</ArticleId></ArticleIdList></Reference><Reference><Citation>Trimmer PA, Smith TS, Jung AB, Bennett Jr JP (1996) Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity. Neurodegeneration 5: 233&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">8910901</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai LH, Takahashi T, Caviness Jr VS, Harlow E (1993) Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system. Development 119: 1029&#x2013;1040.</Citation><ArticleIdList><ArticleId IdType="pubmed">8306873</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai LH, Delalle I, Caviness Jr VS, Chae T, Harlow E (1994) p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371: 419&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">8090221</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16407971</PMID><DateCompleted><Year>2006</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0261-4189</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Jan</Month><Day>25</Day></PubDate></JournalIssue><Title>The EMBO journal</Title><ISOAbbreviation>EMBO J</ISOAbbreviation></Journal><ArticleTitle>The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and Abeta generation in vivo.</ArticleTitle><Pagination><StartPage>432</StartPage><EndPage>443</EndPage><MedlinePgn>432-43</MedlinePgn></Pagination><Abstract><AbstractText>The cholesterol-synthesizing enzyme seladin-1, encoded by the Dhcr24 gene, is a flavin adenine dinucleotide-dependent oxidoreductase and regulates responses to oncogenic and oxidative stimuli. It has a role in neuroprotection and is downregulated in affected neurons in Alzheimer's disease (AD). Here we show that seladin-1-deficient mouse brains had reduced levels of cholesterol and disorganized cholesterol-rich detergent-resistant membrane domains (DRMs). This was associated with inefficient plasminogen binding and plasmin activation, the displacement of beta-secretase (BACE) from DRMs to APP-containing membrane fractions, increased beta-cleavage of APP and high levels of Abeta peptides. In contrast, overexpression of seladin-1 increased both cholesterol and the recruitment of DRM components into DRM fractions, induced plasmin activation and reduced both BACE processing of APP and Abeta formation. These results establish a role of seladin-1 in the formation of DRMs and suggest that seladin-1-dependent cholesterol synthesis is involved in lowering Abeta levels. Pharmacological enhancement of seladin-1 activity may be a novel Abeta-lowering approach for the treatment of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Crameri</LastName><ForeName>Arames</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Psychiatry Research, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biondi</LastName><ForeName>Elisa</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Kuehnle</LastName><ForeName>Katrin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>L&#xfc;tjohann</LastName><ForeName>Dieter</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Thelen</LastName><ForeName>Karin M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Perga</LastName><ForeName>Simona</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Dotti</LastName><ForeName>Carlos G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Nitsch</LastName><ForeName>Roger M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Ledesma</LastName><ForeName>Maria Dolores</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Mohajeri</LastName><ForeName>M Hasan</ForeName><Initials>MH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO J</MedlineTA><NlmUniqueID>8208664</NlmUniqueID><ISSNLinking>0261-4189</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017931">DNA Primers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058255">Protease Nexins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>9001-91-6</RegistryNumber><NameOfSubstance UI="D010958">Plasminogen</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.3.-</RegistryNumber><NameOfSubstance UI="D044925">Oxidoreductases Acting on CH-CH Group Donors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.3.1.-</RegistryNumber><NameOfSubstance UI="C499055">DHCR24 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.7</RegistryNumber><NameOfSubstance UI="D005341">Fibrinolysin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017931" MajorTopicYN="N">DNA Primers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005341" MajorTopicYN="N">Fibrinolysin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044925" MajorTopicYN="N">Oxidoreductases Acting on CH-CH Group Donors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010958" MajorTopicYN="N">Plasminogen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058255" MajorTopicYN="N">Protease Nexins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>5</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>1</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16407971</ArticleId><ArticleId IdType="pmc">PMC1383521</ArticleId><ArticleId IdType="doi">10.1038/sj.emboj.7600938</ArticleId><ArticleId IdType="pii">7600938</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, Dingwall C, De Strooper B, Dotti CG (2004) Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol 167: 953&#x2013;960</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172459</ArticleId><ArticleId IdType="pubmed">15583033</ArticleId></ArticleIdList></Reference><Reference><Citation>Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911&#x2013;917</Citation><ArticleIdList><ArticleId IdType="pubmed">13671378</ArticleId></ArticleIdList></Reference><Reference><Citation>Capell A, Grunberg J, Pesold B, Diehlmann A, Citron M, Nixon R, Beyreuther K, Selkoe DJ, Haass C (1998) The proteolytic fragments of the Alzheimer's disease-associated presenilin-1 form heterodimers and occur as a 100&#x2013;150-kDa molecular mass complex. J Biol Chem 273: 3205&#x2013;3211</Citation><ArticleIdList><ArticleId IdType="pubmed">9452432</ArticleId></ArticleIdList></Reference><Reference><Citation>Casas C, Sergeant N, Itier JM, Blanchard V, Wirths O, van der Kolk N, Vingtdeux V, van de Steeg E, Ret G, Canton T, Drobecq H, Clark A, Bonici B, Delacourte A, Benavides J, Schmitz C, Tremp G, Bayer TA, Benoit P, Pradier L (2004) Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol 165: 1289&#x2013;1300</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618627</ArticleId><ArticleId IdType="pubmed">15466394</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ, Justice A, McConlogue L, Games D, Freedman SB, Morris RG (2000) A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408: 975&#x2013;979</Citation><ArticleIdList><ArticleId IdType="pubmed">11140684</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciana A, Balduini C, Minetti G (2005) Detergent-resistant membranes in human erythrocytes and their connection to the membrane-skeleton. J Biosci 30: 317&#x2013;328</Citation><ArticleIdList><ArticleId IdType="pubmed">16052070</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921&#x2013;923</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Estus S, Tucker HM, van Rooyen C, Wright S, Brigham EF, Wogulis M, Rydel RE (1997) Aggregated amyloid-beta protein induces cortical neuronal apoptosis and concomitant &#x2018;apoptotic' pattern of gene induction. J Neurosci 17: 7736&#x2013;7745</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793913</ArticleId><ArticleId IdType="pubmed">9315895</ArticleId></ArticleIdList></Reference><Reference><Citation>Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 98: 5856&#x2013;5861</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33303</ArticleId><ArticleId IdType="pubmed">11296263</ArticleId></ArticleIdList></Reference><Reference><Citation>Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, LeBlanc A, Smith D, Rigby M, Shearman MS, Clarke EE, Zheng H, Van Der Ploeg LH, Ruffolo SC, Thornberry NA, Xanthoudakis S, Zamboni RJ, Roy S, Nicholson DW (1999) Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 97: 395&#x2013;406</Citation><ArticleIdList><ArticleId IdType="pubmed">10319819</ArticleId></ArticleIdList></Reference><Reference><Citation>Greeve I, Hermans-Borgmeyer I, Brellinger C, Kasper D, Gomez-Isla T, Behl C, Levkau B, Nitsch RM (2000) The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress. J Neurosci 20: 7345&#x2013;7352</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772756</ArticleId><ArticleId IdType="pubmed">11007892</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353&#x2013;356</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao KK, Borchelt DR, Olson K, Johannsdottir R, Kitt C, Yunis W, Xu S, Eckman C, Younkin S, Price D, Iadecola C, Clark HB, Carlson G (1995) Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 15: 1203&#x2013;1218</Citation><ArticleIdList><ArticleId IdType="pubmed">7576662</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR, Stokes KC, Leopold M, Multhaup G, Goldstein LE, Scarpa RC, Saunders AJ, Lim J, Moir RD, Glabe C, Bowden EF, Masters CL, Fairlie DP, Tanzi RE, Bush AI (1999) Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 274: 37111&#x2013;37116</Citation><ArticleIdList><ArticleId IdType="pubmed">10601271</ArticleId></ArticleIdList></Reference><Reference><Citation>Iivonen S, Hiltunen M, Alafuzoff I, Mannermaa A, Kerokoski P, Puolivali J, Salminen A, Helisalmi S, Soininen H (2002) Seladin-1 transcription is linked to neuronal degeneration in Alzheimer's disease. Neuroscience 113: 301&#x2013;310</Citation><ArticleIdList><ArticleId IdType="pubmed">12127087</ArticleId></ArticleIdList></Reference><Reference><Citation>Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408: 979&#x2013;982</Citation><ArticleIdList><ArticleId IdType="pubmed">11140685</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirsch C, Eckert GP, Mueller WE (2003) Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem Pharmacol 65: 843&#x2013;856</Citation><ArticleIdList><ArticleId IdType="pubmed">12628479</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein U, Gimpl G, Fahrenholz F (1995) Alteration of the myometrial plasma membrane cholesterol content with beta-cyclodextrin modulates the binding affinity of the oxytocin receptor. Biochemistry 34: 13784&#x2013;13793</Citation><ArticleIdList><ArticleId IdType="pubmed">7577971</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledesma MD, Abad-Rodriguez J, Galvan C, Biondi E, Navarro P, Delacourte A, Dingwal C, Dotti CG (2003a) Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains. EMBO Rep 4: 1190&#x2013;1196</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1326416</ArticleId><ArticleId IdType="pubmed">14618158</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledesma MD, Da Silva JS, Crassaerts K, Delacourte A, De Strooper B (2000) Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. EMBO Rep 1: 530&#x2013;535</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1083779</ArticleId><ArticleId IdType="pubmed">11263499</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledesma MD, Da Silva JS, Schevchenko A, Wilm M, Dotti CG (2003b) Proteomic characterisation of neuronal sphingolipid&#x2013;cholesterol microdomains: role in plasminogen activation. Brain Res 987: 107&#x2013;116</Citation><ArticleIdList><ArticleId IdType="pubmed">14499952</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutjohann D, Brzezinka A, Barth E, Abramowski D, Staufenbiel M, von Bergmann K, Beyreuther K, Multhaup G, Bayer TA (2002) Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain. J Lipid Res 43: 1078&#x2013;1085</Citation><ArticleIdList><ArticleId IdType="pubmed">12091492</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohajeri MH, Saini K, Schultz JG, Wollmer MA, Hock C, Nitsch RM (2002) Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation. J Biol Chem 277: 33012&#x2013;33017</Citation><ArticleIdList><ArticleId IdType="pubmed">12068009</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982&#x2013;985</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L (2000) High-level neuronal expression of abeta 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20: 4050&#x2013;4058</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Park IH, Hwang EM, Hong HS, Boo JH, Oh SS, Lee J, Jung MW, Bang OY, Kim SU, Mook-Jung I (2003) Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice. Neurobiol Aging 24: 637&#x2013;643</Citation><ArticleIdList><ArticleId IdType="pubmed">12885571</ArticleId></ArticleIdList></Reference><Reference><Citation>Parton RG, Hancock JF (2004) Lipid rafts and plasma membrane microorganization: insights from Ras. Trends Cell Biol 14: 141&#x2013;147</Citation><ArticleIdList><ArticleId IdType="pubmed">15003623</ArticleId></ArticleIdList></Reference><Reference><Citation>Prior IA, Muncke C, Parton RG, Hancock JF (2003) Direct visualization of Ras proteins in spatially distinct cell surface microdomains. J Cell Biol 160: 165&#x2013;170</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172642</ArticleId><ArticleId IdType="pubmed">12527752</ArticleId></ArticleIdList></Reference><Reference><Citation>Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, Tint GS, Wang R, Mercken M, Petanceska SS, Duff KE (2001) A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 8: 890&#x2013;899</Citation><ArticleIdList><ArticleId IdType="pubmed">11592856</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothblat GH, Burns CH, Conner RL, Landrey JR (1970) Desmosterol as the major sterol in L-cell mouse fibroblasts grown in sterol-free culture medium. Science 169: 880&#x2013;882</Citation><ArticleIdList><ArticleId IdType="pubmed">5432584</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz C, Rutten BP, Pielen A, Schafer S, Wirths O, Tremp G, Czech C, Blanchard V, Multhaup G, Rezaie P, Korr H, Steinbusch HW, Pradier L, Bayer TA (2004) Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am J Pathol 164: 1495&#x2013;1502</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1615337</ArticleId><ArticleId IdType="pubmed">15039236</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ (2001) Clearing the brain's amyloid cobwebs. Neuron 32: 177&#x2013;180</Citation><ArticleIdList><ArticleId IdType="pubmed">11683988</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons K, Toomre D (2000) Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 1: 31&#x2013;39</Citation><ArticleIdList><ArticleId IdType="pubmed">11413487</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 95: 6460&#x2013;6464</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27798</ArticleId><ArticleId IdType="pubmed">9600988</ArticleId></ArticleIdList></Reference><Reference><Citation>Small DH, Mok SS, Bornstein JC (2001) Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci 2: 595&#x2013;598</Citation><ArticleIdList><ArticleId IdType="pubmed">11484003</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks DL, Martin TA, Gross DR, Hunsaker JC III (2000) Link between heart disease, cholesterol, and Alzheimer's disease: a review. Microsc Res Tech 50: 287&#x2013;290</Citation><ArticleIdList><ArticleId IdType="pubmed">10936882</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks DL, Martins R, Martin T (2002) Cholesterol and cognition: rationale for the AD cholesterol-lowering treatment trial and sex-related differences in beta-amyloid accumulation in the brains of spontaneously hypercholesterolemic Watanabe rabbits. Ann NY Acad Sci 977: 356&#x2013;366</Citation><ArticleIdList><ArticleId IdType="pubmed">12480773</ArticleId></ArticleIdList></Reference><Reference><Citation>Waterham HR, Koster J, Romeijn GJ, Hennekam RC, Vreken P, Andersson HC, FitzPatrick DR, Kelley RI, Wanders RJ (2001) Mutations in the 3beta-hydroxysterol Delta24-reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis. Am J Hum Genet 69: 685&#x2013;694</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1226055</ArticleId><ArticleId IdType="pubmed">11519011</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler A, Brafman A, Shafir M, Heverin M, Gottlieb H, Damari G, Gozlan-Kelner S, Spivak I, Moshkin O, Fridman E, Becker Y, Skaliter R, Einat P, Faerman A, Bjorkhem I, Feinstein E (2003) Generation of viable cholesterol-free mice. Science 302: 2087.</Citation><ArticleIdList><ArticleId IdType="pubmed">14684813</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Miloslavskaya I, Demontis S, Maestro R, Galaktionov K (2004) Regulation of cellular response to oncogenic and oxidative stress by Seladin-1. Nature 432: 640&#x2013;645</Citation><ArticleIdList><ArticleId IdType="pubmed">15577914</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16407979</PMID><DateCompleted><Year>2006</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0261-4189</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Jan</Month><Day>25</Day></PubDate></JournalIssue><Title>The EMBO journal</Title><ISOAbbreviation>EMBO J</ISOAbbreviation></Journal><ArticleTitle>Essential roles for the FE65 amyloid precursor protein-interacting proteins in brain development.</ArticleTitle><Pagination><StartPage>420</StartPage><EndPage>431</EndPage><MedlinePgn>420-31</MedlinePgn></Pagination><Abstract><AbstractText>Targeted deletion of two members of the FE65 family of adaptor proteins, FE65 and FE65L1, results in cortical dysplasia. Heterotopias resembling those found in cobblestone lissencephalies in which neuroepithelial cells migrate into superficial layers of the developing cortex, aberrant cortical projections and loss of infrapyramidal mossy fibers arise in FE65/FE65L1 compound null animals, but not in single gene knockouts. The disruption of pial basal membranes underlying the heterotopias and poor organization of fibrillar laminin by isolated meningeal fibroblasts from double knockouts suggests that FE65 proteins are involved in basement membrane assembly. A similar phenotype is observed in triple mutant mice lacking the APP family members APP, APLP1 and APLP2, all of which interact with FE65 proteins, suggesting that this phenotype may be caused by decreased transmission of an APP-dependent signal through the FE65 proteins. The defects observed in the double knockout may also involve the family of Ena/Vasp proteins, which participate in actin cytoskeleton remodeling and interact with the WW domains of FE65 proteins.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gu&#xe9;nette</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Charlestown, MA 02129-4404, USA. guenette@helix.mgh.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Yang</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Hiesberger</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>James A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Eckman</LastName><ForeName>Christopher B</ForeName><Initials>CB</Initials></Author><Author ValidYN="Y"><LastName>Eckman</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Hammer</LastName><ForeName>Robert E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Herz</LastName><ForeName>Joachim</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS043408</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 HL020948</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL63762</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL20948</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL063762</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS43408</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015903</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG15903</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 HL063762</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO J</MedlineTA><NlmUniqueID>8208664</NlmUniqueID><ISSNLinking>0261-4189</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C486243">Apbb1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001485" MajorTopicYN="N">Basement Membrane</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="Y">growth &amp; development</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="Y">growth &amp; development</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017403" MajorTopicYN="N">In Situ Hybridization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008578" MajorTopicYN="N">Meninges</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>5</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>1</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16407979</ArticleId><ArticleId IdType="pmc">PMC1383510</ArticleId><ArticleId IdType="doi">10.1038/sj.emboj.7600926</ArticleId><ArticleId IdType="pii">7600926</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ashley J, Packard M, Ataman B, Budnik V (2005) Fasciclin II signals new synapse formation through amyloid precursor protein and the scaffolding protein dX11/Mint. J Neurosci 25: 5943&#x2013;5955</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724788</ArticleId><ArticleId IdType="pubmed">15976083</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballif BA, Arnaud L, Arthur WT, Guris D, Imamoto A, Cooper JA (2004) Activation of a Dab1/CrkL/C3G/Rap1 pathway in Reelin-stimulated neurons. Curr Biol 14: 606&#x2013;610</Citation><ArticleIdList><ArticleId IdType="pubmed">15062102</ArticleId></ArticleIdList></Reference><Reference><Citation>Bear JE, Svitkina TM, Krause M, Schafer DA, Loureiro JJ, Strasser GA, Maly IV, Chaga OY, Cooper JA, Borisy GG, Gertler FB (2002) Antagonism between Ena/VASP proteins and actin filament capping regulates fibroblast motility. Cell 109: 509&#x2013;521</Citation><ArticleIdList><ArticleId IdType="pubmed">12086607</ArticleId></ArticleIdList></Reference><Reference><Citation>Beggs HE, Schahin-Reed D, Zang K, Goebbels S, Nave KA, Gorski J, Jones KR, Sretavan D, Reichardt LF (2003) FAK deficiency in cells contributing to the basal lamina results in cortical abnormalities resembling congenital muscular dystrophies. Neuron 40: 501&#x2013;514</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758566</ArticleId><ArticleId IdType="pubmed">14642275</ArticleId></ArticleIdList></Reference><Reference><Citation>Bicknese AR, Sheppard AM, O'Leary DD, Pearlman AL (1994) Thalamocortical axons extend along a chondroitin sulfate proteoglycan-enriched pathway coincident with the neocortical subplate and distinct from the efferent path. J Neurosci 14: 3500&#x2013;3510</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576951</ArticleId><ArticleId IdType="pubmed">8207468</ArticleId></ArticleIdList></Reference><Reference><Citation>Bielle F, Griveau A, Narboux-Neme N, Vigneau S, Sigrist M, Arber S, Wassef M, Pierani A (2005) Multiple origins of Cajal&#x2013;Retzius cells at the borders of the developing pallium. Nat Neurosci 8: 1002&#x2013;1012</Citation><ArticleIdList><ArticleId IdType="pubmed">16041369</ArticleId></ArticleIdList></Reference><Reference><Citation>Bimonte M, Gianni D, Allegra D, Russo T, Zambrano N (2004) Mutation of the feh-1 gene, the Caenorhabditis elegans orthologue of mammalian Fe65, decreases the expression of two acetylcholinesterase genes. Eur J Neurosci 20: 1483&#x2013;1488</Citation><ArticleIdList><ArticleId IdType="pubmed">15355315</ArticleId></ArticleIdList></Reference><Reference><Citation>Blackshear PJ, Silver J, Nairn AC, Sulik KK, Squier MV, Stumpo DJ, Tuttle JS (1997) Widespread neuronal ectopia associated with secondary defects in cerebrocortical chondroitin sulfate proteoglycans and basal lamina in MARCKS-deficient mice. Exp Neurol 145: 46&#x2013;61</Citation><ArticleIdList><ArticleId IdType="pubmed">9184108</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruni P, Minopoli G, Brancaccio T, Napolitano M, Faraonio R, Zambrano N, Hansen U, Russo T (2002) Fe65, a ligand of the Alzheimer's beta-amyloid precursor protein, blocks cell cycle progression by down-regulating thymidylate synthase expression. J Biol Chem 277: 35481&#x2013;35488</Citation><ArticleIdList><ArticleId IdType="pubmed">12089154</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, Sudhof TC (2001) A transcriptionally (correction of transcriptively) active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 293: 115&#x2013;120</Citation><ArticleIdList><ArticleId IdType="pubmed">11441186</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Y, Tesco G, Jeong WJ, Lindsley L, Eckman EA, Eckman CB, Tanzi RE, Guenette SY (2003) Generation of the beta-amyloid peptide and the amyloid precursor protein C-terminal fragment gamma are potentiated by FE65L1. J Biol Chem 278: 51100&#x2013;51107</Citation><ArticleIdList><ArticleId IdType="pubmed">14527950</ArticleId></ArticleIdList></Reference><Reference><Citation>Costell M, Gustafsson E, Aszodi A, Morgelin M, Bloch W, Hunziker E, Addicks K, Timpl R, Fassler R (1999) Perlecan maintains the integrity of cartilage and some basement membranes. J Cell Biol 147: 1109&#x2013;1122</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2169352</ArticleId><ArticleId IdType="pubmed">10579729</ArticleId></ArticleIdList></Reference><Reference><Citation>Coulson EJ, Paliga K, Beyreuther K, Masters CL (2000) What the evolution of the amyloid protein precursor supergene family tells us about its function. Neurochem Int 36: 175&#x2013;184</Citation><ArticleIdList><ArticleId IdType="pubmed">10676850</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bergeyck V, Naerhuyzen B, Goffinet AM, Lambert de Rouvroit C (1998) A panel of monoclonal antibodies against reelin, the extracellular matrix protein defective in reeler mutant mice. J Neurosci Methods 82: 17&#x2013;24</Citation><ArticleIdList><ArticleId IdType="pubmed">10223511</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Rio JA, Martinez A, Auladell C, Soriano E (2000) Developmental history of the subplate and developing white matter in the murine neocortex. Neuronal organization and relationship with the main afferent systems at embryonic and perinatal stages. Cereb Cortex 10: 784&#x2013;801</Citation><ArticleIdList><ArticleId IdType="pubmed">10920050</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S (1996) Increased amyloid-&#x3b2;42(43) in brains of mice expressing mutant presenilin 1. Nature 383: 710&#x2013;713</Citation><ArticleIdList><ArticleId IdType="pubmed">8878479</ArticleId></ArticleIdList></Reference><Reference><Citation>Ermekova KS, Zambrano N, Linn H, Minopoli G, Gertler F, Russo T, Sudol M (1997) The WW domain of neural protein FE65 interacts with proline-rich motifs in Mena, the mammalian homolog of Drosophila enabled. J Biol Chem 272: 32869&#x2013;32877</Citation><ArticleIdList><ArticleId IdType="pubmed">9407065</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink RP, Heimer L (1967) Two methods for selective silver impregnation of degenerating axons and their synaptic endings in the central nervous system. Brain Res 4: 369&#x2013;374</Citation><ArticleIdList><ArticleId IdType="pubmed">4166480</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer DF, van Dijk R, Sluijs JA, Nair SM, Racchi M, Levelt CN, van Leeuwen FW, Hol EM (2005) Activation of the Notch pathway in Down syndrome: cross-talk of Notch and APP. FASEB J 19: 1451&#x2013;1458</Citation><ArticleIdList><ArticleId IdType="pubmed">16126912</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda T, Kawano H, Ohyama K, Li HP, Takeda Y, Oohira A, Kawamura K (1997) Immunohistochemical localization of neurocan and L1 in the formation of thalamocortical pathway of developing rats. J Comp Neurol 382: 141&#x2013;152</Citation><ArticleIdList><ArticleId IdType="pubmed">9183685</ArticleId></ArticleIdList></Reference><Reference><Citation>Georges-Labouesse E, Mark M, Messaddeq N, Gansmuller A (1998) Essential role of alpha 6 integrins in cortical and retinal lamination. Curr Biol 8: 983&#x2013;986</Citation><ArticleIdList><ArticleId IdType="pubmed">9742403</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh KL, Cai L, Cepko CL, Gertler FB (2002) Ena/VASP proteins regulate cortical neuronal positioning. Curr Biol 12: 565&#x2013;569</Citation><ArticleIdList><ArticleId IdType="pubmed">11937025</ArticleId></ArticleIdList></Reference><Reference><Citation>Graus-Porta D, Blaess S, Senften M, Littlewood-Evans A, Damsky C, Huang Z, Orban P, Klein R, Schittny JC, Muller U (2001) Beta1-class integrins regulate the development of laminae and folia in the cerebral and cerebellar cortex. Neuron 31: 367&#x2013;379</Citation><ArticleIdList><ArticleId IdType="pubmed">11516395</ArticleId></ArticleIdList></Reference><Reference><Citation>Halfter W, Dong S, Yip YP, Willem M, Mayer U (2002) A critical function of the pial basement membrane in cortical histogenesis. J Neurosci 22: 6029&#x2013;6040</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757907</ArticleId><ArticleId IdType="pubmed">12122064</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann D, De Strooper B, Saftig P (1999) Presenilin-1 deficiency leads to loss of Cajal&#x2013;Retzius neurons and cortical dysplasia similar to human type 2 lissencephaly. Curr Biol 9: 719&#x2013;727</Citation><ArticleIdList><ArticleId IdType="pubmed">10421573</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann D, Sievers J, Pehlemann FW, Berry M (1992) Destruction of meningeal cells over the medial cerebral hemisphere of newborn hamsters prevents the formation of the infrapyramidal blade of the dentate gyrus. J Comp Neurol 320: 33&#x2013;61</Citation><ArticleIdList><ArticleId IdType="pubmed">1401241</ArticleId></ArticleIdList></Reference><Reference><Citation>Hass MR, Yankner BA (2005) A {gamma}-secretase-independent mechanism of signal transduction by the amyloid precursor protein. J Biol Chem 280: 36895&#x2013;36904</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1562327</ArticleId><ArticleId IdType="pubmed">16103124</ArticleId></ArticleIdList></Reference><Reference><Citation>Herms J, Anliker B, Heber S, Ring S, Fuhrmann M, Kretzschmar H, Sisodia S, Muller U (2004) Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. EMBO J 23: 4106&#x2013;4115</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524337</ArticleId><ArticleId IdType="pubmed">15385965</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano S, Houdou S, Hasegawa M, Kamei A, Takashima S (1992) Clinicopathologic studies on leptomeningeal glioneuronal heterotopia in congenital anomalies. Pediatr Neurol 8: 441&#x2013;444</Citation><ArticleIdList><ArticleId IdType="pubmed">1476573</ArticleId></ArticleIdList></Reference><Reference><Citation>Kibbey MC, Jucker M, Weeks BS, Neve RL, Van Nostrand WE, Kleinman HK (1993) beta-Amyloid precursor protein binds to the neurite-promoting IKVAV site of laminin. Proc Natl Acad Sci USA 90: 10150&#x2013;10153</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47731</ArticleId><ArticleId IdType="pubmed">8234269</ArticleId></ArticleIdList></Reference><Reference><Citation>King GD, Turner RS (2004) Adaptor protein interactions: modulators of amyloid precursor protein metabolism and Alzheimer's disease risk? Exp Neurol 185: 208&#x2013;219</Citation><ArticleIdList><ArticleId IdType="pubmed">14736502</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert de Rouvroit C, Goffinet AM (2001) Neuronal migration. Mech Dev 105: 47&#x2013;56</Citation><ArticleIdList><ArticleId IdType="pubmed">11429281</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambrechts A, Kwiatkowski AV, Lanier LM, Bear JE, Vandekerckhove J, Ampe C, Gertler FB (2000) cAMP-dependent protein kinase phosphorylation of EVL, a Mena/VASP relative, regulates its interaction with actin and SH3 domains. J Biol Chem 275: 36143&#x2013;36151</Citation><ArticleIdList><ArticleId IdType="pubmed">10945997</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanier LM, Gates MA, Witke W, Menzies AS, Wehman AM, Macklis JD, Kwiatkowski D, Soriano P, Gertler FB (1999) Mena is required for neurulation and commissure formation. Neuron 22: 313&#x2013;325</Citation><ArticleIdList><ArticleId IdType="pubmed">10069337</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebrand C, Dent EW, Strasser GA, Lanier LM, Krause M, Svitkina TM, Borisy GG, Gertler FB (2004) Critical role of Ena/VASP proteins for filopodia formation in neurons and in function downstream of netrin-1. Neuron 42: 37&#x2013;49</Citation><ArticleIdList><ArticleId IdType="pubmed">15066263</ArticleId></ArticleIdList></Reference><Reference><Citation>Ligon KL, Echelard Y, Assimacopoulos S, Danielian PS, Kaing S, Grove EA, McMahon AP, Rowitch DH (2003) Loss of Emx2 function leads to ectopic expression of Wnt1 in the developing telencephalon and cortical dysplasia. Development 130: 2275&#x2013;2287</Citation><ArticleIdList><ArticleId IdType="pubmed">12668639</ArticleId></ArticleIdList></Reference><Reference><Citation>Magara F, Muller U, Li ZW, Lipp HP, Weissmann C, Stagljar M, Wolfer DP (1999) Genetic background changes the pattern of forebrain commissure defects in transgenic mice underexpressing the beta-amyloid-precursor protein. Proc Natl Acad Sci USA 96: 4656&#x2013;4661</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16388</ArticleId><ArticleId IdType="pubmed">10200318</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin O, Rubenstein JL (2003) Cell migration in the forebrain. Annu Rev Neurosci 26: 441&#x2013;483</Citation><ArticleIdList><ArticleId IdType="pubmed">12626695</ArticleId></ArticleIdList></Reference><Reference><Citation>Mischel PS, Nguyen LP, Vinters HV (1995) Cerebral cortical dysplasia associated with pediatric epilepsy. Review of neuropathologic features and proposal for a grading system. J Neuropathol Exp Neurol 54: 137&#x2013;153</Citation><ArticleIdList><ArticleId IdType="pubmed">7876884</ArticleId></ArticleIdList></Reference><Reference><Citation>Molnar Z, Adams R, Goffinet AM, Blakemore C (1998) The role of the first postmitotic cortical cells in the development of thalamocortical innervation in the reeler mouse. J Neurosci 18: 5746&#x2013;5765</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793036</ArticleId><ArticleId IdType="pubmed">9671664</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore SA, Saito F, Chen J, Michele DE, Henry MD, Messing A, Cohn RD, Ross-Barta SE, Westra S, Williamson RA, Hoshi T, Campbell KP (2002) Deletion of brain dystroglycan recapitulates aspects of congenital muscular dystrophy. Nature 418: 422&#x2013;425</Citation><ArticleIdList><ArticleId IdType="pubmed">12140559</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewmierzycka A, Mills J, St-Arnaud R, Dedhar S, Reichardt LF (2005) Integrin-linked kinase deletion from mouse cortex results in cortical lamination defects resembling cobblestone lissencephaly. J Neurosci 25: 7022&#x2013;7031</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2688706</ArticleId><ArticleId IdType="pubmed">16049178</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozaki HS, Wahlsten D (1993) Cortical axon trajectories and growth cone morphologies in fetuses of acallosal mouse strains. J Comp Neurol 336: 595&#x2013;604</Citation><ArticleIdList><ArticleId IdType="pubmed">7504000</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross ME, Walsh CA (2001) Human brain malformations and their lessons for neuronal migration. Annu Rev Neurosci 24: 1041&#x2013;1070</Citation><ArticleIdList><ArticleId IdType="pubmed">11520927</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabo SL, Ikin AF, Buxbaum JD, Greengard P (2001) The Alzheimer amyloid precursor protein (APP) and FE65, an APP-binding protein, regulate cell movement. J Cell Biol 153: 1403&#x2013;1414</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2150733</ArticleId><ArticleId IdType="pubmed">11425871</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheinfeld MH, Ghersi E, Laky K, Fowlkes BJ, D'Adamio L (2002) Processing of beta-amyloid precursor-like protein-1 and -2 by gamma-secretase regulates transcription. J Biol Chem 277: 44195&#x2013;44201</Citation><ArticleIdList><ArticleId IdType="pubmed">12228233</ArticleId></ArticleIdList></Reference><Reference><Citation>Shearer MC, Niclou SP, Brown D, Asher RA, Holtmaat AJ, Levine JM, Verhaagen J, Fawcett JW (2003) The astrocyte/meningeal cell interface is a barrier to neurite outgrowth which can be overcome by manipulation of inhibitory molecules or axonal signalling pathways. Mol Cell Neurosci 24: 913&#x2013;925</Citation><ArticleIdList><ArticleId IdType="pubmed">14697658</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano E, Del Rio JA (2005) The cells of Cajal&#x2013;Retzius: still a mystery one century after. Neuron 46: 389&#x2013;394</Citation><ArticleIdList><ArticleId IdType="pubmed">15882637</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanahashi H, Tabira T (2002) Characterization of an amyloid precursor protein-binding protein Fe65L2 and its novel isoforms lacking phosphotyrosine-interaction domains. Biochem J 367: 687&#x2013;695</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1222940</ArticleId><ArticleId IdType="pubmed">12153398</ArticleId></ArticleIdList></Reference><Reference><Citation>Trommsdorff M, Gotthardt M, Hiesberger T, Shelton J, Stockinger W, Nimpf J, Hammer RE, Richardson JA, Herz J (1999) Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell 97: 689&#x2013;701</Citation><ArticleIdList><ArticleId IdType="pubmed">10380922</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Hu Q, Hearn MG, Shimizu K, Ware CB, Liggitt DH, Jin LW, Cool BH, Storm DR, Martin GM (2004) Isoform-specific knockout of FE65 leads to impaired learning and memory. J Neurosci Res 75: 12&#x2013;24</Citation><ArticleIdList><ArticleId IdType="pubmed">14689444</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Yang G, Mosier DR, Chang P, Zaidi T, Gong YD, Zhao NM, Dominguez B, Lee KF, Gan WB, Zheng H (2005) Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-Like protein 2. J Neurosci 25: 1219&#x2013;1225</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725967</ArticleId><ArticleId IdType="pubmed">15689559</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson TG, Mok SS, Henry A, Cappai R, Lander AD, Nurcombe V, Beyreuther K, Masters CL, Small DH (1996) Secreted glypican binds to the amyloid precursor protein of Alzheimer's disease (APP) and inhibits APP-induced neurite outgrowth. J Biol Chem 271: 31215&#x2013;31221</Citation><ArticleIdList><ArticleId IdType="pubmed">8940123</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambrano N, Bimonte M, Arbucci S, Gianni D, Russo T, Bazzicalupo P (2002) feh-1 and apl-1, the Caenorhabditis elegans orthologues of mammalian Fe65 and beta-amyloid precursor protein genes, are involved in the same pathway that controls nematode pharyngeal pumping. J Cell Sci 115: 1411&#x2013;1422</Citation><ArticleIdList><ArticleId IdType="pubmed">11896189</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambrano N, Bruni P, Minopoli G, Mosca R, Molino D, Russo C, Schettini G, Sudol M, Russo T (2001) The beta-amyloid precursor protein APP is tyrosine-phosphorylated in cells expressing a constitutively active form of the Abl protoncogene. J Biol Chem 276: 19787&#x2013;19792</Citation><ArticleIdList><ArticleId IdType="pubmed">11279131</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16415866</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1097-6256</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease.</ArticleTitle><Pagination><StartPage>234</StartPage><EndPage>242</EndPage><MedlinePgn>234-42</MedlinePgn></Pagination><Abstract><AbstractText>Defects in dendritic spines are common to several forms of cognitive deficits, including mental retardation and Alzheimer disease. Because mutation of p21-activated kinase (PAK) can lead to mental retardation and because PAK-cofilin signaling is critical in dendritic spine morphogenesis and actin dynamics, we hypothesized that the PAK pathway is involved in synaptic and cognitive deficits in Alzheimer disease. Here, we show that PAK and its activity are markedly reduced in Alzheimer disease and that this is accompanied by reduced and redistributed phosphoPAK, prominent cofilin pathology and downstream loss of the spine actin-regulatory protein drebrin, which cofilin removes from actin. We found that beta-amyloid (Abeta) was directly involved in PAK signaling deficits and drebrin loss in Abeta oligomer-treated hippocampal neurons and in the Appswe transgenic mouse model bearing a double mutation leading to higher Abeta production. In addition, pharmacological PAK inhibition in adult mice was sufficient to cause similar cofilin pathology, drebrin loss and memory impairment, consistent with a potential causal role of PAK defects in cognitive deficits in Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Lixia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Greater Los Angeles Veterans Affairs Healthcare System, Sepulveda, California 91343, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Qiu-Lan</ForeName><Initials>QL</Initials></Author><Author ValidYN="Y"><LastName>Calon</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Harris-White</LastName><ForeName>Marni E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Fusheng</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Giselle P</ForeName><Initials>GP</Initials></Author><Author ValidYN="Y"><LastName>Morihara</LastName><ForeName>Takashi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Ubeda</LastName><ForeName>Oliver J</ForeName><Initials>OJ</Initials></Author><Author ValidYN="Y"><LastName>Ambegaokar</LastName><ForeName>Surendra</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>James E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Weisbart</LastName><ForeName>Richard H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Teter</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Frautschy</LastName><ForeName>Sally A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>Greg M</ForeName><Initials>GM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG10685</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG13741</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG16793</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG 16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG013741</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS43946</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022080</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG010685</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG10415</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>01</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051339">Actin Depolymerizing Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009479">Neuropeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C053386">drebrins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D054462">p21-Activated Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051339" MajorTopicYN="N">Actin Depolymerizing Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009479" MajorTopicYN="N">Neuropeptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054462" MajorTopicYN="N">p21-Activated Kinases</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16415866</ArticleId><ArticleId IdType="doi">10.1038/nn1630</ArticleId><ArticleId IdType="pii">nn1630</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16421297</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Jan</Month><Day>18</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Ectopic cell cycle events link human Alzheimer's disease and amyloid precursor protein transgenic mouse models.</ArticleTitle><Pagination><StartPage>775</StartPage><EndPage>784</EndPage><MedlinePgn>775-84</MedlinePgn></Pagination><Abstract><AbstractText>Nerve cells that re-enter a cell cycle will die rather than divide, a fact that likely underlies the neurodegeneration in Alzheimer's disease (AD). Several mouse models of familial AD have been created, and although many display amyloid plaques in their brains, none captures the extensive pattern of nerve cell death found in the human disease. Using both immunocytochemistry and fluorescent in situ hybridization, we show that neurons in three different mouse models reproduce the ectopic cell cycling found in human AD. The temporal and spatial appearance of the cell cycle events in the mouse closely mimics the human disease progression. The cell-cycle events are evident 6 months before the first amyloid deposits and significantly precede the appearance of the first CD45+ microglia. These data suggest that the ectopic initiation of cell-cycle processes in neurons is an early sign of neuronal distress in both human and mouse AD. The close phenotypic correspondence indicates a previously unsuspected level of fidelity of the mouse model to the human disease. Finally, the relative timing suggests that neither the activated microglia nor the amyloid plaques themselves are necessary to initiate the pathogenic events in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospitals of Cleveland, Cleveland, Ohio 44106, USA. yxy33@case.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varvel</LastName><ForeName>Nicholas H</ForeName><Initials>NH</Initials></Author><Author ValidYN="Y"><LastName>Lamb</LastName><ForeName>Bruce T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Herrup</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG023012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS020591</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS20591</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG023012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008811" MajorTopicYN="N">Mice, Inbred DBA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>7</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16421297</ArticleId><ArticleId IdType="pmc">PMC6675370</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3707-05.2006</ArticleId><ArticleId IdType="pii">26/3/775</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P (2005) Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 25: 5446&#x2013;5454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725006</ArticleId><ArticleId IdType="pubmed">15930395</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T (2000) Alzheimer's disease as a loss of differentiation control in a subset of neurons that retain immature features in the adult brain. Neurobiol Aging 21: 783&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pubmed">11124422</ArticleId></ArticleIdList></Reference><Reference><Citation>Boone CW, Kelloff GJ, Steele VE (1992) Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy. Cancer Res 52: 1651&#x2013;1659.</Citation><ArticleIdList><ArticleId IdType="pubmed">1551096</ArticleId></ArticleIdList></Reference><Reference><Citation>Bornemann KD, Staufenbiel M (2000) Transgenic mouse models of Alzheimer's disease. Ann NY Acad Sci 908: 260&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">10911965</ArticleId></ArticleIdList></Reference><Reference><Citation>Busser J, Geldmacher DS, Herrup K (1998) Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain. J Neurosci 18: 2801&#x2013;2807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792587</ArticleId><ArticleId IdType="pubmed">9525997</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CP, Eastwood SL, Hope T, McDonald B, Francis PT, Esiri MM (2000) Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer's disease prospectively assessed for behavioural changes. Neuropathol Appl Neurobiol 26: 347&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">10931368</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu Y, Cochran EJ, Bennett DA, Mufson EJ, Kordower JH (2001) Down-regulation of trkA mRNA within nucleus basalis neurons in individuals with mild cognitive impairment and Alzheimer's disease. J Comp Neurol 437: 296&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">11494257</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke A, Maandag E, van Roon M, van der Lugt N, van der Valk M, Hooper M, Berns A, te Riele H (1992) Requirement for a functional Rb-1 gene in murine development. Nature 359: 328&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">1406937</ArticleId></ArticleIdList></Reference><Reference><Citation>Claycomb JM, Benasutti M, Bosco G, Fenger DD, Orr-Weaver TL (2004) Gene amplification as a developmental strategy: isolation of two developmental amplicons in Drosophila Dev Cell 6: 145&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">14723854</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5: 452&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">11941374</ArticleId></ArticleIdList></Reference><Reference><Citation>Farinelli S, Greene L (1996) Cell cycle blockers mimosine, ciclopirox, and deferoxamine prevent the death of PC12 cells and postmitotic sympathetic neurons after removal of trophic support. J Neurosci 16: 1150&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578784</ArticleId><ArticleId IdType="pubmed">8558244</ArticleId></ArticleIdList></Reference><Reference><Citation>Feddersen RM, Ehlenfeldt R, Yunis WS, Clark HB, Orr HT (1992) Disrupted cerebellar cortical development and progressive degeneration of Purkinje cells in SV40 T antigen transgenic mice. Neuron 9: 955&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pubmed">1419002</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, Mcconlogue L, et al. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373: 523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Gartner U, Bruckner MK, Krug S, Schmetsdorf S, Stanfenbiel M, Arendt T (2003) Amyloid deposition in APP23 mice is associated with the expression of cyclins in astrocytes but not in neurons. Acta Neuropathol (Berl) 106: 535&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">12923647</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovanni A, Wirtz-Brugger F, Keramaris E, Slack R, Park DS (1999) Involvement of cell cycle elements, cyclin-dependent kinases, pRb, and E2F x DP, in B-amyloid-induced neuronal death. J Biol Chem 274: 19011&#x2013;19016.</Citation><ArticleIdList><ArticleId IdType="pubmed">10383401</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene LA, Biswas SC, Liu DX (2004) Cell cycle molecules and vertebrate neuron death: E2F at the hub. Cell Death Differ 11: 49&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">14647236</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartlage-Rubsamen M, Zeitschel U, Apelt J, Gartner U, Franke H, Stahl T, Gunther A, Schliebs R, Penkowa M, Bigl V, Rossner S (2003) Astrocytic expression of the Alzheimer's disease beta-secretase (BACE1) is stimulus-dependent. Glia 41: 169&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">12509807</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrup K, Arendt T (2002) Re-expression of cell cycle proteins induces neuronal cell death during Alzheimer's disease. J Alzheimers Dis 4: 243&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">12226544</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrup K, Busser JC (1995) The induction of multiple cell cycle events precedes target-related neuronal death. Development 121: 2385&#x2013;2395.</Citation><ArticleIdList><ArticleId IdType="pubmed">7671804</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock Jr BJ, Lamb BT (2001) Transgenic mouse models of Alzheimer's disease. Trends Genet 17: S7&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">11585670</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4: 97&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">9427614</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacks T, Fazeli A, Schmitt E, Bronson R, Goodell M, Weinberg R (1992) Effects of an Rb mutation in the mouse. Nature 359: 295&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">1406933</ArticleId></ArticleIdList></Reference><Reference><Citation>Katchanov J, Harms C, Gertz K, Hauck L, Waeber C, Hirt L, Priller J, von Harsdorf R, Bruck W, Hortnagl H, Dirnagl U, Bhide PG, Endres M (2001) Mild cerebral ischemia induces loss of cyclin-dependent kinase inhibitors and activation of cell cycle machinery before delayed neuronal cell death. J Neurosci 21: 5045&#x2013;5053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762829</ArticleId><ArticleId IdType="pubmed">11438580</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein JA, Longo-Guess CM, Rossmann MP, Seburn KL, Hurd RE, Frankel WN, Bronson RT, Ackerman SL (2002) The harlequin mouse mutation downregulates apoptosis-inducing factor. Nature 419: 367&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">12353028</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuan CY, Schloemer AJ, Lu A, Burns KA, Weng WL, Williams MT, Strauss KI, Vorhees CV, Flavell RA, Davis RJ, Sharp FR, Rakic P (2004) Hypoxia&#x2013;ischemia induces DNA synthesis without cell proliferation in dying neurons in adult rodent brain. J Neurosci 24: 10763&#x2013;10772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2590933</ArticleId><ArticleId IdType="pubmed">15564594</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulnane LS, Lamb BT (2001) Neuropathological characterization of mutant amyloid precursor protein yeast artificial chromosome transgenic mice. Neurobiol Dis 8: 982&#x2013;992.</Citation><ArticleIdList><ArticleId IdType="pubmed">11741394</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb BT (1995) Making models for Alzheimer's disease. Nat Genet 9: 4&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">7704022</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EY-HP, Chang C-Y, Hu N, Wang Y-CJ, Lai C-C, Herrup K, Lee W-H, Bradley A (1992) Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359: 288&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">1406932</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Zwingman T, Li R, Pan T, Wong BS, Petersen RB, Gambetti P, Herrup K, Sy MS (2001) Differential expression of cellular prion protein in mouse brain as detected with multiple anti-PrP monoclonal antibodies. Brain Res 896: 118&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">11277980</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyness SA, Zarow C, Chui HC (2003) Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol Aging 24: 1&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">12493547</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam M, Shaw P, Mash D, Weintraub S (2004) Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol 55: 815&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">15174015</ArticleId></ArticleIdList></Reference><Reference><Citation>Mufson EJ, Ma SY, Dills J, Cochran EJ, Leurgans S, Wuu J, Bennett DA, Jaffar S, Gilmor ML, Levey AI, Kordower JH (2002) Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol 443: 136&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">11793352</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39: 409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganathan S, Bowser R (2003) Alterations in G(1) to S phase cell-cycle regulators during amyotrophic lateral sclerosis. Am J Pathol 162: 823&#x2013;835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868100</ArticleId><ArticleId IdType="pubmed">12598317</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganathan S, Scudiere S, Bowser R (2001) Hyperphosphorylation of the retinoblastoma gene product and altered subcellular distribution of E2F-1 during Alzheimer's disease and amyotrophic lateral sclerosis. J Alzheimers Dis 3: 377&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">12214040</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossner S, Apelt J, Schliebs R, Perez-Polo JR, Bigl V (2001) Neuronal and glial beta-secretase (BACE) protein expression in transgenic Tg2576 mice with amyloid plaque pathology. J Neurosci Res 64: 437&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">11391698</ArticleId></ArticleIdList></Reference><Reference><Citation>Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning, a laboratory manual, p B13. Cold Spring Harbor, NY: Cold Spring Harbor.</Citation></Reference><Reference><Citation>Schenk D (2002) Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 3: 824&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">12360327</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalder MPA, Probst A, Sommer B, Staufenbiel M, Jucker M (1999) Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol 154: 1673&#x2013;1684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866618</ArticleId><ArticleId IdType="pubmed">10362792</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94: 13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen TC, Rogido M, Genetta T, Sola A (2004) Permanent focal cerebral ischemia activates erythropoietin receptor in the neonatal rat brain. Neurosci Lett 355: 165&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">14732457</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR (1982) Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215: 1237&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">7058341</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Herrup K (2005) Loss of neuronal cell cycle control in ataxia-telangiectasia: a unified disease mechanism. J Neurosci 25: 2522&#x2013;2529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725172</ArticleId><ArticleId IdType="pubmed">15758161</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Geldmacher DS, Herrup K (2001) DNA replication precedes neuronal cell death in Alzheimer's disease. J Neurosci 21: 2661&#x2013;2668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762514</ArticleId><ArticleId IdType="pubmed">11306619</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Mufson EJ, Herrup K (2003) Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci 23: 2557&#x2013;2563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742098</ArticleId><ArticleId IdType="pubmed">12684440</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarow C, Lyness SA, Mortimer JA, Chui HC (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60: 337&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">12633144</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Raina AK, Perry G, Smith MA (2004) Alzheimer's disease: the two-hit hypothesis. Lancet Neurol 3: 219&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">15039034</ArticleId></ArticleIdList></Reference><Reference><Citation>Zweig RM, Ross CA, Hedreen JC, Steele C, Cardillo JE, Whitehouse PJ, Folstein MF, Price DL (1988) The neuropathology of aminergic nuclei in Alzheimer's disease. Ann Neurol 24: 233&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">3178178</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16421561</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>439</Volume><Issue>7074</Issue><PubDate><Year>2006</Year><Month>Jan</Month><Day>19</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>A brain-specific microRNA regulates dendritic spine development.</ArticleTitle><Pagination><StartPage>283</StartPage><EndPage>289</EndPage><MedlinePgn>283-9</MedlinePgn></Pagination><Abstract><AbstractText>MicroRNAs are small, non-coding RNAs that control the translation of target messenger RNAs, thereby regulating critical aspects of plant and animal development. In the mammalian nervous system, the spatiotemporal control of mRNA translation has an important role in synaptic development and plasticity. Although a number of microRNAs have been isolated from the mammalian brain, neither the specific microRNAs that regulate synapse function nor their target mRNAs have been identified. Here we show that a brain-specific microRNA, miR-134, is localized to the synapto-dendritic compartment of rat hippocampal neurons and negatively regulates the size of dendritic spines--postsynaptic sites of excitatory synaptic transmission. This effect is mediated by miR-134 inhibition of the translation of an mRNA encoding a protein kinase, Limk1, that controls spine development. Exposure of neurons to extracellular stimuli such as brain-derived neurotrophic factor relieves miR-134 inhibition of Limk1 translation and in this way may contribute to synaptic development, maturation and/or plasticity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schratt</LastName><ForeName>Gerhard M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Neurobiology Program, Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuebing</LastName><ForeName>Fabian</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Nigh</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Kane</LastName><ForeName>Christina G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Sabatini</LastName><ForeName>Mary E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Kiebler</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Greenberg</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D054461">Lim Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C515894">Limk1 protein, rat</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nature. 2006 Jun 15;441(7095):902</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048430" MajorTopicYN="N">Cell Shape</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018507" MajorTopicYN="Y">Gene Expression Regulation, Developmental</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054461" MajorTopicYN="N">Lim Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009928" MajorTopicYN="N">Organ Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014176" MajorTopicYN="Y">Protein Biosynthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16421561</ArticleId><ArticleId IdType="doi">10.1038/nature04367</ArticleId><ArticleId IdType="pii">nature04367</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16426772</PMID><DateCompleted><Year>2006</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0378-1119</ISSN><JournalIssue CitedMedium="Print"><Volume>371</Volume><Issue>1</Issue><PubDate><Year>2006</Year><Month>Apr</Month><Day>12</Day></PubDate></JournalIssue><Title>Gene</Title><ISOAbbreviation>Gene</ISOAbbreviation></Journal><ArticleTitle>Allele-specific silencing of Alzheimer's disease genes: the amyloid precursor protein genes with Swedish or London mutations.</ArticleTitle><Pagination><StartPage>68</StartPage><EndPage>74</EndPage><MedlinePgn>68-74</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) is the most common cause of dementia in humans. A pathological hallmark in the brain of an AD patient is extracellular amyloid plaques formed by accumulated beta-amyloid protein (Abeta), a metabolic product of amyloid precursor protein (APP). Studies have revealed a strong genetic linkage in the early-onset familial form (&lt;60 years old) of AD. For example, some mutant APPs are transmitted dominantly and are segregated with inheritance of early onset AD. These mutants facilitate Abeta production. The "Swedish" mutations (APP(SW)) and the "London" mutation (APP(LON)) are examples of these mutants. Selective silencing of these mutant alleles holds therapeutic promise for AD. Here we show that the expression of the mutant APPs was selectively inhibited by RNA interference. The best selectivity was obtained when the mismatches were centrally placed in the antisense strand of small interfering RNAs. Introducing an additional mismatch in the antisense strand may improve the selectivity. The addition of a G at 5' end of the antisense strand may enhance the efficacy of gene silencing by RNA interference. Our results illustrate the guiding principles for selection of targeted sequences to achieve allele-specific silencing. The sequences that are effective to silence APP(SW) and APP(LON) as identified in this study may be useful in both in vivo and in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Xiaorong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, University of Virginia, Charlottesville, VA 22908, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Ping</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Yunxiu</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Zuo</LastName><ForeName>Zhiyi</ForeName><Initials>Z</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM065211</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS045983</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>01</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Gene</MedlineTA><NlmUniqueID>7706761</NlmUniqueID><ISSNLinking>0378-1119</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="Y">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034622" MajorTopicYN="Y">RNA Interference</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>6</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16426772</ArticleId><ArticleId IdType="doi">10.1016/j.gene.2005.11.006</ArticleId><ArticleId IdType="pii">S0378-1119(05)00712-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16434391</PMID><DateCompleted><Year>2006</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>281</Volume><Issue>12</Issue><PubDate><Year>2006</Year><Month>Mar</Month><Day>24</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Secretion of the Notch-1 Abeta-like peptide during Notch signaling.</ArticleTitle><Pagination><StartPage>7890</StartPage><EndPage>7898</EndPage><MedlinePgn>7890-8</MedlinePgn></Pagination><Abstract><AbstractText>The canonical pathway of Notch signaling is mediated by regulated intramembrane proteolysis (RIP). In the pathway, ligand binding results in sequential proteolysis of the Notch receptor, and presenilin (PS)-dependent intramembrane proteolysis at the interface between the membrane and cytosol liberates the Notch-1 intracellular domain (NICD), a transcription modifier. Because the degradation of the Notch-1 transmembrane domain is thought to require an additional cleavage near the middle of the transmembrane domain, extracellular small peptides (Notch-1 Abeta-like peptide (Nbeta)) should be produced. Here we showed that Nbeta species are indeed secreted during the process of Notch signaling. We identified mainly two distinct molecular species of novel Nbeta, Nbeta21 and C-terminally elongated Nbeta25, which were produced in an approximately 5:1 ratio. This process is reminiscent of the production of Alzheimer disease-associated Abeta. PS pathogenic mutants increased the production of the longer species of Abeta (Abeta42) from beta-amyloid protein precursor. We revealed that several Alzheimer disease mutants also cause a parallel increase in the secretion of the longer form of Nbeta. Strikingly, chemicals that modify the Abeta42 level caused parallel changes in the Nbeta25 level. These results demonstrated that the characteristics of C-terminal elongation of Nbeta and Abeta are almost identical. In addition, because many other type 1 membrane-bound receptors release intracellular domains by PS-dependent intramembrane proteolysis, we suspect that the release of Abeta- or Nbeta-like peptides is a common feature of the proteolysis during RIP signaling. We anticipate that this study will open the door to searches for markers of RIP signaling and surrogate markers for Abeta42 production.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Okochi</LastName><ForeName>Masayasu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Post-Genomics and Diseases, Division of Psychiatry and Behavioral Proteomics, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan. mokochi@psy.med.osaka-u.ac.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukumori</LastName><ForeName>Akio</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Jingwei</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Itoh</LastName><ForeName>Naohiro</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Ryo</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>Harald</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Tagami</LastName><ForeName>Shinji</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Takeda</LastName><ForeName>Masatoshi</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>01</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C489697">APLP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078201">Aplp1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018076">DNA, Complementary</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497761">NOTCH1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497762">Notch1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051881">Receptor, Notch1</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003600" MajorTopicYN="N">Cytosol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018076" MajorTopicYN="N">DNA, Complementary</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017930" MajorTopicYN="N">Genes, Reporter</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051881" MajorTopicYN="N">Receptor, Notch1</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>5</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16434391</ArticleId><ArticleId IdType="doi">10.1074/jbc.M513250200</ArticleId><ArticleId IdType="pii">S0021-9258(19)76603-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16443603</PMID><DateCompleted><Year>2006</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>281</Volume><Issue>16</Issue><PubDate><Year>2006</Year><Month>Apr</Month><Day>21</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation.</ArticleTitle><Pagination><StartPage>10825</StartPage><EndPage>10838</EndPage><MedlinePgn>10825-38</MedlinePgn></Pagination><Abstract><AbstractText>One of the key pathological hallmarks of Alzheimer disease (AD) is the accumulation of paired helical filaments (PHFs) of hyperphosphorylated microtubule-associated protein Tau. Tandem mass spectrometry was employed to examine PHF-Tau post-translational modifications, in particular protein phosphorylation and ubiquitination, to shed light on their role in the early stages of Alzheimer disease. PHF-Tau from Alzheimer disease brain was affinity-purified by MC1 monoclonal antibody to isolate a soluble fraction of PHF-Tau in a conformation unique to human AD brain. A large number of phosphorylation sites were identified by employing a data-dependent neutral loss algorithm to trigger MS3 scans of phosphopeptides. It was found that soluble PHF-Tau is ubiquitinated at its microtubule-binding domain at residues Lys-254, Lys-311, and Lys-353, suggesting that ubiquitination of PHF-Tau may be an earlier pathological event than previously thought and that ubiquitination could play a regulatory role in modulating the integrity of microtubules during the course of AD. Tandem mass spectrometry data for ubiquitin itself indicate that PHF-Tau is modified by three polyubiquitin linkages, at Lys-6, Lys-11, and Lys-48. Relative quantitative analysis indicates that Lys-48-linked polyubiquitination is the primary form of polyubiquitination with a minor portion of ubiquitin linked at Lys-6 and Lys-11. Because modification by Lys-48-linked polyubiquitin chains is known to serve as the essential means of targeting proteins for degradation by the ubiquitin-proteasome system, and it has been reported that modification at Lys-6 inhibits ubiquitin-dependent protein degradation, a failure of the ubiquitin-proteasome system could play a role in initiating the formation of degradation-resistant PHF tangles.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cripps</LastName><ForeName>Diane</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, University of Southern California, Los Angeles, California 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Stefani N</ForeName><Initials>SN</Initials></Author><Author ValidYN="Y"><LastName>Jeng</LastName><ForeName>Young</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Austin J</ForeName><Initials>AJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH038623</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG25323</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025323</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH059786</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH020069</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH59786</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>38623</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>01</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012997">Solvents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>2ZD004190S</RegistryNumber><NameOfSubstance UI="D013912">Threonine</NameOfSubstance></Chemical><Chemical><RegistryNumber>452VLY9402</RegistryNumber><NameOfSubstance UI="D012694">Serine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.4</RegistryNumber><NameOfSubstance UI="D014357">Trypsin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>K3Z4F929H6</RegistryNumber><NameOfSubstance UI="D008239">Lysine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002853" MajorTopicYN="N">Chromatography, Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008239" MajorTopicYN="N">Lysine</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017386" MajorTopicYN="N">Sequence Homology, Amino Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012694" MajorTopicYN="N">Serine</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012997" MajorTopicYN="N">Solvents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013912" MajorTopicYN="N">Threonine</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014357" MajorTopicYN="N">Trypsin</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025801" MajorTopicYN="N">Ubiquitin</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>6</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16443603</ArticleId><ArticleId IdType="doi">10.1074/jbc.M512786200</ArticleId><ArticleId IdType="pii">S0021-9258(19)56257-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16446437</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>103</Volume><Issue>6</Issue><PubDate><Year>2006</Year><Month>Feb</Month><Day>07</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1953</StartPage><EndPage>1958</EndPage><MedlinePgn>1953-8</MedlinePgn></Pagination><Abstract><AbstractText>To date, there is no reasonable explanation as to why plaques and tangles simultaneously accumulate in Alzheimer's disease (AD). We demonstrate here by Western blotting and ELISA that a stable complex can form between tau and amyloid-beta protein (Abeta). This complex enhances tau phosphorylation by GSK3beta, but the phosphorylation then promotes dissociation of the complex. We have localized the sites of this interaction by using peptide membrane arrays. Abeta binds to multiple tau peptides, especially those in exons 7 and 9. This binding is sharply reduced or abolished by phosphorylation of specific serine and threonine residues. Conversely, tau binds to multiple Abeta peptides in the mid to C-terminal regions of Abeta. This binding is also significantly decreased by GSK3beta phosphorylation of tau. We used surface plasmon resonance to determine the binding affinity of Abeta for tau and found it to be in the low nanomolar range and almost 1,000-fold higher than tau for itself. In soluble extracts from AD and control brain tissue, we detected Abeta bound to tau in ELISAs. We also found by double immunostaining of AD brain tissue that phosphorylated tau and Abeta form separate insoluble complexes within the same neurons and their processes. We hypothesize that in AD, an initial step in the pathogenesis may be the intracellular binding of soluble Abeta to soluble nonphosphorylated tau, thus promoting tau phosphorylation and Abeta nucleation. Blocking the sites where Abeta initially binds to tau might arrest the simultaneous formation of plaques and tangles in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Jian-Ping</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, BC, Canada V6T 1Z3.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arai</LastName><ForeName>Tetsuaki</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Miklossy</LastName><ForeName>Judit</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>McGeer</LastName><ForeName>Patrick L</ForeName><Initials>PL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>01</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D046912">Multiprotein Complexes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046912" MajorTopicYN="N">Multiprotein Complexes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040081" MajorTopicYN="N">Protein Array Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020349" MajorTopicYN="N">Surface Plasmon Resonance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest statement: No conflicts declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>8</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16446437</ArticleId><ArticleId IdType="pmc">PMC1413647</ArticleId><ArticleId IdType="doi">10.1073/pnas.0509386103</ArticleId><ArticleId IdType="pii">0509386103</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Iqbal K., Alonso Adel C., Chen S., Cholan M. O., El-Akkad E., Gong C. X., Khatoon S., Li B., Liu F., Rahman A., et al. Biochim. Biophys. Acta. 2005;1739:198&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615638</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. A., Higgins G. A. Science. 1992;256:184&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J., Selkoe D. J. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M. Movement Disorders. 2002;17:1402&#x2013;1403.</Citation></Reference><Reference><Citation>Goedert M., Jakes R. Biochim. Biophys. Acta. 2005;1739:240&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615642</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T., Guo J. P., McGeer P. L. J. Biol. Chem. 2005;280:5145&#x2013;5153.</Citation><ArticleIdList><ArticleId IdType="pubmed">15542598</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J. P., Petric M., Campbell W., McGeer P. L. Virology. 2004;324:251&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125913</ArticleId><ArticleId IdType="pubmed">15207612</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson U., Fagerstam L., Ivarsson B., Johnsson B., Karlsson R., Lundh K., Lofas S., Persson B., Roos H., Ronnberg I., et al. BioTechniques. 1991;11:620&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">1804254</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa K., Ono K., Yamada M., Naiki H. Biochemistry. 2002;41:13489&#x2013;13498.</Citation><ArticleIdList><ArticleId IdType="pubmed">12427009</ArticleId></ArticleIdList></Reference><Reference><Citation>Rank K. B., Pauley A. M., Bhattacharya K., Wang Z., Evans D. B., Fleck T. J., Johnston J. A., Sharma S. K. FEBS Lett. 2002;514:263&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">11943163</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J., Lemaire H. G., Unterbeck A., Salbaum J. M., Masters C. L., Grzeschik K. H., Multhaup G., Beyreuther K., Muller-Hill B. Nature. 1987;325:733&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pubmed">2881207</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer P. L., Akiyama H., Kawamata T., Yamada T., Walker D. G., Ishii T. J. Neurosci. Res. 1992;31:428&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">1640495</ArticleId></ArticleIdList></Reference><Reference><Citation>Benowitz L. I., Rodriguez W., Paskevich P., Mufson E. J., Schenk D., Neve R. L. Exp. Neurol. 1989;106:237&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">2591522</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole G. M., Masliah E., Shelton E. R., Chan H. W., Terry R. D., Saitoh T. Neurobiol. Aging. 1991;12:85&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">1711161</ArticleId></ArticleIdList></Reference><Reference><Citation>Card J. P., Meade R. P., Davis L. G. Neuron. 1988;1:835&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pubmed">3152290</ArticleId></ArticleIdList></Reference><Reference><Citation>Shivers B. D., Hilbich C., Multhaup G., Salbaum M., Beyreuther K., Seeburg P. H. EMBO J. 1988;7:1365&#x2013;1370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC458385</ArticleId><ArticleId IdType="pubmed">2900758</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Andrea M. R., Nagele R. G., Wang H. Y., Peterson P. A., Lee D. H. Histopathology. 2001;38:120&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">11207825</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenfield J. P., Tsai J., Gouras G. K., Hai B., Thinakaran G., Checler F., Sisodia S. S., Greengard P., Xu H. Proc. Natl. Acad. Sci. USA. 1999;96:742&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15207</ArticleId><ArticleId IdType="pubmed">9892704</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi R. H., Milner T. A., Li F., Nam E. E., Edgar M. A., Yamaguchi H., Beal M. F., Xu H., Greengard P., Gouras G. K. Am. J. Pathol. 2002;161:1869&#x2013;1879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850783</ArticleId><ArticleId IdType="pubmed">12414533</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras G. K., Tsai J., Naslund J., Vincent B., Edgar M., Checler F., Greenfield J. P., Haroutunian V., Buxbaum J. D., Xu H., et al. Am. J. Pathol. 2000;156:15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868613</ArticleId><ArticleId IdType="pubmed">10623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Gyure K. A., Durham R., Stewart W. F., Smialek J. E., Troncoso J. C. Arch. Pathol. Lab. Med. 2001;125:489&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">11260621</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H., Sweeney D., Wang R., Thinakaran G., Lo A. C., Sisodia S. S., Greengard P., Gandy S. Proc. Natl. Acad. Sci. USA. 1997;94:3748&#x2013;3752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20512</ArticleId><ArticleId IdType="pubmed">9108049</ArticleId></ArticleIdList></Reference><Reference><Citation>Skovronsky D. M., Doms R. W., Lee V. M. J. Cell Biol. 1998;141:1031&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2132781</ArticleId><ArticleId IdType="pubmed">9585420</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook D. G., Forman M. S., Sung J. C., Leight S., Kolson D. L., Iwatsubo T., Lee V. M., Doms R. W. Nat. Med. 1997;3:1021&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pubmed">9288730</ArticleId></ArticleIdList></Reference><Reference><Citation>Wild-Bode C., Yamazaki T., Capell A., Leimer U., Steiner H., Ihara Y., Haass C. J. Biol. Chem. 1997;272:16085&#x2013;16088.</Citation><ArticleIdList><ArticleId IdType="pubmed">9195901</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann T., Bieger S. C., Bruhl B., Tienari P. J., Ida N., Allsop D., Roberts G. W., Masters C. L., Dotti C. G., Unsicker K., et al. Nat. Med. 1997;3:1016&#x2013;1020.</Citation><ArticleIdList><ArticleId IdType="pubmed">9288729</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccini A., Russo C., Gliozzi A., Relini A., Vitali A., Borghi R., Giliberto L., Armirotti A., D&#x2019;Arrigo C., Bachi A., et al. J. Biol. Chem. 2005;280:34186&#x2013;34192.</Citation><ArticleIdList><ArticleId IdType="pubmed">16103127</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabaton M., Piccini A. Int. J. Exp. Pathol. 2005;86:139&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2517412</ArticleId><ArticleId IdType="pubmed">15910548</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue F., Kuo Y., Roher A. E., Brachova L, Shen Y., Sue L., Beach T., Kurth J. H., Rydel R. E., Rogers J. Am. J. Pathol. 1999;155:853&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla F. M., Troncoso J. C., Strickland D. K., Kawas C. H., Jay G. J. Clin. Invest. 1997;100:310&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC508193</ArticleId><ArticleId IdType="pubmed">9218507</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundke-Iqbal I., Iqbal K., George L., Tung Y. C., Kim K. S., Wisniewski H. M. Proc. Natl. Acad. Sci. USA. 1989;86:2853&#x2013;2857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC287017</ArticleId><ArticleId IdType="pubmed">2649895</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson B. I., Forman M. S., Higuchi M., Golbe L. I., Graves C. L., Kotzbauer P. T., Trojanowski J. Q., Lee V. M. Science. 2003;300:636&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">12714745</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J., Chen F., vanDorpe J., Nitsch R. M. Science. 2001;293:1446&#x2013;1447.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16449385</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>103</Volume><Issue>6</Issue><PubDate><Year>2006</Year><Month>Feb</Month><Day>07</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Phospholipase D1 corrects impaired betaAPP trafficking and neurite outgrowth in familial Alzheimer's disease-linked presenilin-1 mutant neurons.</ArticleTitle><Pagination><StartPage>1936</StartPage><EndPage>1940</EndPage><MedlinePgn>1936-40</MedlinePgn></Pagination><Abstract><AbstractText>Presenilins (PS1/PS2) regulate proteolysis of beta-amyloid precursor protein (betaAPP) and affect its intracellular trafficking. Here, we demonstrate that a PS1-interacting protein, phospholipase D1 (PLD1), affects intracellular trafficking of betaAPP. Overexpression of PLD1 in PS1wt cells promotes generation of betaAPP-containing vesicles from the trans-Golgi network. Conversely, inhibition of PLD1 activity by 1-butanol decreases betaAPP trafficking in both wt and PS1-deficient cells. The subcellular localization of PLD1 is altered, and PLD enzymatic activity is reduced in cells expressing familial Alzheimer's disease (FAD) PS1 mutations compared with PS1wt cells. Overexpression of wt, but not catalytically inactive, PLD1 increases budding of betaAPP-containing vesicles from the trans-Golgi network in FAD mutant cells. Surface delivery of betaAPP is also increased by PLD1 in these cells. The impaired neurite outgrowth capacity in FAD mutant neurons was corrected by introducing PLD1 into these cells. The results indicate that PLD1 may represent a therapeutic target for rescuing compromised neuronal function in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Dongming</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, and Fisher Center for Research on Alzheimer Disease, The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Minghao</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Runsheng</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Netzer</LastName><ForeName>William J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Shields</LastName><ForeName>Dennis</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Hui</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Sisodia</LastName><ForeName>Sangram S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Foster</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Gorelick</LastName><ForeName>Fred S</ForeName><Initials>FS</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Huaxi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Greengard</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CA46677</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK021860</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG009464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS046673</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG09464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DK21860</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS046673</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG023431</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA046677</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5F32AG023431</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>01</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.4</RegistryNumber><NameOfSubstance UI="D010739">Phospholipase D</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.4</RegistryNumber><NameOfSubstance UI="C106801">phospholipase D1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002384" MajorTopicYN="N">Catalysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010739" MajorTopicYN="N">Phospholipase D</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest statement: No conflicts declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>8</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16449385</ArticleId><ArticleId IdType="pmc">PMC1413666</ArticleId><ArticleId IdType="doi">10.1073/pnas.0510710103</ArticleId><ArticleId IdType="pii">0510710103</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Greenfield J. P., Tsai J., Gouras G. K., Hai B., Thinakaran G., Checler F., Sisodia S. S., Greengard P., Xu H. Proc. Natl. Acad. Sci. USA. 1999;96:742&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15207</ArticleId><ArticleId IdType="pubmed">9892704</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenfield J. P., Gross R. S., Gouras G. K., Xu H. Front. Biosci. 2000;5:D72&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">10702374</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenfield J. P., Leung L. W., Cai D., Kaasik K., Gross R. S., Rodriguez-Boulan E., Greengard P., Xu H. J. Biol. Chem. 2002;277:12128&#x2013;12136.</Citation><ArticleIdList><ArticleId IdType="pubmed">11823458</ArticleId></ArticleIdList></Reference><Reference><Citation>Caporaso G. L., Takei K., Gandy S. E., Matteoli M., Mundigl O., Greengard P., De Camilli P. J. Neurosci. 1994;14:3122&#x2013;3138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577440</ArticleId><ArticleId IdType="pubmed">8182461</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordstedt C., Caporaso G. L., Thyberg J., Gandy S. E., Greengard P. J. Biol. Chem. 1993;268:608&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pubmed">8416966</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai D., Leem J. Y., Greenfield J. P., Wang P., Kim B. S., Wang R., Lopes K. O., Kim S. H., Zheng H., Greengard P., et al. J. Biol. Chem. 2003;278:3446&#x2013;3454.</Citation><ArticleIdList><ArticleId IdType="pubmed">12435726</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman J. E. Nature. 1994;372:55&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">7969419</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney D. A., Siddhanta A., Shields D. J. Biol. Chem. 2002;277:3030&#x2013;3039.</Citation><ArticleIdList><ArticleId IdType="pubmed">11704660</ArticleId></ArticleIdList></Reference><Reference><Citation>Exton J. H. FEBS Lett. 2002;531:58&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">12401203</ArticleId></ArticleIdList></Reference><Reference><Citation>Shields D., Arvan P. Curr. Opin. Cell Biol. 1999;11:489&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">10449333</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y. G., Siddhanta A., Austin C. D., Hammond S. M., Sung T. C., Frohman M. A., Morris A. J., Shields D. J. Cell Biol. 1997;138:495&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2141634</ArticleId><ArticleId IdType="pubmed">9245781</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y., Xu L., Foster D. A. Mol. Cell. Biol. 2001;21:595&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC86627</ArticleId><ArticleId IdType="pubmed">11134345</ArticleId></ArticleIdList></Reference><Reference><Citation>Humeau Y., Vitale N., Chasserot-Golaz S., Dupont J. L., Du G., Frohman M. A., Bader M. F., Poulain B. Proc. Natl. Acad. Sci. USA. 2001;98:15300&#x2013;15305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC65024</ArticleId><ArticleId IdType="pubmed">11752468</ArticleId></ArticleIdList></Reference><Reference><Citation>Cockcroft S. Cell. Mol. Life Sci. 2001;58:1674&#x2013;1687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11337288</ArticleId><ArticleId IdType="pubmed">11706993</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai D., Netzer W. J., Zhong M., Lin Y., Du G., Frohman M., Foster D. A., Sisodia S. S., Xu H., Gorelick F. S., et al. Proc. Natl. Acad. Sci. USA. 2006;103:1941&#x2013;1946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413665</ArticleId><ArticleId IdType="pubmed">16449386</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddhanta A., Backer J. M., Shields D. J. Biol. Chem. 2000;275:12023&#x2013;12031.</Citation><ArticleIdList><ArticleId IdType="pubmed">10766834</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung T. C., Roper R. L., Zhang Y., Rudge S. A., Temel R., Hammond S. M., Morris A. J., Moss B., Engebrecht J., Frohman M. A. EMBO J. 1997;16:4519&#x2013;4530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1170078</ArticleId><ArticleId IdType="pubmed">9303296</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollefsen S. E., Kornfeld R. J. Biol. Chem. 1983;258:5172&#x2013;5176.</Citation><ArticleIdList><ArticleId IdType="pubmed">6403544</ArticleId></ArticleIdList></Reference><Reference><Citation>Annaert W., De Strooper B. Annu. Rev. Cell Dev. Biol. 2002;18:25&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">12142279</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab M. E. Curr. Opin. Neurol. Neurosurg. 1993;6:549&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">8400467</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin T. F. Annu. Rev. Cell Dev. Biol. 1998;14:231&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">9891784</ArticleId></ArticleIdList></Reference><Reference><Citation>Powner D. J., Wakelam M. J. FEBS Lett. 2002;531:62&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">12401204</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H. L., Roch J. M., Sundsmo M., Otero D., Sisodia S., Thomas R., Saitoh T. J. Neurobiol. 1997;32:469&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">9110259</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe H., Yokozeki T., Yamazaki M., Miyazaki H., Sasaki T., Maehama T., Itoh K., Frohman M. A., Kanaho Y. J. Biol. Chem. 2004;279:37870&#x2013;37877.</Citation><ArticleIdList><ArticleId IdType="pubmed">15226317</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe H., Yamazaki M., Miyazaki H., Arikawa C., Itoh K., Sasaki T., Maehama T., Frohman M. A., Kanaho Y. J. Neurochem. 2004;89:142&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">15030398</ArticleId></ArticleIdList></Reference><Reference><Citation>McDermott M., Wakelam M. J., Morris A. J. Biochem. Cell Biol. 2004;82:225&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">15052340</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowburn R. F., O&#x2019;Neill C., Bonkale W. L., Ohm T. G., Fastbom J. Biochem. Soc. Symp. 2001;67:163&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">11447833</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H. C., Fellenz-Maloney M. P., Liscovitch M., Blusztajn J. K. Proc. Natl. Acad. Sci. USA. 1993;90:10086&#x2013;10090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47718</ArticleId><ArticleId IdType="pubmed">8234260</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanfer J. N., Hattori H., Orihel D. Ann. Neurol. 1986;20:265&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">3019230</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt D. R., Thinakaran G., Eckman C. B., Lee M. K., Davenport F., Ratovitsky T., Prada C. M., Kim G., Seekins S., Yager D., et al. Neuron. 1996;17:1005&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H., Shields D. J. Cell Biol. 1993;122:1169&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2119863</ArticleId><ArticleId IdType="pubmed">8104189</ArticleId></ArticleIdList></Reference><Reference><Citation>Berechid B. E., Thinakaran G., Wong P. C., Sisodia S. S., Nye J. S. Curr. Biol. 1999;9:1493&#x2013;1496.</Citation><ArticleIdList><ArticleId IdType="pubmed">10607593</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong P. C., Zheng H., Chen H., Becher M. W., Sirinathsinghji D. J., Trumbauer M. E., Chen H. Y., Price D. L., Van der Ploeg L. H., Sisodia S. S. Nature. 1997;387:288&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153393</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai D., Shen Y., De Bellard M., Tang S., Filbin M. T. Neuron. 1999;22:89&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">10027292</ArticleId></ArticleIdList></Reference><Reference><Citation>Leem J. Y., Vijayan S., Han P., Cai D., Machura M., Lopes K. O., Veselits M. L., Xu H., Thinakaran G. J. Biol. Chem. 2002;277:19236&#x2013;19240.</Citation><ArticleIdList><ArticleId IdType="pubmed">11943765</ArticleId></ArticleIdList></Reference><Reference><Citation>Freyberg Z., Sweeney D., Siddhanta A., Bourgoin S., Frohman M., Shields D. Mol. Biol. Cell. 2001;12:943&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC32278</ArticleId><ArticleId IdType="pubmed">11294898</ArticleId></ArticleIdList></Reference><Reference><Citation>Musch A., Xu H., Shields D., Rodriguez-Boulan E. J. Cell Biol. 1996;133:543&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120809</ArticleId><ArticleId IdType="pubmed">8636230</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H., Gouras G. K., Greenfield J. P., Vincent B., Naslund J., Mazzarelli L., Fried G., Jovanovic J. N., Seeger M., Relkin N., et al. Nat. Med. 1998;4:447&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">9546791</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16449386</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>103</Volume><Issue>6</Issue><PubDate><Year>2006</Year><Month>Feb</Month><Day>07</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Presenilin-1 uses phospholipase D1 as a negative regulator of beta-amyloid formation.</ArticleTitle><Pagination><StartPage>1941</StartPage><EndPage>1946</EndPage><MedlinePgn>1941-6</MedlinePgn></Pagination><Abstract><AbstractText>Presenilin (PS1/PS2) is a major component of gamma-secretase, the activity that mediates proteolysis of beta-amyloid precursor protein to generate beta-amyloid (Abeta). Here we demonstrate that PS1, through its loop region, binds to phospholipase D1 (PLD1), thereby recruiting it to the Golgi/trans-Golgi network. Overexpression of wild-type PLD1 reduces Abeta generation. Conversely, down-regulation of endogenous PLD1 by small hairpin RNA elevates Abeta production. The Abeta-lowering effect of PLD1 is independent of its ability to promote vesicular budding of beta-amyloid precursor protein. The data indicate that overexpression of PLD1 decreases, and down-regulation of PLD1 increases, the catalytic activity, and the association of the subunits, of gamma-secretase.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Dongming</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, and Fisher Center for Research on Alzheimer Disease, The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Netzer</LastName><ForeName>William J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Minghao</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yixin</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Guangwei</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Frohman</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Foster</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Sisodia</LastName><ForeName>Sangram S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Huaxi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Gorelick</LastName><ForeName>Fred S</ForeName><Initials>FS</Initials></Author><Author ValidYN="Y"><LastName>Greengard</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CA46677</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG009464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS046673</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG09464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS046673</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG023431</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA046677</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5F32AG023431</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>01</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.4</RegistryNumber><NameOfSubstance UI="D010739">Phospholipase D</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.4</RegistryNumber><NameOfSubstance UI="C106801">phospholipase D1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010739" MajorTopicYN="N">Phospholipase D</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="Y">Protein Processing, Post-Translational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021601" MajorTopicYN="N">trans-Golgi Network</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest statement: No conflicts declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>8</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16449386</ArticleId><ArticleId IdType="pmc">PMC1413665</ArticleId><ArticleId IdType="doi">10.1073/pnas.0510708103</ArticleId><ArticleId IdType="pii">0510708103</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Haass C., De Strooper B. Science. 1999;286:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10542139</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., Von Figura K., Van Leuven F. Nature. 1998;391:387&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt D. R., Thinakaran G., Eckman C. B., Lee M. K., Davenport F., Ratovitsky T., Prada C. M., Kim G., Seekins S., Yager D., et al. Neuron. 1996;17:1005&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T. D., Hardy J., Hutton M., Kukull W., et al. Nat. Med. 1996;2:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia S. S., St George-Hyslop P. H. Nat. Rev. Neurosci. 2002;3:281&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">11967558</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B., Annaert W., Cupers P., Saftig P., Craessaerts K., Mumm J. S., Schroeter E. H., Schrijvers V., Wolfe M. S., Ray W. J., et al. Nature. 1999;398:518&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206645</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis R., McGrath G., Zhang J., Ruddy D. A., Sym M., Apfeld J., Nicoll M., Maxwell M., Hai B., Ellis M. C., et al. Dev. Cell. 2002;3:85&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">12110170</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutte C., Tsunozaki M., Hale V. A., Priess J. R. Proc. Natl. Acad. Sci. USA. 2002;99:775&#x2013;779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC117381</ArticleId><ArticleId IdType="pubmed">11792846</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray W. J., Yao M., Mumm J., Schroeter E. H., Saftig P., Wolfe M., Selkoe D. J., Kopan R., Goate A. M. J. Biol. Chem. 1999;274:36801&#x2013;36807.</Citation><ArticleIdList><ArticleId IdType="pubmed">10593990</ArticleId></ArticleIdList></Reference><Reference><Citation>Struhl G., Greenwald I. Nature. 1999;398:522&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206646</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B., Konig G. Nature. 1999;402:471&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591201</ArticleId></ArticleIdList></Reference><Reference><Citation>Edbauer D., Winkler E., Regula J. T., Pesold B., Steiner H., Haass C. Nat. Cell Biol. 2003;5:486&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">12679784</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraering P. C., Ye W., Strub J. M., Dolios G., LaVoie M. J., Ostaszewski B. L., van Dorsselaer A., Wang R., Selkoe D. J., Wolfe M. S. Biochemistry. 2004;43:9774&#x2013;9789.</Citation><ArticleIdList><ArticleId IdType="pubmed">15274632</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenfield J. P., Leung L. W., Cai D., Kaasik K., Gross R. S., Rodriguez-Boulan E., Greengard P., Xu H. J. Biol. Chem. 2002;277:12128&#x2013;12136.</Citation><ArticleIdList><ArticleId IdType="pubmed">11823458</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H. C., Fellenz-Maloney M. P., Liscovitch M., Blusztajn J. K. Proc. Natl. Acad. Sci. USA. 1993;90:10086&#x2013;10090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47718</ArticleId><ArticleId IdType="pubmed">8234260</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanfer J. N., Hattori H., Orihel D. Ann. Neurol. 1986;20:265&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">3019230</ArticleId></ArticleIdList></Reference><Reference><Citation>Annaert W. G., Esselens C., Baert V., Boeve C., Snellings G., Cupers P., Craessaerts K., De Strooper B. Neuron. 2001;32:579&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">11719200</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai D., Leem J. Y., Greenfield J. P., Wang P., Kim B. S., Wang R., Lopes K. O., Kim S. H., Zheng H., Greengard P., et al. J. Biol. Chem. 2003;278:3446&#x2013;3454.</Citation><ArticleIdList><ArticleId IdType="pubmed">12435726</ArticleId></ArticleIdList></Reference><Reference><Citation>Leem J. Y., Saura C. A., Pietrzik C., Christianson J., Wanamaker C., King L. T., Veselits M. L., Tomita T., Gasparini L., Iwatsubo T., et al. Neurobiol. Dis. 2002;11:64&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">12460547</ArticleId></ArticleIdList></Reference><Reference><Citation>Naruse S., Thinakaran G., Luo J. J., Kusiak J. W., Tomita T., Iwatsubo T., Qian X., Ginty D. D., Price D. L., Borchelt D. R., et al. Neuron. 1998;21:1213&#x2013;1221.</Citation><ArticleIdList><ArticleId IdType="pubmed">9856475</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Luo W. J., Zhang Y. W., Li Y. M., Thinakaran G., Greengard P., Xu H. J. Biol. Chem. 2004;279:40560&#x2013;40566.</Citation><ArticleIdList><ArticleId IdType="pubmed">15247291</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai D., Zhong M., Wang R., Netzer W. J., Shields D., Zheng H., Sisodia S. S., Foster D. A., Gorelick F. S., Xu H., et al. Proc. Natl. Acad. Sci. USA. 2006;103:1936&#x2013;1940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413666</ArticleId><ArticleId IdType="pubmed">16449385</ArticleId></ArticleIdList></Reference><Reference><Citation>Geling A., Steiner H., Willem M., Bally-Cuif L., Haass C. EMBO Rep. 2002;3:688&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1084181</ArticleId><ArticleId IdType="pubmed">12101103</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimm M. O., Grimm H. S., Patzold A. J., Zinser E. G., Halonen R., Duering M., Tschape J. A., Strooper B. D., Muller U., Shen J., et al. Nat. Cell Biol. 2005;7:1118&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pubmed">16227967</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H., Shields D. J. Cell Biol. 1993;122:1169&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2119863</ArticleId><ArticleId IdType="pubmed">8104189</ArticleId></ArticleIdList></Reference><Reference><Citation>Berechid B. E., Thinakaran G., Wong P. C., Sisodia S. S., Nye J. S. Curr. Biol. 1999;9:1493&#x2013;1496.</Citation><ArticleIdList><ArticleId IdType="pubmed">10607593</ArticleId></ArticleIdList></Reference><Reference><Citation>Leem J. Y., Vijayan S., Han P., Cai D., Machura M., Lopes K. O., Veselits M. L., Xu H., Thinakaran G. J. Biol. Chem. 2002;277:19236&#x2013;19240.</Citation><ArticleIdList><ArticleId IdType="pubmed">11943765</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond S. M., Altshuller Y. M., Sung T. C., Rudge S. A., Rose K., Engebrecht J., Morris A. J., Frohman M. A. J. Biol. Chem. 1995;270:29640&#x2013;29643.</Citation><ArticleIdList><ArticleId IdType="pubmed">8530346</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung T. C., Roper R. L., Zhang Y., Rudge S. A., Temel R., Hammond S. M., Morris A. J., Moss B., Engebrecht J., Frohman M. A. EMBO J. 1997;16:4519&#x2013;4530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1170078</ArticleId><ArticleId IdType="pubmed">9303296</ArticleId></ArticleIdList></Reference><Reference><Citation>Du G., Huang P., Liang B. T., Frohman M. A. Mol. Biol. Cell. 2004;15:1024&#x2013;1030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC363061</ArticleId><ArticleId IdType="pubmed">14718562</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang P., Altshuller Y. M., Hou J. C., Pessin J. E., Frohman M. A. Mol. Biol. Cell. 2005;16:2614&#x2013;2623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1142410</ArticleId><ArticleId IdType="pubmed">15772157</ArticleId></ArticleIdList></Reference><Reference><Citation>Freyberg Z., Sweeney D., Siddhanta A., Bourgoin S., Frohman M., Shields D. Mol. Biol. Cell. 2001;12:943&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC32278</ArticleId><ArticleId IdType="pubmed">11294898</ArticleId></ArticleIdList></Reference><Reference><Citation>Musch A., Xu H., Shields D., Rodriguez-Boulan E. J. Cell Biol. 1996;133:543&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120809</ArticleId><ArticleId IdType="pubmed">8636230</ArticleId></ArticleIdList></Reference><Reference><Citation>Caporaso G. L., Takei K., Gandy S. E., Matteoli M., Mundigl O., Greengard P., De Camilli P. J. Neurosci. 1994;14:3122&#x2013;3138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577440</ArticleId><ArticleId IdType="pubmed">8182461</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H., Gouras G. K., Greenfield J. P., Vincent B., Naslund J., Mazzarelli L., Fried G., Jovanovic J. N., Seeger M., Relkin N. R., et al. Nat. Med. 1998;4:447&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">9546791</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopan R., Schroeter E. H., Weintraub H., Nye J. S. Proc. Natl. Acad. Sci. USA. 1996;93:1683&#x2013;1688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40002</ArticleId><ArticleId IdType="pubmed">8643690</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16452662</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>5</Issue><PubDate><Year>2006</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Alzheimer precursor protein interaction with the Nogo-66 receptor reduces amyloid-beta plaque deposition.</ArticleTitle><Pagination><StartPage>1386</StartPage><EndPage>1395</EndPage><MedlinePgn>1386-95</MedlinePgn></Pagination><Abstract><AbstractText>Pathophysiologic hypotheses for Alzheimer's disease (AD) are centered on the role of the amyloid plaque Abeta peptide and the mechanism of its derivation from the amyloid precursor protein (APP). As part of the disease process, an aberrant axonal sprouting response is known to occur near Abeta deposits. A Nogo to Nogo-66 receptor (NgR) pathway contributes to determining the ability of adult CNS axons to extend after traumatic injuries. Here, we consider the potential role of NgR mechanisms in AD. Both Nogo and NgR are mislocalized in AD brain samples. APP physically associates with the NgR. Overexpression of NgR decreases Abeta production in neuroblastoma culture, and targeted disruption of NgR expression increases transgenic mouse brain Abeta levels, Abeta plaque deposition, and dystrophic neurites. Infusion of a soluble NgR fragment reduces Abeta levels, amyloid plaque deposits, and dystrophic neurites in a mouse transgenic AD model. Changes in NgR level produce parallel changes in secreted APPalpha and Abeta, implicating NgR as a blocker of secretase processing of APP. The NgR provides a novel site for modifying the course of AD and highlights the role of axonal dysfunction in the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>James H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale University School of Medicine, New Haven, Connecticut 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gimbel</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>GrandPre</LastName><ForeName>Tadzia</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jung-Kil</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ji-Eun</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Weiwei</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Daniel H S</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Strittmatter</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS039962</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS042304</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS056485</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS033020</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058851">GPI-Linked Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009185">Myelin Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000070798">Nogo Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000070816">Nogo Receptor 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000603199">RTN4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C486580">RTN4R protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000603201">Rtn4 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000603197">Rtn4 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C419790">Rtn4r protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058851" MajorTopicYN="N">GPI-Linked Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009185" MajorTopicYN="N">Myelin Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000070798" MajorTopicYN="N">Nogo Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070816" MajorTopicYN="N">Nogo Receptor 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16452662</ArticleId><ArticleId IdType="mid">NIHMS162900</ArticleId><ArticleId IdType="pmc">PMC2846286</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3291-05.2006</ArticleId><ArticleId IdType="pii">26/5/1386</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS (1997). Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19:939&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354339</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen MS, Huber AB, van der Haar ME, Frank M, Schnell L, Spillmann AA, Christ F, Schwab ME (2000). Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature 403:434&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">10667796</ArticleId></ArticleIdList></Reference><Reference><Citation>Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD (2001). &#x3b2;-Amyloid activates the mitogen-activated protein kinase cascade via hippocampal &#x3b1;7 nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer&#x2019;s disease. J Neurosci 21:4125&#x2013;4133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762764</ArticleId><ArticleId IdType="pubmed">11404397</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehehalt R, Keller P, Haass C, Thiele C, Simons K (2003). Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 160:113&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172747</ArticleId><ArticleId IdType="pubmed">12515826</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier AE, GrandPre T, Strittmatter SM (2001). Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature 409:341&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pubmed">11201742</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier AE, Gould GC, Liu BP, Strittmatter SM (2002). Truncated soluble Nogo receptor binds Nogo-66 and blocks inhibition of axon growth by myelin. J Neurosci 22:8876&#x2013;8883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757674</ArticleId><ArticleId IdType="pubmed">12388594</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentleman SM, Nash MJ, Sweeting CJ, Graham DI, Roberts GW (1993). Beta-amyloid precursor protein (beta APP) as a marker for axonal injury after head injury. Neurosci Lett 160:139&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">8247344</ArticleId></ArticleIdList></Reference><Reference><Citation>GrandPre T, Nakamura F, Vartanian T, Strittmatter SM (2000). Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature 403:439&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">10667797</ArticleId></ArticleIdList></Reference><Reference><Citation>GrandPre T, Li S, Strittmatter SM (2002). Nogo-66 receptor antagonist peptide promotes axonal regeneration. Nature 417:547&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">12037567</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ (2002). The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science 297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>He W, Lu Y, Qahwash I, Hu XY, Chang A, Yan R (2004). Reticulon family members modulate BACE1 activity and amyloid-beta peptide generation. Nat Med 10:959&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pubmed">15286784</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Xu G, Fromholt D, Gonzales V, Borchelt DR (2003). Environmental enrichment exacerbates amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Neuropathol Exp Neurol 62:1220&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pubmed">14692698</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, Goldstein LS (2001). Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature 414:643&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">11740561</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R (2003). APP processing and synaptic function. Neuron 37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JE, Li S, GrandPre T, Qiu D, Strittmatter SM (2003). Axon regeneration in young adult mice lacking Nogo-A/B. Neuron 38:187&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">12718854</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JE, Liu BP, Park JH, Strittmatter SM (2004). Nogo-66 receptor prevents raphespinal and rubrospinal axon regeneration and limits functional recovery from spinal cord injury. Neuron 44:439&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">15504325</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL (2002). Abeta toxicity in Alzheimer&#x2019;s disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 41:345&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">12176077</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuner P, Schubenel R, Hertel C (1998). Beta-amyloid binds to p57NTR and activates NFkappaB in human neuroblastoma cells. J Neurosci Res 54:798&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pubmed">9856863</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Lee M, Peterson DA, Sisodia SS (2002). Evidence that synaptically released &#x3b2;-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci 22:9785&#x2013;9793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757836</ArticleId><ArticleId IdType="pubmed">12427834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JK, Kim JE, Sivula M, Strittmatter SM (2004). Nogo receptor antagonism promotes stroke recovery by enhancing axonal plasticity. J Neurosci 24:6209&#x2013;6217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729662</ArticleId><ArticleId IdType="pubmed">15240813</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Strittmatter SM (2003). Delayed systemic Nogo-66 receptor antagonist promotes recovery from spinal cord injury. J Neurosci 23:4219&#x2013;4227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741116</ArticleId><ArticleId IdType="pubmed">12764110</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Liu BP, Budel S, Li M, Ji B, Walus L, Li W, Jirik A, Rabacchi S, Choi E, Worley D, Sah DW, Pepinsky B, Lee D, Relton J, Strittmatter SM (2004). Blockade of nogo-66, myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein by soluble nogo-66 receptor promotes axonal sprouting and recovery after spinal injury. J Neurosci 24:10511&#x2013;10520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730300</ArticleId><ArticleId IdType="pubmed">15548666</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardo JA, Stern EA, McLellan ME, Kajdasz ST, Hickey GA, Bacskai BJ, Hyman BT (2003). Amyloid-&#x3b2; antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci 23:10879&#x2013;10883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740984</ArticleId><ArticleId IdType="pubmed">14645482</ArticleId></ArticleIdList></Reference><Reference><Citation>McGee AW, Strittmatter SM (2003). The Nogo-66 receptor: focusing myelin inhibition of axon regeneration. Trends Neurosci 26:193&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">12689770</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagele RG, D&#x2019;Andrea MR, Anderson WJ, Wang HY (2002). Intracellular accumulation of beta-amyloid(1&#x2013;42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer&#x2019;s disease. Neuroscience 110:199&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">11958863</ArticleId></ArticleIdList></Reference><Reference><Citation>Otsuka N, Tomonaga M, Ikeda K (1991). Rapid appearance of beta-amyloid precursor protein immunoreactivity in damaged axons and reactive glial cells in rat brain following needle stab injury. Brain Res 568:335&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">1814579</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinjha R, Moore SE, Vinson M, Blake S, Morrow R, Christie G, Michalovich D, Simmons DL, Walsh FS (2000). Inhibitor of neurite outgrowth in humans. Nature 403:383&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">10667780</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott JN, Parhad IM, Clark AW (1991). Beta-amyloid precursor protein gene is differentially expressed in axotomized sensory and motor systems. Brain Res Mol Brain Res 10:315&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">1656158</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Schenk D (2003). Alzheimer&#x2019;s disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43:545&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415125</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Price DL, Koliatsos VE (2002). Disruption of corticocortical connections ameliorates amyloid burden in terminal fields in a transgenic model of A&#x3b2; amyloidosis. J Neurosci 22:9794&#x2013;9799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757847</ArticleId><ArticleId IdType="pubmed">12427835</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Teplow DB, Siman R, Greenberg B, Sisodia SS (1996). Metabolism of the &#x201c;Swedish&#x201d; amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the &#x201c;beta-secretase&#x201d; site occurs in the golgi apparatus. J Biol Chem 271:9390&#x2013;9397.</Citation><ArticleIdList><ArticleId IdType="pubmed">8621605</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ (2002a). Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans 30:552&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">12196135</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002b). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HY, Lee DH, D&#x2019;Andrea MR, Peterson PA, Shank RP, Reitz AB (2000). beta-Amyloid(1&#x2013;42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer&#x2019;s disease pathology. J Biol Chem 275:5626&#x2013;5632.</Citation><ArticleIdList><ArticleId IdType="pubmed">10681545</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Chun SJ, Treloar H, Vartanian T, Greer CA, Strittmatter SM (2002). Localization of Nogo-A and Nogo-66 receptor proteins at sites of axon-myelin and synaptic contact. J Neurosci 22:5505&#x2013;5515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758202</ArticleId><ArticleId IdType="pubmed">12097502</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Hyder F, Shulman RG (1996). Activation of single whisker barrel in rat brain localized by functional magnetic resonance imaging. Proc Natl Acad Sci USA 93:475&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40261</ArticleId><ArticleId IdType="pubmed">8552664</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16461276</PMID><DateCompleted><Year>2006</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0960-9822</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Feb</Month><Day>07</Day></PubDate></JournalIssue><Title>Current biology : CB</Title><ISOAbbreviation>Curr Biol</ISOAbbreviation></Journal><ArticleTitle>TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model.</ArticleTitle><Pagination><StartPage>230</StartPage><EndPage>241</EndPage><MedlinePgn>230-41</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous studies have demonstrated reexpression of cell-cycle markers within postmitotic neurons in neurodegenerative tauopathies, including Alzheimer's disease (AD). However, the critical questions of whether cell-cycle activation is causal or epiphenomenal to tau-induced neurodegeneration and which signaling pathways mediate cell-cycle activation in tauopathy remain unresolved.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Cell-cycle activation accompanies wild-type and mutant tau-induced neurodegeneration in Drosophila, and genetically interfering with cell-cycle progression substantially reduces neurodegeneration. Our data support a role for cell-cycle activation downstream of tau phosphorylation, directly preceding apoptosis. We accordingly show that ectopic cell-cycle activation leads to apoptosis of postmitotic neurons in vivo. As in AD, TOR (target of rapamycin kinase) activity is increased in our model and is required for neurodegeneration. TOR activation enhances tau-induced neurodegeneration in a cell cycle-dependent manner and, when ectopically activated, drives cell-cycle activation and apoptosis in postmitotic neurons.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model, identifying TOR and the cell cycle as potential therapeutic targets in tauopathies and AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khurana</LastName><ForeName>Vikram</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Harvard New Research Building Room 652, 77 Louis Pasteur Avenue, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yiran</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Steinhilb</LastName><ForeName>Michelle L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Oldham</LastName><ForeName>Sean</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Shulman</LastName><ForeName>Joshua M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Feany</LastName><ForeName>Mel B</ForeName><Initials>MB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG19790</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG88001</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Biol</MedlineTA><NlmUniqueID>9107782</NlmUniqueID><ISSNLinking>0960-9822</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="C416303">target of rapamycin protein, Drosophila</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029721" MajorTopicYN="N">Drosophila Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020287" MajorTopicYN="N">In Situ Nick-End Labeling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16461276</ArticleId><ArticleId IdType="doi">10.1016/j.cub.2005.12.042</ArticleId><ArticleId IdType="pii">S0960-9822(06)01025-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16461855</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Perspectives on depression, mild cognitive impairment, and cognitive decline.</ArticleTitle><Pagination><StartPage>130</StartPage><EndPage>138</EndPage><MedlinePgn>130-8</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">The public health implications of depression and cognitive impairment in late life are enormous. Cognitive impairment and late-life depression are associated with increased risk for subsequent dementia; however, investigations of these phenomena appear to be proceeding along separate tracks. OBJECTIVES AND DATA SOURCE: The National Institute of Mental Health organized the conference "Perspectives on Depression, Mild Cognitive Impairment, and Cognitive Decline" to consider how the varied perspectives might be better integrated to examine the associations among depression, mild cognitive impairment, and cognitive decline and to illuminate the common or distinct mechanisms involved in these associations.</AbstractText><AbstractText Label="DATA SYNTHESIS" NlmCategory="RESULTS">The following 2 broad questions were addressed: (1) What gaps in our knowledge have the greatest public health significance? (2) Can we more efficiently use our research dollars and participant resources to fill these gaps? Meeting participants included grantees from the National Institute of Mental Health and the National Institute on Aging and program staff from the National Institute of Mental Health, the National Institute on Aging, and the National Institute of Neurological Disorders and Stroke.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">One of the most important recommendations to emerge from the meeting discussions is for increased collaboration among clinical and epidemiological investigators whose work focuses in the area of depression with those working primarily in the area of memory disorders. Directions for future research were identified.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Steffens</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otey</LastName><ForeName>Emeline</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Alexopoulos</LastName><ForeName>George S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Butters</LastName><ForeName>Meryl A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Cuthbert</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Ganguli</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Geda</LastName><ForeName>Yonas E</ForeName><Initials>YE</Initials></Author><Author ValidYN="Y"><LastName>Hendrie</LastName><ForeName>Hugh C</ForeName><Initials>HC</Initials></Author><Author ValidYN="Y"><LastName>Krishnan</LastName><ForeName>Ranga R</ForeName><Initials>RR</Initials></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Anand</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Mast</LastName><ForeName>Benjamin T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Norton</LastName><ForeName>Maria C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Peavy</LastName><ForeName>Guerry M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Charles F</ForeName><Initials>CF</Initials></Author><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Welsh-Bohmer</LastName><ForeName>Kathleen A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Yesavage</LastName><ForeName>Jerome</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG06786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG07562</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG09956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG11380</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG12713</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG16574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG16705</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG20098</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG21136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH01487</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH01684</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH35182</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH43832</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH52247</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH54846</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH60451</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH61567</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH63764</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH63782</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH65653</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH68351</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH68638</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH70027</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR15578</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016423">Congress</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003299" MajorTopicYN="N">Cooperative Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007373" MajorTopicYN="N">Interinstitutional Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009315" MajorTopicYN="N">National Institute of Mental Health (U.S.)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009316" MajorTopicYN="N">National Institutes of Health (U.S.)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012109" MajorTopicYN="N">Research Support as Topic</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009626" MajorTopicYN="N">Terminology as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16461855</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.63.2.130</ArticleId><ArticleId IdType="pii">63/2/130</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16461857</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Depressive symptoms and cognitive decline in late life: a prospective epidemiological study.</ArticleTitle><Pagination><StartPage>153</StartPage><EndPage>160</EndPage><MedlinePgn>153-60</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Depression is associated with cognitive impairment and dementia. It is less clear whether depression contributes to further cognitive decline over time, independently of incipient dementia.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the relationship between depressive symptoms and subsequent cognitive decline in a cohort of nondemented older adults, some of whom remained dementia free during follow-up and others in whom incident dementia eventually developed.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Twelve-year prospective epidemiological study, including biennial measurement of cognition and depressive symptoms, biennial assessment of dementia, and comparison of cognitive function at baseline and over time in persons with and without baseline depressive symptoms in the dementia-free and eventual-dementia groups, using random-effects models.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">A largely blue-collar rural community.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Population-based sample of 1265 adults 67 years and older without dementia at baseline.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Scores over time on each of several cognitive test composites.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 1094 participants who remained dementia free, those with baseline depressive symptoms had significantly lower baseline scores on all cognitive composites than the nondepressed participants. Among the 171 individuals in whom dementia later developed, depression was associated with worse performance in some but not all baseline cognitive composites. Cognitive decline over time was minimal in the dementia-free group, whereas marked decline was seen in the eventual-dementia group. Depressive symptoms were not associated with rate of cognitive decline over time in either group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Depressive symptoms are cross-sectionally associated with cognitive impairment but not subsequent cognitive decline. Substantial cognitive decline over time cannot be explained by depression and most likely reflects incipient dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ganguli</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Geriatrics and Neuropsychiatry, Department of Psychiatry, University of Pittsburgh School of Medicine, PA, USA. gangulim@upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Yangchun</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Dodge</LastName><ForeName>Hiroko H</ForeName><Initials>HH</Initials></Author><Author ValidYN="Y"><LastName>Ratcliff</LastName><ForeName>Graham G</ForeName><Initials>GG</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Chung-Chou H</ForeName><Initials>CC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG023014</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG022035</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG07562</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012424" MajorTopicYN="N">Rural Population</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012494" MajorTopicYN="N">Sampling Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16461857</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.63.2.153</ArticleId><ArticleId IdType="pii">63/2/153</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16461859</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression.</ArticleTitle><Pagination><StartPage>161</StartPage><EndPage>167</EndPage><MedlinePgn>161-7</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">The hallmark pathological changes in Alzheimer disease (AD) are abundant plaque and tangle formation, especially in the temporal lobes and hippocampus. Although there is increasing evidence that major depression may interact with neuropathological processes in AD, there have been no studies of neuropathological changes in AD as a function of history of major depression.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To test the hypothesis that neuritic plaques and neurofibrillary tangles are more pronounced in the hippocampus of patients with AD with a lifetime history of major depressive disorder, as compared with patients with AD without depression history.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Postmortem study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Nursing home.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">The brains of 52 patients with AD without a lifetime history of major depression were compared with the brains of 50 patients with AD with a lifetime history of major depression.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Neuropathological ratings from the Consortium to Establish a Registry in Alzheimer Disease battery.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Brains of patients with AD with a lifetime history of depression showed higher levels of both plaque (P&lt;.005) and tangle (P&lt;.002) formation within the hippocampus than brains of patients with AD without a history of depression. Post hoc analyses showed that patients with AD who had a history of depression exhibited more rapid cognitive decline than patients without a history of depression (P&lt;.004). Furthermore, within the group of patients with AD with a history of depression, patients who exhibited concurrent depression at the time of first diagnosis of AD exhibited more pronounced neuropathological changes in the hippocampus (P&lt;.006).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In AD, the presence of a lifetime history of depression corresponds to increases in AD-related neuropathological changes within the hippocampus. These changes go along with more rapid cognitive decline in patients with AD with a history of depression, and are more pronounced in patients with AD suffering from depression early on in the disease process, suggesting an interaction between major depression and AD neuropathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rapp</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA. michael.rapp@mssm.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schnaider-Beeri</LastName><ForeName>Michal</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Grossman</LastName><ForeName>Hillel T</ForeName><Initials>HT</Initials></Author><Author ValidYN="Y"><LastName>Sano</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Perl</LastName><ForeName>Daniel P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Purohit</LastName><ForeName>Dushyant P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Gorman</LastName><ForeName>Jack M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Haroutunian</LastName><ForeName>Vahram</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01-AG02219</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG05138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16461859</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.63.2.161</ArticleId><ArticleId IdType="pii">63/2/161</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16461860</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Role of genes and environments for explaining Alzheimer disease.</ArticleTitle><Pagination><StartPage>168</StartPage><EndPage>174</EndPage><MedlinePgn>168-74</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Twin studies using selected samples have shown high heritability for Alzheimer disease (AD).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate genetic and environmental influences on AD in a fully ascertained population of older twins, including like- and unlike-sex pairs.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Five-group quantitative genetic model: male monozygotic twins, female monozygotic twins, male dizygotic twins, female dizygotic twins, and unlike-sex twins.</AbstractText><AbstractText Label="SETTING AND PARTICIPANTS" NlmCategory="METHODS">All twins in the Swedish Twin Registry aged 65 years and older. The study included 11,884 twin pairs, among whom were 392 pairs in which 1 or both members had AD.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">All individuals were screened for cognitive dysfunction. Suspected cases of dementia and their co-twins received complete clinical diagnostic evaluations for AD. Estimates of heritability, shared environmental influences, and nonshared environmental influences, adjusting for age, were derived from the twin data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Heritability for AD was estimated to be 58% in the full model and 79% in the best-fitting model, with the balance of variation explained by nonshared environmental influences. There were no significant differences between men and women in prevalence or heritability after controlling for age. Within pairs concordant for AD, intrapair difference in age at onset was significantly greater in dizygotic than in monozygotic pairs, suggesting genetic influences on timing of the disease.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In the largest twin study to date, we confirmed that heritability for AD is high and that the same genetic factors are influential for both men and women. However, nongenetic risk factors also play an important role and might be the focus for interventions to reduce disease risk or delay disease onset.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gatz</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Southern California, Los Angeles 90089-1061, USA. gatz@usc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Chandra A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Fratiglioni</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Johansson</LastName><ForeName>Boo</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Mortimer</LastName><ForeName>James A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Berg</LastName><ForeName>Stig</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Fiske</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Pedersen</LastName><ForeName>Nancy L</ForeName><Initials>NL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01-AG08724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D018486">Twin Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004200" MajorTopicYN="N">Diseases in Twins</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008957" MajorTopicYN="N">Models, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012931" MajorTopicYN="Y">Social Environment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014429" MajorTopicYN="N">Twins, Dizygotic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014430" MajorTopicYN="N">Twins, Monozygotic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.63.2.168</ArticleId><ArticleId IdType="pii">63/2/168</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16476660</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>49</Volume><Issue>4</Issue><PubDate><Year>2006</Year><Month>Feb</Month><Day>16</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>489</StartPage><EndPage>502</EndPage><MedlinePgn>489-502</MedlinePgn></Pagination><Abstract><AbstractText>Microglia are the immune cells of the brain. Here we show a massive infiltration of highly ramified and elongated microglia within the core of amyloid plaques in transgenic mouse models of Alzheimer's disease (AD). Many of these cells originate from the bone marrow, and the beta-amyloid-40 and -42 isoforms are able to trigger this chemoattraction. These newly recruited cells also exhibit a specific immune reaction to both exogenous and endogenous beta-amyloid in the brain. Creation of a new AD transgenic mouse that expresses the thymidine kinase protein under the control of the CD11b promoter allowed us to show that blood-derived microglia and not their resident counterparts have the ability to eliminate amyloid deposits by a cell-specific phagocytic mechanism. These bone marrow-derived microglia are thus very efficient in restricting amyloid deposits. Therapeutic strategies aiming to improve their recruitment could potentially lead to a new powerful tool for the elimination of toxic senile plaques.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simard</LastName><ForeName>Alain R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Endocrinology, CHUL Research Center and Department of Anatomy and Physiology, Laval University, 2705 Laurier boul., Qu&#xe9;bec G1V 4G2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soulet</LastName><ForeName>Denis</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Gowing</LastName><ForeName>Genevieve</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Julien</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Rivest</LastName><ForeName>Serge</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C491049">Aif1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002135">Calcium-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052119">Lysosomal-Associated Membrane Protein 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497859">Mcp protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051916">Membrane Cofactor Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008840">Microfilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493486">Tlr2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051195">Toll-Like Receptor 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>47165-04-8</RegistryNumber><NameOfSubstance UI="C007293">DAPI</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001854" MajorTopicYN="N">Bone Marrow Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016026" MajorTopicYN="N">Bone Marrow Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002135" MajorTopicYN="N">Calcium-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021621" MajorTopicYN="N">Imaging, Three-Dimensional</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017403" MajorTopicYN="N">In Situ Hybridization</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007276" MajorTopicYN="N">Injections, Intraventricular</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052119" MajorTopicYN="N">Lysosomal-Associated Membrane Protein 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051916" MajorTopicYN="N">Membrane Cofactor Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008840" MajorTopicYN="N">Microfilament Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051195" MajorTopicYN="N">Toll-Like Receptor 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014916" MajorTopicYN="N">Whole-Body Irradiation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16476660</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2006.01.022</ArticleId><ArticleId IdType="pii">S0896-6273(06)00075-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16488378</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1474-4422</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.</ArticleTitle><Pagination><StartPage>228</StartPage><EndPage>234</EndPage><MedlinePgn>228-34</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Disease-modifying treatment strategies for Alzheimer's disease have led to an urgent need for biomarkers to identify the disease at a very early stage. Here, we assess the association between CSF biomarkers and incipient Alzheimer's in patients with mild cognitive impairment (MCI).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">From a series of 180 consecutive patients with MCI, we assessed 137 who underwent successful lumbar puncture at baseline. Patients at risk of developing dementia were followed clinically for 4-6 years. Additionally, 39 healthy individuals, cognitively stable over 3 years, served as controls. We analysed CSF concentrations of beta amyloid(1-42) (Abeta42), total tau (T-tau), and phosphorylated tau (P-tau181) using Luminex xMAP technology.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">During follow-up, 57 (42%) patients with MCI developed Alzheimer's disease, 21 (15%) developed other forms of dementia, and 56 (41%) remained cognitively stable for 5.2 years (range 4.0-6.8). A combination of CSF T-tau and Abeta42 at baseline yielded a sensitivity of 95% and a specificity of 83% for detection of incipient AD in patients with MCI. The relative risk of progression to Alzheimer's disease was substantially increased in patients with MCI who had pathological concentrations of T-tau and Abeta42 at baseline (hazard ratio 17.7, p&lt;0.0001). The association between pathological CSF and progression to Alzheimer's disease was much stronger than, and independent of, established risk factors including age, sex, education, APOE genotype, and plasma homocysteine. The combination of T-tau and Abeta42/P-tau181 ratio yielded closely similar results (sensitivity 95%, specificity 87%, hazard ratio 19.8).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Concentrations of T-tau, P-tau181, and Abeta42 in CSF are strongly associated with future development of Alzheimer's disease in patients with MCI.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Buchhave</LastName><ForeName>Peder</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Londos</LastName><ForeName>Elisabet</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Minthon</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Lancet Neurol. 2006 Apr;5(4):293</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2006 Mar;5(3):198-9. doi: 10.1016/S1474-4422(06)70357-X.</RefSource><PMID Version="1">16488371</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Clin Pract Neurol. 2006 Oct;2(10):530-1. doi: 10.1038/ncpneuro0295.</RefSource><PMID Version="1">16990823</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16488378</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(06)70355-6</ArticleId><ArticleId IdType="pii">S1474-4422(06)70355-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16504943</PMID><DateCompleted><Year>2006</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>49</Volume><Issue>5</Issue><PubDate><Year>2006</Year><Month>Mar</Month><Day>02</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>M1 receptors play a central role in modulating AD-like pathology in transgenic mice.</ArticleTitle><Pagination><StartPage>671</StartPage><EndPage>682</EndPage><MedlinePgn>671-82</MedlinePgn></Pagination><Abstract><AbstractText>We investigated the therapeutic efficacy of the selective M1 muscarinic agonist AF267B in the 3xTg-AD model of Alzheimer disease. AF267B administration rescued the cognitive deficits in a spatial task but not contextual fear conditioning. The effect of AF267B on cognition predicted the neuropathological outcome, as both the Abeta and tau pathologies were reduced in the hippocampus and cortex, but not in the amygdala. The mechanism underlying the effect on the Abeta pathology was caused by the selective activation of ADAM17, thereby shifting APP processing toward the nonamyloidogenic pathway, whereas the reduction in tau pathology is mediated by decreased GSK3beta activity. We further demonstrate that administration of dicyclomine, an M1 antagonist, exacerbates the Abeta and tau pathologies. In conclusion, AF267B represents a peripherally administered low molecular weight compound to attenuate the major hallmarks of AD and to reverse deficits in cognition. Therefore, selective M1 agonists may be efficacious for the treatment of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caccamo</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, Irvine, California 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oddo</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Billings</LastName><ForeName>Lauren M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Kim N</ForeName><Initials>KN</Initials></Author><Author ValidYN="Y"><LastName>Martinez-Coria</LastName><ForeName>Hilda</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Fisher</LastName><ForeName>Abraham</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>LaFerla</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG0212982</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497887">Bsg protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018727">Muscarinic Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C512806">NIN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C099035">Nin protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C085349">PHF-1 monoclonal antibody</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043643">Receptor, Muscarinic M1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013141">Spiro Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>136894-56-9</RegistryNumber><NameOfSubstance UI="D051926">Basigin</NameOfSubstance></Chemical><Chemical><RegistryNumber>4KV4X8IF6V</RegistryNumber><NameOfSubstance UI="D004025">Dicyclomine</NameOfSubstance></Chemical><Chemical><RegistryNumber>8D3PZX7G73</RegistryNumber><NameOfSubstance UI="C470586">(S)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro(4.5)decan-3-one</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.13</RegistryNumber><NameOfSubstance UI="D011493">Protein Kinase C</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.-</RegistryNumber><NameOfSubstance UI="D051722">ADAM Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D019204">GTP-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051722" MajorTopicYN="N">ADAM Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051926" MajorTopicYN="N">Basigin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003598" MajorTopicYN="N">Cytoskeletal Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004025" MajorTopicYN="N">Dicyclomine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004924" MajorTopicYN="N">Escape Reaction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019204" MajorTopicYN="N">GTP-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018727" MajorTopicYN="N">Muscarinic Antagonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011493" MajorTopicYN="N">Protein Kinase C</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043643" MajorTopicYN="N">Receptor, Muscarinic M1</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013037" MajorTopicYN="N">Spatial Behavior</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013141" MajorTopicYN="N">Spiro Compounds</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16504943</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2006.01.020</ArticleId><ArticleId IdType="pii">S0896-6273(06)00073-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16511867</PMID><DateCompleted><Year>2006</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0360-4012</ISSN><JournalIssue CitedMedium="Print"><Volume>83</Volume><Issue>7</Issue><PubDate><Year>2006</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of neuroscience research</Title><ISOAbbreviation>J Neurosci Res</ISOAbbreviation></Journal><ArticleTitle>Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1252</StartPage><EndPage>1261</EndPage><MedlinePgn>1252-61</MedlinePgn></Pagination><Abstract><AbstractText>Cerebrolysin is a peptide mixture with neurotrophic effects that might reduce the neurodegenerative pathology in Alzheimer's disease (AD). We have previously shown in an amyloid protein precursor (APP) transgenic (tg) mouse model of AD-like neuropathology that Cerebrolysin ameliorates behavioral deficits, is neuroprotective, and decreases amyloid burden; however, the mechanisms involved are not completely clear. Cerebrolysin might reduce amyloid deposition by regulating amyloid-beta (Abeta) degradation or by modulating APP expression, maturation, or processing. To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin and analyzed in the water maze, followed by RNA, immunoblot, and confocal microscopy analysis of full-length (FL) APP and its fragments, beta-secretase (BACE1), and Abeta-degrading enzymes [neprilysin (Nep) and insulin-degrading enzyme (IDE)]. Consistent with previous studies, Cerebrolysin ameliorated the performance deficits in the spatial learning portion of the water maze and reduced the synaptic pathology and amyloid burden in the brains of APP tg mice. These effects were associated with reduced levels of FL APP and APP C-terminal fragments, but levels of BACE1, Notch1, Nep, and IDE were unchanged. In contrast, levels of active cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3beta [GSK-3beta; but not stress-activated protein kinase-1 (SAPK1)], kinases that phosphorylate APP, were reduced. Furthermore, Cerebrolysin reduced the levels of phosphorylated APP and the accumulation of APP in the neuritic processes. Taken together, these results suggest that Cerebrolysin might reduce AD-like pathology in the APP tg mice by regulating APP maturation and transport to sites where Abeta protein is generated. This study clarifies the mechanisms through which Cerebrolysin might reduce Abeta production and deposition in AD and further supports the importance of this compound in the potential treatment of early AD.</AbstractText><CopyrightInformation>Copyright 2006 Wiley-Liss, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rockenstein</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California San Diego, School of Medicine, La Jolla, California 92093-0624, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torrance</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mante</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Adame</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Paulino</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>John B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Crews</LastName><ForeName>Leslie</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Moessler</LastName><ForeName>Herbert</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci Res</MedlineTA><NlmUniqueID>7600111</NlmUniqueID><ISSNLinking>0360-4012</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>37KZM6S21G</RegistryNumber><NameOfSubstance UI="C006952">cerebrolysin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051360">Cyclin-Dependent Kinase 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C000605507">Gsk3b protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.11</RegistryNumber><NameOfSubstance UI="D015260">Neprilysin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.56</RegistryNumber><NameOfSubstance UI="D007339">Insulysin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000596" MajorTopicYN="N">Amino Acids</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051360" MajorTopicYN="N">Cyclin-Dependent Kinase 5</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007339" MajorTopicYN="N">Insulysin</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015260" MajorTopicYN="N">Neprilysin</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>7</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16511867</ArticleId><ArticleId IdType="doi">10.1002/jnr.20818</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16531402</PMID><DateCompleted><Year>2006</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>281</Volume><Issue>21</Issue><PubDate><Year>2006</Year><Month>May</Month><Day>26</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>SorLA signaling by regulated intramembrane proteolysis.</ArticleTitle><Pagination><StartPage>14547</StartPage><EndPage>14553</EndPage><MedlinePgn>14547-53</MedlinePgn></Pagination><Abstract><AbstractText>The single-transmembrane receptor SorLA/LR11 contains binding domains typical for lipoprotein receptors and a VPS10 domain, which binds the neuropeptide head-activator. This undecapeptide enhances proliferation of neuronal precursor cells in a SorLA-dependent manner. Using specific inhibitors we found previously that head activator activates shedding of SorLA by the metalloprotease TACE close to the transmembrane domain releasing the large extra-cellular part of the receptor. Here we show that the remaining COOH-terminal membrane fragment of SorLA is processed by gamma-secretase. Inhibition of gamma-secretase by specific inhibitors or overexpression of dominant negative presenilin mutants and knock out of the presenilin genes led to accumulation of the SorLA membrane fragment and also of full-length SorLA in the membrane. In an in vitro assay we observed the gamma-secretase-dependent release of the two soluble cleavage products, the SorLA cytoplasmic domain and the SorLA beta-peptide. These processing steps are reminiscent of a novel signaling pathway that has been described for the notch receptor. Here, the notch cytoplasmic domain is released into the cytoplasm by the gamma-secretase and migrates to the nucleus where it acts as a transcriptional regulator. In parallel we found that a fusion protein of the released cytoplasmic tail of SorLA with EGFP located to the nucleus only if the nuclear localization signal of SorLA was intact. In a reporter gene assay the cytoplasmic domain of SorLA acted as a transcriptional activator indicating that SorLA might directly regulate transcription after activation by gamma-secretase.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>B&#xf6;hm</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University Medical Center Hamburg-Eppendorf, Center of Experimental Medicine, Department of Biochemistry and Molecular Biology II: Molecular Cell Biology, Martinistrasse 52, D-20246 Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seibel</LastName><ForeName>Nicole M</ForeName><Initials>NM</Initials></Author><Author ValidYN="Y"><LastName>Henkel</LastName><ForeName>Birgit</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>Harald</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hampe</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>03</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026502">LDL-Receptor Related Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019913">Nuclear Localization Signals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D021382">Protein Sorting Signals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011973">Receptors, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102582">SORL1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026502" MajorTopicYN="N">LDL-Receptor Related Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019913" MajorTopicYN="N">Nuclear Localization Signals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021382" MajorTopicYN="N">Protein Sorting Signals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011973" MajorTopicYN="N">Receptors, LDL</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16531402</ArticleId><ArticleId IdType="doi">10.1074/jbc.M601660200</ArticleId><ArticleId IdType="pii">S0021-9258(20)72395-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16552612</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0001-6322</ISSN><JournalIssue CitedMedium="Print"><Volume>111</Volume><Issue>4</Issue><PubDate><Year>2006</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies.</ArticleTitle><Pagination><StartPage>329</StartPage><EndPage>340</EndPage><MedlinePgn>329-40</MedlinePgn></Pagination><Abstract><AbstractText>The pathological distinctions between the various clinical and pathological manifestations of frontotemporal lobar degeneration (FTLD) remain unclear. Using monoclonal antibodies specific for 3- and 4-repeat isoforms of the microtubule associated protein, tau (3R- and 4R-tau), we have performed an immunohistochemical study of the tau pathology present in 14 cases of sporadic forms of FTLD, 12 cases with Pick bodies and two cases without and in 27 cases of familial FTLD associated with 12 different mutations in the tau gene (MAPT), five cases with Pick bodies and 22 cases without. In all 12 cases of sporadic FTLD where Pick bodies were present, these contained only 3R-tau isoforms. Clinically, ten of these cases had frontotemporal dementia and two had progressive apraxia. Only 3R-tau isoforms were present in Pick bodies in those patients with familial FTLD associated with L266V, Q336R, E342V, K369I or G389R MAPT mutations. Patients with familial FTLD associated with exon 10 N279K, N296H or +16 splice site mutations showed tau pathology characterised by neuronal neurofibrillary tangles (NFT) and glial cell tangles that contained only 4R-tau isoforms, as did the NFT in P301L MAPT mutation. With the R406W mutation, NFT contained both 3R- and 4R-tau isoforms. We also observed two patients with sporadic FTLD, but without Pick bodies, in whom the tau pathology comprised only of 4R-tau isoforms. We have therefore shown by immunohistochemistry that different specific tau isoform compositions underlie the various kinds of tau pathology present in sporadic and familial FTLD. The use of such tau isoform specific antibodies may refine pathological criteria underpinning FTLD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Silva</LastName><ForeName>Rohan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Reta Lila Weston Institute of Neurological Studies, University College London, Windeyer Building, 46 Cleveland St, W1T 4JF, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lashley</LastName><ForeName>Tammaryn</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Strand</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Shiarli</LastName><ForeName>Anna-Maria</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Jing</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Jinzhou</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bailey</LastName><ForeName>Kathryn L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Bigio</LastName><ForeName>Eileen H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Arima</LastName><ForeName>Kunimasa</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Iseki</LastName><ForeName>Eizo</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Murayama</LastName><ForeName>Shigeo</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kretzschmar</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Manuela</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lippa</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Halliday</LastName><ForeName>Glenda</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>MacKenzie</LastName><ForeName>James</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ravid</LastName><ForeName>Rivka</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Wszolek</LastName><ForeName>Zbigniew</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Iwatsubo</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Pickering-Brown</LastName><ForeName>Stuart M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Holton</LastName><ForeName>Janice</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lees</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Revesz</LastName><ForeName>Tamas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Mann</LastName><ForeName>David M A</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0400356</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0501560</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>03</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="Y">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16552612</ArticleId><ArticleId IdType="doi">10.1007/s00401-006-0048-x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16571759</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>13</Issue><PubDate><Year>2006</Year><Month>Mar</Month><Day>29</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy.</ArticleTitle><Pagination><StartPage>3514</StartPage><EndPage>3523</EndPage><MedlinePgn>3514-23</MedlinePgn></Pagination><Abstract><AbstractText>The microtubule binding protein tau is implicated in neurodegenerative tauopathies, including frontotemporal dementia (FTD) with Parkinsonism caused by diverse mutations in the tau gene. Hyperphosphorylation of tau is considered crucial in the age-related formation of neurofibrillary tangles (NFTs) correlating well with neurotoxicity and cognitive defects. Transgenic mice expressing FTD mutant tau-P301L recapitulate the human pathology with progressive neuronal impairment and accumulation of NFT. Here, we studied tau-P301L mice for parameters of learning and memory at a young age, before hyperphosphorylation and tauopathy were apparent. Unexpectedly, in young tau-P301L mice, increased long-term potentiation in the dentate gyrus was observed in parallel with improved cognitive performance in object recognition tests. Neither tau phosphorylation, neurogenesis, nor other morphological parameters that were analyzed could account for these cognitive changes. The data demonstrate that learning and memory processes in the hippocampus of young tau-P301L mice are not impaired and actually improved in the absence of marked phosphorylation of human tau. We conclude that protein tau plays an important beneficial role in normal neuronal processes of hippocampal memory, and conversely, that not tau mutations per se, but the ensuing hyperphosphorylation must be critical for cognitive decline in tauopathies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boekhoorn</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Swammerdam Institute for Life Sciences, Center for Neuroscience, University of Amsterdam, 1098 SM Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terwel</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Biemans</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Borghgraef</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Wiegert</LastName><ForeName>Olof</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Ramakers</LastName><ForeName>Ger J A</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><LastName>de Vos</LastName><ForeName>Koos</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Krugers</LastName><ForeName>Harm</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Tomiyama</LastName><ForeName>Takami</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Joels</LastName><ForeName>Marian</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>van Leuven</LastName><ForeName>Fred</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Lucassen</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>9</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16571759</ArticleId><ArticleId IdType="pmc">PMC6673867</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5425-05.2006</ArticleId><ArticleId IdType="pii">26/13/3514</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alfarez DN, Joels M, Krugers HJ (2003). Chronic unpredictable stress impairs long-term potentiation in rat hippocampal CA1 area and dentate gyrus in vitro. Eur J Neurosci 17:1928&#x2013;1934.</Citation><ArticleIdList><ArticleId IdType="pubmed">12752792</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C, Davies P (2000). PKA phosphorylation on tau: developmental studies in the mouse. Dev Neurosci 4:303&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">10965152</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P (2005). Cell-cycle reentry and cell death in transgenic mice expressing wild-type human tau isoforms. J Neurosci 25:5446&#x2013;5454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725006</ArticleId><ArticleId IdType="pubmed">15930395</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelo M, Plattner F, Irvine EE, Giese KP (2003). Improved reversal learning and altered fear conditioning in transgenic mice with regionally restricted p25 expression. Eur J Neurosci 18:423&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pubmed">12887424</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendash GW, Lewis J, Leighty RE, McGowan E, Cracchiolo JR, Hutton M, Garcia MF (2004). Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain. Brain Res 1012:29&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">15158158</ArticleId></ArticleIdList></Reference><Reference><Citation>Bast T, da Silva BM, Morris RG (2005). Distinct contributions of hippocampal NMDA and AMPA receptors to encoding and retrieval of one-trial place memory. J Neurosci 25:5845&#x2013;5856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724786</ArticleId><ArticleId IdType="pubmed">15976073</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronner IF, Ter Meulen BC, Azmani A, Severijnen LA, Willemsen R, Kamphorst W, Ravid R, Heutink P, van Swieten JC (2005). Hereditary Pick's disease with the G272V tau mutation shows predominant three-repeat tau pathology. Brain 128:2645&#x2013;2653.</Citation><ArticleIdList><ArticleId IdType="pubmed">16014652</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu&#xe9;e L, Bussiere T, Bu&#xe9;e-Scherrer V, Delacourte A, Hof PR (2000). Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33:95&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">10967355</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussey TJ, Muir JL, Aggleton JP (1999). Functionally dissociating aspects of event memory: the effects of combined perirhinal and postrhinal cortex lesions on object and place memory in the rat. J Neurosci 19:495&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782353</ArticleId><ArticleId IdType="pubmed">9870977</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YG (2005). Specific tau phosphorylation sites in hippocampus correlate with impairment of step-down inhibitory avoidance task in rats. Behav Brain Res 158:277&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">15698894</ArticleId></ArticleIdList></Reference><Reference><Citation>Couillard-Despres S, Winner B, Schaubeck S, Aigner R, Vroemen M, Weidner N, Bogdahn U, Winkler J, Kuhn HG, Aigner L (2005). Doublecortin expression levels in adult brain reflect neurogenesis. Eur J Neurosci 21:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">15654838</ArticleId></ArticleIdList></Reference><Reference><Citation>Crusio WE (2001). Genetic dissection of mouse exploratory behaviour. Behav Brain Res 125:127&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">11682103</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis S, Butcher SP, Morris RG (1992). The NMDA receptor antagonist d-2-amino-5-phosphonopentanoate (d-AP-5) impairs spatial learning and LTP in vivo at intracerebral concentrations comparable to those that block LTP in vitro J Neurosci 12:21&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575679</ArticleId><ArticleId IdType="pubmed">1345945</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson HN, Ferreira A, Eyster MV, Ghoshal N, Binder LI, Vitek MP (2001). Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci 114:1179&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">11228161</ArticleId></ArticleIdList></Reference><Reference><Citation>Decker MW, Curzon P, Brioni JD (1995). Influence of separate and combined septal and amygdala lesions on memory, acoustic startle, anxiety, and locomotor activity in rats. Neurobiol Learn Mem 64:156&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">7582824</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewachter I, Reverse D, Caluwaerts N, Ris L, Kuiperi C, Van Den Haute C, Spittaels K, Umans L, Serneels L, Thiry E, Moechars D, Mercken M, Godaux E, Van Leuven F (2002). Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice. J Neurosci 22:3445&#x2013;3453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758348</ArticleId><ArticleId IdType="pubmed">11978821</ArticleId></ArticleIdList></Reference><Reference><Citation>Duchrow M, Schmidt MH, Zingler M, Anemuller S, Bruch HP, Broll R (2001). Suppression of cell division by pKi-67 antisense-RNA and recombinant protein. Cell Physiol Biochem 11:331&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832658</ArticleId></ArticleIdList></Reference><Reference><Citation>Endl E, Gerdes J (2000). The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res 257:231&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">10837136</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H 4 (1984). Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710&#x2013;1715.</Citation><ArticleIdList><ArticleId IdType="pubmed">6206131</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R (2005). Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta 1739:240&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615642</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould E, Beylin A, Tanapat P, Reeves A, Shors TJ (1999). Learning enhances adult neurogenesis in the hippocampal formation. Nat Neurosci 2:260&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195219</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond RS, Tull LE, Stackman RW (2004). On the delay-dependent involvement of the hippocampus in object recognition memory. Neurobiol Learn Mem 82:26&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">15183168</ArticleId></ArticleIdList></Reference><Reference><Citation>Harley CW, Martin GM (1999). Open field motor patterns and object marking, but not object sniffing, are altered by ibotenate lesions of the hippocampus. Neurobiol Learn Mem 72:202&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">10536098</ArticleId></ArticleIdList></Reference><Reference><Citation>Heine VM, Maslam S, Joels M, Lucassen PJ (2004a). Prominent decline of newborn cell proliferation, differentiation, and apoptosis in the aging dentate gyrus, in absence of an age-related hypothalamus-pituitary-adrenal axis activation. Neurobiol Aging 25:361&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">15123342</ArticleId></ArticleIdList></Reference><Reference><Citation>Heine VM, Maslam S, Zareno J, Joels M, Lucassen PJ 1 (2004b). Suppressed proliferation and apoptotic changes in the rat dentate gyrus after acute and chronic stress are reversible. Eur J Neurosci 19:131&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">14750971</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, Miller BI, Geschwind DH, Bird TD, McKeel D, Goate A, Morris JC, Wilhelmsen KC, Schellenberg GD, Trojanowski JQ, Lee VM (1998). Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282:1914&#x2013;1917.</Citation><ArticleIdList><ArticleId IdType="pubmed">9836646</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda M, Shoji M, Kawarai T, Kawarabayashi T, Matsubara E, Murakami T, Sasaki A, Tomidokoro Y, Ikarashi Y, Kuribara H, Ishiguro K, Hasegawa M, Yen SH, Chishti MA, Harigaya Y, Abe K, Okamoto K, St George-Hyslop P, Westaway D (2005). Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice. Am J Pathol 166:521&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1602315</ArticleId><ArticleId IdType="pubmed">15681835</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingram EM, Spillantini MG (2002). Tau gene mutations: dissecting the pathogenesis of FTDP-17. Trends Mol Med 8:555&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pubmed">12470988</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K, Peel AL, Mao XO, Xie L, Cottrell BA, Henshall DC, Greenberg DA (2004). Increased hippocampal neurogenesis in Alzheimer's disease. Proc Natl Acad Sci USA 101:343&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314187</ArticleId><ArticleId IdType="pubmed">14660786</ArticleId></ArticleIdList></Reference><Reference><Citation>Kee N, Sivalingam S, Boonstra R, Wojtowicz JM (2002). The utility of Ki-67 and BrdU as proliferative markers of adult neurogenesis. J Neurosci Methods 115:97&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">11897369</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesner RP, Ravindranathan A, Jackson P, Giles R, Chiba AA (2001). A neural circuit analysis of visual recognition memory: role of perirhinal, medial, and lateral entorhinal cortex. Learn Mem 8:87&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC311369</ArticleId><ArticleId IdType="pubmed">11274254</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi K, Kidani T, Ujike H, Hayashi M, Ishihara T, Miyazu K, Kuroda S, Koshino Y (2003). Another phenotype of frontotemporal dementia and parkinsonism linked to chromosome-17 (FTDP-17) with a missense mutation of S305N closely resembling Pick's disease. J Neurol 250:990&#x2013;992.</Citation><ArticleIdList><ArticleId IdType="pubmed">12928922</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Kenyon TK, Trojanowski JQ (2005). Transgenic animal models of tauopathies. Biochim Biophys Acta 1739:251&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615643</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M (2000). Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25:402&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Malinow R, Malenka RC (2002). AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci 25:103&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">12052905</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller S, Yasuda M, Coats JK, Jones Y, Martone ME, Mayford M (2002). Disruption of dendritic translation of CaMKIIalpha impairs stabilization of synaptic plasticity and memory consolidation. Neuron 36:507&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">12408852</ArticleId></ArticleIdList></Reference><Reference><Citation>Mumby DG (2001). Perspectives on object-recognition memory following hippocampal damage: lessons from studies in rats. Behav Brain Res 127:159&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">11718890</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennanen L, Welzl H, D'Adamo P, Nitsch RM, Gotz J (2004). Accelerated extinction of conditioned taste aversion in P301L tau transgenic mice. Neurobiol Dis 15:500&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">15056457</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez M, Lim F, Arrasate M, Avila J (2000). The FTDP-17-linked mutation R406W abolishes the interaction of phosphorylated tau with microtubules. J Neurochem 74:2583&#x2013;2589.</Citation><ArticleIdList><ArticleId IdType="pubmed">10820221</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugh PL, Ahmed SF, Smith MI, Upton N, Hunter AJ (2004). A behavioral characterization of the FVB/N mouse strain. Behav Brain Res 155:283&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">15364488</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakers GJ, Winter J, Hoogland TM, Lequin MB, van Hulten P, van Pelt J, Pool CW (1998). Depolarization stimulates lamellipodia formation and axonal but not dendritic branching in cultured rat cerebral cortex neurons. Brain Res Dev Brain Res 108:205&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">9693797</ArticleId></ArticleIdList></Reference><Reference><Citation>Santa Cruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH (2005). Tau suppression in a neurodegenerative mouse model improves memory function. Science 309:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ (2005). Defining molecular targets to prevent Alzheimer disease. Arch Neurol 62:192&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">15710846</ArticleId></ArticleIdList></Reference><Reference><Citation>Setou M, Nakagawa T, Seog DH, Hirokawa N (2000). Kinesin superfamily motor protein KIF17 and mLin-10 in NMDA receptor-containing vesicle transport. Science 288:1796&#x2013;1802.</Citation><ArticleIdList><ArticleId IdType="pubmed">10846156</ArticleId></ArticleIdList></Reference><Reference><Citation>Setou M, Seog DH, Tanaka Y, Kanai Y, Takei Y, Kawagishi M, Hirokawa N (2002). Glutamate-receptor-interacting protein GRIP1 directly steers kinesin to dendrites. Nature 417:83&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">11986669</ArticleId></ArticleIdList></Reference><Reference><Citation>Shors TJ (2004). Memory traces of trace memories: neurogenesis, synaptogenesis and awareness. Trends Neurosci 27:250&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3363970</ArticleId><ArticleId IdType="pubmed">15111006</ArticleId></ArticleIdList></Reference><Reference><Citation>Shors TJ, Miesegaes G, Beylin A, Zhao M, Rydel T, Gould E (2001). Neurogenesis in the adult is involved in the formation of trace memories. Nature 410:372&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">11268214</ArticleId></ArticleIdList></Reference><Reference><Citation>Shors TJ, Townsend DA, Zhao M, Kozorovitskiy Y, Gould E (2002). Neurogenesis may relate to some but not all types of hippocampal-dependent learning. Hippocampus 12:578&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3289536</ArticleId><ArticleId IdType="pubmed">12440573</ArticleId></ArticleIdList></Reference><Reference><Citation>Spittaels K, Van den Haute C, Van Dorpe J, Bruynseels K, Vandezande K, Laenen I, Geerts H, Mercken M, Sciot R, Van Lommel A, Loos R, Van Leuven F (1999). Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol 155:2153&#x2013;2165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866931</ArticleId><ArticleId IdType="pubmed">10595944</ArticleId></ArticleIdList></Reference><Reference><Citation>Spittaels K, Van den Haute C, Van Dorpe J, Geerts H, Mercken M, Bruynseels K, Lasrado R, Vandezande K, Laenen I, Boon T, Van Lint J, Vandenheede J, Moechars D, Loos R, Van Leuven F (2000). Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J Biol Chem 275:41340&#x2013;41349.</Citation><ArticleIdList><ArticleId IdType="pubmed">11007782</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Wang X, Liu S, Wang Q, Wang J, Bennecib M, Gong CX, Sengupta A, Grundke-Iqbal I, Iqbal K (2005). Bilateral injection of isoproterenol into hippocampus induces Alzheimer-like hyperphosphorylation of tau and spatial memory deficit in rat. FEBS Lett 579:251&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">15620722</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei Y, Teng J, Harada A, Hirokawa N (2000). Defects in axonal elongation and neuronal migration in mice with disrupted tau and map1b genes. J Cell Biol 150:989&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2175245</ArticleId><ArticleId IdType="pubmed">10973990</ArticleId></ArticleIdList></Reference><Reference><Citation>Takuma H, Arawaka S, Mori H (2003). Isoforms changes of tau protein during development in various species. Brain Res Dev Brain Res 142:121&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">12711363</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanemura K, Murayama M, Akagi T, Hashikawa T, Tominaga T, Ichikawa M, Yamaguchi H, Takashima A (2002). Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau. J Neurosci 22:133&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757582</ArticleId><ArticleId IdType="pubmed">11756496</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatebayashi Y, Miyasaka T, Chui DH, Akagi T, Mishima K, Iwasaki K, Fujiwara M, Tanemura K, Murayama M, Ishiguro K, Planel E, Sato S, Hashikawa T, Takashima A (2002). Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc Natl Acad Sci USA 99:13896&#x2013;13901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC129794</ArticleId><ArticleId IdType="pubmed">12368474</ArticleId></ArticleIdList></Reference><Reference><Citation>Terwel D, Lasrado R, Snauwaert J, Vandeweert E, Van Haesendonck C, Borghgraef P, Van Leuven F (2005). Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, non-lethal axonopathy of Tau-4R/2N transgenic mice. J Biol Chem 280:3963&#x2013;3973.</Citation><ArticleIdList><ArticleId IdType="pubmed">15509565</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolnay M, Probst A (1999). Tau protein pathology in Alzheimer's disease and related disorders. Neuropathol Appl Neurobiol 25:171&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">10417659</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai LH, Lee MS, Cruz J (2004). Cdk5, a therapeutic target for Alzheimer's disease? Biochim Biophys Acta 1697:137&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">15023356</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, Christie BR, Sejnowski TJ, Gage FH (1999). Running enhances neurogenesis, learning, and long-term potentiation in mice. Proc Natl Acad Sci USA 96:13427&#x2013;13431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23964</ArticleId><ArticleId IdType="pubmed">10557337</ArticleId></ArticleIdList></Reference><Reference><Citation>van Swieten JC, Stevens M, Rosso SM, Rizzu P, Joosse M, de Koning I, Kamphorst W, Ravid R, Spillantini MG, Niermeijer MG, Heutink P (1999). Phenotypic variation in hereditary frontotemporal dementia with tau mutations. Ann Neurol 46:617&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pubmed">10514099</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Ferguson GD, Pineda VV, Cundiff PE, Storm DR (2004). Overexpression of type-1 adenylyl cyclase in mouse forebrain enhances recognition memory and LTP. Nat Neurosci 7:635&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">15133516</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuen EY, Jiang Q, Feng J, Yan Z (2005). Microtubule regulation of N-methyl-d-aspartate receptor channels in neurons. J Biol Chem 280:29420&#x2013;29427.</Citation><ArticleIdList><ArticleId IdType="pubmed">15975919</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Higuchi M, Yoshiyama Y, Ishihara T, Forman MS, Martinez D, Joyce S, Trojanowski JQ, Lee VM (2004). Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy. J Neurosci 24:4657&#x2013;4667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729383</ArticleId><ArticleId IdType="pubmed">15140937</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, Lee EB, Xie SX, Joyce S, Li C, Toleikis PM, Lee VM, Trojanowski JQ (2005). Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA 102:227&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC544048</ArticleId><ArticleId IdType="pubmed">15615853</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Ho L, Suh J, Qin W, Pyo H, Pompl P, Ksiezak-Reding H, Pasinetti GM (2003). A role of P301L tau mutant in anti-apoptotic gene expression, cell cycle and apoptosis. Mol Cell Neurosci 24:367&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">14572459</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16597739</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>14</Issue><PubDate><Year>2006</Year><Month>Apr</Month><Day>05</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Deletion of presenilin 1 hydrophilic loop sequence leads to impaired gamma-secretase activity and exacerbated amyloid pathology.</ArticleTitle><Pagination><StartPage>3845</StartPage><EndPage>3854</EndPage><MedlinePgn>3845-54</MedlinePgn></Pagination><Abstract><AbstractText>gamma-Secretase processing of the amyloid precursor protein (APP) generates Abeta40 and Abeta42, peptides that constitute the principal components of the beta-amyloid plaque pathology of Alzheimer's disease (AD). The gamma-secretase activity is executed by a high-molecular-weight complex of which presenilin 1 (PS1) is an essential component. PS1 is a multi-pass membrane protein, and the large hydrophilic loop domain between transmembrane domains 6 and 7 has been shown to interact with various proteins. To determine the physiological function of the loop domain, we created a strain of PS1 knock-in mice in which the exon 10, which encodes most of the hydrophilic loop sequence, was deleted from the endogenous PS1 gene. We report here that the homozygous exon 10-deleted mice are viable but exhibit drastically reduced gamma-secretase cleavage at the Abeta40, but not the Abeta42, site. Surprisingly, this reduction of Abeta40 is associated with exacerbated plaque pathology when expressed on APP transgenic background. Thus, the PS1 loop plays a regulatory role in gamma-secretase processing, and decreased Abeta40, not increased Abeta42 is likely the cause for the accelerated plaque deposition in these animals. Our finding supports a protective role of Abeta40 against amyloid pathology and raises the possibility that impaired gamma-secretase activity could be the basis for AD pathogenesis in general.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Huffington Center on Aging, Baylor College of Medicine, Houston, Texas 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarassishin</LastName><ForeName>Leonid</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Kallhoff</LastName><ForeName>Verena</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Peethumnongsin</LastName><ForeName>Erica</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Ling</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yue-Ming</ForeName><Initials>YM</Initials></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Hui</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG026660</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG20670</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG21141</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS40039</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016297" MajorTopicYN="N">Mutagenesis, Site-Directed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>4</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>4</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>10</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16597739</ArticleId><ArticleId IdType="pmc">PMC6674120</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5384-05.2006</ArticleId><ArticleId IdType="pii">26/14/3845</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Annaert W, De Strooper B (2002). A cell biological perspective on Alzheimer's disease. Annu Rev Cell Dev Biol 18:25&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">12142279</ArticleId></ArticleIdList></Reference><Reference><Citation>Baki L, Marambaud P, Efthimiopoulos S, Georgakopoulos A, Wen P, Cui W, Shioi J, Koo E, Ozawa M, Friedrich VL Jr, Robakis NK (2001). Presenilin-1 binds cytoplasmic epithelial cadherin, inhibits cadherin/p120 association, and regulates stability and function of the cadherin/catenin adhesion complex. Proc Natl Acad Sci USA 98:2381&#x2013;2386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30147</ArticleId><ArticleId IdType="pubmed">11226248</ArticleId></ArticleIdList></Reference><Reference><Citation>Berezovska O, Lleo A, Herl LD, Frosch MP, Stern EA, Bacskai BJ, Hyman BT (2005). Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein. J Neurosci 25:3009&#x2013;3017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725136</ArticleId><ArticleId IdType="pubmed">15772361</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown MS, Ye J, Rawson RB, Goldstein JL (2000). Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 100:391&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">10693756</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervantes S, Saura CA, Pomares E, Gonzalez-Duarte R, Marfany G (2004). Functional implications of the presenilin dimerization: reconstitution of gamma-secretase activity by assembly of a catalytic site at the dimer interface of two catalytically inactive presenilins. J Biol Chem 279:36519&#x2013;36529.</Citation><ArticleIdList><ArticleId IdType="pubmed">15220354</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen F, Gu Y, Hasegawa H, Ruan X, Arawaka S, Fraser P, Westaway D, Mount H, St George-Hyslop P (2002). Presenilin 1 mutations activate gamma 42-secretase but reciprocally inhibit epsilon-secretase cleavage of amyloid precursor protein (APP) and S3-cleavage of notch. J Biol Chem 277:36521&#x2013;36526.</Citation><ArticleIdList><ArticleId IdType="pubmed">12119298</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ, Goate A, Kopan R (1999). A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 398:518&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206645</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewachter I, Reverse D, Caluwaerts N, Ris L, Kuiperi C, Van den Haute C, Spittaels K, Umans L, Serneels L, Thiry E, Moechars D, Mercken M, Godaux E, Van Leuven F (2002). Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice. J Neurosci 22:3445&#x2013;3453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758348</ArticleId><ArticleId IdType="pubmed">11978821</ArticleId></ArticleIdList></Reference><Reference><Citation>Donoviel DB, Hadjantonakis AK, Ikeda M, Zheng H, Hyslop PS, Bernstein A (1999). Mice lacking both presenilin genes exhibit early embryonic patterning defects. Genes Dev 13:2801&#x2013;2810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC317124</ArticleId><ArticleId IdType="pubmed">10557208</ArticleId></ArticleIdList></Reference><Reference><Citation>Esler WP, Kimberly WT, Ostaszewski BL, Diehl TS, Moore CL, Tsai JY, Rahmati T, Xia W, Selkoe DJ, Wolfe MS (2000). Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat Cell Biol 2:428&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">10878808</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgakopoulos A, Marambaud P, Efthimiopoulos S, Shioi J, Cui W, Li HC, Schutte M, Gordon R, Holstein GR, Martinelli G, Mehta P, Friedrich VL Jr, Robakis NK (1999). Presenilin-1 forms complexes with the cadherin/catenin cell-cell adhesion system and is recruited to intercellular and synaptic contacts. Mol Cell 4:893&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pubmed">10635315</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y, Sanjo N, Chen F, Hasegawa H, Petit A, Ruan X, Li W, Shier C, Kawarai T, Schmitt-Ulms G, Westaway D, St. George-Hyslop P, Fraser PE (2004). The presenilin proteins are components of multiple membrane-bound complexes that have different biological activities. J Biol Chem 279:31329&#x2013;31336.</Citation><ArticleIdList><ArticleId IdType="pubmed">15123598</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta-Rossi N, Le Bail O, Gonen H, Brou C, Logeat F, Six E, Ciechanover A, Israel A (2001). Functional interaction between SEL-10, an F-box protein, and the nuclear form of activated Notch1 receptor. J Biol Chem 276:34371&#x2013;34378.</Citation><ArticleIdList><ArticleId IdType="pubmed">11425854</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, Serneels L, Umans L, Schrijvers V, Checler F, Vanderstichele H, Baekelandt V, Dressel R, Cupers P, Huylebroeck D, Zwijsen A, Van Leuven F, De Strooper B (1999). Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci USA 96:11872&#x2013;11877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18379</ArticleId><ArticleId IdType="pubmed">10518543</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996). Correlative memory deficits, A&#x3b2; elevation, and amyloid plaques in transgenic mice. Science 274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T (2004). The &#x3b3;-secretase complex: machinery for intramembrane proteolysis. Curr Opin Neurobiol 14:379&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">15194119</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994). Visualization of A&#x3b2;42(43) and A&#x3b2;40 in senile plaques with end- specific A&#x3b2; monoclonals: evidence that an initially deposited species is A&#x3b2;42(43). Neuron 13:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">8043280</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Gonzales V, Jenkins NA, Copeland NG, Borchelt DR (2004). APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1. Neurobiol Aging 25:885&#x2013;892.</Citation><ArticleIdList><ArticleId IdType="pubmed">15212842</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang DE, Soriano S, Frosch MP, Collins T, Naruse S, Sisodia SS, Leibowitz G, Levine F, Koo EH (1999). Presenilin 1 facilitates the constitutive turnover of &#x3b2;-catenin: differential activity of Alzheimer's disease-linked PS1 mutants in &#x3b2;-catenin-signaling pathway. J Neurosci 19:4229&#x2013;4237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782616</ArticleId><ArticleId IdType="pubmed">10341227</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang DE, Soriano S, Xia X, Eberhart CG, De Strooper B, Zheng H, Koo EH (2002). Presenilin couples the paired phosphorylation of &#x3b2;-catenin independent of axin: implications for &#x3b2;-catenin activation in tumorigenesis. Cell 110:751&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">12297048</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirschenbaum F, Hsu SC, Cordell B, McCarthy JV (2001). Substitution of a glycogen synthase kinase-3&#x3b2; phosphorylation site in presenilin 1 separates presenilin function from &#x3b2;-catenin signaling. J Biol Chem 276:7366&#x2013;7375.</Citation><ArticleIdList><ArticleId IdType="pubmed">11104755</ArticleId></ArticleIdList></Reference><Reference><Citation>Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, Harper JW, Elledge SJ (2001). Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 294:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">11533444</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopan R, Ilagan MX (2004). &#x3b3;-secretase: proteasome of the membrane? Nat Rev Mol Cell Biol 5:499&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">15173829</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulic L, Walter J, Multhaup G, Teplow DB, Baumeister R, Romig H, Capell A, Steiner H, Haass C (2000). Separation of presenilin function in amyloid &#x3b2;-peptide generation and endoproteolysis of Notch. Proc Natl Acad Sci USA 97:5913&#x2013;5918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18533</ArticleId><ArticleId IdType="pubmed">10811883</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YM, Lai MT, Xu M, Huang Q, DiMuzio-Mower J, Sardana MK, Shi XP, Yin KC, Shafer JA, Gardell SJ (2000a). Presenilin 1 is linked with &#x3b3;-secretase activity in the detergent solubilized state. Proc Natl Acad Sci USA 97:6138&#x2013;6143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18571</ArticleId><ArticleId IdType="pubmed">10801983</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YM, Xu M, Lai MT, Huang Q, Castro JL, DiMuzio-Mower J, Harrison T, Lellis C, Nadin A, Neduvelil JG, Register RB, Sardana MK, Shearman MS, Smith AL, Shi XP, Yin KC, Shafer JA, Gardell SJ (2000b). Photoactivated &#x3b3;-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405:689&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">10864326</ArticleId></ArticleIdList></Reference><Reference><Citation>Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S, Nagy V, Baki L, Wen P, Efthimiopoulos S, Shao Z, Wisniewski T, Robakis NK (2002). A presenilin-1/&#x3b3;-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J 21:1948&#x2013;1956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125968</ArticleId><ArticleId IdType="pubmed">11953314</ArticleId></ArticleIdList></Reference><Reference><Citation>Marambaud P, Wen PH, Dutt A, Shioi J, Takashima A, Siman R, Robakis NK (2003). A CBP binding transcriptional repressor produced by the PS1/&#x3f5;-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell 114:635&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678586</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T (2005). A&#x3b2;42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47:191&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1373682</ArticleId><ArticleId IdType="pubmed">16039562</ArticleId></ArticleIdList></Reference><Reference><Citation>Moehlmann T, Winkler E, Xia X, Edbauer D, Murrell J, Capell A, Kaether C, Zheng H, Ghetti B, Haass C, Steiner H (2002). Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on A&#x3b2;42 production. Proc Natl Acad Sci USA 99:8025&#x2013;8030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123014</ArticleId><ArticleId IdType="pubmed">12048239</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, Hui CC, Clevers H, Dotto GP, Radtke F (2003). Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 33:416&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12590261</ArticleId></ArticleIdList></Reference><Reference><Citation>Qyang Y, Chambers SM, Wang P, Xia X, Chen X, Goodell MA, Zheng H (2004). Myeloproliferative disease in mice with reduced presenilin gene dosage: effect of &#x3b3;-secretase blockage. Biochemistry 43:5352&#x2013;5359.</Citation><ArticleIdList><ArticleId IdType="pubmed">15122901</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Tomita T, Davenport F, Harris CL, Iwatsubo T, Thinakaran G (1999). Evidence that intramolecular associations between presenilin domains are obligatory for endoproteolytic processing. J Biol Chem 274:13818&#x2013;13823.</Citation><ArticleIdList><ArticleId IdType="pubmed">10318786</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Tomita T, Soriano S, Takahashi M, Leem JY, Honda T, Koo EH, Iwatsubo T, Thinakaran G (2000). The nonconserved hydrophilic loop domain of presenilin (PS) is not required for PS endoproteolysis or enhanced A&#x3b2;42 production mediated by familial early onset Alzheimer's disease-linked PS variants. J Biol Chem 275:17136&#x2013;17142.</Citation><ArticleIdList><ArticleId IdType="pubmed">10748144</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Chen G, Malkani S, Choi SY, Takahashi RH, Zhang D, Gouras GK, Kirkwood A, Morris RG, Shen J (2005). Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. J Neurosci 25:6755&#x2013;6764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725351</ArticleId><ArticleId IdType="pubmed">16033885</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeter EH, Ilagan MX, Brunkan AL, Hecimovic S, Li YM, Xu M, Lewis HD, Saxena MT, De Strooper B, Coonrod A, Tomita T, Iwatsubo T, Moore CL, Goate A, Wolfe MS, Shearman M, Kopan R (2003). A presenilin dimer at the core of the &#x3b3;-secretase enzyme: insights from parallel analysis of Notch 1 and APP proteolysis. Proc Natl Acad Sci USA 100:13075&#x2013;13080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240747</ArticleId><ArticleId IdType="pubmed">14566063</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah S, Lee SF, Tabuchi K, Hao YH, Yu C, LaPlant Q, Ball H, Dann CE III, Sudhof T, Yu G (2005). Nicastrin functions as a &#x3b3;-secretase-substrate receptor. Cell 122:435&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">16096062</ArticleId></ArticleIdList></Reference><Reference><Citation>Siman R, Reaume AG, Savage MJ, Trusko S, Lin YG, Scott RW, Flood DG (2000). Presenilin-1 P264L knock-in mutation: differential effects on A&#x3b2; production, amyloid deposition, and neuronal vulnerability. J Neurosci 20:8717&#x2013;8726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6773081</ArticleId><ArticleId IdType="pubmed">11102478</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W, Nadeau P, Yuan M, Yang X, Shen J, Yankner BA (1999). Proteolytic release and nuclear translocation of Notch-1 are induced by presenilin-1 and impaired by pathogenic presenilin-1 mutations. Proc Natl Acad Sci USA 96:6959&#x2013;6963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22024</ArticleId><ArticleId IdType="pubmed">10359821</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano S, Kang DE, Fu M, Pestell R, Chevallier N, Zheng H, Koo EH (2001). Presenilin 1 negatively regulates &#x3b2;-catenin/T cell factor/lymphoid enhancer factor-1 signaling independently of &#x3b2;-amyloid precursor protein and notch processing. J Cell Biol 152:785&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2195782</ArticleId><ArticleId IdType="pubmed">11266469</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarassishin L, Yin YI, Bassit B, Li YM (2004). Processing of Notch and amyloid precursor protein by &#x3b3;-secretase is spatially distinct. Proc Natl Acad Sci USA 101:17050&#x2013;17055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC535399</ArticleId><ArticleId IdType="pubmed">15563588</ArticleId></ArticleIdList></Reference><Reference><Citation>Tetzlaff MT, Yu W, Li M, Zhang P, Finegold M, Mahon K, Harper JW, Schwartz RJ, Elledge SJ (2004). Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein. Proc Natl Acad Sci USA 101:3338&#x2013;3345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC373463</ArticleId><ArticleId IdType="pubmed">14766969</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G (1999). The role of presenilins in Alzheimer's disease. J Clin Invest 104:1321&#x2013;1327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC409849</ArticleId><ArticleId IdType="pubmed">10562290</ArticleId></ArticleIdList></Reference><Reference><Citation>Tournoy J, Bossuyt X, Snellinx A, Regent M, Garmyn M, Serneels L, Saftig P, Craessaerts K, De Strooper B, Hartmann D (2004). Partial loss of presenilins causes seborrheic keratosis and autoimmune disease in mice. Hum Mol Genet 13:1321&#x2013;1331.</Citation><ArticleIdList><ArticleId IdType="pubmed">15128703</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiley JC, Hudson M, Kanning KC, Schecterson LC, Bothwell M (2005). Familial Alzheimer's disease mutations inhibit &#x3b3;-secretase-mediated liberation of &#x3b2;-amyloid precursor protein carboxy-terminal fragment. J Neurochem 94:1189&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pubmed">15992373</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ (1999). Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and &#x3b3;-secretase activity. Nature 398:513&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu G, Hubbard EJ, Kitajewski JK, Greenwald I (1998). Evidence for functional and physical association between Caenorhabditis elegans SEL-10, a Cdc4p-related protein, and SEL-12 presenilin. Proc Natl Acad Sci USA 95:15787&#x2013;15791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC28122</ArticleId><ArticleId IdType="pubmed">9861048</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia X, Qian S, Soriano S, Wu Y, Fletcher AM, Wang X-J, Koo EH, Wu X, Zheng H (2001). Loss of presenilin 1 is associated with enhanced &#x3b2;-catenin signaling and skin tumorigenesis. Proc Natl Acad Sci USA 98:10863&#x2013;10868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC58565</ArticleId><ArticleId IdType="pubmed">11517342</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia X, Wang P, Sun X, Soriano S, Shum WK, Yamaguchi H, Trumbauer ME, Takashima A, Koo EH, Zheng H (2002). The aspartate-257 of presenilin 1 is indispensable for mouse development and production of &#x3b2;-amyloid peptides through &#x3b2;-catenin-independent mechanisms. Proc Natl Acad Sci USA 99:8760&#x2013;8765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124372</ArticleId><ArticleId IdType="pubmed">12070348</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, Carter DB, Tomasselli AG, Parodi LA, Heinrikson RL, Gurney ME (1999). Membrane-anchored aspartyl protease with Alzheimer's disease &#x3b2;-secretase activity. Nature 402:533&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591213</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Chen F, Levesque G, Nishimura M, Zhang DM, Levesque L, Rogaeva E, Xu D, Liang Y, Duthie M, St George-Hyslop PH, Fraser PE (1998). The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains &#x3b2;-catenin. J Biol Chem 273:16470&#x2013;16475.</Citation><ArticleIdList><ArticleId IdType="pubmed">9632714</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16598260</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>440</Volume><Issue>7085</Issue><PubDate><Year>2006</Year><Month>Apr</Month><Day>06</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Omega-3 and omega-6 fatty acids stimulate cell membrane expansion by acting on syntaxin 3.</ArticleTitle><Pagination><StartPage>813</StartPage><EndPage>817</EndPage><MedlinePgn>813-7</MedlinePgn></Pagination><Abstract><AbstractText>Growth of neurite processes from the cell body is the critical step in neuronal development and involves a large increase in cell membrane surface area. Arachidonic-acid-releasing phospholipases are highly enriched in nerve growth cones and have previously been implicated in neurite outgrowth. Cell membrane expansion is achieved through the fusion of transport organelles with the plasma membrane; however, the identity of the molecular target of arachidonic acid has remained elusive. Here we show that syntaxin 3 (STX3), a plasma membrane protein, has an important role in the growth of neurites, and also serves as a direct target for omega-6 arachidonic acid. By using syntaxin 3 in a screening assay, we determined that the dietary omega-3 linolenic and docosahexaenoic acids can efficiently substitute for arachidonic acid in activating syntaxin 3. Our findings provide a molecular basis for the previously established action of omega-3 and omega-6 polyunsaturated fatty acids in membrane expansion at the growth cones, and represent the first identification of a single effector molecule for these essential nutrients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Darios</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 2QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davletov</LastName><ForeName>Bazbek</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U105178791</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043371">Fatty Acids, Omega-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050765">Qa-SNARE Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050600">SNARE Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>27YG812J1I</RegistryNumber><NameOfSubstance UI="D016718">Arachidonic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016718" MajorTopicYN="N">Arachidonic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015525" MajorTopicYN="N">Fatty Acids, Omega-3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043371" MajorTopicYN="N">Fatty Acids, Omega-6</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020439" MajorTopicYN="N">Growth Cones</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008561" MajorTopicYN="N">Membrane Fusion</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016716" MajorTopicYN="N">PC12 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050765" MajorTopicYN="N">Qa-SNARE Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050600" MajorTopicYN="N">SNARE Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>4</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>4</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16598260</ArticleId><ArticleId IdType="doi">10.1038/nature04598</ArticleId><ArticleId IdType="pii">nature04598</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16604074</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1061-4036</ISSN><JournalIssue CitedMedium="Print"><Volume>38</Volume><Issue>5</Issue><PubDate><Year>2006</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease.</ArticleTitle><Pagination><StartPage>515</StartPage><EndPage>517</EndPage><MedlinePgn>515-7</MedlinePgn></Pagination><Abstract><AbstractText>Here we show that in substantia nigra neurons from both aged controls and individuals with Parkinson disease, there is a high level of deleted mitochondrial DNA (mtDNA) (controls, 43.3% +/- 9.3%; individuals with Parkinson disease, 52.3% +/- 9.3%). These mtDNA mutations are somatic, with different clonally expanded deletions in individual cells, and high levels of these mutations are associated with respiratory chain deficiency. Our studies suggest that somatic mtDNA deletions are important in the selective neuronal loss observed in brain aging and in Parkinson disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bender</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mitochondrial Research Group, School of Neurology, Neurobiology and Psychiatry, The Medical School, University of Newcastle upon Tyne, Newcastle upon Tyne, NE2 4HH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krishnan</LastName><ForeName>Kim J</ForeName><Initials>KJ</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Geoffrey A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Reeve</LastName><ForeName>Amy K</ForeName><Initials>AK</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Jaros</LastName><ForeName>Evelyn</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Hersheson</LastName><ForeName>Joshua S</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Betts</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Klopstock</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Robert W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Turnbull</LastName><ForeName>Douglass M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>074454</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0700718</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>04</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004272">DNA, Mitochondrial</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Genet. 2006 May;38(5):507-8. doi: 10.1038/ng0506-507.</RefSource><PMID Version="1">16642013</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004272" MajorTopicYN="N">DNA, Mitochondrial</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017384" MajorTopicYN="Y">Sequence Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>4</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>4</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16604074</ArticleId><ArticleId IdType="doi">10.1038/ng1769</ArticleId><ArticleId IdType="pii">ng1769</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16625204</PMID><DateCompleted><Year>2006</Year><Month>07</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>441</Volume><Issue>7095</Issue><PubDate><Year>2006</Year><Month>Jun</Month><Day>15</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice.</ArticleTitle><Pagination><StartPage>885</StartPage><EndPage>889</EndPage><MedlinePgn>885-9</MedlinePgn></Pagination><Abstract><AbstractText>Autophagy is an intracellular bulk degradation process through which a portion of the cytoplasm is delivered to lysosomes to be degraded. Although the primary role of autophagy in many organisms is in adaptation to starvation, autophagy is also thought to be important for normal turnover of cytoplasmic contents, particularly in quiescent cells such as neurons. Autophagy may have a protective role against the development of a number of neurodegenerative diseases. Here we report that loss of autophagy causes neurodegeneration even in the absence of any disease-associated mutant proteins. Mice deficient for Atg5 (autophagy-related 5) specifically in neural cells develop progressive deficits in motor function that are accompanied by the accumulation of cytoplasmic inclusion bodies in neurons. In Atg5-/- cells, diffuse, abnormal intracellular proteins accumulate, and then form aggregates and inclusions. These results suggest that the continuous clearance of diffuse cytosolic proteins through basal autophagy is important for preventing the accumulation of abnormal proteins, which can disrupt neural function and ultimately lead to neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hara</LastName><ForeName>Taichi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Bioregulation and Metabolism, Tokyo Metropolitan Institute of Medical Science, Tokyo 113-8613, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Kenji</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Matsui</LastName><ForeName>Makoto</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Akitsugu</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Nakahara</LastName><ForeName>Yohko</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Suzuki-Migishima</LastName><ForeName>Rika</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Yokoyama</LastName><ForeName>Minesuke</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mishima</LastName><ForeName>Kenji</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Ichiro</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Okano</LastName><ForeName>Hideyuki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Mizushima</LastName><ForeName>Noboru</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495773">Atg5 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071187">Autophagy-Related Protein 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007381">Intermediate Filament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577485">Nes protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064231">Nestin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2006 Jun 15;441(7095):819-20. doi: 10.1038/441819a.</RefSource><PMID Version="1">16778876</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Mol Cell Biol. 2010 Oct;11(10):681. doi: 10.1038/nrm2978.</RefSource><PMID Version="1">20861878</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071187" MajorTopicYN="N">Autophagy-Related Protein 5</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007381" MajorTopicYN="N">Intermediate Filament Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064231" MajorTopicYN="N">Nestin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011689" MajorTopicYN="N">Purkinje Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025801" MajorTopicYN="N">Ubiquitin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>4</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>7</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>4</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16625204</ArticleId><ArticleId IdType="doi">10.1038/nature04724</ArticleId><ArticleId IdType="pii">nature04724</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16625205</PMID><DateCompleted><Year>2006</Year><Month>07</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>441</Volume><Issue>7095</Issue><PubDate><Year>2006</Year><Month>Jun</Month><Day>15</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Loss of autophagy in the central nervous system causes neurodegeneration in mice.</ArticleTitle><Pagination><StartPage>880</StartPage><EndPage>884</EndPage><MedlinePgn>880-4</MedlinePgn></Pagination><Abstract><AbstractText>Protein quality-control, especially the removal of proteins with aberrant structures, has an important role in maintaining the homeostasis of non-dividing neural cells. In addition to the ubiquitin-proteasome system, emerging evidence points to the importance of autophagy--the bulk protein degradation pathway involved in starvation-induced and constitutive protein turnover--in the protein quality-control process. However, little is known about the precise roles of autophagy in neurons. Here we report that loss of Atg7 (autophagy-related 7), a gene essential for autophagy, leads to neurodegeneration. We found that mice lacking Atg7 specifically in the central nervous system showed behavioural defects, including abnormal limb-clasping reflexes and a reduction in coordinated movement, and died within 28 weeks of birth. Atg7 deficiency caused massive neuronal loss in the cerebral and cerebellar cortices. Notably, polyubiquitinated proteins accumulated in autophagy-deficient neurons as inclusion bodies, which increased in size and number with ageing. There was, however, no obvious alteration in proteasome function. Our results indicate that autophagy is essential for the survival of neural cells, and that impairment of autophagy is implicated in the pathogenesis of neurodegenerative disorders involving ubiquitin-containing inclusion bodies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Komatsu</LastName><ForeName>Masaaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Frontier Science, Tokyo Metropolitan Institute of Medical Science, Bunkyo-ku, Tokyo 113-8613, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waguri</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Chiba</LastName><ForeName>Tomoki</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Murata</LastName><ForeName>Shigeo</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Iwata</LastName><ForeName>Jun-ichi</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tanida</LastName><ForeName>Isei</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Ueno</LastName><ForeName>Takashi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Koike</LastName><ForeName>Masato</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Uchiyama</LastName><ForeName>Yasuo</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kominami</LastName><ForeName>Eiki</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Keiji</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C502661">Atg7 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007381">Intermediate Filament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577485">Nes protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064231">Nestin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 6.2.1.45</RegistryNumber><NameOfSubstance UI="D000071193">Autophagy-Related Protein 7</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2006 Jun 15;441(7095):819-20. doi: 10.1038/441819a.</RefSource><PMID Version="1">16778876</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Mol Cell Biol. 2010 Oct;11(10):681. doi: 10.1038/nrm2978.</RefSource><PMID Version="1">20861878</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071193" MajorTopicYN="N">Autophagy-Related Protein 7</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007381" MajorTopicYN="N">Intermediate Filament Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064231" MajorTopicYN="N">Nestin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025801" MajorTopicYN="N">Ubiquitin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>4</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>7</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>4</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16625205</ArticleId><ArticleId IdType="doi">10.1038/nature04723</ArticleId><ArticleId IdType="pii">nature04723</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16632311</PMID><DateCompleted><Year>2006</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1474-4422</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>5</Issue><PubDate><Year>2006</Year><Month>May</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>The effect of social networks on the relation between Alzheimer's disease pathology and level of cognitive function in old people: a longitudinal cohort study.</ArticleTitle><Pagination><StartPage>406</StartPage><EndPage>412</EndPage><MedlinePgn>406-12</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Few data are available about how social networks reduce the risk of cognitive impairment in old age. We aimed to measure this effect using data from a large, longitudinal, epidemiological clinicopathological study.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">89 elderly people without known dementia participating in the Rush Memory and Aging Project underwent annual clinical evaluation. Brain autopsy was done at the time of death. Social network data were obtained by structured interview. Cognitive function tests were Z scored and averaged to yield a global and specific measure of cognitive function. Alzheimer's disease pathology was quantified as a global measure based on modified Bielschowsky silver stain. Amyloid load and the density of paired helical filament tau tangles were also quantified with antibody-specific immunostains. We used linear regression to examine the relation of disease pathology scores and social networks to level of cognitive function.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Cognitive function was inversely related to all measures of disease pathology, indicating lower function at more severe levels of pathology. Social network size modified the association between pathology and cognitive function (parameter estimate 0.097, SE 0.039, p=0.016, R(2)=0.295). Even at more severe levels of global disease pathology, cognitive function remained higher for participants with larger network sizes. A similar modifying association was observed with tangles (parameter estimate 0.011, SE 0.003, p=0.001, R(2)=0.454). These modifying effects were most pronounced for semantic memory and working memory. Amyloid load did not modify the relation between pathology and network size. The results were unchanged after controlling for cognitive, physical, and social activities, depressive symptoms, or number of chronic diseases.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">These findings suggest that social networks modify the relation of some measures of Alzheimer's disease pathology to level of cognitive function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL 60612, USA. dbennett@rush.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Yuxiao</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Robert S</ForeName><Initials>RS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01AG17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016021" MajorTopicYN="N">Epidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007398" MajorTopicYN="N">Interpersonal Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012944" MajorTopicYN="Y">Social Support</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>4</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>4</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16632311</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(06)70417-3</ArticleId><ArticleId IdType="pii">S1474-4422(06)70417-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16636269</PMID><DateCompleted><Year>2006</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>103</Volume><Issue>18</Issue><PubDate><Year>2006</Year><Month>May</Month><Day>02</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Electron microscopic structure of purified, active gamma-secretase reveals an aqueous intramembrane chamber and two pores.</ArticleTitle><Pagination><StartPage>6889</StartPage><EndPage>6894</EndPage><MedlinePgn>6889-94</MedlinePgn></Pagination><Abstract><AbstractText>Gamma-secretase is an intramembrane-cleaving aspartyl protease required for the normal development of metazoans because it processes Notch within cellular membranes to release its signaling domain. More than two dozen additional substrates of diverse functions have been reported, including the Notch ligands Delta and Jagged, N- and E-cadherins, and a sodium channel subunit. The protease is causally implicated in Alzheimer's disease because it releases the neurotoxic amyloid beta-peptide (Abeta) from its precursor, APP. Gamma-secretase occurs as a large complex containing presenilin (bearing the active site aspartates), nicastrin, Aph-1, and Pen-2. Because the complex contains at least 18 transmembrane domains, crystallographic approaches to its structure are difficult and remote. We recently purified the human complex essentially to homogeneity from stably expressing mammalian cells. Here, we use EM and single-particle image analysis on the purified enzyme, which produces physiological ratios of Abeta40 and Abeta42, to obtain structural information on an intramembrane protease. The 3D EM structure revealed a large, cylindrical interior chamber of approximately 20-40 A in length, consistent with a proteinaceous proteolytic site that is occluded from the hydrophobic environment of the lipid bilayer. Lectin tagging of the nicastrin ectodomain enabled proper orientation of the globular, approximately 120-A-long complex within the membrane and revealed approximately 20-A pores at the top and bottom that provide potential exit ports for cleavage products to the extra- and intracellular compartments. Our reconstructed 3D map provides a physical basis for hydrolysis of transmembrane substrates within a lipid bilayer and release of the products into distinct subcellular compartments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lazarov</LastName><ForeName>Vlado K</ForeName><Initials>VK</Initials><AffiliationInfo><Affiliation>Biology Department, Brookhaven National Laboratory, Upton, NY 11973, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fraering</LastName><ForeName>Patrick C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Wenjuan</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Wolfe</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Huilin</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG029979</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG1537</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>04</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D046912">Multiprotein Complexes</NameOfSubstance></Chemical><Chemical><RegistryNumber>11028-71-0</RegistryNumber><NameOfSubstance UI="D003208">Concanavalin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003208" MajorTopicYN="N">Concanavalin A</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="Y">Endopeptidases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046912" MajorTopicYN="N">Multiprotein Complexes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="Y">Protein Structure, Tertiary</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest statement: No conflicts declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>4</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>7</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>4</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>11</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16636269</ArticleId><ArticleId IdType="pmc">PMC1458989</ArticleId><ArticleId IdType="doi">10.1073/pnas.0602321103</ArticleId><ArticleId IdType="pii">0602321103</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aguzzi A., Haass C. Science. 2003;302:814&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593165</ArticleId></ArticleIdList></Reference><Reference><Citation>Struhl G., Adachi A. Mol. Cell. 2000;6:625&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">11030342</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Greenwald I. Proc. Natl. Acad. Sci. USA. 1998;95:7109&#x2013;7114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22757</ArticleId><ArticleId IdType="pubmed">9618547</ArticleId></ArticleIdList></Reference><Reference><Citation>Henricson A., Kall L., Sonnhammer E. L. FEBS J. 2005;272:2727&#x2013;2733.</Citation><ArticleIdList><ArticleId IdType="pubmed">15943807</ArticleId></ArticleIdList></Reference><Reference><Citation>Laudon H., Hansson E. M., Melen K., Bergman A., Farmery M. R., Winblad B., Lendahl U., von Heijne G., Naslund J. J. Biol. Chem. 2005;280:35352&#x2013;35360.</Citation><ArticleIdList><ArticleId IdType="pubmed">16046406</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasugi N., Tomita T., Hayashi I., Tsuruoka M., Niimura M., Takahashi Y., Thinakaran G., Iwatsubo T. Nature. 2003;422:438&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">12660785</ArticleId></ArticleIdList></Reference><Reference><Citation>LaVoie M. J., Fraering P. C., Ostaszewski B. L., Ye W., Kimberly W. T., Wolfe M. S., Selkoe D. J. J. Biol. Chem. 2003;278:37213&#x2013;37222.</Citation><ArticleIdList><ArticleId IdType="pubmed">12857757</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraering P. C., Ye W., Strub J. M., Dolios G., LaVoie M. J., Ostaszewski B. L., van Dorsselaer A., Wang R., Selkoe D. J., Wolfe M. S. Biochemistry. 2004;43:9774&#x2013;9789.</Citation><ArticleIdList><ArticleId IdType="pubmed">15274632</ArticleId></ArticleIdList></Reference><Reference><Citation>Esler W. P., Das C., Campbell W. A., Kimberly W. T., Kornilova A. Y., Diehl T. S., Ye W., Ostaszewski B. L., Xia W., Selkoe D. J., Wolfe M. S. Nat. Cell Biol. 2002;4:E110&#x2013;E111.</Citation><ArticleIdList><ArticleId IdType="pubmed">11988746</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T. D., Hardy J., Hutton M., Kukull W., et al. Nat. Med. 1996;2:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Asami-Odaka A., Ishibashi Y., Kikuchi T., Kitada C., Suzuki N. Biochemistry. 1995;34:10272&#x2013;10278.</Citation><ArticleIdList><ArticleId IdType="pubmed">7640283</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraering P. C., LaVoie M. J., Ye W., Ostaszewski B. L., Kimberly W. T., Selkoe D. J., Wolfe M. S. Biochemistry. 2004;43:323&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pubmed">14717586</ArticleId></ArticleIdList></Reference><Reference><Citation>Radermacher M., Wagenknecht T., Verschoor A., Frank J. J. Microsc. (Oxford) 1987;146:113&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">3302267</ArticleId></ArticleIdList></Reference><Reference><Citation>Venzke D., Domgall I., Kocher T., Fethiere J., Fischer S., Bottcher B. J. Mol. Biol. 2005;349:659&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pubmed">15890365</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Q. X., Wang D. N., MacKinnon R. Nature. 2004;430:806&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">15306816</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouckaert J., Hamelryck T., Wyns L., Loris R. Curr. Opin. Struct. Biol. 1999;9:572&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">10508764</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarassishin L., Yin Y. I., Bassit B., Li Y. M. Proc. Natl. Acad. Sci. USA. 2004;101:17050&#x2013;17055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC535399</ArticleId><ArticleId IdType="pubmed">15563588</ArticleId></ArticleIdList></Reference><Reference><Citation>Chyung J. H., Raper D. M., Selkoe D. J. J. Biol. Chem. 2005;280:4383&#x2013;4392.</Citation><ArticleIdList><ArticleId IdType="pubmed">15569674</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumeister W., Walz J., Zuhl F., Seemuller E. Cell. 1998;92:367&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">9476896</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickart C. M., Cohen R. E. Nat. Rev. Mol. Cell Biol. 2004;5:177&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">14990998</ArticleId></ArticleIdList></Reference><Reference><Citation>Voges D., Zwickl P., Baumeister W. Annu. Rev. Biochem. 1999;68:1015&#x2013;1068.</Citation><ArticleIdList><ArticleId IdType="pubmed">10872471</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornilova A. Y., Bihel F., Das C., Wolfe M. S. Proc. Natl. Acad. Sci. USA. 2005;102:3230&#x2013;3235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC552920</ArticleId><ArticleId IdType="pubmed">15722417</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Berg B., Clemons W. M., Jr., Collinson I., Modis Y., Hartmann E., Harrison S. C., Rapoport T. A. Nature. 2004;427:36&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">14661030</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah S., Lee S., Tabuchi K., Hao Y., Yu C., LaPlant Q., Ball H., Dann C. E., III, S&#xfc;dhof T., Yu G. Cell. 2005;122:435&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">16096062</ArticleId></ArticleIdList></Reference><Reference><Citation>Andel F., III, Ladurner A. G., Inouye C., Tjian R., Nogales E. Science. 1999;286:2153&#x2013;2156.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591646</ArticleId></ArticleIdList></Reference><Reference><Citation>Golas M. M., Sander B., Will C. L., Luhrmann R., Stark H. Science. 2003;300:980&#x2013;984.</Citation><ArticleIdList><ArticleId IdType="pubmed">12738865</ArticleId></ArticleIdList></Reference><Reference><Citation>Viadiu H., Stemmann O., Kirschner M. W., Walz T. Nat. Struct. Mol. Biol. 2005;12:552&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">15880121</ArticleId></ArticleIdList></Reference><Reference><Citation>Esler W. P., Kimberly W. T., Ostaszewski B. L., Ye W., Diehl T. S., Selkoe D. J., Wolfe M. S. Proc. Natl. Acad. Sci. USA. 2002;99:2720&#x2013;2725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122414</ArticleId><ArticleId IdType="pubmed">11867728</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimberly W. T., Esler W. P., Ye W., Ostaszewski B. L., Gao J., Diehl T., Selkoe D. J., Wolfe M. S. Biochemistry. 2003;42:137&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">12515548</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W., Zhang J., Ostaszewski B. L., Kimberly W. T., Seubert P., Koo E. H., Shen J., Selkoe D. J. Biochemistry. 1998;37:16465&#x2013;16471.</Citation><ArticleIdList><ArticleId IdType="pubmed">9843412</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank J., Radermacher M., Penczek P., Zhu J., Li Y., Ladjadj M., Leith A. J. Struct. Biol. 1996;116:190&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">8742743</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludtke S. J., Baldwin P. R., Chiu W. J. Struct. Biol. 1999;128:82&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">10600563</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen E. F., Goddard T. D., Huang C. C., Couch G. S., Greenblatt D. M., Meng E. C., Ferrin T. E. J. Comput. Chem. 2004;25:1605&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16641106</PMID><DateCompleted><Year>2006</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>103</Volume><Issue>18</Issue><PubDate><Year>2006</Year><Month>May</Month><Day>02</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664.</ArticleTitle><Pagination><StartPage>7130</StartPage><EndPage>7135</EndPage><MedlinePgn>7130-5</MedlinePgn></Pagination><Abstract><AbstractText>The deficits characteristic of Alzheimer's disease (AD) are believed to result, at least in part, from the neurotoxic effects of beta-amyloid peptides, a set of 39-43 amino acid fragments derived proteolytically from beta-amyloid precursor protein (APP). APP also is cleaved intracytoplasmically at Asp-664 to generate a second cytotoxic peptide, APP-C31, but whether this C-terminal processing of APP plays a role in the pathogenesis of AD is unknown. Therefore, we compared elements of the Alzheimer's phenotype in transgenic mice modeling AD with vs. without a functional Asp-664 caspase cleavage site. Surprisingly, whereas beta-amyloid production and plaque formation were unaltered, synaptic loss, astrogliosis, dentate gyral atrophy, increased neuronal precursor proliferation, and behavioral abnormalities were completely prevented by a mutation at Asp-664. These results suggest that Asp-664 plays a critical role in the generation of Alzheimer-related pathophysiological and behavioral changes in human APP transgenic mice, possibly as a cleavage site or via protein-protein interactions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Galvan</LastName><ForeName>Veronica</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorostiza</LastName><ForeName>Olivia F</ForeName><Initials>OF</Initials></Author><Author ValidYN="Y"><LastName>Banwait</LastName><ForeName>Surita</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ataie</LastName><ForeName>Marina</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Logvinova</LastName><ForeName>Anna V</ForeName><Initials>AV</Initials></Author><Author ValidYN="Y"><LastName>Sitaraman</LastName><ForeName>Sandhya</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>Elaine</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Sagi</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Chevallier</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Kunlin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Greenberg</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Bredesen</LastName><ForeName>Dale E</ForeName><Initials>DE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS045093</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS45093</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>30KYC7MIAI</RegistryNumber><NameOfSubstance UI="D001224">Aspartic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6876</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="Y">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001224" MajorTopicYN="N">Aspartic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="Y">Point Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest statement: No conflicts declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>4</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>7</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>4</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>11</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16641106</ArticleId><ArticleId IdType="pmc">PMC1459029</ArticleId><ArticleId IdType="doi">10.1073/pnas.0509695103</ArticleId><ArticleId IdType="pii">0509695103</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe D. J. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia A. Y., Masliah E., McConlogue L., Yu G.-Q., Tatsuno G., Hu K., Kholodenko D., Malenka R. C., Nicoll R. A., Mucke L. Proc. Natl. Acad. Sci. USA. 1999;96:3228&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L., Masliah E., Yu G. Q., Mallory M., Rockenstein E. M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. J. Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Gervais F. G., Xu D., Robertson G. S., Vaillancourt J. P., Zhu Y., Huang J., LeBlanc A., Smith D., Rigby M., Shearman M. S., et al. Cell. 1999;97:395&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">10319819</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu D. C., Rabizadeh S., Chandra S., Shayya R. F., Ellerby L. M., Ye X., Salvesen G. S., Koo E. H., Bredesen D. E. Nat. Med. 2000;6:397&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">10742146</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvan V., Chen S., Lu D., Logvinova A., Goldsmith P., Koo E. H., Bredesen D. E. J. Neurochem. 2002;82:283&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">12124429</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu D. C., Shaked G. M., Masliah E., Bredesen D. E., Koo E. H. Ann. Neurol. 2003;54:781&#x2013;789.</Citation><ArticleIdList><ArticleId IdType="pubmed">14681887</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzo A., Yuan M., Zhang Z., Paganetti P. A., Sturchler-Pierrat C., Staufenbiel M., Mautino J., Vigo F. S., Sommer B., Yankner B. A. Nat. Neurosci. 2000;3:460&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">10769385</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J., Palop J. J., Puolivali J., Massaro C., Bien-Ly N., Gerstein H., Scearce-Levie K., Masliah E., Mucke L. J. Neurosci. 2005;25:9694&#x2013;9703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725734</ArticleId><ArticleId IdType="pubmed">16237174</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvan V., Saganich M., Schroeder B., Gorostiza O. F., Logvinova A., Banwait S., Jin K., Greenberg D. A., Mucke L., Heinemann S., et al. Society for Neuroscience. San Diego: ScholarOne; 2004.</Citation></Reference><Reference><Citation>Schroeder B., Saganich M., Galvan V., Long J. M., Bredesen D. E., Heinemann S., Koo E. H. Society for Neuroscience. San Diego: ScholarOne; 2004.</Citation></Reference><Reference><Citation>Soriano S., Lu D. C., Chandra S., Pietrzik C. U., Koo E. H. J. Biol. Chem. 2001;276:29045&#x2013;29050.</Citation><ArticleIdList><ArticleId IdType="pubmed">11397796</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesco G., Koh Y. H., Tanzi R. E. J. Biol. Chem. 2003;278:46074&#x2013;46080.</Citation><ArticleIdList><ArticleId IdType="pubmed">12960154</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry R. D., Masliah E., Salmon D. P., Butters N., DeTeresa R., Hill R., Hansen L. A., Katzman R. Ann. Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit W. J. J. Neurosci. Res. 2004;77:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15197750</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry M. C., Soriano F., McNamara M., Page K. J., Schenk D., Games D., Hyman B. T. J. Neurosci. 1997;17:7053&#x2013;7059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573263</ArticleId><ArticleId IdType="pubmed">9278541</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart J. C., Mathis C., Saura J., Bales K. R., Paul S. M., Ungerer A. Neurobiol. Dis. 2000;7:71&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">10783292</ArticleId></ArticleIdList></Reference><Reference><Citation>Redwine J. M., Kosofsky B., Jacobs R. E., Games D., Reilly J. F., Morrison J. H., Young W. G., Bloom F. E. Proc. Natl. Acad. Sci. USA. 2003;100:1381&#x2013;1386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC298781</ArticleId><ArticleId IdType="pubmed">12552120</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop J. J., Jones B., Kekonius L., Chin J., Yu G.-Q., Raber J., Masliah E., Mucke L. Proc. Natl. Acad. Sci. USA. 2003;100:9572&#x2013;9577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC170959</ArticleId><ArticleId IdType="pubmed">12881482</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris R. J. Neurosci. Methods. 1984;11:47&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">6471907</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerman M. A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L. H., Carlson G. A., Younkin S. G., Ashe K. H. J. Neurosci. 2002;22:1858&#x2013;1867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758862</ArticleId><ArticleId IdType="pubmed">11880515</ArticleId></ArticleIdList></Reference><Reference><Citation>Janus C., Pearson J., McLaurin J., Mathews P. M., Jiang Y., Schmidt S. D., Chishti M. A., Horne P., Heslin D., French J., et al. Nature. 2000;408:979&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140685</ArticleId></ArticleIdList></Reference><Reference><Citation>Moran P. M., Higgins L. S., Cordell B., Moser P. C. Proc. Natl. Acad. Sci. USA. 1995;92:5341&#x2013;5345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC41690</ArticleId><ArticleId IdType="pubmed">7777509</ArticleId></ArticleIdList></Reference><Reference><Citation>King D. L., Arendash G. W., Crawford F., Sterk T., Menendez J., Mullan M. J. Behav. Brain Res. 1999;103:145&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">10513583</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb L., Gordon M. N., McGowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., et al. Nat. Med. 1998;4:97&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">9427614</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb L. A., Gordon M. N., Jantzen P., Hsiao K., Duff K., Morgan D. Behav. Genet. 1999;29:177&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">10547924</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K. K., Borchelt D. R., Olson K., Johannsdottir R., Kitt C., Yunis W., Xu S., Eckman C., Younkin S., Price D., et al. Neuron. 1995;15:1203&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pubmed">7576662</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K., Peel A. L., Mao X. O., Xie L., Cottrell B. A., Henshall D. C., Greenberg D. A. Proc. Natl. Acad. Sci. USA. 2004;101:343&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314187</ArticleId><ArticleId IdType="pubmed">14660786</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K., Galvan V., Xie L., Mao X. O., Gorostiza O. F., Bredesen D. E., Greenberg D. A. Proc. Natl. Acad. Sci. USA. 2004;101:13363&#x2013;13367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC516572</ArticleId><ArticleId IdType="pubmed">15340159</ArticleId></ArticleIdList></Reference><Reference><Citation>Haughey N. J., Nath A., Chan S. L., Borchard A. C., Rao M. S., Mattson M. P. J. Neurochem. 2002;83:1509&#x2013;1524.</Citation><ArticleIdList><ArticleId IdType="pubmed">12472904</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K. H., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P. A., et al. Proc. Natl. Acad. Sci. USA. 1997;94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu D. C., Soriano S., Bredesen D. E., Koo E. H. J. Neurochem. 2003;87:733&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">14535955</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuermann S., Hambsch B., Hesse L., Stumm J., Schmidt C., Beher D., Bayer T. A., Beyreuther K., Multhaup G. J. Biol. Chem. 2001;276:33923&#x2013;33929.</Citation><ArticleIdList><ArticleId IdType="pubmed">11438549</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S., Eriksen J. L., Das P., Sagi S. A., Wang R., Pietrzik C. U., Findlay K. A., Smith T. E., Murphy M. P., Bulter T., et al. Nature. 2001;414:212&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">11700559</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16648133</PMID><DateCompleted><Year>2006</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1756-1833</ISSN><JournalIssue CitedMedium="Internet"><Volume>332</Volume><Issue>7550</Issue><PubDate><Year>2006</Year><Month>May</Month><Day>13</Day></PubDate></JournalIssue><Title>BMJ (Clinical research ed.)</Title><ISOAbbreviation>BMJ</ISOAbbreviation></Journal><ArticleTitle>Cerebral emboli as a potential cause of Alzheimer's disease and vascular dementia: case-control study.</ArticleTitle><Pagination><StartPage>1119</StartPage><EndPage>1124</EndPage><MedlinePgn>1119-24</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare the occurrence of spontaneous cerebral emboli and venous to arterial circulation shunts in patients with Alzheimer's disease or vascular dementia and controls without dementia.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cross sectional case-control study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Secondary care old age psychiatry services, Manchester.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">170 patients with dementia (85 with Alzheimer's disease, 85 with vascular dementia) and 150 age and sex matched controls. Patients on anticoagulant treatment, patients with severe dementia, and controls with marked cognitive impairment were excluded.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Frequencies of detection of spontaneous cerebral emboli during one hour monitoring of the middle cerebral arteries with transcranial Doppler and venous to arterial circulation shunts by a transcranial Doppler technique using intravenous microbubbles as an ultrasound contrast.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Spontaneous cerebral emboli were detected in 32 (40%) of patients with Alzheimer's disease and 31 (37%) of those with vascular dementia compared with just 12 each (15% and 14%) of their controls, giving significant odds ratios adjusted for vascular risk factors of 2.70 (95% confidence interval 1.18 to 6.21) for Alzheimer's disease and 5.36 (1.24 to 23.18) for vascular dementia. These spontaneous cerebral emboli were not caused by carotid disease, which was equally frequent in dementia patients and their controls. A venous to arterial circulation shunt indicative of patent foramen ovale was found in 27 (32%) Alzheimer's disease patients and 25 (29%) vascular dementia patients compared with 19 (22%) and 17 (20%) controls, giving non-significant odds ratios of 1.57 (0.80 to 3.07) and 1.67 (0.81 to 3.41).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Spontaneous cerebral emboli were significantly associated with both Alzheimer's disease and vascular dementia. They may represent a potentially preventable or treatable cause of dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Purandare</LastName><ForeName>Nitin</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Manchester, Manchester.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Alistair</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Daly</LastName><ForeName>Kevin J</ForeName><Initials>KJ</Initials></Author><Author ValidYN="Y"><LastName>Hardicre</LastName><ForeName>Jayne</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Macfarlane</LastName><ForeName>Gary</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>McCollum</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>04</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ</MedlineTA><NlmUniqueID>8900488</NlmUniqueID><ISSNLinking>0959-8138</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>BMJ. 2006 May 13;332(7550):1104-5. doi: 10.1136/bmj.332.7550.1104.</RefSource><PMID Version="1">16690644</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016893" MajorTopicYN="N">Carotid Stenosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002538" MajorTopicYN="N">Intracranial Arteriovenous Malformations</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020766" MajorTopicYN="N">Intracranial Embolism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002546" MajorTopicYN="N">Ischemic Attack, Transient</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020768" MajorTopicYN="N">Middle Cerebral Artery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>5</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>5</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16648133</ArticleId><ArticleId IdType="pmc">PMC1459546</ArticleId><ArticleId IdType="doi">10.1136/bmj.38814.696493.AE</ArticleId><ArticleId IdType="pii">bmj.38814.696493.AE</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stewart R, Prince M, Mann A. Vascular risk factors and Alzheimer's disease. Aust N Z J Psychiatry 1999;33: 809-13.</Citation><ArticleIdList><ArticleId IdType="pubmed">10619206</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoog I, Kalaria RN, Breteler MMB. Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord 1999;13: S106-14.</Citation><ArticleIdList><ArticleId IdType="pubmed">10609689</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam study. Lancet 1997;349: 151-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9111537</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchinson S, Riding G, Coull S, McCollum CN. Are spontaneous cerebral microemboli consistent in carotid disease? Stroke 2002;33: 685-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11872888</ArticleId></ArticleIdList></Reference><Reference><Citation>Deklunder G, Roussel M, Lecroart JL, Prat A, Gautier C. Microemboli in cerebral circulation and alteration of cognitive abilities in patients with mechanical prosthetic heart valves. Stroke 1998:29; 1821-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9731602</ArticleId></ArticleIdList></Reference><Reference><Citation>Fearn SJ, Pole R, Wesnes K, Faragher EB, Hooper TL, McCollum CN. Cerebral injury during cardiopulmonary bypass: emboli impair memory. J Thorac Cardiovasc Surg 2001;121: 1150-60.</Citation><ArticleIdList><ArticleId IdType="pubmed">11385383</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell D. Cerebral microemboli and cognitive impairment. J Neurol Sci 2002;203-204: 211-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">12417386</ArticleId></ArticleIdList></Reference><Reference><Citation>Stygall J, Newman SP, Fitzgerald G, Mulligan K, Arrowsmith JE, Pugsley W, et al. Cognitive change 5 years after coronary artery bypass surgery. Health Psychol 2003;22: 579-86.</Citation><ArticleIdList><ArticleId IdType="pubmed">14640854</ArticleId></ArticleIdList></Reference><Reference><Citation>Sliwka U, Job FP, Wissuwa D, Diehl RR, Flachskampf FA, Hanrath P, et al. Occurrence of transcranial Doppler high-intensity transient signals in patients with potential cardiac sources of embolism: a prospective study. Stroke 1995;26: 2067-70.</Citation><ArticleIdList><ArticleId IdType="pubmed">7482651</ArticleId></ArticleIdList></Reference><Reference><Citation>Anzola GP. Clinical impact of patent foramen ovale diagnosis with transcranial Doppler. Eur J Ultrasound 2002;16: 11-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">12470846</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. Stroke 1997;28: 316-21.</Citation><ArticleIdList><ArticleId IdType="pubmed">9040682</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechat P, Mas JL, Lascault G. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988;318: 1148-52.</Citation><ArticleIdList><ArticleId IdType="pubmed">3362165</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster MW, Chancellor AM, Smith HJ, Swift DL, Sharpe DN, Bass NM, et al. Patent foramen ovale in young stroke patients. Lancet 1988;ii: 11-2.</Citation><ArticleIdList><ArticleId IdType="pubmed">2898621</ArticleId></ArticleIdList></Reference><Reference><Citation>Riding G, Rao S, Hutchinson S, Kilic J, Lovell M, McCollum C. Cerebral emboli during hip and knee replacement: the role of venous to arterial shunting [abstract]. Br J Surg 2001;88: 745.</Citation></Reference><Reference><Citation>Meier B, Lock JE. Contemporary management of patent foramen ovale. Circulation 2003;107: 5-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12515733</ArticleId></ArticleIdList></Reference><Reference><Citation>Sastry S, MacNab A, Daly K, Ray SG, McCollum CN. Transcranial Doppler or transoesophageal echocardiography for the detection of venous-to-arterial circulation shunts [abstract]. Heart 2002;88(suppl IV): 32.</Citation></Reference><Reference><Citation>Purandare N, Welsh S, Hutchinson S, Riding G, Burns A, McCollum C. Cerebral emboli and paradoxical embolisation in dementia: a pilot study. Int J Geriatr Psychiatry 2005;20: 12-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15578671</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34: 939-44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43: 250-60.</Citation><ArticleIdList><ArticleId IdType="pubmed">8094895</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. Psychiatry Res 1975;12: 189-98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringelstein EB, Droste DW, Babikian VL, Evans DH, Grosset DG, Kaps M, et al. Consensus on microembolus detection by TCD. Stroke 1998;29: 725-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9506619</ArticleId></ArticleIdList></Reference><Reference><Citation>Consensus Committee of the Ninth International Cerebral Hemodynamic Symposium. Basic identification criteria of Doppler microembolic signals. Stroke 1995;26: 1123.</Citation><ArticleIdList><ArticleId IdType="pubmed">7762033</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidhu PS, Allen PL. Ultrasound assessment of internal carotid artery stenosis. Clin Radiol 1997;52: 654-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9313728</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Tullio M, Sacco RL, Venketasubramanian N, Sherman D, Mohr JP, Homma S. Comparison of diagnostic techniques for the detection of a patent foramen ovale in stroke patients. Stroke 1993;24: 1020-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8322376</ArticleId></ArticleIdList></Reference><Reference><Citation>Nygren AT, Jogestrand T. Detection of patent foramen ovale by transcranial Doppler and carotid duplex ultrasonography: a comparison with transoesophageal echocardiography. Clin Physiol 1998;18: 327-30.</Citation><ArticleIdList><ArticleId IdType="pubmed">9715758</ArticleId></ArticleIdList></Reference><Reference><Citation>Droste DW, Silling K, Stypmann J, Grude M, Kemeny V, Wichter T, et al. Contrast transcranial doppler ultrasound in the detection of right-to-left shunts: time window and threshold in microbubble numbers. Stroke 2000;31: 1640-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10884466</ArticleId></ArticleIdList></Reference><Reference><Citation>Jauss M, Zanette E. Detection of right-to-left shunt with ultrasound contrast agent and transcranial Doppler sonography. Cerebrovasc Dis 2000;10: 490-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11070388</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagan PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 1984;59: 17-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">6694427</ArticleId></ArticleIdList></Reference><Reference><Citation>Stork JL, Kimura K, Levi CR, Chambers BR, Abbott AL, Donnan GA. Source of micro-embolic signals in patients with high-grade carotid stenosis. Stroke 2002;33: 2014-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12154255</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier B. Closure of patent foramen ovale: technique, pitfalls, complications, and follow up. Heart 2005;91: 444-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1768795</ArticleId><ArticleId IdType="pubmed">15772193</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16648635</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>281</Volume><Issue>26</Issue><PubDate><Year>2006</Year><Month>Jun</Month><Day>30</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity.</ArticleTitle><Pagination><StartPage>17670</StartPage><EndPage>17680</EndPage><MedlinePgn>17670-80</MedlinePgn></Pagination><Abstract><AbstractText>Biometals play an important role in Alzheimer disease, and recent reports have described the development of potential therapeutic agents based on modulation of metal bioavailability. The metal ligand clioquinol (CQ) has shown promising results in animal models and small phase clinical trials; however, the actual mode of action in vivo has not been determined. We now report a novel effect of CQ on amyloid beta-peptide (Abeta) metabolism in cell culture. Treatment of Chinese hamster ovary cells overexpressing amyloid precursor protein with CQ and Cu(2+) or Zn(2+) resulted in an approximately 85-90% reduction of secreted Abeta-(1-40) and Abeta-(1-42) compared with untreated controls. Analogous effects were seen in amyloid precursor protein-overexpressing neuroblastoma cells. The secreted Abeta was rapidly degraded through up-regulation of matrix metalloprotease (MMP)-2 and MMP-3 after addition of CQ and Cu(2+). MMP activity was increased through activation of phosphoinositol 3-kinase and JNK. CQ and Cu(2+) also promoted phosphorylation of glycogen synthase kinase-3, and this potentiated activation of JNK and loss of Abeta-(1-40). Our findings identify an alternative mechanism of action for CQ in the reduction of Abeta deposition in the brains of CQ-treated animals and potentially in Alzheimer disease patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>White</LastName><ForeName>Anthony R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Melbourne, Cnr. Grattan Street and Royal Parade, Victoria 3010, Australia. arwhite@unimelb.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Tai</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Laughton</LastName><ForeName>Katrina M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Volitakis</LastName><ForeName>Irene</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Sharples</LastName><ForeName>Robyn A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Xilinas</LastName><ForeName>Michel E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Hoke</LastName><ForeName>David E</ForeName><Initials>DE</Initials></Author><Author ValidYN="Y"><LastName>Holsinger</LastName><ForeName>R M Damian</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Evin</LastName><ForeName>Genevi&#xe8;ve</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Cherny</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Andrew F</ForeName><Initials>AF</Initials></Author><Author ValidYN="Y"><LastName>Barnham</LastName><ForeName>Kevin J</ForeName><Initials>KJ</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qiao-Xin</ForeName><Initials>QX</Initials></Author><Author ValidYN="Y"><LastName>Bush</LastName><ForeName>Ashley I</ForeName><Initials>AI</Initials></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 05887</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG 12686</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>04</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000891">Anti-Infective Agents, Local</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>789U1901C5</RegistryNumber><NameOfSubstance UI="D003300">Copper</NameOfSubstance></Chemical><Chemical><RegistryNumber>7BHQ856EJ5</RegistryNumber><NameOfSubstance UI="D007464">Clioquinol</NameOfSubstance></Chemical><Chemical><RegistryNumber>E1UOL152H7</RegistryNumber><NameOfSubstance UI="D007501">Iron</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048049">Extracellular Signal-Regulated MAP Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048031">JNK Mitogen-Activated Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.17</RegistryNumber><NameOfSubstance UI="D019278">Matrix Metalloproteinase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.24</RegistryNumber><NameOfSubstance UI="D020778">Matrix Metalloproteinase 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>J41CSQ7QDS</RegistryNumber><NameOfSubstance UI="D015032">Zinc</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000891" MajorTopicYN="N">Anti-Infective Agents, Local</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007464" MajorTopicYN="N">Clioquinol</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003300" MajorTopicYN="N">Copper</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048049" MajorTopicYN="N">Extracellular Signal-Regulated MAP Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048031" MajorTopicYN="N">JNK Mitogen-Activated Protein Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020778" MajorTopicYN="N">Matrix Metalloproteinase 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019278" MajorTopicYN="N">Matrix Metalloproteinase 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015032" MajorTopicYN="N">Zinc</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16648635</ArticleId><ArticleId IdType="doi">10.1074/jbc.M602487200</ArticleId><ArticleId IdType="pii">S0021-9258(20)55638-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16651626</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-9440</ISSN><JournalIssue CitedMedium="Print"><Volume>168</Volume><Issue>5</Issue><PubDate><Year>2006</Year><Month>May</Month></PubDate></JournalIssue><Title>The American journal of pathology</Title><ISOAbbreviation>Am J Pathol</ISOAbbreviation></Journal><ArticleTitle>Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy.</ArticleTitle><Pagination><StartPage>1598</StartPage><EndPage>1607</EndPage><MedlinePgn>1598-607</MedlinePgn></Pagination><Abstract><AbstractText>Neurofibrillary tangles form in a specific spatial and temporal pattern in Alzheimer's disease. Although tangle formation correlates with dementia and neuronal loss, it remains unknown whether neurofibrillary pathology causes cell death. Recently, a mouse model of tauopathy was developed that reversibly expresses human tau with the dementia-associated P301L mutation. This model (rTg4510) exhibits progressive behavioral deficits that are ameliorated with transgene suppression. Using quantitative analysis of PHF1 immunostaining and neuronal counts, we estimated neuron number and accumulation of neurofibrillary pathology in five brain regions. Accumulation of PHF1-positive tau in neurons appeared between 2.5 and 7 months of age in a region-specific manner and increased with age. Neuron loss was dramatic and region-specific in these mice, reaching over 80% loss in hippocampal area CA1 and dentate gyrus by 8.5 months. We observed regional dissociation of neuronal loss and accumulation of neurofibrillary pathology, because there was loss of neurons before neurofibrillary lesions appeared in the dentate gyrus and, conversely, neurofibrillary pathology appeared without major cell loss in the striatum. Finally, suppressing the transgene prevented further neuronal loss without removing or preventing additional accumulation of neurofibrillary pathology. Together, these results imply that neurofibrillary tangles do not necessarily lead to neuronal death.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spires</LastName><ForeName>Tara L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown 02129, USA. tspires@partners.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orne</LastName><ForeName>Jennifer D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>SantaCruz</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Pitstick</LastName><ForeName>Rose</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>George A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Ashe</LastName><ForeName>Karen H</ForeName><Initials>KH</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG26249</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG008487</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000277</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG00277</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026249</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08487</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Pathol</MedlineTA><NlmUniqueID>0370502</NlmUniqueID><ISSNLinking>0002-9440</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C533390">Phf1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D063146">Polycomb-Group Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C404785">tau 40 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020868" MajorTopicYN="N">Gene Silencing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009454" MajorTopicYN="N">Neurofibrils</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063146" MajorTopicYN="N">Polycomb-Group Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056427" MajorTopicYN="N">t-Complex Genome Region</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16651626</ArticleId><ArticleId IdType="pmc">PMC1606598</ArticleId><ArticleId IdType="doi">10.2353/ajpath.2006.050840</ArticleId><ArticleId IdType="pii">S0002-9440(10)62182-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kidd M. Paired helical filaments in electron microscopy in Alzheimer&#x2019;s disease. Nature. 1963;197:192&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">14032480</ArticleId></ArticleIdList></Reference><Reference><Citation>Brion JP, Couck AM, Passareiro E, Flament-Durand J. Neurofibrillary tangles of Alzheimer&#x2019;s disease: an immunohistochemical study. J Submicrosc Cytol. 1985;17:89&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">3973960</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA. 1986;83:4913&#x2013;4917.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323854</ArticleId><ArticleId IdType="pubmed">3088567</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci USA. 1986;83:4044&#x2013;4048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323662</ArticleId><ArticleId IdType="pubmed">2424016</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball MJ. Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia. A quantitative study. Acta Neuropathol (Berl) 1977;37:111&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">848276</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondareff W, Mountjoy CQ, Roth M, Hauser DL. Neurofibrillary degeneration and neuronal loss in Alzheimer&#x2019;s disease. Neurobiol Aging. 1989;10:709&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">2628782</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Peck A, DeTeresa R, Schechter R, Horoupian DS. Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol. 1981;10:184&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">7283403</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer&#x2019;s disease. Ann Neurol. 1997;41:17&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">9005861</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada P, Growdon J, Hedley-Whyte E, Hyman B. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer&#x2019;s disease. Neurology. 1992;42:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski JQ, Basun H, Lannfelt L, Neystat M, Fahn S, Dark F, Tannenberg T, Dodd PR, Hayward N, Kwok JB, Schofield PR, Andreadis A, Snowden JS, Craufurd D, Neary D, Owen F, Oostra BA, Hardy J, Goate A, Van Swieten JC, Mann DM, Lynch T, Heutink P. Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Hyman BT. Ageing and dementia/Alzheimer&#x2019;s disease. Graham DI, Lantos PL, editors. New York: Arnold,; Greenfield&#x2019;s Neuropathology. 2002:pp 200&#x2013;226.</Citation></Reference><Reference><Citation>Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA. 1992;89:5547&#x2013;5551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC49329</ArticleId><ArticleId IdType="pubmed">1319065</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayford M, Bach ME, Huang YY, Wang L, Hawkins RD, Kandel ER. Control of memory formation through regulated expression of a CaMKII transgene. Science. 1996;274:1678&#x2013;1683.</Citation><ArticleIdList><ArticleId IdType="pubmed">8939850</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Price JL, McKeel DW, Jr, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer&#x2019;s disease. J Neurosci. 1996;16:4491&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordower JH, Chu Y, Stebbins GT, DeKosky ST, Cochran EJ, Bennett D, Mufson EJ. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol. 2001;49:202&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">11220740</ArticleId></ArticleIdList></Reference><Reference><Citation>West MJ, Gundersen HJ. Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol. 1990;296:1&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">2358525</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT. APPSw transgenic mice develop age-related A beta deposits and neurophil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol. 1997;56:965&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">9291938</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, Guimaraes A, Yue M, Lewis J, Carlson G, Hutton M, Ashe KH. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci. 2005;25:10637&#x2013;10647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725849</ArticleId><ArticleId IdType="pubmed">16291936</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishizawa K, Ksiezak-Reding H, Davies P, Delacourte A, Tiseo P, Yen SH, Dickson DW. A double-labeling immunohistochemical study of tau exon 10 in Alzheimer&#x2019;s disease, progressive supranuclear palsy and Pick&#x2019;s disease. Acta Neuropathol (Berl) 2000;100:235&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">10965792</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Weaver C, Lane E, Vianna C, Kress Y, Rockwood J, Davies P. cAMP-dependent protein kinase phosphorylations on tau in Alzheimer&#x2019;s disease. J Neurosci. 1999;19:7486&#x2013;7494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782506</ArticleId><ArticleId IdType="pubmed">10460255</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Bowser R, Kazam IG, Davies P. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res. 1997;48:128&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">9130141</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Van Horsen GW, Damasio AR, Barnes CL. Alzheimer&#x2019;s disease: cell-specific pathology isolates the hippocampal formation. Science. 1984;225:1168&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">6474172</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof PR, Morrison JH. The cellular basis of cortical disconnection in Alzheimer disease and related dementing conditions. Terry R, Katzman R, Bick KL, Sisoda SS, editors. Philadelphia: Lippincott Williams &amp; Wilkins,; Alzheimer disease. 1999:pp 207&#x2013;232.</Citation></Reference><Reference><Citation>Pearson RC, Esiri MM, Hiorns RW, Wilcock GK, Powell TP. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proc Natl Acad Sci USA. 1985;82:4531&#x2013;4534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC391136</ArticleId><ArticleId IdType="pubmed">3859874</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis DA, Campbell MJ, Terry RD, Morrison JH. Laminar and regional distributions of neurofibrillary tangles and neuritic plaques in Alzheimer&#x2019;s disease: a quantitative study of visual and auditory cortices. J Neurosci. 1987;7:1799&#x2013;1808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568896</ArticleId><ArticleId IdType="pubmed">2439665</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer&#x2019;s disease. Cereb Cortex. 1991;1:103&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">1822725</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosso SM, Kamphorst W, Ravid R, Van Swieten JC. Coexistent tau and amyloid pathology in hereditary frontotemporal dementia with tau mutations. Ann NY Acad Sci. 2000;920:115&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193139</ArticleId></ArticleIdList></Reference><Reference><Citation>West MJ, Coleman PD, Flood DG, Troncoso JC. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer&#x2019;s disease. Lancet. 1994;344:769&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pubmed">7916070</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Jones B, Kekonius L, Chin J, Yu G-Q, Raber J, Masliah E, Mucke L. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer&#x2019;s disease-related cognitive deficits. Proc Natl Acad Sci USA. 2003;100:9572&#x2013;9577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC170959</ArticleId><ArticleId IdType="pubmed">12881482</ArticleId></ArticleIdList></Reference><Reference><Citation>van Swieten JC, Stevens M, Rosso SM, Rizzu P, Joosse M, de Koning I, Kamphorst W, Ravid R, Spillantini MG, Niermeijer, Heutink P. Phenotypic variation in hereditary frontotemporal dementia with tau mutations. Ann Neurol. 1999;46:617&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pubmed">10514099</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum D, Chtarto A, Tenenbaum L, Brotchi J, Levivier M. Clinical potential of minocycline for neurodegenerative disorders. Neurobiol Dis. 2004;17:359&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">15571972</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark WM, Lessov N, Lauten JD, Hazel K. Doxycycline treatment reduces ischemic brain damage in transient middle cerebral artery occlusion in the rat. J Mol Neurosci. 1997;9:103&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">9407391</ArticleId></ArticleIdList></Reference><Reference><Citation>Jantzie LL, Cheung P-Y, Todd KG. Doxycycline reduces cleaved caspase-3 and microglial activation in an animal model of neonatal hypoxia-ischemia. J Cereb Blood Flow Metab. 2005;25:314&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">15647741</ArticleId></ArticleIdList></Reference><Reference><Citation>Bantubungi K, Jacquard C, Greco A, Pintor A, Chtarto A, Tai K, Galas M-C, Tenenbaum L, Deglon N, Popoli P. Minocycline in phenotypic models of Huntington&#x2019;s disease. Neurobiol Dis. 2005;18:206&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">15649711</ArticleId></ArticleIdList></Reference><Reference><Citation>Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407:770&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">11048727</ArticleId></ArticleIdList></Reference><Reference><Citation>Behl C. Apoptosis and Alzheimer&#x2019;s disease. J Neural Transm. 2000;107:1325&#x2013;1344.</Citation><ArticleIdList><ArticleId IdType="pubmed">11145007</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans. 2002;30:552&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">12196135</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, Hickman SE, Thomas CA, Loike JD, Silverstein SC. Microglia, scavenger receptors, and the pathogenesis of Alzheimer&#x2019;s disease. Neurobiol Aging. 1998;19:S81&#x2013;S84.</Citation><ArticleIdList><ArticleId IdType="pubmed">9562474</ArticleId></ArticleIdList></Reference><Reference><Citation>McLellan ME, Kajdasz ST, Hyman BT, Bacskai BJ. In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J Neurosci. 2003;23:2212&#x2013;2217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742052</ArticleId><ArticleId IdType="pubmed">12657680</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Chen F, Barmettler R, Nitsch RM. Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem. 2001;276:529&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">11013246</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara T, Hong M, Zhang B, Nakagawa Y, Lee MK, Trojanowski JQ, Lee VM. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron. 1999;24:751&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">10595524</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Murphy M Paul, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25:402&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, Duff K, Davies P. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003;86:582&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">12859672</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci. 2005;25:5446&#x2013;5454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725006</ArticleId><ArticleId IdType="pubmed">15930395</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, Feany MB. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science. 2001;293:711&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">11408621</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman JM, Feany MB. Genetic modifiers of tauopathy in Drosophila. Genetics. 2003;165:1233&#x2013;1242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1462852</ArticleId><ArticleId IdType="pubmed">14668378</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16672644</PMID><DateCompleted><Year>2006</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>18</Issue><PubDate><Year>2006</Year><Month>May</Month><Day>03</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response.</ArticleTitle><Pagination><StartPage>4717</StartPage><EndPage>4728</EndPage><MedlinePgn>4717-28</MedlinePgn></Pagination><Abstract><AbstractText>Amyloid-beta (Abeta) immunotherapy lowers cerebral Abeta and improves cognition in mouse models of Alzheimer's disease (AD). A clinical trial using active immunization with Abeta1-42 was suspended after approximately 6% of patients developed meningoencephalitis, possibly because of a T-cell reaction against Abeta. Nevertheless, beneficial effects were reported in antibody responders. Consequently, alternatives are required for a safer vaccine. The Abeta1-15 sequence contains the antibody epitope(s) but lacks the T-cell reactive sites of full-length Abeta1-42. Therefore, we tested four alternative peptide immunogens encompassing either a tandem repeat of two lysine-linked Abeta1-15 sequences (2xAbeta1-15) or the Abeta1-15 sequence synthesized to a cross-species active T1 T-helper-cell epitope (T1-Abeta1-15) and each with the addition of a three-amino-acid RGD (Arg-Gly-Asp) motif (R-2xAbeta1-15; T1-R-Abeta1-15). High anti-Abeta antibody titers were observed in wild-type mice after intranasal immunization with R-2xAbeta1-15 or 2xAbeta1-15 plus mutant Escherichia coli heat-labile enterotoxin LT(R192G) adjuvant. Moderate antibody levels were induced after immunization with T1-R-Abeta1-15 or T1-Abeta1-15 plus LT(R192G). Restimulation of splenocytes with the corresponding immunogens resulted in moderate proliferative responses, whereas proliferation was absent after restimulation with full-length Abeta or Abeta1-15. Immunization of human amyloid precursor protein, familial AD (hAPP(FAD)) mice with R-2xAbeta1-15 or 2xAbeta1-15 resulted in high anti-Abeta titers of noninflammatory T-helper 2 isotypes (IgG1 and IgG2b), a lack of splenocyte proliferation against full-length Abeta, significantly reduced Abeta plaque load, and lower cerebral Abeta levels. In addition, 2xAbeta1-15-immunized hAPP(FAD) animals showed improved acquisition of memory compared with vehicle controls in a reference-memory Morris water-maze behavior test that approximately correlated with anti-Abeta titers. Thus, our novel immunogens show promise for future AD vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Neurological Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seabrook</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Lazo</LastName><ForeName>Noel D</ForeName><Initials>ND</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Liying</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Pritam</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Janus</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Lemere</LastName><ForeName>Cynthia A</ForeName><Initials>CA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG20159</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001427">Bacterial Toxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004768">Enterotoxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029968">Escherichia coli Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>D9K3SN2LNY</RegistryNumber><NameOfSubstance UI="C027538">heat-labile enterotoxin, E coli</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001427" MajorTopicYN="N">Bacterial Toxins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055592" MajorTopicYN="N">Biophysical Phenomena</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001703" MajorTopicYN="N">Biophysics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004768" MajorTopicYN="N">Enterotoxins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018604" MajorTopicYN="N">Epitope Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029968" MajorTopicYN="N">Escherichia coli Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007859" MajorTopicYN="N">Learning Disabilities</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="N">Vaccines</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>6</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>11</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16672644</ArticleId><ArticleId IdType="pmc">PMC6674171</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0381-06.2006</ArticleId><ArticleId IdType="pii">26/18/4717</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, Mkrtichyan M, Saing T, Cribbs DH (2005). Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from &#x3b2;-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 174:1580&#x2013;1586.</Citation><ArticleIdList><ArticleId IdType="pubmed">15661919</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahlers JD, Takeshita T, Pendleton CD, Berzofsky JA (1997). Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. Proc Natl Acad Sci USA 94:10856&#x2013;10861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23507</ArticleId><ArticleId IdType="pubmed">9380724</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE (2002). Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 23:2223&#x2013;2226.</Citation><ArticleIdList><ArticleId IdType="pubmed">12535702</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B (2000). Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N (2003). Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 100:2023&#x2013;2028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC149952</ArticleId><ArticleId IdType="pubmed">12566568</ArticleId></ArticleIdList></Reference><Reference><Citation>Cain D, Beiko J, Boon F (1997). Navigation in the water maze: the role of proximal and distal visual cues, path integration, and magnetic field information. Psychobiology 25:286&#x2013;293.</Citation></Reference><Reference><Citation>Cease KB, Margalit H, Cornette JL, Putney SD, Robey WG, Ouyang C, Streicher HZ, Fischinger PJ, Gallo RC, DeLisi C, Berzofsky JA (1987). Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. Proc Natl Acad Sci USA 84:4249&#x2013;4253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC305062</ArticleId><ArticleId IdType="pubmed">2438696</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M (2004). Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 5:677&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">15322526</ArticleId></ArticleIdList></Reference><Reference><Citation>Cribbs D, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, Sadzikava N, Babikyan D, Kesslak P, Kieber-Emmons T, Cotman C, Agadjanyan M (2003). Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 15:505&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1483061</ArticleId><ArticleId IdType="pubmed">12663680</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Sagare A, Hamm K, Parisi M, LaRue B, Guo H, Wu Z, Holtzman DM, Zlokovic BV (2005). IgG-assisted age-dependent clearance of Alzheimer's amyloid &#x3b2; peptide by the blood&#x2013;brain barrier neonatal Fc receptor. J Neurosci 25:11495&#x2013;11503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6726020</ArticleId><ArticleId IdType="pubmed">16354907</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001). Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98:8850&#x2013;8855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC37524</ArticleId><ArticleId IdType="pubmed">11438712</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickinson BL, Clements JD (1995). Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun 63:1617&#x2013;1623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC173200</ArticleId><ArticleId IdType="pubmed">7729864</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart J-C, Bales K, Gannon K, Greene S, DeMattos R, Mathis C, DeLong C, Wu S, Wu X, Holtzman D, Paul S (2002). Immunization reverses memory deficits without reducing brain A&#x3b2; burden in Alzheimer's disease model. Nat Neurosci 5:452&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">11941374</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F (2004). Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14:11&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095815</ArticleId><ArticleId IdType="pubmed">14997933</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M (2005). Effects of A&#x3b2; immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64:1563&#x2013;1572.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883317</ArticleId></ArticleIdList></Reference><Reference><Citation>Frautschy SA, Yang F, Irrizarry M, Hyman B, Saido TC, Hsiao K, Cole GM (1998). Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 152:307&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858113</ArticleId><ArticleId IdType="pubmed">9422548</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenkel D, Katz O, Solomon B (2000). Immunization against Alzheimer's beta-amyloid plaques via EFRH phage administration. Proc Natl Acad Sci USA 97:11455&#x2013;11459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC17221</ArticleId><ArticleId IdType="pubmed">11027345</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Boada Rovira M, Forette F, Orgogozo JM (2005). Clinical effects of A&#x3b2; immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:1553&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883316</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor K, Melachrino J, O'Callaghan JP, Morgan D (2002). Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol 173:183&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">11822882</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart MK, Palker TJ, Matthews TJ, Langlois AJ, Lerche NW, Martin ME, Scearce RM, McDanal C, Bolognesi DP, Haynes BF (1990). Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys. J Immunol 145:2677&#x2013;2685.</Citation><ArticleIdList><ArticleId IdType="pubmed">1698859</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartman RE, Izumi Y, Bales KR, Paul SM, Wozniak DF, Holtzman DM (2005). Treatment with an amyloid-&#x3b2; antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J Neurosci 25:6213&#x2013;6220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725066</ArticleId><ArticleId IdType="pubmed">15987951</ArticleId></ArticleIdList></Reference><Reference><Citation>Haynes BF, Arthur LO, Frost P, Matthews TJ, Langlois AJ, Palker TJ, Hart MK, Scearce RM, Jones DM, McDanal C (1993). Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein. J Exp Med 177:717&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2190925</ArticleId><ArticleId IdType="pubmed">7679708</ArticleId></ArticleIdList></Reference><Reference><Citation>Janus C (2004). Search strategies used by APP transgenic mice during navigation in the Morris water maze. Learn Mem 11:337&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC419737</ArticleId><ArticleId IdType="pubmed">15169864</ArticleId></ArticleIdList></Reference><Reference><Citation>Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D (2000). A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408:979&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140685</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen MT, Mottin MD, Cracchiolo JR, Leighty RE, Arendash GW (2005). Lifelong immunization with human beta-amyloid (1&#x2013;42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging. Neuroscience 130:667&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">15590151</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson WC Jr (1990). Protein secondary structure and circular dichroism: a practical guide. Proteins 7:205&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">2194218</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM (2005). Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 25:8843&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725603</ArticleId><ArticleId IdType="pubmed">16192374</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith SG, Black RS, Schenk D, Seubert P (2005). Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol 58:430&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pubmed">16130106</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere C, Spooner E, LaFrancois J, Malester B, Mori C, Leverone J, Matsuoka Y, DeMattos R, Holtzman D, Clements J, Selkoe D, Duff K (2003). Evidence for peripheral clearance of A&#x3b2; following chronic, active A&#x3b2; immunization in PSAPP mice. Neurobiol Dis 14:10&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678662</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Desai R, Hancock WW, Weiner HL, Selkoe DJ (2000). Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann NY Acad Sci 920:328&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193172</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere CA, Spooner ET, Leverone JF, Mori C, Clements JD (2002). Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol Aging 23:991&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pubmed">12470794</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, Zheng JB, Seabrook TJ, Louard D, Li D, Selkoe DJ, Palmour RM, Ervin FR (2004). Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol 165:283&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618542</ArticleId><ArticleId IdType="pubmed">15215183</ArticleId></ArticleIdList></Reference><Reference><Citation>Leverone JF, Spooner ET, Lehman HK, Clements JD, Lemere CA (2003). Abeta1&#x2013;15 is less immunogenic than Abeta1&#x2013;40/42 for intranasal immunization of wild-type mice but may be effective for &#x201c;boosting.&#x201d;. Vaccine 21:2197&#x2013;2206.</Citation><ArticleIdList><ArticleId IdType="pubmed">12706711</ArticleId></ArticleIdList></Reference><Reference><Citation>Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy MP, Golde TE (2006). Anti-Abeta(42)- and anti-Abeta(40)-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest 116:193&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1307561</ArticleId><ArticleId IdType="pubmed">16341263</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier M, Seabrook TJ, Lemere CA (2005a). Developing novel immunogens for an effective, safe Alzheimer's disease vaccine. Neurodegenerative Dis 2:267&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">16909008</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier M, Seabrook TJ, Lemere CA (2005b). Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G). Vaccine 23:5149&#x2013;5159.</Citation><ArticleIdList><ArticleId IdType="pubmed">16054274</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D (2005). Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64:129&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642916</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaurin J, Cecal R, Kierstead M, Tian X, Phinney A, Manea M, French J, Lambermon M, Darabie A, Brown M, Janus C, Chishti M, Horne P, Westaway D, Fraser P, Mount H, Przybylski M, St George-Hyslop P (2002). Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4&#x2013;10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8:1263&#x2013;1269.</Citation><ArticleIdList><ArticleId IdType="pubmed">12379850</ArticleId></ArticleIdList></Reference><Reference><Citation>Mecham RP (1991). Laminin receptors. Annu Rev Cell Biol 7:71&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">1667086</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsonego A, Maron R, Zota V, Selkoe DJ, Weiner HL (2001). Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci USA 98:10273&#x2013;10278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC56951</ArticleId><ArticleId IdType="pubmed">11517335</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsonego A, Zota V, Karni A, Krieger JI, Bar-Or A, Bitan G, Budson AE, Sperling R, Selkoe DJ, Weiner HL (2003). Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 112:415&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC166296</ArticleId><ArticleId IdType="pubmed">12897209</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000). A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris RG, Garrud P, Rawlins JN, O'Keefe J (1982). Place navigation impaired in rats with hippocampal lesions. Nature 297:681&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">7088155</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu G-Q, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L (2000). High-level neuronal expression of A&#x3b2;1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003). Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">12640446</ArticleId></ArticleIdList></Reference><Reference><Citation>Oishi Y, Onozuka A, Kato H, Shimura N, Imai S, Nisizawa T (2001). The effect of amino acid spacers on the antigenicity of dimeric peptide-inducing cross-reacting antibodies to a cell surface protein antigen of Streptococcus mutans. Oral Microbiol Immunol 16:40&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">11169138</ArticleId></ArticleIdList></Reference><Reference><Citation>Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003). Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61:46&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">12847155</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Toole M, Janszen DB, Slonim DK, Reddy PS, Ellis DK, Legault HM, Hill AA, Whitley MZ, Mounts WM, Zuberek K, Immermann FW, Black RS, Dorner AJ (2005). Risk factors associated with beta-amyloid(1&#x2013;42) immunotherapy in preimmunization gene expression patterns of blood cells. Arch Neurol 62:1531&#x2013;1536.</Citation><ArticleIdList><ArticleId IdType="pubmed">16216935</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M (2002). Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298:1379.</Citation><ArticleIdList><ArticleId IdType="pubmed">12434053</ArticleId></ArticleIdList></Reference><Reference><Citation>Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB (2005). Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid &#x3b2;. J Neurosci 25:629&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725332</ArticleId><ArticleId IdType="pubmed">15659599</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Strohmeyer R, Kovelowski C, Li R (2002). Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia 40:260&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">12379913</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruoslahti E (1988). Fibronectin and its receptors. Annu Rev Biochem 57:375&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">2972252</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruoslahti E (1996). RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 12:697&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">8970741</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vendevert C (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Seabrook TJ, Bloom JK, Iglesias M, Spooner ET, Walsh DM, Lemere CA (2004). Species-specific immune response to immunization with human versus rodent A beta peptide. Neurobiol Aging 25:1141&#x2013;1151.</Citation><ArticleIdList><ArticleId IdType="pubmed">15312960</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM, Knudsen E, Asuni A, Fitzer-Attas C, Sage D, Quartermain D, Goni F, Frangione B, Wisniewski T (2004). An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-&#x3b2; derivatives. J Neurosci 24:6277&#x2013;6282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729550</ArticleId><ArticleId IdType="pubmed">15254082</ArticleId></ArticleIdList></Reference><Reference><Citation>Town T, Tan J, Sansone N, Obregon D, Klein T, Mullan M (2001). Characterization of murine immunoglobulin G antibodies against human amyloid-&#x3b2;1&#x2013;42. Neurosci Lett 307:101&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">11427310</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend KP, Obregon D, Quadros A, Patel N, Volmar C, Paris D, Mullan M (2002). Proinflammatory and vasoactive effects of Abeta in the cerebrovasculature. Ann NY Acad Sci 977:65&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">12480734</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ (2004). Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44:181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450169</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Issazadeh S, Hancock WW, Selkoe DJ (2000). Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 48:567&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pubmed">11026440</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN, Morgan D (2004a). Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 24:6144&#x2013;6151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729674</ArticleId><ArticleId IdType="pubmed">15240806</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D (2004b). Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC539292</ArticleId><ArticleId IdType="pubmed">15588287</ArticleId></ArticleIdList></Reference><Reference><Citation>Yano A, Onozuka A, Matin K, Imai S, Hanada N, Nisizawa T (2003). RGD motif enhances immunogenicity and adjuvanticity of peptide antigens following intranasal immunization. Vaccine 22:237&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">14615151</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16682536</PMID><DateCompleted><Year>2006</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>5</Issue><PubDate><Year>2006</Year><Month>May</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Neuropathologic features of amnestic mild cognitive impairment.</ArticleTitle><Pagination><StartPage>665</StartPage><EndPage>672</EndPage><MedlinePgn>665-72</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The neuropathologic substrate of amnestic mild cognitive impairment (aMCI) is not known.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the neuropathologic features of patients who died while their clinical classification was aMCI.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Community based.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Sixty-six individuals, including 15 who had memory impairment beyond that allowed for aging but who were not demented, were studied along with 28 clinically healthy individuals and 23 patients with probable Alzheimer disease (AD) for comparison.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Standard neuropathologic techniques and classification according to Khachaturian, Consortium to Establish a Registry for Alzheimer Disease, and National Institute on Aging-Reagan criteria were used to analyze autopsy tissue from 15 individuals who died while their clinical diagnosis was aMCI. For comparison, autopsy data on age-matched groups of clinically healthy individuals and patients with probable AD were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Most patients with aMCI did not meet the neuropathologic criteria for AD, but their pathologic findings suggest a transitional state of evolving AD. All the patients with aMCI had pathologic findings involving medial temporal lobe structures, likely accounting for their memory impairment. In addition, there were many concomitant pathologic abnormalities, including argyrophilic grain disease, hippocampal sclerosis, and vascular lesions.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The neuropathologic features of aMCI matched the clinical features and seemed to be intermediate between the neurofibrillary changes of aging and the pathologic features of very early AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center and Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA. peter8@mayo.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parisi</LastName><ForeName>Joseph E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kris A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials></Author><Author ValidYN="Y"><LastName>Jicha</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Ivnik</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Glenn E</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><LastName>Tangalos</LastName><ForeName>Eric G</ForeName><Initials>EG</Initials></Author><Author ValidYN="Y"><LastName>Braak</LastName><ForeName>Heiko</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Kokmen</LastName><ForeName>Emre</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG 16574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG 06786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2006 May;63(5):645-6. doi: 10.1001/archneur.63.5.645.</RefSource><PMID Version="1">16682532</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000647" MajorTopicYN="N">Amnesia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011180" MajorTopicYN="N">Postmortem Changes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012111" MajorTopicYN="N">Residence Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>6</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16682536</ArticleId><ArticleId IdType="doi">10.1001/archneur.63.5.665</ArticleId><ArticleId IdType="pii">63/5/665</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16682537</PMID><DateCompleted><Year>2006</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>5</Issue><PubDate><Year>2006</Year><Month>May</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia.</ArticleTitle><Pagination><StartPage>674</StartPage><EndPage>681</EndPage><MedlinePgn>674-81</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The pathologic outcome of patients diagnosed with mild cognitive impairment (MCI) following progression to dementia is poorly understood.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the pathologic substrates of dementia in cases with prior diagnosis of amnestic MCI.</AbstractText><AbstractText Label="DESIGN AND SETTING" NlmCategory="METHODS">Community-based cohort.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Thirty-four subjects followed up prospectively as part of a community-based study who were diagnosed with amnestic MCI, progressed to clinical dementia, and underwent subsequent postmortem brain analysis.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Neuropathologic analyses resulted in assignment of a primary pathologic diagnosis and included staging of Alzheimer pathologic abnormalities and identification of contributing vascular disease, Lewy bodies, and argyrophilic grains.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Although the majority of subjects progressed both clinically and pathologically to Alzheimer disease (AD), 10 (29%) of them developed non-AD primary pathologic abnormalities. All of the cases were found to have sufficient pathologic abnormalities in mesial temporal lobe structures to account for their amnestic symptoms regardless of the cause. Most subjects were found to have secondary contributing pathologic abnormalities in addition to primary pathologic diagnoses. No significant differences between subjects with and without neuropathologically proven AD were detected in demographic variables, apolipoprotein E genotype, or cognitive test measures at onset of MCI, onset of dementia, or last clinical evaluation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The neuropathologic outcome of amnestic MCI following progression to dementia is heterogeneous, and it includes AD at a high frequency. Complex neuropathologic findings including 2 or more distinct pathologic entities contributing to dementia may be common in community-based cohorts. Neither demographic variables nor cognitive measures had predictive value in determining which patients diagnosed with MCI will develop the neuropathologic features of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jicha</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center and Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parisi</LastName><ForeName>Joseph E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kris</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Cha</LastName><ForeName>Ruth</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Ivnik</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Tangalos</LastName><ForeName>Eric G</ForeName><Initials>EG</Initials></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Braak</LastName><ForeName>Heiko</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG 16574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG 06786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2006 May;63(5):647-8. doi: 10.1001/archneur.63.5.647.</RefSource><PMID Version="1">16682533</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009460" MajorTopicYN="N">Neurologic Examination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011180" MajorTopicYN="N">Postmortem Changes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012111" MajorTopicYN="N">Residence Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>6</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16682537</ArticleId><ArticleId IdType="doi">10.1001/archneur.63.5.674</ArticleId><ArticleId IdType="pii">63/5/674</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16682538</PMID><DateCompleted><Year>2006</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>5</Issue><PubDate><Year>2006</Year><Month>May</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps.</ArticleTitle><Pagination><StartPage>693</StartPage><EndPage>699</EndPage><MedlinePgn>693-9</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">While most patients with mild cognitive impairment (MCI) transition to Alzheimer disease (AD), others develop non-AD dementia, remain in the MCI state, or improve.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To test the following hypotheses: smaller hippocampal volumes predict conversion of MCI to AD, whereas larger hippocampal volumes predict cognitive stability and/or improvement; and patients with MCI who convert to AD have greater atrophy in the CA1 hippocampal subfield and subiculum.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective longitudinal cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">University of California-Los Angeles Alzheimer's Disease Research Center.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">We followed up 20 MCI subjects clinically and neuropsychologically for 3 years.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Baseline regional hippocampal atrophy was analyzed with region-of-interest and 3-dimensional hippocampal mapping techniques.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During the 3-year study, 6 patients developed AD (MCI-c), 7 remained stable (MCI-nc), and 7 improved (MCI-i). Patients with MCI-c had 9% smaller left and 13% smaller right mean hippocampal volumes compared with MCI-nc patients. Radial atrophy maps showed greater atrophy of the CA1 subregion in MCI-c. Patients with MCI-c had significantly smaller hippocampi than MCI-i patients (left, 24%; right, 27%). Volumetric analyses showed a trend for greater hippocampal atrophy in MCI-nc relative to MCI-i patients (eg, 16% volume loss). After permutation tests corrected for multiple comparison, the atrophy maps showed a significant difference on the right. Subicular differences were seen between MCI-c and MCI-i patients, and MCI-nc and MCI-i patients. Multiple linear regression analysis confirmed the group effect to be highly significant and independent of age, hemisphere, and Mini-Mental State Examination scores at baseline.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Smaller hippocampi and specifically CA1 and subicular involvement are associated with increased risk for conversion from MCI to AD. Patients with MCI-i tend to have larger hippocampal volumes and relative preservation of both the subiculum and CA1.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana G</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Laboratory of Neuro Imaging, Department of Neurology, The David Geffen School of Medicine at UCLA, University of California-Los Angeles, Los Angeles, CA, USA. lapostolova@mednet.ucla.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dutton</LastName><ForeName>Rebecca A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Dinov</LastName><ForeName>Ivo D</ForeName><Initials>ID</Initials></Author><Author ValidYN="Y"><LastName>Hayashi</LastName><ForeName>Kiralee M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EB 01651</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG 026803</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>LM 05639</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 RR 013642</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH 071940</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR 019771</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 RR 021813</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Arch Neurol. 2007 Sep;64(9):1360-1</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="Y">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003952" MajorTopicYN="N">Diagnostic Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007839" MajorTopicYN="N">Functional Laterality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021621" MajorTopicYN="N">Imaging, Three-Dimensional</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>6</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16682538</ArticleId><ArticleId IdType="doi">10.1001/archneur.63.5.693</ArticleId><ArticleId IdType="pii">63/5/693</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16698938</PMID><DateCompleted><Year>2006</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>103</Volume><Issue>21</Issue><PubDate><Year>2006</Year><Month>May</Month><Day>23</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>PKCepsilon increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice.</ArticleTitle><Pagination><StartPage>8215</StartPage><EndPage>8220</EndPage><MedlinePgn>8215-20</MedlinePgn></Pagination><Abstract><AbstractText>Deposition of plaques containing amyloid beta (Abeta) peptides is a neuropathological hallmark of Alzheimer's disease (AD). Here we demonstrate that neuronal overexpression of the epsilon isozyme of PKC decreases Abeta levels, plaque burden, and plaque-associated neuritic dystrophy and reactive astrocytosis in transgenic mice expressing familial AD-mutant forms of the human amyloid precursor protein (APP). Compared with APP singly transgenic mice, APP/PKCepsilon doubly transgenic mice had decreased Abeta levels but showed no evidence for altered cleavage of APP. Instead, PKCepsilon overexpression selectively increased the activity of endothelin-converting enzyme, which degrades Abeta. The activities of other Abeta-degrading enzymes, insulin degrading enzyme and neprilysin, were unchanged. These results indicate that increased neuronal PKCepsilon activity can promote Abeta clearance and reduce AD neuropathology through increased endothelin-converting enzyme activity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Doo-Sup</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Ernest Gallo Clinic and Research Center, Emeryville, CA 94608, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Gui-Qui</ForeName><Initials>GQ</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Guofen</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Kharazia</LastName><ForeName>Viktor N</ForeName><Initials>VN</Initials></Author><Author ValidYN="Y"><LastName>Paredes</LastName><ForeName>J Peter</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Wesley S</ForeName><Initials>WS</Initials></Author><Author ValidYN="Y"><LastName>Deitchman</LastName><ForeName>Jason K</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Mucke</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Messing</LastName><ForeName>Robert O</ForeName><Initials>RO</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS41787</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG005834</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AA013588</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG011385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG11385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AA013588</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05834</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041787</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AA013588</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>05</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.13</RegistryNumber><NameOfSubstance UI="D051744">Protein Kinase C-epsilon</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.-</RegistryNumber><NameOfSubstance UI="D008666">Metalloendopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.71</RegistryNumber><NameOfSubstance UI="D000072396">Endothelin-Converting Enzymes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2006 May 23;103(21):7943-4. doi: 10.1073/pnas.0602860103.</RefSource><PMID Version="1">16705031</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072396" MajorTopicYN="N">Endothelin-Converting Enzymes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005911" MajorTopicYN="N">Gliosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008666" MajorTopicYN="N">Metalloendopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051744" MajorTopicYN="N">Protein Kinase C-epsilon</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest statement: No conflicts declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>7</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>11</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16698938</ArticleId><ArticleId IdType="pmc">PMC1472455</ArticleId><ArticleId IdType="doi">10.1073/pnas.0509725103</ArticleId><ArticleId IdType="pii">0509725103</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe D. J. Physiol. Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H., Greengard P., Gandy S. J. Biol. Chem. 1995;270:23243&#x2013;23245.</Citation><ArticleIdList><ArticleId IdType="pubmed">7559474</ArticleId></ArticleIdList></Reference><Reference><Citation>Skovronsky D. M., Moore D. B., Milla M. E., Doms R. W., Lee V. M. J. Biol. Chem. 2000;275:2568&#x2013;2575.</Citation><ArticleIdList><ArticleId IdType="pubmed">10644715</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage M. J., Trusko S. P., Howland D. S., Pinsker L. R., Mistretta S., Reaume A. G., Greenberg B. D., Siman R., Scott R. W. J. Neurosci. 1998;18:1743&#x2013;1752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792617</ArticleId><ArticleId IdType="pubmed">9464999</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. J., Schenk D. Annu. Rev. Pharmacol. Toxicol. 2003;43:545&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415125</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. J. Neuron. 2001;32:177&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">11683988</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring M. A., Farris W., Chang A. Y., Walsh D. M., Wu X., Sun X., Frosch M. P., Selkoe D. J. Neuron. 2003;40:1087&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pubmed">14687544</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckman E. A., Watson M., Marlow L., Sambamurti K., Eckman C. B. J. Biol. Chem. 2003;278:2081&#x2013;2084.</Citation><ArticleIdList><ArticleId IdType="pubmed">12464614</ArticleId></ArticleIdList></Reference><Reference><Citation>Funalot B., Ouimet T., Claperon A., Fallet C., Delacourte A., Epelbaum J., Subkowski T., Leonard N., Codron V., David J. P., et al. Mol. Psychiatry. 2004;9:1122&#x2013;1128.</Citation><ArticleIdList><ArticleId IdType="pubmed">15340356</ArticleId></ArticleIdList></Reference><Reference><Citation>Slack B. E., Nitsch R. M., Livneh E., Kunz G. M., Breu J., Eldar H., Wurtman R. J. J. Biol. Chem. 1993;268:21097&#x2013;21101.</Citation><ArticleIdList><ArticleId IdType="pubmed">8407946</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinouchi T., Sorimachi H., Maruyama K., Mizuno K., Ohno S., Ishiura S., Suzuki K. FEBS Lett. 1995;364:203&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">7750571</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolly-Tornetta C., Wolf B. A. Biochemistry. 2000;39:7428&#x2013;7435.</Citation><ArticleIdList><ArticleId IdType="pubmed">10858291</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeon S. W., Jung M. W., Ha M. J., Kim S. U., Huh K., Savage M. J., Masliah E., Mook-Jung I. Biochem. Biophys. Res. Commun. 2001;280:782&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">11162589</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanni C., Mazzucchelli M., Porrello E., Govoni S., Racchi M. Eur. J. Biochem. 2004;271:3068&#x2013;3075.</Citation><ArticleIdList><ArticleId IdType="pubmed">15233804</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu G., Wang D., Lin Y. H., McMahon T., Koo E. H., Messing R. O. Biochem. Biophys. Res. Commun. 2001;285:997&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pubmed">11467851</ArticleId></ArticleIdList></Reference><Reference><Citation>Caroni P. J. Neurosci. Methods. 1997;71:3&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9125370</ArticleId></ArticleIdList></Reference><Reference><Citation>Aigner L., Arber S., Kapfhammer J. P., Laux T., Schneider C., Botteri F., Brenner H. R., Caroni P. Cell. 1995;83:269&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">7585944</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L., Masliah E., Yu G. Q., Mallory M., Rockenstein E. M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. J. Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Orzechowski H. D., Gunther A., Menzel S., Zimmermann A., Funke-Kaiser H., Real R., Subkowski T., Zollmann F. S., Paul M. Mol. Pharmacol. 2001;60:1332&#x2013;1342.</Citation><ArticleIdList><ArticleId IdType="pubmed">11723240</ArticleId></ArticleIdList></Reference><Reference><Citation>Khasar S. G., Lin Y.-H., Martin A., Dadgar J., McMahon T., Wang D., Hundle B., Aley K. O., Isenberg W., McCarter G., et al. Neuron. 1999;24:253&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11587340</ArticleId><ArticleId IdType="pubmed">10677042</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner A. J., Murphy L. J. Biochem. Pharmacol. 1996;51:91&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8615890</ArticleId></ArticleIdList></Reference><Reference><Citation>Korth P., Bohle R. M., Corvol P., Pinet F. J. Histochem. Cytochem. 1999;47:447&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">10082746</ArticleId></ArticleIdList></Reference><Reference><Citation>Sluck J. M., Lin R. C., Katolik L. I., Jeng A. Y., Lehmann J. C. Neuroscience. 1999;91:1483&#x2013;1497.</Citation><ArticleIdList><ArticleId IdType="pubmed">10391453</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanagisawa H., Hammer R. E., Richardson J. A., Emoto N., Williams S. C., Takeda S., Clouthier D. E., Yanagisawa M. J. Clin. Invest. 2000;105:1373&#x2013;1382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC315458</ArticleId><ArticleId IdType="pubmed">10811845</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Orleans-Juste P., Plante M., Honore J. C., Carrier E., Labonte J. Can. J. Physiol. Pharmacol. 2003;81:503&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">12839262</ArticleId></ArticleIdList></Reference><Reference><Citation>Naito S., Shimizu S., Matsuu M., Nakashima M., Nakayama T., Yamashita S., Sekine I. Biochem. Biophys. Res. Commun. 2002;291:130&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">11829472</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi R. E., Moir R. D., Wagner S. L. Neuron. 2004;43:605&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">15339642</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T., Masliah E., Mallory M., McConlogue L., Johnson-Wood K., Lin C., Mucke L. Nature. 1997;389:603&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">9335500</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Wood K., Lee M., Motter R., Hu K., Gordon G., Barbour R., Khan K., Gordon M., Tan H., Games D., et al. Proc. Natl. Acad. Sci. USA. 1997;94:1550&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Ongil S., Saura M., Zaragoza C., Gonzalez-Santiago L., Rodriguez-Puyol M., Lowenstein C. J., Rodriguez-Puyol D. Free Radical Biol. Med. 2002;32:406&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">11864780</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn K., Pan S., Beningo K., Hupe D. Life Sci. 1995;56:2331&#x2013;2341.</Citation><ArticleIdList><ArticleId IdType="pubmed">7791520</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring M. A., Lu A., Condron M. M., Teplow D. B., Stein R. L., Farris W., Selkoe D. J. J. Biol. Chem. 2003;278:37314&#x2013;37320.</Citation><ArticleIdList><ArticleId IdType="pubmed">12867419</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T., Iwata N., Tsubuki S., Takaki Y., Takano J., Huang S. M., Suemoto T., Higuchi M., Saido T. C. Nat. Med. 2005;11:434&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">15778722</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16713961</PMID><DateCompleted><Year>2006</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0960-9822</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>10</Issue><PubDate><Year>2006</Year><Month>May</Month><Day>23</Day></PubDate></JournalIssue><Title>Current biology : CB</Title><ISOAbbreviation>Curr Biol</ISOAbbreviation></Journal><ArticleTitle>Modeling clinically heterogeneous presenilin mutations with transgenic Drosophila.</ArticleTitle><Pagination><StartPage>1026</StartPage><EndPage>1033</EndPage><MedlinePgn>1026-33</MedlinePgn></Pagination><Abstract><AbstractText>To assess the potential of Drosophila to analyze clinically graded aspects of human disease, we developed a transgenic fly model to characterize Presenilin (PS) gene mutations that cause early-onset familial Alzheimer's disease (FAD). FAD exhibits a wide range in severity defined by ages of onset from 24 to 65 years . PS FAD mutants have been analyzed in mammalian cell culture, but conflicting data emerged concerning correlations between age of onset and PS biochemical activity . Choosing from over 130 FAD mutations in Presenilin-1, we introduced 14 corresponding mutations at conserved residues in Drosophila Presenilin (Psn) and assessed their biological activity in transgenic flies by using genetic, molecular, and statistical methods. Psn FAD mutant activities were tightly linked to their age-of-onset values, providing evidence that disease severity in humans primarily reflects differences in PS mutant lesions rather than contributions from unlinked genetic or environmental modifiers. Our study establishes a precedent for using transgenic Drosophila to study clinical heterogeneity in human disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seidner</LastName><ForeName>Glen A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Laboratory of Protein Dynamics and Signaling, NCI-Frederick, National Institutes of Health, Frederick, Maryland 21702, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Yihong</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Faraday</LastName><ForeName>Martha M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Alvord</LastName><ForeName>W Gregory</ForeName><Initials>WG</Initials></Author><Author ValidYN="Y"><LastName>Fortini</LastName><ForeName>Mark E</ForeName><Initials>ME</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG14583</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-CO12400</GrantID><Acronym>CO</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Biol</MedlineTA><NlmUniqueID>9107782</NlmUniqueID><ISSNLinking>0960-9822</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053763">Presenilins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C106427">Psn protein, Drosophila</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029721" MajorTopicYN="N">Drosophila Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018740" MajorTopicYN="N">Genetic Heterogeneity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053763" MajorTopicYN="N">Presenilins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16713961</ArticleId><ArticleId IdType="doi">10.1016/j.cub.2006.04.004</ArticleId><ArticleId IdType="pii">S0960-9822(06)01465-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16724068</PMID><DateCompleted><Year>2006</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>441</Volume><Issue>7092</Issue><PubDate><Year>2006</Year><Month>May</Month><Day>25</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration.</ArticleTitle><Pagination><StartPage>513</StartPage><EndPage>517</EndPage><MedlinePgn>513-7</MedlinePgn></Pagination><Abstract><AbstractText>Stress proteins located in the cytosol or endoplasmic reticulum (ER) maintain cell homeostasis and afford tolerance to severe insults. In neurodegenerative diseases, several chaperones ameliorate the accumulation of misfolded proteins triggered by oxidative or nitrosative stress, or of mutated gene products. Although severe ER stress can induce apoptosis, the ER withstands relatively mild insults through the expression of stress proteins or chaperones such as glucose-regulated protein (GRP) and protein-disulphide isomerase (PDI), which assist in the maturation and transport of unfolded secretory proteins. PDI catalyses thiol-disulphide exchange, thus facilitating disulphide bond formation and rearrangement reactions. PDI has two domains that function as independent active sites with homology to the small, redox-active protein thioredoxin. During neurodegenerative disorders and cerebral ischaemia, the accumulation of immature and denatured proteins results in ER dysfunction, but the upregulation of PDI represents an adaptive response to protect neuronal cells. Here we show, in brains manifesting sporadic Parkinson's or Alzheimer's disease, that PDI is S-nitrosylated, a reaction transferring a nitric oxide (NO) group to a critical cysteine thiol to affect protein function. NO-induced S-nitrosylation of PDI inhibits its enzymatic activity, leads to the accumulation of polyubiquitinated proteins, and activates the unfolded protein response. S-nitrosylation also abrogates PDI-mediated attenuation of neuronal cell death triggered by ER stress, misfolded proteins or proteasome inhibition. Thus, PDI prevents neurotoxicity associated with ER stress and protein misfolding, but NO blocks this protective effect in neurodegenerative disorders through the S-nitrosylation of PDI.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Uehara</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Neuroscience and Aging, Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, California 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Tomohiro</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Dongdong</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Zhong-Qing</ForeName><Initials>ZQ</Initials></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Zezong</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yuliang</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Nomura</LastName><ForeName>Yasuyuki</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Lipton</LastName><ForeName>Stuart A</ForeName><Initials>SA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C480827">GPR37 receptor, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061988">Proteasome Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013438">Sulfhydryl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance></Chemical><Chemical><RegistryNumber>31C4KY9ESH</RegistryNumber><NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>6384-92-5</RegistryNumber><NameOfSubstance UI="D016202">N-Methylaspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 5.3.4.1</RegistryNumber><NameOfSubstance UI="D019704">Protein Disulfide-Isomerases</NameOfSubstance></Chemical><Chemical><RegistryNumber>K848JZ4886</RegistryNumber><NameOfSubstance UI="D003545">Cysteine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003545" MajorTopicYN="N">Cysteine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016202" MajorTopicYN="N">N-Methylaspartate</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061988" MajorTopicYN="N">Proteasome Inhibitors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019704" MajorTopicYN="N">Protein Disulfide-Isomerases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="Y">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043562" MajorTopicYN="N">Receptors, G-Protein-Coupled</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013438" MajorTopicYN="N">Sulfhydryl Compounds</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025801" MajorTopicYN="N">Ubiquitin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16724068</ArticleId><ArticleId IdType="doi">10.1038/nature04782</ArticleId><ArticleId IdType="pii">nature04782</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">1673054</PMID><DateCompleted><Year>1991</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>4</Issue><PubDate><Year>1991</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>The molecular pathology of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>487</StartPage><EndPage>498</EndPage><MedlinePgn>487-98</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>D J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts 02115.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018377">Neurotransmitter Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003598" MajorTopicYN="N">Cytoskeletal Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018377" MajorTopicYN="N">Neurotransmitter Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>136</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1673054</ArticleId><ArticleId IdType="doi">10.1016/0896-6273(91)90052-2</ArticleId><ArticleId IdType="pii">0896-6273(91)90052-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16734669</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1398-9219</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>7</Issue><PubDate><Year>2006</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Traffic (Copenhagen, Denmark)</Title><ISOAbbreviation>Traffic</ISOAbbreviation></Journal><ArticleTitle>Inhibition of APP trafficking by tau protein does not increase the generation of amyloid-beta peptides.</ArticleTitle><Pagination><StartPage>873</StartPage><EndPage>888</EndPage><MedlinePgn>873-88</MedlinePgn></Pagination><Abstract><AbstractText>Amyloid-beta, a peptide derived from the precursor protein APP, accumulates in the brain and contributes to the neuropathology of Alzheimer's disease. Increased generation of amyloid-beta might be caused by axonal transport inhibition, via increased dwell time of APP vesicles and thereby higher probability of APP cleavage by secretase enzymes residing on the same vesicles. We tested this hypothesis using a neuronal cell culture model of inhibited axonal transport and by imaging vesicular transport of fluorescently tagged APP and beta-secretase (BACE1). Microtubule-associated tau protein blocks vesicle traffic by inhibiting the access of motor proteins to the microtubule tracks. In neurons co-transfected with CFP-tau, APP-YFP traffic into distal neurites was strongly reduced. However, this did not increase amyloid-beta levels. In singly transfected axons, APP-YFP was transported in large tubules and vesicles moving very fast (on average 3 microm/s) and with high fluxes in the anterograde direction (on average 8.4 vesicles/min). By contrast, BACE1-CFP movement was in smaller tubules and vesicles that were almost 2x slower (on average 1.6 microm/s) with approximately 18x lower fluxes (on average 0.5 vesicles/min). Two-colour microscopy of co-transfected axons confirmed that the two proteins were sorted into distinct carriers. The results do not support the above hypothesis. Instead, they indicate that APP is transported on vesicles distinct from the secretase components and that amyloid-beta is not generated in transit when transport is blocked by tau.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goldsbury</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Max Planck Unit for Structural Molecular Biology, c/o DESY, Notkestrasse 85, 22607 Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mocanu</LastName><ForeName>Maria-Magdalena</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Thies</LastName><ForeName>Edda</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Kaether</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Biernat</LastName><ForeName>Jacek</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eckhard</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eva-Maria</ForeName><Initials>EM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Traffic</MedlineTA><NlmUniqueID>100939340</NlmUniqueID><ISSNLinking>1398-9219</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012165" MajorTopicYN="N">Retinal Ganglion Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>6</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>6</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16734669</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0854.2006.00434.x</ArticleId><ArticleId IdType="pii">TRA434</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16738255</PMID><DateCompleted><Year>2006</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>22</Issue><PubDate><Year>2006</Year><Month>May</Month><Day>31</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Tau aggregation and progressive neuronal degeneration in the absence of changes in spine density and morphology after targeted expression of Alzheimer's disease-relevant tau constructs in organotypic hippocampal slices.</ArticleTitle><Pagination><StartPage>6103</StartPage><EndPage>6114</EndPage><MedlinePgn>6103-14</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) is characterized by progressive loss of neurons in selected brain regions, extracellular accumulations of amyloid beta, and intracellular fibrils containing hyperphosphorylated tau. Tau mutations in familial tauopathies confirmed a central role of tau pathology; however, the role of tau alteration and the sequence of tau-dependent neurodegeneration in AD remain elusive. Using Sindbis virus-mediated expression of AD-relevant tau constructs in hippocampal slices, we show that disease-like tau modifications affect tau phosphorylation at selected sites, induce Alz50/MC1-reactive pathological tau conformation, cause accumulation of insoluble tau, and induce region-specific neurodegeneration. Live imaging demonstrates that tau-dependent degeneration is associated with the development of a "ballooned" phenotype, a distinct feature of cell death. Spine density and morphology is not altered as judged from algorithm-based evaluation of dendritic spines, suggesting that synaptic integrity is remarkably stable against tau-dependent degeneration. The data provide evidence that tau-induced cell death involves apoptotic as well as nonapoptotic mechanisms. Furthermore, they demonstrate that targeted expression of tau in hippocampal slices provides a novel model to analyze tau modification and spatiotemporal dynamics of tau-dependent neurodegeneration in an authentic CNS environment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shahani</LastName><ForeName>Neelam</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of Osnabr&#xfc;ck, 49076 Osnabr&#xfc;ck, Germany. neelam.shahani@biologie.uni-osnabrueck.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subramaniam</LastName><ForeName>Srinivasa</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Tackenberg</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Brandt</LastName><ForeName>Roland</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017930" MajorTopicYN="N">Genes, Reporter</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>6</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>6</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>6</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>11</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16738255</ArticleId><ArticleId IdType="pmc">PMC6675219</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4245-05.2006</ArticleId><ArticleId IdType="pii">26/22/6103</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, Yoshida H, Holzer M, Craxton M, Emson PC, Atzori C, Migheli A, Crowther RA, Ghetti B, Spillantini MG, Goedert M (2002). Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 22:9340&#x2013;9351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758022</ArticleId><ArticleId IdType="pubmed">12417659</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T, Holzer M, Grossmann A, Zedlick D, Bruckner MK (1995). Increased expression and subcellular translocation of the mitogen activated protein kinase kinase and mitogen-activated protein kinase in Alzheimer's disease. Neuroscience 68:5&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">7477934</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustinack JC, Schneider A, Mandelkow EM, Hyman BT (2002). Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol (Berl) 103:26&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">11837744</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E, Strothjohann M (1994). Abnormally phosphorylated tau protein related to the formation of neurofibrillary tangles and neuropil threads in the cerebral cortex of sheep and goat. Neurosci Lett 171:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">7521944</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt R, Hundelt M, Shahani N (2005). Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. Biochim Biophys Acta 1739:331&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615650</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman PD, Yao PJ (2003). Synaptic slaughter in Alzheimer's disease. Neurobiol Aging 24:1023&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643374</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis BG (2004). Mimicking posttranslational modifications of proteins. Science 303:480&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pubmed">14739446</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Yen SH, Suzuki KI, Davies P, Garcia JH, Hirano A (1986). Ballooned neurons in select neurodegenerative diseases contain phosphorylated neurofilament epitopes. Acta Neuropathol (Berl) 71:216&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">2432750</ArticleId></ArticleIdList></Reference><Reference><Citation>Drewes G, Lichtenberg-Kraag B, Doring F, Mandelkow EM, Biernat J, Goris J, Doree M, Mandelkow E (1992). Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. EMBO J 11:2131&#x2013;2138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556680</ArticleId><ArticleId IdType="pubmed">1376245</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrengruber MU, Lundstrom K, Schweitzer C, Heuss C, Schlesinger S, Gahwiler BH (1999). Recombinant Semliki Forest virus and Sindbis virus efficiently infect neurons in hippocampal slice cultures. Proc Natl Acad Sci USA 96:7041&#x2013;7046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22049</ArticleId><ArticleId IdType="pubmed">10359835</ArticleId></ArticleIdList></Reference><Reference><Citation>Eidenm&#xfc;ller J, Fath T, Hellwig A, Reed J, Sontag E, Brandt R (2000). Structural and functional implications of tau hyperphosphorylation: information from phosphorylation-mimicking mutated tau proteins. Biochemistry 39:13166&#x2013;13175.</Citation><ArticleIdList><ArticleId IdType="pubmed">11052669</ArticleId></ArticleIdList></Reference><Reference><Citation>Eidenm&#xfc;ller J, Fath T, Maas T, Pool M, Sontag E, Brandt R (2001). Phosphorylation-mimicking glutamate clusters in the proline-rich region are sufficient to simulate the functional deficiencies of hyperphosphorylated tau protein. Biochem J 357:759&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1222005</ArticleId><ArticleId IdType="pubmed">11463346</ArticleId></ArticleIdList></Reference><Reference><Citation>el Hachimi KH, Foncin JF (1990). [Loss of dendritic spines in Alzheimer's disease]. C R Acad Sci III 311:397&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">2125849</ArticleId></ArticleIdList></Reference><Reference><Citation>Fath T, Eidenm&#xfc;ller J, Brandt R (2002). Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer's disease. J Neurosci 22:9733&#x2013;9741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757822</ArticleId><ArticleId IdType="pubmed">12427828</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, Gullotta F (1990). Down's syndrome and Alzheimer's disease: dendritic spine counts in the hippocampus. Acta Neuropathol (Berl) 79:680&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">2141748</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujino Y, Delucia MW, Davies P, Dickson DW (2004). Ballooned neurones in the limbic lobe are associated with Alzheimer type pathology and lack diagnostic specificity. Neuropathol Appl Neurobiol 30:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">15541007</ArticleId></ArticleIdList></Reference><Reference><Citation>Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, LeBlanc A, Smith D, Rigby M, Shearman MS, Clarke EE, Zheng H, Van Der Ploeg LH, Ruffolo SC, Thornberry NA, Xanthoudakis S, Zamboni RJ, Roy S, Nicholson DW (1999). Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 97:395&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">10319819</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianinazzi C, Grandgirard D, Simon F, Imboden H, Joss P, Tauber MG, Leib SL (2004). Apoptosis of hippocampal neurons in organotypic slice culture models: direct effect of bacteria revisited. J Neuropathol Exp Neurol 63:610&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">15217089</ArticleId></ArticleIdList></Reference><Reference><Citation>Gleckman AM, Jiang Z, Liu Y, Smith TW (1999). Neuronal and glial DNA fragmentation in Pick's disease. Acta Neuropathol (Berl) 98:55&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">10412801</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT (1997). Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 41:17&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">9005861</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Chen F, van Dorpe J, Nitsch RM (2001). Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293:1491&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>Holzer M, Holzapfel HP, Zedlick D, Bruckner MK, Arendt T (1994). Abnormally phosphorylated tau protein in Alzheimer's disease: heterogeneity of individual regional distribution and relationship to clinical severity. Neuroscience 63:499&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">7891861</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu BR, Wieloch T (1994). Tyrosine phosphorylation and activation of mitogen-activated protein kinase in the rat brain following transient cerebral ischemia. J Neurochem 62:1357&#x2013;1367.</Citation><ArticleIdList><ArticleId IdType="pubmed">7510779</ArticleId></ArticleIdList></Reference><Reference><Citation>Huffine ME, Scholtz JM (1996). Energetic implications for protein phosphorylation. Conformational stability of HPr variants that mimic phosphorylated forms. J Biol Chem 271:28898&#x2013;28902.</Citation><ArticleIdList><ArticleId IdType="pubmed">8910537</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, Khatoon S, Li B, Liu F, Rahman A, Tanimukai H, Grundke-Iqbal I (2005). Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 1739:198&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615638</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Bowser R, Kazam IG, Davies P (1997). Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res 48:128&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">9130141</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh IY, Lindquist WB, Zito K, Nimchinsky EA, Svoboda K (2002). An image analysis algorithm for dendritic spines. Neural Comput 14:1283&#x2013;1310.</Citation><ArticleIdList><ArticleId IdType="pubmed">12020447</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowall NW, McKee AC (1993). The histopathology of neuronal degeneration and plasticity in Alzheimer disease. Adv Neurol 59:5&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">8420123</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassmann H, Bancher C, Breitschopf H, Wegiel J, Bobinski M, Jellinger K, Wisniewski HM (1995). Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ Acta Neuropathol (Berl) 89:35&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">7709729</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauckner J, Frey P, Geula C (2003). Comparative distribution of tau phosphorylated at Ser262 in pre-tangles and tangles. Neurobiol Aging 24:767&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">12927759</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Goedert M, Trojanowski JQ (2001). Neurodegenerative tauopathies. Annu Rev Neurosci 24:1121&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E (2001). Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:1487&#x2013;1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520987</ArticleId></ArticleIdList></Reference><Reference><Citation>Maas T, Eidenm&#xfc;ller J, Brandt R (2000). Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments. J Biol Chem 275:15733&#x2013;15740.</Citation><ArticleIdList><ArticleId IdType="pubmed">10747907</ArticleId></ArticleIdList></Reference><Reference><Citation>Maciejewski PM, Peterson FC, Anderson PJ, Brooks CL (1995). Mutation of serine 90 to glutamic acid mimics phosphorylation of bovine prolactin. J Biol Chem 270:27661&#x2013;27665.</Citation><ArticleIdList><ArticleId IdType="pubmed">7499231</ArticleId></ArticleIdList></Reference><Reference><Citation>Maletic-Savatic M, Malinow R, Svoboda K (1999). Rapid dendritic morphogenesis in CA1 hippocampal dendrites induced by synaptic activity. Science 283:1923&#x2013;1927.</Citation><ArticleIdList><ArticleId IdType="pubmed">10082466</ArticleId></ArticleIdList></Reference><Reference><Citation>Maragos WF, Tillman P, Jones M, Bruce-Keller AJ, Roth S, Bell JE, Nath A (2003). Neuronal injury in hippocampus with human immunodeficiency virus transactivating protein, Tat. Neuroscience 117:43&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">12605891</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuo ES, Shin RW, Billingsley ML, Van de Voorde A, O&#x2019;Connor M, Trojanowski JQ, Lee VM (1994). Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron 13:989&#x2013;1002.</Citation><ArticleIdList><ArticleId IdType="pubmed">7946342</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Kowall NW, Kosik KS (1989). Microtubular reorganization and dendritic growth response in Alzheimer's disease. Ann Neurol 26:652&#x2013;659.</Citation><ArticleIdList><ArticleId IdType="pubmed">2817839</ArticleId></ArticleIdList></Reference><Reference><Citation>Megias M, Emri Z, Freund TF, Gulyas AI (2001). Total number and distribution of inhibitory and excitatory synapses on hippocampal CA1 pyramidal cells. Neuroscience 102:527&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">11226691</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrick SE, Demoise DC, Lee VM (1996). Site-specific dephosphorylation of tau protein at Ser202/Thr205 in response to microtubule depolymerization in cultured human neurons involves protein phosphatase 2A. J Biol Chem 271:5589&#x2013;5594.</Citation><ArticleIdList><ArticleId IdType="pubmed">8621419</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei JJ, Braak H, An WL, Winblad B, Cowburn RF, Iqbal K, Grundke-Iqbal I (2002). Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. Brain Res Mol Brain Res 109:45&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">12531514</ArticleId></ArticleIdList></Reference><Reference><Citation>Runden E, Seglen PO, Haug FM, Ottersen OP, Wieloch T, Shamloo M, Laake JH (1998). Regional selective neuronal degeneration after protein phosphatase inhibition in hippocampal slice cultures: evidence for a MAP kinase-dependent mechanism. J Neurosci 18:7296&#x2013;7305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793243</ArticleId><ArticleId IdType="pubmed">9736650</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt-Kastner R, Freund TF (1991). Selective vulnerability of the hippocampus in brain ischemia. Neuroscience 40:599&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">1676492</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ (2002). Alzheimer's disease is a synaptic failure. Science 298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Ihara Y, Salazar FJ (1982). Alzheimer's disease: insolubility of partially purified paired helical filaments in sodium dodecyl sulfate and urea. Science 215:1243&#x2013;1245.</Citation><ArticleIdList><ArticleId IdType="pubmed">6120571</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahani N, Brandt R (2002). Functions and malfunctions of the tau proteins. Cell Mol Life Sci 59:1668&#x2013;1680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11337454</ArticleId><ArticleId IdType="pubmed">12475178</ArticleId></ArticleIdList></Reference><Reference><Citation>Smale G, Nichols NR, Brady DR, Finch CE, Horton WE Jr (1995). Evidence for apoptotic cell death in Alzheimer's disease. Exp Neurol 133:225&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">7544290</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoothoff WH, Johnson GV (2005). Tau phosphorylation: physiological and pathological consequences. Biochim Biophys Acta 1739:280&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615646</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoppini L, Buchs PA, Muller D (1991). A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 37:173&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">1715499</ArticleId></ArticleIdList></Reference><Reference><Citation>Su JH, Cummings BJ, Cotman CW (1994a). Subpopulations of dystrophic neurites [correction of neuritis] in Alzheimer's brain with distinct immunocytochemical and argentophilic characteristics. Brain Res 637:37&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">8180819</ArticleId></ArticleIdList></Reference><Reference><Citation>Su JH, Anderson AJ, Cummings BJ, Cotman CW (1994b). Immunohistochemical evidence for apoptosis in Alzheimer's disease. NeuroReport 5:2529&#x2013;2533.</Citation><ArticleIdList><ArticleId IdType="pubmed">7696596</ArticleId></ArticleIdList></Reference><Reference><Citation>Su JH, Zhao M, Anderson AJ, Srinivasan A, Cotman CW (2001). Activated caspase-3 expression in Alzheimer's and aged control brain: correlation with Alzheimer pathology. Brain Res 898:350&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">11306022</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramaniam S, Zirrgiebel U, von Bohlen Und Halbach O, Strelau J, Laliberte C, Kaplan DR, Unsicker K (2004). ERK activation promotes neuronal degeneration predominantly through plasma membrane damage and independently of caspase-3. J Cell Biol 165:357&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172179</ArticleId><ArticleId IdType="pubmed">15123736</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991). Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Uboga NV, Price JL (2000). Formation of diffuse and fibrillar tangles in aging and early Alzheimer's disease. Neurobiol Aging 21:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">10794842</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang ZY, Wang F, Sellers JR, Korn ED, Hammer III JA (1998). Analysis of the regulatory phosphorylation site in Acanthamoeba myosin IC by using site-directed mutagenesis. Proc Natl Acad Sci USA 95:15200&#x2013;15205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC28020</ArticleId><ArticleId IdType="pubmed">9860946</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver CL, Espinoza M, Kress Y, Davies P (2000). Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol Aging 21:719&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">11016541</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver CM, Hof PR, Wearne SL, Lindquist WB (2004). Automated algorithms for multiscale morphometry of neuronal dendrites. Neural Comput 16:1353&#x2013;1383.</Citation><ArticleIdList><ArticleId IdType="pubmed">15165394</ArticleId></ArticleIdList></Reference><Reference><Citation>West MJ, Coleman PD, Flood DG, Troncoso JC (1994). Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet 344:769&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pubmed">7916070</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin BL, Pruchnicki A, Dickson DW, Davies P (1986). A neuronal antigen in the brains of Alzheimer patients. Science 232:648&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">3083509</ArticleId></ArticleIdList></Reference><Reference><Citation>Zehr C, Lewis J, McGowan E, Crook J, Lin WL, Godwin K, Knight J, Dickson DW, Hutton M (2004). Apoptosis in oligodendrocytes is associated with axonal degeneration in P310L tau mice. Neurobiol Dis 15:553&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pubmed">15056463</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z, Li X, Chen W, Zhao Y, Li H, Qing C, Jia N, Bai Z, Liu J (2004). Prenatal stress causes gender-dependent neuronal loss and oxidative stress in rat hippocampus. J Neurosci Res 78:837&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">15499594</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhukareva V, Trojanowski JQ, Lee VM (2004). Assessment of pathological tau proteins in frontotemporal dementias: qualitative and quantitative approaches. Am J Geriatr Psychiatry 12:136&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">15010343</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16751189</PMID><DateCompleted><Year>2006</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>281</Volume><Issue>31</Issue><PubDate><Year>2006</Year><Month>Aug</Month><Day>04</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction.</ArticleTitle><Pagination><StartPage>21745</StartPage><EndPage>21754</EndPage><MedlinePgn>21745-21754</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M602909200</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0021-9258(19)47693-X</ELocationID><Abstract><AbstractText>Nicotinamide adenine dinucleotide (NAD)+-dependent sirtuins have been identified to be key regulators in the lifespan extending effects of calorie restriction (CR) in a number of species. In this study we report for the first time that promotion of the NAD+-dependent sirtuin, SIRT1-mediated deacetylase activity, may be a mechanism by which CR influences Alzheimer disease (AD)-type amyloid neuropathology. Most importantly, we report that the predicted attenuation of beta-amyloid content in the brain during CR can be reproduced in mouse neurons in vitro by manipulating cellular SIRT1 expression/activity through mechanisms involving the regulation of the serine/threonine Rho kinase ROCK1, known in part for its role in the inhibition of the non-amyloidogenic alpha-secretase processing of the amyloid precursor protein. Conversely, we found that the expression of constitutively active ROCK1 in vitro cultures significantly prevented SIRT1-mediated response, suggesting that alpha-secretase activity is required for SIRT1-mediated prevention of AD-type amyloid neuropathology. Consistently we found that the expression of exogenous human (h) SIRT1 in the brain of hSIRT1 transgenics also resulted in decreased ROCK1 expression and elevated alpha-secretase activity in vivo. These results demonstrate for the first time a role for SIRT1 activation in the brain as a novel mechanism through which CR may influence AD amyloid neuropathology. The study provides a potentially novel pharmacological strategy for AD prevention and/or treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Weiping</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Tianle</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Tri-Institutional Program in Chemical Biology, Weill Medical College of Cornell University, New York, New York 10021.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Lap</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029; Department of Neuroscience, Mount Sinai School of Medicine, New York, New York 10029; Geriatric Research and Clinical Center, Bronx Veterans Affairs Medical Center, Bronx, New York 10468.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Zhong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Linghong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thiyagarajan</LastName><ForeName>Meenakshisundaram</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacGrogan</LastName><ForeName>Donal</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodgers</LastName><ForeName>Joseph T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puigserver</LastName><ForeName>Pere</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadoshima</LastName><ForeName>Junichi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Institute, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey 07103.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Haiteng</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Proteomics Resource Center, The Rockefeller University, New York, New York 10021.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedrini</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Farber Institute for Neurosciences, Thomas Jefferson University, Philadelphia, Pennsylvania 19107-5099.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gandy</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Farber Institute for Neurosciences, Thomas Jefferson University, Philadelphia, Pennsylvania 19107-5099.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sauve</LastName><ForeName>Anthony A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Tri-Institutional Program in Chemical Biology, Weill Medical College of Cornell University, New York, New York 10021. Electronic address: as2004@med.cornell.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasinetti</LastName><ForeName>Giulio M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029; Department of Neuroscience, Mount Sinai School of Medicine, New York, New York 10029; Geriatric Research and Clinical Center, Bronx Veterans Affairs Medical Center, Bronx, New York 10468. Electronic address: giulio.pasinetti@mssm.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG010491</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C515851">ROCK1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C515854">Rock1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D054460">rho-Associated Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="C470545">Sirt1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="D056564">Sirtuin 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="D037761">Sirtuins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="Y">diet therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D031204" MajorTopicYN="Y">Caloric Restriction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008815" MajorTopicYN="N">Mice, Inbred Strains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056564" MajorTopicYN="N">Sirtuin 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D037761" MajorTopicYN="N">Sirtuins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054460" MajorTopicYN="N">rho-Associated Kinases</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>10</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16751189</ArticleId><ArticleId IdType="doi">10.1074/jbc.M602909200</ArticleId><ArticleId IdType="pii">S0021-9258(19)47693-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16763046</PMID><DateCompleted><Year>2006</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>23</Issue><PubDate><Year>2006</Year><Month>Jun</Month><Day>07</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>6377</StartPage><EndPage>6385</EndPage><MedlinePgn>6377-85</MedlinePgn></Pagination><Abstract><AbstractText>Presenilins (PSs) are part of the gamma-secretase complex that produces the amyloid beta-peptide (Abeta) from its precursor [beta-amyloid precursor protein (betaAPP)]. Mutations in PS that cause familial Alzheimer's disease (FAD) increase Abeta production and trigger p53-dependent cell death. We demonstrate that PS deficiency, catalytically inactive PS mutants, gamma-secretase inhibitors, and betaAPP or amyloid precursor protein-like protein 2 (APLP2) depletion all reduce the expression and activity of p53 and lower the transactivation of its promoter and mRNA expression. p53 expression also is diminished in the brains of PS- or betaAPP-deficient mice. The gamma- and epsilon-secretase-derived amyloid intracellular C-terminal domain (AICD) fragments (AICDC59 and AICDC50, respectively) of betaAPP trigger p53-dependent cell death and increase p53 activity and mRNA. Finally, PS1 mutations enhance p53 activity in human embryonic kidney 293 cells and p53 expression in FAD-affected brains. Thus our study shows that AICDs control p53 at a transcriptional level, in vitro and in vivo, and that FAD mutations increase p53 expression and activity in cells and human brains.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alves da Costa</LastName><ForeName>Cristine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Molecular and Cellular Pharmacology, Coeducational Unit of Research 6097, National Center of Scientific Research/Nice-Sophia-Antipolis University, 06560 Valbonne, France. acosta@ipmc.cnrs.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sunyach</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pardossi-Piquard</LastName><ForeName>Raphaelle</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>S&#xe9;valle</LastName><ForeName>Jean</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Vincent</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Boyer</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Kawarai</LastName><ForeName>Toshitaka</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Girardot</LastName><ForeName>Nad&#xe8;ge</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>St George-Hyslop</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Checler</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C084104">APLP2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508861">PSEN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C505407">CASP3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D020169">Caspases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015533" MajorTopicYN="N">Transcriptional Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>6</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>6</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>12</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16763046</ArticleId><ArticleId IdType="pmc">PMC6675197</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0651-06.2006</ArticleId><ArticleId IdType="pii">26/23/6377</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alves da Costa C, Paitel E, Mattson MP, Amson R, Telerman A, Ancolio K, Checler F (2002). Wild-type and mutated presenilin-2 trigger p53-dependent apoptosis and down-regulate presenilin-1 expression in HEK 293 human cells and in murine neurons. Proc Natl Acad Sci USA 99:4043&#x2013;4048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122645</ArticleId><ArticleId IdType="pubmed">11904448</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves da Costa C, Mattson M, Ancolio K, Checler F (2003). The C-terminal fragment of presenilin 2 triggers p53-mediated staurosporine-induced apoptosis, a function independent of the presenilinase-derived N-terminal counterpart. J Biol Chem 278:12064&#x2013;12069.</Citation><ArticleIdList><ArticleId IdType="pubmed">12556443</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki W, Yuasa K, Takeda S, Shirotani K, Takahashi K, Tabira T (2000). Overexpression of presenilin-2 enhances apoptotic death of cultured cortical neurons. Ann NY Acad Sci 920:241&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193157</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki W, Yuasa K, Takeda S, Takeda K, Shirotani K, Takahashi K, Tabira T (2001). Pro-apoptotic effect of presenilin 2 (PS2) overexpression is associated with down-regulation of Bcl-2 in cultured neurons. J Neurochem 79:1161&#x2013;1168.</Citation><ArticleIdList><ArticleId IdType="pubmed">11752057</ArticleId></ArticleIdList></Reference><Reference><Citation>Baek SH, Ohgi KA, Rose DW, Koo EH, Glass CK, Rosenfeld MG (2002). Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-&#x3ba;B and &#x3b2;-amyloid precursor protein. Cell 110:55&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">12150997</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar J, Cohen-Noyman E, Geiger B, Oren M (2004). Attenuation of the p53 response to DNA damage by high cell density. Oncogene 23:2128&#x2013;2137.</Citation><ArticleIdList><ArticleId IdType="pubmed">14755247</ArticleId></ArticleIdList></Reference><Reference><Citation>Bursztajn S, DeSouza R, McPhie DL, Berman SA, Shioi J, Robakis NK, Neve RL (1998). Overexpression in neurons of human presenilin-1 or a presenilin-1 familial Alzheimer's disease mutant does not enhance apoptosis. J Neurosci 18:9790&#x2013;9799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793279</ArticleId><ArticleId IdType="pubmed">9822738</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, S&#xfc;dhof TC (2001). A transcriptively active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 293:115&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441186</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan SL, Culmsee C, Haughey N, Klapper W, Mattson MP (2002). Presenilin-1 mutations sensitize neurons to DNA damage-induced death by a mechanism involving perturbed calcium homeostasis and activation of calpains and caspase 12. Neurobiol Dis 11:2&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">12460542</ArticleId></ArticleIdList></Reference><Reference><Citation>Checler F (1995). Processing of the &#x3b2;-amyloid precursor protein and its regulation in Alzheimer's disease. J Neurochem 65:1431&#x2013;1444.</Citation><ArticleIdList><ArticleId IdType="pubmed">7561836</ArticleId></ArticleIdList></Reference><Reference><Citation>Checler F (1999). Presenilins: multifunctional proteins involved in Alzheimer's disease pathology. IUBMB Life 48:33&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">10791913</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen F, Tandon A, Sanjo N, Gu YJ, Hasegawa H, Arawaka S, Lee FJS, Ruan X, Mastrangelo P, Erdebil S, Wang L, Westaway D, Mount HTJ, Yankner B, Fraser PE, St. George-Hyslop P (2003). Presenilin 1 and presenilin 2 have different effects on the stability and maturation of nicastrin in mammalian cells. J Biol Chem 278:19974&#x2013;19979.</Citation><ArticleIdList><ArticleId IdType="pubmed">12646573</ArticleId></ArticleIdList></Reference><Reference><Citation>Cregan SP, MacLaurin JG, Craig CG, Robertson GS, Nicholson DW, Park DS, Slack RS (1999). Bax-dependent caspase-3 activation is a key determinant in p53-induced apoptosis in neurons. J Neurosci 19:7860&#x2013;7869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782440</ArticleId><ArticleId IdType="pubmed">10479688</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Monte S, Sohn YK, Wands JR (1997). Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J Neurol Sci 152:73&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">9395128</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B (2003). Aph-1, Pen-2, and nicastrin with presenilin generate an active &#x3b3;-secretase complex. Neuron 38:9&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12691659</ArticleId></ArticleIdList></Reference><Reference><Citation>Edbauer D, Willem M, Lammich S, Steiner H, Haass C (2002). Insulin-degrading enzyme rapidly removes the &#x3b2;-amyloid precursor protein intracellular domain (AICD). J Biol Chem 277:13389&#x2013;13393.</Citation><ArticleIdList><ArticleId IdType="pubmed">11809755</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggert S, Paliga K, Soba P, Evin G, Masters CL, Weidemann A, Beyreuther K (2004). The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves &#x3b1;-, &#x3b2;-, &#x3b3;-, and &#x3b5;-like cleavages. Modulation of APLP-1 processing by N-glycosylation. J Biol Chem 279:18146&#x2013;18156.</Citation><ArticleIdList><ArticleId IdType="pubmed">14970212</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Deiry W, Kern S, Pietenpol J, Kinzler K, Vogelstein B (1992). Definition of a consensus binding site for p53. Nat Genet 1:45&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">1301998</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher DE (2001). The p53 tumor suppressor: critical regulator of life and death in cancer. Apoptosis 6:7&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">11321044</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis R, McGrath G, Zhang J, Ruddy DA, Sym M, Apfeld J, Nicoli M, Maxwell M, Hai B, Ellis MC, Parks AL, Xu W, Li H, Gurney M, Myers RL, Himes CS, Hiebsch R, Ruble C, Nye JS, Curtis D (2002). Aph-1 and Pen-2 are required for Notch pathway signaling, &#x3b3;-secretase cleavage of &#x3b2;APP, and presenilin protein accumulation. Dev Cell 3:85&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">12110170</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Ospina GP, Ginenez-Del Rio M, Lopera F, Velez-Pardo C (2003). Neuronal DNA damage correlates with a positive detection of c-Jun, nuclear factor &#x3ba;B, p53, and Par-4 transcription factors in Alzheimer's disease. Rev Neurol 36:1004&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">12808492</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg D, Oren M, Yaniv M, Piette J (1990). Protein-binding elements in the promoter region of the mouse p53 gene. Oncogene 5:1285&#x2013;1290.</Citation><ArticleIdList><ArticleId IdType="pubmed">2216454</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutte C, Tsunozaki M, Hale VA, Priess JR (2002). APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc Natl Acad Sci USA 99:775&#x2013;779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC117381</ArticleId><ArticleId IdType="pubmed">11792846</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y, Misonou H, Sato T, Dohmae N, Takio K, Ihara Y (2001). Distinct intramembrane cleavages of the &#x3b2;-amyloid precursor protein family resembling &#x3b3;-secretase-like cleavage of Notch. J Biol Chem 276:35235&#x2013;35238.</Citation><ArticleIdList><ArticleId IdType="pubmed">11483588</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y, Chen F, Sanjo N, Kawarai T, Hasegawa H, Duthie M, Li W, Ruan X, Luthra A, Mount HTJ, Tandon A, Fraser FW, St. George-Hyslop P (2003). APH-1 interacts with mature and immature forms of presenilins and nicastrin and may play a role in maturation of presenilin&#x2013;nicastrin complexes. J Biol Chem 278:7374&#x2013;7380.</Citation><ArticleIdList><ArticleId IdType="pubmed">12471034</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y, Sanjo N, Chen F, Hasegawa H, Petit A, Ruan X, Li W, Shier C, Kawarai T, Schmitt-Ulms G, Westaway D, St. George-Hyslop P, Fraser FW (2004). The presenilin proteins are components of multiple membrane-bound complexes which have different biological activities. J Biol Chem 279:31329&#x2013;31336.</Citation><ArticleIdList><ArticleId IdType="pubmed">15123598</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Sebastian L, Sopher BL, Miller MW, Ware CB, Martin GM, Mattson MP (1999). Increased vulnerability of hippocampal neurons from presenilin-1 mutant knock-in mice to amyloid &#x3b2;-peptide toxicity: central roles of superoxide production and caspase activation. J Neurochem 72:1019&#x2013;1029.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037473</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Radha V, Furukawa Y, Swarup G (2001). Direct transcriptional activation of human caspase-1 by tumor suppressor p53. J Biol Chem 276:10585&#x2013;10588.</Citation><ArticleIdList><ArticleId IdType="pubmed">11278253</ArticleId></ArticleIdList></Reference><Reference><Citation>Heber S, Herms J, Gajic V, Hainfellner JA, Aguzzi A, R&#xfc;licke T, Kretzschmar H, von Koch C, Sisodia SS, Tremml P, Lipp H-P, Wolfer DP, M&#xfc;ller U (2000). Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. J Neurosci 20:7951&#x2013;7963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772747</ArticleId><ArticleId IdType="pubmed">11050115</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman A, Serneels L, Annaert W, Collen D, Schoonjans L, De Strooper B (2000). Total inactivation of &#x3b3;-secretase activity in presenilin-deficient embryonic stem cells. Nat Cell Biol 2:461&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">10878813</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong C-S, Caromille L, Nomata Y, Mori H, Bredesen DE, Koo EH (1999). Contrasting role of presenilin-1 and presenilin-2 in neuronal differentiation in vitro J Neurosci 19:637&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782201</ArticleId><ArticleId IdType="pubmed">9880584</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamijo T, Zindy F, Roussel M, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Scherr CJ (1997). Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF Cell 91:649&#x2013;659.</Citation><ArticleIdList><ArticleId IdType="pubmed">9393858</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang DE, Yoon IS, Repetto E, Busse T, Yermian N, Ie L, Koo EH (2005). Presenilins mediate PI3K/AKT and ERK activation via select signaling receptors: selectivity of PS2 in PDGF signaling. J Biol Chem 280:31537&#x2013;31547.</Citation><ArticleIdList><ArticleId IdType="pubmed">16014629</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimberly WT, Zheng JB, Gu&#xe9;nette S, Selkoe DJ (2001). The intracellular domain of the &#x3b2;-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a Notch-like manner. J Biol Chem 276:40288&#x2013;40292.</Citation><ArticleIdList><ArticleId IdType="pubmed">11544248</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita A, Whelan CM, Berezovska O, Hyman BT (22217). The &#x3b3;-secretase-generated carboxy-terminal domain of the amyloid precursor protein induces apoptosis via Tip60 in H4 cells. J Biol Chem 277:28530&#x2013;28536.</Citation><ArticleIdList><ArticleId IdType="pubmed">12032152</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita A, Whelan CM, Smith CJ, Berezovska O, Hyman BT (2002b). Direct visualization of the gamma secretase-generated carboxy-terminal domain of the amyloid precursor protein: association with Fe65 and translocation to the nucleus. J Neurochem 82:839&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pubmed">12358789</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura Y, Shimohama S, Kamoshima W, Matsuoka Y, Nomura Y, Taniguchi T (1997). Changes of p53 in the brains of patients with Alzheimer's disease. Biochem Biophys Res Commun 232:418&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">9125193</ArticleId></ArticleIdList></Reference><Reference><Citation>Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV (1999). A chemical inhibitor of p53 that protects mice from the side effect of cancer therapy. Science 285:1733&#x2013;1737.</Citation><ArticleIdList><ArticleId IdType="pubmed">10481009</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo WJ, Wang H, Li H, Kim BS, Shah S, Lee H-J, Thinakaran G, Kim T-W, Yu G, Xu H (2003). PEN-2 and APH-1 coordinately regulate proteolytic processing of presenilin 1. J Biol Chem 278:7850&#x2013;7854.</Citation><ArticleIdList><ArticleId IdType="pubmed">12522139</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma G, Li T, Price D, Wong PC (2005). APH-1a is the principal mammalian APH-1 isoform present in &#x3b3;-secretase complexes during embryonic development. J Neurosci 25:192&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725209</ArticleId><ArticleId IdType="pubmed">15634781</ArticleId></ArticleIdList></Reference><Reference><Citation>Marambaud P, Ancolio K, Lopez-Perez E, Checler F (1998). Proteasome inhibitors prevent the degradation of familial Alzheimer's disease-linked presenilin 1 and trigger increased A&#x3b2;42 secretion by human cells. Mol Med 4:147&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2230353</ArticleId><ArticleId IdType="pubmed">9562973</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyashita T, Reed JC (1995). Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">7834749</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohyagi Y, Asahara H, Chui DH, Tsuruta Y, Sakae N, Miyoshi K, Yamada T, Kikuchi H, Taniwaki T, Murai H, Ikezoe K, Furuya H, Kawarabayashi T, Shoji M, Checler F, Iwaki T, Makifuchi T, Takeda K, Kira J, Tabira T (2005). Intracellular A&#x3b2;42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease. FASEB J 19:255&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">15548589</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardossi-Piquard R, Petit A, Kawarai T, Sunyach C, Alves da Costa C, Vincent B, Ring S, D'Adamio L, Shen J, M&#xfc;ller U, St. George-Hyslop P, Checler F (2005). Presenilin-dependent transcriptional control of the A&#x3b2;-degrading enzyme neprilysin by intracellular domains of &#x3b2;APP and APLP. Neuron 46:541&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944124</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardossi-Piquard R, Dunys J, Yu G, St. George-Hyslop P, Alves da Costa C, Checler F (2006). Neprilysin activity and expression are controlled by nicastrin. J Neurochem 97:1052&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pubmed">16606360</ArticleId></ArticleIdList></Reference><Reference><Citation>Passer B, Pellegrini L, Russo C, Siegel RM, Lenardio MJ, Schettini G, Bachmann M, Tabaton M, D'Adamio L (2000). Generation of an apoptotic intracellular peptide by &#x3b3;-secretase cleavage of Alzheimer's amyloid &#x3b2; protein precursor. J Alzheimers Dis 2:289&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">12214090</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastorcic M, Das HK (2000). Regulation of transcription of the human presenilin-1 gene by Ets transcription factor and the p53 protooncogene. J Biol Chem 275:34938&#x2013;34945.</Citation><ArticleIdList><ArticleId IdType="pubmed">10942770</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez A, Morelli L, Cresto JC, Castano EM (2000). Degradation of soluble amyloid &#x3b2;-peptides 1&#x2013;40, 1&#x2013;42, and the Dutch variant 1&#x2013;40Q by insulin-degrading enzyme from Alzheimer disease and control brains. Neurochem Res 25:247&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">10786709</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Tur J, Froelich S, Prihar G, Crook R, Baker M, Duff K, Wragg M, Busfield F, Lendon C, Clark RF, Roques P, Fuldner RA, Johnston J, Cowburn R, Forsell C, Axelman K, Lilius L, Houlden H, Karran E, Roberts GW, Rossor M, Adams MD, Hardy J, Goate A, Lannfelt L, Hutton M (1995). A mutation in Alzheimer's disease destroying a splice acceptor site in the presenilin-1 gene. NeuroReport 7:297&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">8742474</ArticleId></ArticleIdList></Reference><Reference><Citation>Roperch J-P, Alvaro V, Prieur S, Tyunder M, Nemani M, Lethrosne F, Piouffre L, Gendron M-C, Israeli D, Dausset J, Oren M, Amson R, Telerman A (1998). Inhibition of presenilin1 expression is promoted by p53 and p21WAF-1 and results in apoptosis and tumor suppression. Nat Med 4:835&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pubmed">9662377</ArticleId></ArticleIdList></Reference><Reference><Citation>Sastre M, Steiner H, Fuchs K, Capell A, Multhaup G, Condron MM, Teplow DB, Haass C (2001). Presenilin-dependent &#x3b3;-secretase processing of &#x3b2;-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep 2:835&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1084035</ArticleId><ArticleId IdType="pubmed">11520861</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Choi S-Y, Beglopoulos V, Malkani S, Zhang D, Rao BSS, Chattarji S, Kelleher RJ III, Kandel ER, Duff K, Kirkwood A, Shen J (2004). Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 42:23&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheinfeld MH, Ghersi E, Laky K, Fowlkes BJ, D'Adamio L (2002). Processing of &#x3b2;-amyloid precursor-like protein-1 and -2 by &#x3b3;-secretase regulates transcription. J Biol Chem 277:44195&#x2013;44201.</Citation><ArticleIdList><ArticleId IdType="pubmed">12228233</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirotani K, Edbauer D, Prokop S, Haass C, Steiner H (2004). Identification of distinct &#x3b3;-secretase complexes with different APH-1 variants. J Biol Chem 279:41340&#x2013;41345.</Citation><ArticleIdList><ArticleId IdType="pubmed">15286082</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia SS, St. George-Hyslop P (2002). &#x3b3;-Secretase, Notch, A&#x3b2;, and Alzheimer's disease: where do the presenilins fit in? Nat Rev Neurosci 3:281&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">11967558</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Winkler E, Edbauer D, Prokop S, Basset G, Yamasaki A, Kostka M, Haass C (2002). PEN-2 is an integral component of the &#x3b3;-secretase complex required for coordinated expression of presenilin and nicastrin. J Biol Chem 277:39062&#x2013;39065.</Citation><ArticleIdList><ArticleId IdType="pubmed">12198112</ArticleId></ArticleIdList></Reference><Reference><Citation>Tournoy J, Bossuyt X, Snellinx A, Regent M, Garmyn M, Serneels L, Saftig P, Craessaerts K, De Strooper B, Hartmann D (2004). Partial loss of presenilins causes seborrheic keratosis and autoimmune disease in mice. Hum Mol Genet 13:1321&#x2013;1331.</Citation><ArticleIdList><ArticleId IdType="pubmed">15128703</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Fadeeva JV, LaVoie MJ, Paliga K, Eggert S, Kimberly WT, Wasco W, Selkoe DJ (2003). &#x3b3;-Secretase cleavage and binding to Fe65 regulate the nuclear translocation of the intracellular C-terminal domain (ICD) of the APP family of proteins. Biochemistry 42:6664&#x2013;6673.</Citation><ArticleIdList><ArticleId IdType="pubmed">12779321</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel M, Sherr CJ, Zambetti GP (2000). p53-independent functions of the p19 (ARF) tumor suppressor. Genes Dev 14:2358&#x2013;2365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC316930</ArticleId><ArticleId IdType="pubmed">10995391</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS (2001). &#x3b3;-Secretase inhibitors as molecular probes of presenilin function. J Mol Neurosci 17:199&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">11816793</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B, Iwasaki K, Vito P, Ganjei JK, Lacana E, Sunderland T, Zhao B, Kusiak JW, Wasco W, D'Adamio L (1996). Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science 274:1710&#x2013;1713.</Citation><ArticleIdList><ArticleId IdType="pubmed">8939861</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia X, Qian S, Soriano S, Wu Y, Fletcher AM, Wang XJ, Koo EH, Wu X, Zheng H (2001). Loss of presenilin 1 is associated with enhanced &#x3b2;-catenin signaling and skin tumorigenesis. Proc Natl Acad Sci USA 98:10863&#x2013;10868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC58565</ArticleId><ArticleId IdType="pubmed">11517342</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Nishimura M, Arawaka S, Levitan D, Zhang L, Tandon A, Song Y-Q, Rogaeva E, Chen F, Kawarai T, Supala A, Levesque L, Yu H, Yang D-S, Holmes E, Milman P, Liang Y, Zhang D-M, Xu D-H, Sato C, Rogaev E, Smith M, Janus C, Zhang Y, Aebersold R, Farrer L, Sorbi S, Bruni A, Fraser P, St. George-Hyslop P (2000). Nicastrin modulates presenilin-mediated notch/glp1 signal transduction and &#x3b2;APP processing. Nature 407:48&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">10993067</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Nadeau P, Song W, Donoviel D, Yuan M, Bernstein A, Yankner BA (2000). Presenilins are required for &#x3b3;-secretase cleavage of &#x3b2;APP and transmembrane cleavage of Notch. Nat Cell Biol 2:463&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">10878814</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16766195</PMID><DateCompleted><Year>2006</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2012</Year><Month>06</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0969-9961</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Neurobiology of disease</Title><ISOAbbreviation>Neurobiol Dis</ISOAbbreviation></Journal><ArticleTitle>The regulation of tau phosphorylation by PCTAIRE 3: implications for the pathogenesis of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>398</StartPage><EndPage>408</EndPage><MedlinePgn>398-408</MedlinePgn></Pagination><Abstract><AbstractText>In the course of Alzheimer's disease, phosphorylated tau aggregates to form paired helical filaments, highly ordered filamentous structures that accumulate within neurons and contribute to the formation of neurofibrillary tangles. This study examines the role of PCTAIRE 3, a cdc2 family protein kinase, within this disease process. We report an elevation in the protein levels of PCTAIRE 3 in the temporal cortex of AD relative to control brains. Analysis of paired helical filaments prepared from AD brain tissue indicates that PCTAIRE 3 is concentrated within this pathological material. Overexpression of PCTAIRE 3 in cell culture suggests that the protein acts indirectly to stimulate phosphorylation at the pT231 and pS235 sites on tau, residues that are modified early in the process of AD pathogenesis. The resurgence of cell cycle proteins is an important mechanism in Alzheimer's disease (AD), and we propose that PCTAIRE 3 is a PHF-associated kinase that modulates tau phosphorylation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herskovits</LastName><ForeName>A Z</ForeName><Initials>AZ</Initials><AffiliationInfo><Affiliation>Department of Pathology, Albert Einstein College of Medicine, Forchheimer 526, Bronx, NY 10461, USA. aherskov@aecom.yu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH 38623</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32GM07288</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Dis</MedlineTA><NlmUniqueID>9500169</NlmUniqueID><ISSNLinking>0969-9961</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000199">Actins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017931">DNA Primers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018076">DNA, Complementary</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="D018844">Cyclin-Dependent Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="C089464">PCTAIRE-3 protein kinase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000199" MajorTopicYN="N">Actins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003001" MajorTopicYN="N">Cloning, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018844" MajorTopicYN="N">Cyclin-Dependent Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017931" MajorTopicYN="N">DNA Primers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018076" MajorTopicYN="N">DNA, Complementary</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015183" MajorTopicYN="N">Restriction Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>6</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>6</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16766195</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2006.04.004</ArticleId><ArticleId IdType="pii">S0969-9961(06)00077-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16769157</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2011</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>6</Issue><PubDate><Year>2007</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease.</ArticleTitle><Pagination><StartPage>824</StartPage><EndPage>830</EndPage><MedlinePgn>824-30</MedlinePgn></Pagination><Abstract><AbstractText>In this study we report that the membrane-bound, but not cytosolic insulin degrading enzyme (IDE) protein concentration and IDE activity are significantly decreased in the hippocampal formation of cases affected by mild cognitive impairment (MCI) which are at high risk to develop Alzheimer's disease (AD), relative to normal neurological controls. Membrane-bound IDE protein concentrations and activity in the hippocampal formation continued to decrease during the conversion from MCI to mild-severe AD. This selective decrease in hippocampal membrane-bound, but not cytosolic, IDE concentration and activity was tissue specific since no changes in either membrane-bound or cytosolic IDE were found in the occipital cortex of the same cases examined. Most interestingly, the decreased hippocampal membrane-bound IDE protein activity negatively correlated with brain beta-amyloid (Abeta)X-42 content in MCI and in AD brain. The study tentatively suggests that interventions aimed at promoting membrane-bound IDE activities in the brain of MCI cases may help to prevent the onset and possibly the progression into AD through mechanisms involving the clearance of monomeric Abeta from the brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Zhong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Neuroinflammation Research Laboratories, The Mount Sinai School of Medicine, New York, NY 10029, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Zhongmin</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Haroutunian</LastName><ForeName>Vahram</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Buxbaum</LastName><ForeName>Joseph D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Stetka</LastName><ForeName>Breton</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Pasinetti</LastName><ForeName>Giulio Maria</ForeName><Initials>GM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG13799</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG14239</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG14766</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>06</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007456">Iodine Isotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.56</RegistryNumber><NameOfSubstance UI="D007339">Insulysin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003600" MajorTopicYN="N">Cytosol</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="N">Entorhinal Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007339" MajorTopicYN="N">Insulysin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007456" MajorTopicYN="N">Iodine Isotopes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011180" MajorTopicYN="N">Postmortem Changes</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>6</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>5</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>6</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16769157</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.05.001</ArticleId><ArticleId IdType="pii">S0197-4580(06)00141-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16777606</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0092-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>125</Volume><Issue>6</Issue><PubDate><Year>2006</Year><Month>Jun</Month><Day>16</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin.</ArticleTitle><Pagination><StartPage>1179</StartPage><EndPage>1191</EndPage><MedlinePgn>1179-91</MedlinePgn></Pagination><Abstract><AbstractText>Cleavage of huntingtin (htt) has been characterized in vitro, and accumulation of caspase cleavage fragments represents an early pathological change in brains of Huntington's disease (HD) patients. However, the relationship between htt proteolysis and the pathogenesis of HD is unknown. To determine whether caspase cleavage of htt is a key event in the neuronal dysfunction and selective neurodegeneration in HD, we generated YAC mice expressing caspase-3- and caspase-6-resistant mutant htt. Mice expressing mutant htt, resistant to cleavage by caspase-6 but not caspase-3, maintain normal neuronal function and do not develop striatal neurodegeneration. Furthermore, caspase-6-resistant mutant htt mice are protected against neurotoxicity induced by multiple stressors including NMDA, quinolinic acid (QA), and staurosporine. These results are consistent with proteolysis of htt at the caspase-6 cleavage site being an important event in mediating neuronal dysfunction and neurodegeneration and highlight the significant role of htt proteolysis and excitotoxicity in HD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>Rona K</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Department of Medical Genetics, Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, BC V5Z 4H4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Yu</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Slow</LastName><ForeName>Elizabeth J</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Haigh</LastName><ForeName>Brendan</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Bissada</LastName><ForeName>Nagat</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Ge</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Pearson</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Shehadeh</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bertram</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Zoe</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Warby</LastName><ForeName>Simon C</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Doty</LastName><ForeName>Crystal N</ForeName><Initials>CN</Initials></Author><Author ValidYN="Y"><LastName>Roy</LastName><ForeName>Sophie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wellington</LastName><ForeName>Cheryl L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Leavitt</LastName><ForeName>Blair R</ForeName><Initials>BR</Initials></Author><Author ValidYN="Y"><LastName>Raymond</LastName><ForeName>Lynn A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>Donald W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Hayden</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C086055">HTT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071058">Huntingtin Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>6384-92-5</RegistryNumber><NameOfSubstance UI="D016202">N-Methylaspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C505514">CASP6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C505516">Casp6 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053178">Caspase 6</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D020169">Caspases</NameOfSubstance></Chemical><Chemical><RegistryNumber>F6F0HK1URN</RegistryNumber><NameOfSubstance UI="D017378">Quinolinic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>H88EPA0A3N</RegistryNumber><NameOfSubstance UI="D019311">Staurosporine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D021581" MajorTopicYN="N">Active Transport, Cell Nucleus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053178" MajorTopicYN="N">Caspase 6</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071058" MajorTopicYN="N">Huntingtin Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006868" MajorTopicYN="N">Hydrolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016202" MajorTopicYN="N">N-Methylaspartate</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017378" MajorTopicYN="N">Quinolinic Acid</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019311" MajorTopicYN="N">Staurosporine</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16777606</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2006.04.026</ArticleId><ArticleId IdType="pii">S0092-8674(06)00558-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16785436</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>103</Volume><Issue>26</Issue><PubDate><Year>2006</Year><Month>Jun</Month><Day>27</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Hippocampal disconnection contributes to memory dysfunction in individuals at risk for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>10041</StartPage><EndPage>10045</EndPage><MedlinePgn>10041-5</MedlinePgn></Pagination><Abstract><AbstractText>The concept of amnestic mild cognitive impairment (MCI) describes older people who show a decline predominantly in memory function, but who do not meet criteria for dementia. Because such individuals are at high risk for developing Alzheimer's disease, they are of great interest for understanding the prodromal stages of the disease process. The mechanism underlying memory dysfunction in people with MCI is not fully understood. The present study uses quantitative, high-resolution structural MRI techniques to investigate, in vivo, the anatomical substrate of memory dysfunction associated with MCI. Changes in brain structures were assessed with two imaging techniques: (i) whole-brain, voxel-based morphometry to determine regions of reduced white matter volume and (ii) sensitive volumetric segmentation of the entorhinal cortex and hippocampus, gray matter regions that are critically important for memory function. In participants with amnestic MCI, compared with age-matched controls, results showed a significant decrease in white matter volume in the region of the parahippocampal gyrus that includes the perforant path. There was also significant atrophy in both the entorhinal cortex and the hippocampus. Regression models demonstrated that both hippocampal volume and parahippocampal white matter volume were significant predictors of declarative memory performance. These results suggest that, in addition to hippocampal atrophy, disruption of parahippocampal white matter fibers contributes to memory decline in elderly individuals with MCI by partially disconnecting the hippocampus from incoming sensory information.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stoub</LastName><ForeName>Travis R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, 1653 West Congress Parkway, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>deToledo-Morrell</LastName><ForeName>Leyla</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Stebbins</LastName><ForeName>Glenn T</ForeName><Initials>GT</Initials></Author><Author ValidYN="Y"><LastName>Leurgans</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Raj C</ForeName><Initials>RC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG 09466</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000269</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG009466</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG 10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG 17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG 00269</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>06</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000647" MajorTopicYN="N">Amnesia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009412" MajorTopicYN="N">Nerve Fibers</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest statement: No conflicts declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>6</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>6</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>6</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16785436</ArticleId><ArticleId IdType="pmc">PMC1479867</ArticleId><ArticleId IdType="doi">10.1073/pnas.0603414103</ArticleId><ArticleId IdType="pii">0603414103</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Milner B. In: INSERM Symposium No. 6. Buser P. A., Rougeul-Buser A., editors. Amsterdam: Elsevier Biomedical; 1978. pp. 139&#x2013;153.</Citation></Reference><Reference><Citation>Squire L. R., Zola-Morgan S. Science. 1991;253:1380&#x2013;1386.</Citation><ArticleIdList><ArticleId IdType="pubmed">1896849</ArticleId></ArticleIdList></Reference><Reference><Citation>Zola-Morgan S., Squire L. R., Amaral D. G. J. Neurosci. 1986;6:2950&#x2013;2967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568782</ArticleId><ArticleId IdType="pubmed">3760943</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Braak E. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Braak E. Neurobiol. Aging. 1995;16:271&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Braak E., Bohl J., Bratzke H. J. Neural Transm. Suppl. 1998;54:97&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">9850918</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordower J. H., Chu Y., Stebbins G. T., DeKosky S. T., Cochran E. J., Bennett D., Mufson E. J. Ann. Neurol. 2001;49:202&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">11220740</ArticleId></ArticleIdList></Reference><Reference><Citation>Mufson E. J., Chen E. Y., Cochran E. J., Beckett L. A., Bennett D. A., Kordower J. H. Exp. Neurol. 1999;158:469&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pubmed">10415154</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T., Price J. L., McKeel D. W., Morris J. C., Growdon J. H, Hyman B. T. J. Neurosci. 1996;16:4491&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman B. T., Van Hoesen G. W., Damasio A. R., Barnes C. L. Science. 1984;225:1168&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">6474172</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen R. C., Smith G. E., Waring S. C., Ivnik R. J., Tangalos E. G., Kokmen E. Arch. Neurol. 1999;56:303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen R. C., Doody R, Kurz A., Mohs R. C., Morris J. C., Rabins V. P., Ritchie K., Rossor M., Thal L., Winblad B. Arch. Neurol. 2001;58:1985&#x2013;1992.</Citation><ArticleIdList><ArticleId IdType="pubmed">11735772</ArticleId></ArticleIdList></Reference><Reference><Citation>Amaral D. G., Insausti R., Cowan W. M. J. Comp. Neurol. 1987;264:326&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">2445795</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hoesen G. W., Pandya D. N. Brain Res. 1975;95:39&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">1156868</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hoesen G. W., Pandya D. N., Butters N. Brain Res. 1975;95:25&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">1156867</ArticleId></ArticleIdList></Reference><Reference><Citation>Convit A., de Leon M. J., Tarshish C., De Santi S., Tsui W., Rusinek H., George A. Neurobiol. Aging. 1997;18:131&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">9258889</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon M. J., Convit A., George A. E., Golomb J., De Santi S., Tarshish C., Rusinek H., Bobinski M., Ince C., Miller D., Wisniewski H. Ann. N.Y. Acad. Sci. 1996;777:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">8624070</ArticleId></ArticleIdList></Reference><Reference><Citation>deToledo-Morrell L., Sullivan M. P., Morrell F., Wilson R. S., Bennett D. A., Spencer S. Neurobiol. Aging. 1997;18:463&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">9390771</ArticleId></ArticleIdList></Reference><Reference><Citation>deToledo-Morrell L., Goncharova I., Dickerson B. C., Wilson R. S., Bennett D. A. Ann. N.Y. Acad. Sci. 2000;911:240&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">10911878</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson B. C., Goncharova I., Sullivan M. P, Forchetti C., Wilson R. S., Bennett D. A., Beckett L. A., deToledo-Morrell L. Neurobiol. Aging. 2001;22:747&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">11705634</ArticleId></ArticleIdList></Reference><Reference><Citation>Du A. T., Schuff N., Amend D., Laakso M. P., Hsu Y. Y., Jagust W. J., Yaffe K., Kramer J. H., Reed B., Norman D., et al. J. Neurol. Neurosurg. Psychiatry. 2001;71:441&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1763497</ArticleId><ArticleId IdType="pubmed">11561025</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C. R., Jr, Petersen R. C., Xu Y. C., O&#x2019;Brien P. C., Smith G. E., Ivnik R. J., Boeve B. F., Waring S. C., Tangalos E. G., Kokmen E. Neurology. 1999;52:1397&#x2013;1407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730146</ArticleId><ArticleId IdType="pubmed">10227624</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C. R., Jr, Petersen R. C, Xu Y. C., Waring S. C., O&#x2019;Brien P. C., Tangalos E. G., Smith G. E., Ivnik R. J., Kokmen E. Neurology. 1997;49:786&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730601</ArticleId><ArticleId IdType="pubmed">9305341</ArticleId></ArticleIdList></Reference><Reference><Citation>Killiany R. J., Gomez-Isla T., Moss M., Kikinis R., Sandor T., Jolesz F., Tanzi R., Jones K., Hyman B. T., Albert M. S. Ann. Neurol. 2000;47:430&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">10762153</ArticleId></ArticleIdList></Reference><Reference><Citation>Killiany R. J., Hyman B. T., Gomez-Isla T., Moss M. B., Kikinis R., Jolesz F., Tanzi R., Jones K., Albert M. Neurology. 2002;58:1188&#x2013;1196.</Citation><ArticleIdList><ArticleId IdType="pubmed">11971085</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennanen C., Kivipelto M., Tuomainen S., Hartikainen T., Hanninen T, Laakso M. P., Hallikainen M., Vanhanen M., Nissinen H., Helkala E. L., et al. Neurobiol. Aging. 2004;25:303&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">15123335</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoub T. R., Bulgakova M., Leurgans S., Bennett D. A., Fleischman D., Turner D. A., deToledo-Morrell L. Neurology. 2005;64:1520&#x2013;1524.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883311</ArticleId></ArticleIdList></Reference><Reference><Citation>Good C. D., Johnsrude I. S., Ashburner J., Henson R. N., Friston K. J., Frackowiak R. S. NeuroImage. 2001;14:21&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">11525331</ArticleId></ArticleIdList></Reference><Reference><Citation>Talairach J., Turnoux P. New York: Thieme; 1988. Co-Planar Stereotaxic Atlas of the Human Brain.</Citation></Reference><Reference><Citation>Friston K. J., Holmes A. P., Worsley K. J., Poline J. B., Frith J. D., Frackowiak R. S. Hum. Brain Mapp. 1995;2:189&#x2013;210.</Citation></Reference><Reference><Citation>Bennett D. A., Wilson R. S., Schneider J. A., Evans D. A., Beckett L. A., Agarwall N. T., Barnes L. L., Fox J. H., Bach J. Neurology. 2002;59:198&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">12136057</ArticleId></ArticleIdList></Reference><Reference><Citation>Young B. J., Otto T., Fox G. D., Eichenbaum H. J. Neurosci. 1997;17:5183&#x2013;5195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573311</ArticleId><ArticleId IdType="pubmed">9185556</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett D. A., Schneider J. A., Buchman A. S., Mendes de Leon C., Bienias J. L., Wilson R. S. Neuroepidemiology. 2005;25:163&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">16103727</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris J. C., Heyman A., Mohs R. C., Hughes J. P., van Belle G., Fillenbaum G., Mellits E. D., Clark C. Neurology. 1989;39:1159&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">2771064</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert M., Smith L., Scherr P., Taylor J., Evans D., Funkenstein H. Int. J. Neurosci. 1991;57:167&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">1938160</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Wechsler Memory Scale&#x2013;Revised (WMS-R) San Antonio, TX: Psychol. Corp.; 1987.</Citation></Reference><Reference><Citation>Folstein M. F., Folstein S. E., McHugh P. R. J. Psychiatr. Res. 1975;12:189&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancaster J. L., Woldorff M. G., Parsons L. M., Liotti M., Freitas C. S., Rainey L., Kochunov P. V., Nickerson D., Mikiten S. A., Fox P. T. Hum. Brain Mapp. 2000;10:120&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871915</ArticleId><ArticleId IdType="pubmed">10912591</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechelli A., Price C. J., Friston K. J., Ashburner J. Curr. Med. Imaging Rev. 2005;1:105&#x2013;113.</Citation></Reference><Reference><Citation>Goncharova I. I., Dickerson B. C., Stoub T. R., deToledo-Morrell L. Neurobiol. Aging. 2001;22:737&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">11705633</ArticleId></ArticleIdList></Reference><Reference><Citation>Insausti R., Juottonen K., Soininen H., Insausit A. M., Partanen K., Vainio P., Laakso M. P., Pitkanen A. Am. J. Neuroradiol. 1998;19:659&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8337393</ArticleId><ArticleId IdType="pubmed">9576651</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson R. S., Sullivan M. P., deToledo-Morrell L., Stebbins G. T., Bennett D. A., Morrell F. Neuropsychology. 1996;10:459&#x2013;463.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16794039</PMID><DateCompleted><Year>2006</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>313</Volume><Issue>5785</Issue><PubDate><Year>2006</Year><Month>Jul</Month><Day>21</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models.</ArticleTitle><Pagination><StartPage>324</StartPage><EndPage>328</EndPage><MedlinePgn>324-8</MedlinePgn></Pagination><Abstract><AbstractText>Alpha-synuclein (alphaSyn) misfolding is associated with several devastating neurodegenerative disorders, including Parkinson's disease (PD). In yeast cells and in neurons alphaSyn accumulation is cytotoxic, but little is known about its normal function or pathobiology. The earliest defect following alphaSyn expression in yeast was a block in endoplasmic reticulum (ER)-to-Golgi vesicular trafficking. In a genomewide screen, the largest class of toxicity modifiers were proteins functioning at this same step, including the Rab guanosine triphosphatase Ypt1p, which associated with cytoplasmic alphaSyn inclusions. Elevated expression of Rab1, the mammalian YPT1 homolog, protected against alphaSyn-induced dopaminergic neuron loss in animal models of PD. Thus, synucleinopathies may result from disruptions in basic cellular functions that interface with the unique biology of particular neurons to make them especially vulnerable.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Antony A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>School of Biological Sciences, University of Missouri-Kansas City, Kansas City, MO 64110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gitler</LastName><ForeName>Aaron D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Cashikar</LastName><ForeName>Anil</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Haynes</LastName><ForeName>Cole M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Kathryn J</ForeName><Initials>KJ</Initials></Author><Author ValidYN="Y"><LastName>Bhullar</LastName><ForeName>Bhupinder</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Kangning</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Kexiang</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Strathearn</LastName><ForeName>Katherine E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Fang</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Songsong</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Caldwell</LastName><ForeName>Kim A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Caldwell</LastName><ForeName>Guy A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Marsischky</LastName><ForeName>Gerald</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Kolodner</LastName><ForeName>Richard D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Labaer</LastName><ForeName>Joshua</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rochet</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Bonini</LastName><ForeName>Nancy M</ForeName><Initials>NM</Initials></Author><Author ValidYN="Y"><LastName>Lindquist</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 NS038372</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-HG002923</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029701">Saccharomyces cerevisiae Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C060755">YPT1 protein, S cerevisiae</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="D020691">rab GTP-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="D020761">rab1 GTP-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017173" MajorTopicYN="N">Caenorhabditis elegans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015723" MajorTopicYN="N">Gene Library</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006056" MajorTopicYN="N">Golgi Apparatus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="Y">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012441" MajorTopicYN="N">Saccharomyces cerevisiae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029701" MajorTopicYN="N">Saccharomyces cerevisiae Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020691" MajorTopicYN="N">rab GTP-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020761" MajorTopicYN="N">rab1 GTP-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>6</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>6</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>9</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16794039</ArticleId><ArticleId IdType="mid">NIHMS15898</ArticleId><ArticleId IdType="pmc">PMC1983366</ArticleId><ArticleId IdType="doi">10.1126/science.1129462</ArticleId><ArticleId IdType="pii">1129462</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vila M, Przedborski S. Nat Med. 2004;10(Suppl):S58.</Citation><ArticleIdList><ArticleId IdType="pubmed">15272270</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, Trojanowski JQ, Lee VM. Nat Med. 2004;10:1055.</Citation><ArticleIdList><ArticleId IdType="pubmed">15459709</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Proc Natl Acad Sci USA. 1998;95:6469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27806</ArticleId><ArticleId IdType="pubmed">9600990</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos MH, et al. Science. 1997;276:2045.</Citation><ArticleIdList><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger R, et al. Nat Genet. 1998;18:106.</Citation><ArticleIdList><ArticleId IdType="pubmed">9462735</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarranz JJ, et al. Ann Neurol. 2004;55:164.</Citation><ArticleIdList><ArticleId IdType="pubmed">14755719</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton AB, et al. Science. 2003;302:841.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>Chartier-Harlin MC, et al. Lancet. 2004;364:1167.</Citation><ArticleIdList><ArticleId IdType="pubmed">15451224</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibanez P, et al. Lancet. 2004;364:1169.</Citation><ArticleIdList><ArticleId IdType="pubmed">15451225</ArticleId></ArticleIdList></Reference><Reference><Citation>Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Science. 2002;295:865.</Citation><ArticleIdList><ArticleId IdType="pubmed">11823645</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P. Proc Natl Acad Sci USA. 2002;99:10813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125054</ArticleId><ArticleId IdType="pubmed">12122208</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, et al. Science. 2000;287:1265.</Citation><ArticleIdList><ArticleId IdType="pubmed">10678833</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao S, Gelwix CC, Caldwell KA, Caldwell GA. J Neurosci. 2005;25:3801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724936</ArticleId><ArticleId IdType="pubmed">15829632</ArticleId></ArticleIdList></Reference><Reference><Citation>Dauer W, Przedborski S. Neuron. 2003;39:889.</Citation><ArticleIdList><ArticleId IdType="pubmed">12971891</ArticleId></ArticleIdList></Reference><Reference><Citation>Outeiro TF, Lindquist S. Science. 2003;302:1772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1780172</ArticleId><ArticleId IdType="pubmed">14657500</ArticleId></ArticleIdList></Reference><Reference><Citation>McCracken AA, Brodsky JL. Bioessays. 2003;25:868.</Citation><ArticleIdList><ArticleId IdType="pubmed">12938176</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochstrasser M, Varshavsky A. Cell. 1990;61:697.</Citation><ArticleIdList><ArticleId IdType="pubmed">2111732</ArticleId></ArticleIdList></Reference><Reference><Citation>Knop M, Hauser N, Wolf DH. Yeast. 1996;12:1229.</Citation><ArticleIdList><ArticleId IdType="pubmed">8905927</ArticleId></ArticleIdList></Reference><Reference><Citation>Biederer T, Volkwein C, Sommer T. EMBO J. 1996;15:2069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC450128</ArticleId><ArticleId IdType="pubmed">8641272</ArticleId></ArticleIdList></Reference><Reference><Citation>Caldwell SR, Hill KJ, Cooper AA. J Biol Chem. 2001;276:23296.</Citation><ArticleIdList><ArticleId IdType="pubmed">11316816</ArticleId></ArticleIdList></Reference><Reference><Citation>Spear ED, Ng DT. Mol Biol Cell. 2003;14:2756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165674</ArticleId><ArticleId IdType="pubmed">12857862</ArticleId></ArticleIdList></Reference><Reference><Citation>Klionsky DJ, Emr SD. EMBO J. 1989;8:2241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC401154</ArticleId><ArticleId IdType="pubmed">2676517</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens T, Esmon B, Schekman R. Cell. 1982;30:439.</Citation><ArticleIdList><ArticleId IdType="pubmed">6754086</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossig R, Dascher C, Trepte HH, Schmitt HD, Gallwitz D. Mol Cell Biol. 1991;11:2980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC360128</ArticleId><ArticleId IdType="pubmed">1903839</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortin DL, et al. J Neurosci. 2004;24:6715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729723</ArticleId><ArticleId IdType="pubmed">15282274</ArticleId></ArticleIdList></Reference><Reference><Citation>Rochet JC, et al. J Mol Neurosci. 2004;23:23.</Citation><ArticleIdList><ArticleId IdType="pubmed">15126689</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson BS, et al. J Cell Biol. 1994;125:557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2119990</ArticleId><ArticleId IdType="pubmed">8175881</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosavi N, Lee HJ, Lee JS, Patel S, Lee SJ. J Biol Chem. 2002;277:48984.</Citation><ArticleIdList><ArticleId IdType="pubmed">12351643</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu EJ, et al. J Neurosci. 2002;22:10690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758450</ArticleId><ArticleId IdType="pubmed">12486162</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen M, Stutz F, Belgareh N, Haguenauer-Tsapis R, Dargemont C. Nat Cell Biol. 2003;5:661.</Citation><ArticleIdList><ArticleId IdType="pubmed">12778054</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC. Cell. 2005;123:383.</Citation><ArticleIdList><ArticleId IdType="pubmed">16269331</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotharius J, et al. J Biol Chem. 2002;277:38884.</Citation><ArticleIdList><ArticleId IdType="pubmed">12145295</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16799555</PMID><DateCompleted><Year>2006</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1078-8956</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>7</Issue><PubDate><Year>2006</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo.</ArticleTitle><Pagination><StartPage>856</StartPage><EndPage>861</EndPage><MedlinePgn>856-61</MedlinePgn></Pagination><Abstract><AbstractText>Certain disease states are characterized by disturbances in production, accumulation or clearance of protein. In Alzheimer disease, accumulation of amyloid-beta (Abeta) in the brain and disease-causing mutations in amyloid precursor protein or in enzymes that produce Abeta indicate dysregulation of production or clearance of Abeta. Whether dysregulation of Abeta synthesis or clearance causes the most common form of Alzheimer disease (sporadic, &gt;99% of cases), however, is not known. Here, we describe a method to determine the production and clearance rates of proteins within the human central nervous system (CNS). We report the first measurements of the fractional production and clearance rates of Abeta in vivo in the human CNS to be 7.6% per hour and 8.3% per hour, respectively. This method may be used to search for novel biomarkers of disease, to assess underlying differences in protein metabolism that contribute to disease and to evaluate treatments in terms of their pharmacodynamic effects on proposed disease-causing pathways.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8111, St. Louis, Missouri 63110, USA. batemanr@neuro.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munsell</LastName><ForeName>Ling Y</ForeName><Initials>LY</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Swarm</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Yarasheski</LastName><ForeName>Kevin E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DK056341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR000036</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK056341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR00036</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR000954</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG027091</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 RR000954</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AG024455</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>06</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2011 Oct 11;17(10):1178-9; author reply 1179-80. doi: 10.1038/nm.2495.</RefSource><PMID Version="1">21988985</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>11</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16799555</ArticleId><ArticleId IdType="mid">NIHMS31444</ArticleId><ArticleId IdType="pmc">PMC2983090</ArticleId><ArticleId IdType="doi">10.1038/nm1438</ArticleId><ArticleId IdType="pii">nm1438</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wolfe RR. Regulation of skeletal muscle protein metabolism in catabolic states. Curr Opin Clin Nutr Metab Care. 2005;8:61&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">15586001</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe RR. Regulation of muscle protein by amino acids. J Nutr. 2002;132:3219S&#x2013;3224S.</Citation><ArticleIdList><ArticleId IdType="pubmed">12368421</ArticleId></ArticleIdList></Reference><Reference><Citation>San Pietro A, Rittenberg D. A study of the rate of protein synthesis in humans. II. Measurement of the metabolic pool and the rate of protein synthesis. J Biol Chem. 1953;201:457&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">13044815</ArticleId></ArticleIdList></Reference><Reference><Citation>Balagopal P, Rooyackers OE, Adey DB, Ades PA, Nair KS. Effects of aging on in vivo synthesis of skeletal muscle myosin heavy-chain and sarcoplasmic protein in humans. Am J Physiol. 1997;273:E790&#x2013;E800.</Citation><ArticleIdList><ArticleId IdType="pubmed">9357810</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarasheski KE. Exercise, aging, and muscle protein metabolism. J Gerontol A Biol Sci Med Sci. 2003;58:M918&#x2013;M922.</Citation><ArticleIdList><ArticleId IdType="pubmed">14570859</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias N, Patterson BW, Schonfeld G. In vivo metabolism of ApoB, ApoA-I, and VLDL triglycerides in a form of hypobetalipoproteinemia not linked to the ApoB gene. Arterioscler Thromb Vasc Biol. 2000;20:1309&#x2013;1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">10807747</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen F, et al. Insertion in prion protein gene in familial Creutzfeldt-Jakob disease. Lancet. 1989;1:51&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">2563037</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos MH, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997;276:2045&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Podlisny MB, Lee G, Selkoe DJ. Gene dosage of the amyloid beta precursor protein in Alzheimer's disease. Science. 1987;238:669&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pubmed">2960019</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Eckman CB, Younkin SG. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim Biophys Acta. 2000;1502:172&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">10899442</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, et al. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem. 1996;271:4077&#x2013;4081.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626743</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, et al. Society for Neuroscience Abstracts. Washington, DC: 2002.</Citation></Reference><Reference><Citation>Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol. 1985;17:278&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">3158266</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams MA. Spinal catheter insertion via seated lumbar puncture using a massage chair. Neurology. 2002;58:1859&#x2013;1860.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084893</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2001;98:8850&#x2013;8855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC37524</ArticleId><ArticleId IdType="pubmed">11438712</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishman RA. Cerebrospinal fluid in diseases of the nervous system. Philadelphia: Saunders; 1992.</Citation></Reference><Reference><Citation>Yarasheski KE, Smith SR, Powderly WG. Reducing plasma HIV RNA improves muscle amino acid metabolism. Am J Physiol Endocrinol Metab. 2005;288:E278&#x2013;E284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170408</ArticleId><ArticleId IdType="pubmed">15367396</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarasheski KE, et al. Increased plasma gln and Leu Ra and inappropriately low muscle protein synthesis rate in AIDS wasting. Am J Physiol. 1998;275:E577&#x2013;E583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3177303</ArticleId><ArticleId IdType="pubmed">9755075</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith QR, Momma S, Aoyagi M, Rapoport SI. Kinetics of neutral amino acid transport across the blood-brain barrier. J Neurochem. 1987;49:1651&#x2013;1658.</Citation><ArticleIdList><ArticleId IdType="pubmed">3668544</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe RR, Chinkes DL, Wolfe RR. Isotope tracers in metabolic research: principles and practice of kinetic analysis. Hoboken, N.J.: Wiley-Liss; 2005.</Citation></Reference><Reference><Citation>Patterson BW. Use of stable isotopically labeled tracers for studies of metabolic kinetics: an overview. Metabolism. 1997;46:322&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">9054476</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarasheski KE, Smith K, Rennie MJ, Bier DM. Measurement of muscle protein fractional synthetic rate by capillary gas chromatography/combustion isotope ratio mass spectrometry. Biol Mass Spectrom. 1992;21:486&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4003887</ArticleId><ArticleId IdType="pubmed">1420371</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasten DL, Morris GS, Ramanadham S, Yarasheski KE. Isolation of human skeletal muscle myosin heavy chain and actin for measurement of fractional synthesis rates. Am J Physiol. 1998;275:E1092&#x2013;E1099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4139966</ArticleId><ArticleId IdType="pubmed">9843753</ArticleId></ArticleIdList></Reference><Reference><Citation>Merchak A, Patterson BW, Yarasheski KE, Hamvas A. Use of stable isotope labeling technique and mass isotopomer distribution analysis of [(13)C]palmitate isolated from surfactant disaturated phospholipids to study surfactant in vivo kinetics in a premature infant. J Mass Spectrom. 2000;35:734&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">10862126</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulte JN, Yarasheski KE. Effects of resistance training on the rate of muscle protein synthesis in frail elderly people. Int J Sport Nutr Exerc Metab. 2001;11 Suppl:S111&#x2013;S118.</Citation><ArticleIdList><ArticleId IdType="pubmed">11915909</ArticleId></ArticleIdList></Reference><Reference><Citation>Garlick PJ, McNurlan MA, Preedy VR. A rapid and convenient technique for measuring the rate of protein synthesis in tissues by injection of [3H]phenylalanine. Biochem J. 1980;192:719&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1162389</ArticleId><ArticleId IdType="pubmed">6786283</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16801647</PMID><DateCompleted><Year>2006</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>12</Issue><PubDate><Year>2006</Year><Month>Jun</Month><Day>27</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Neuropathology of older persons without cognitive impairment from two community-based studies.</ArticleTitle><Pagination><StartPage>1837</StartPage><EndPage>1844</EndPage><MedlinePgn>1837-44</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the relation of National Institute on Aging-Reagan (NIA-Reagan) neuropathologic criteria of Alzheimer disease (AD) to level of cognitive function in persons without dementia or mild cognitive impairment (MCI).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">More than 2,000 persons without dementia participating in the Religious Orders Study or the Memory and Aging Project agreed to annual detailed clinical evaluation and brain donation. The studies had 19 neuropsychological performance tests in common that assessed five cognitive domains, including episodic memory, semantic memory, working memory, perceptual speed, and visuospatial ability. A total of 134 persons without cognitive impairment died and underwent brain autopsy and postmortem assessment for AD pathology using NIA-Reagan neuropathologic criteria for AD, cerebral infarctions, and Lewy bodies. Linear regression was used to examine the relation of AD pathology to level of cognitive function proximate to death.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Two (1.5%) persons met NIA-Reagan criteria for high likelihood AD, and 48 (35.8%) met criteria for intermediate likelihood; 29 (21.6%) had cerebral infarctions, and 18 (13.4%) had Lewy bodies. The mean Mini-Mental State Examination score proximate to death was 28.2 for those meeting high or intermediate likelihood AD by NIA-Reagan criteria and 28.4 for those not meeting criteria. In linear regression models adjusted for age, sex, and education, persons meeting criteria for intermediate or high likelihood AD scored about a quarter standard unit lower on tests of episodic memory (p = 0.01). There were no significant differences in any other cognitive domain.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Alzheimer disease pathology can be found in the brains of older persons without dementia or mild cognitive impairment and is related to subtle changes in episodic memory.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>D A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA. dbennett@rush.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Arvanitakis</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>N T</ForeName><Initials>NT</Initials></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>R C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>R S</ForeName><Initials>RS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08AG00849</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23AG23675</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG15819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2006 Jun 27;66(12):1801-2. doi: 10.1212/01.wnl.0000234879.82633.f3.</RefSource><PMID Version="1">16801639</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003153" MajorTopicYN="N">Community Health Services</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>7</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000219668.47116.e6</ArticleId><ArticleId IdType="pii">66/12/1837</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>